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Abstract 
Background: Mutation and loss of TP53 function is one of the most frequent genetic 
abnormalities in ovarian cancer. TP53 genomic and functional status have been shown to 
provide potentially prognostic and predictive value in ovarian cancer; however, the results are 
controversial and evaluation in the context of a controlled clinical trial with single agent 
treatment have been lacking. Reactivation of p53 using MDM2-p53 antagonists is a promising 
therapeutic target for most patients with type I epithelial ovarian cancer and those left from 
type II harbouring wild-type TP53. BRCA1/2 mutations are present in 70-85% of germline 
mutations in patients with inherited ovarian cancer, and deficiencies in homologous 
recombination repair (HRR) account for up to 50% of epithelial ovarian cancer, indicating the 
possible sensitivity of ovarian cancer patients to PARP inhibitors. MDM2-p53 antagonists and 
PARP inhibitors are now undergoing clinical trials as targeted therapy for different types of 
cancer. The effect of RG7388 on its own and in combination with cisplatin, and combined 
treatment between MDM2-p53 antagonists and PARP inhibitors have not been investigated in 
ovarian cancer. 
Hypotheses: 1) Different genomic and functional status of p53 and some of its downstream 
targets such as p21WAF1, MDM2 and WIP1 can be used as prognostic and predictive biomarkers 
for the outcome of chemotherapy and overall survival in ovarian cancer. 2) Reactivation of p53 
by inhibition of its negative regulator MDM2, using the MDM2-p53 antagonists Nutlin-3 and 
RG7388, will result in p53-mediated growth arrest and apoptosis in wild-type TP53 ovarian 
cancer cells, and combination of them with current therapeutic agents or rucaparib increases 
growth inhibition and/or apoptosis in ovarian cancer cell lines compared to either agent alone.  
Methods: TP53 was sequenced in 260 ovarian cancer samples from the ICON3 trial using 
Sanger sequencing and Next Generation Sequencing (NGS) methods. The prognostic value of 
the expression levels of p53, p21WAF1, MDM2 and WIP1 was investigated using immunohistochemistry 
(IHC). The effect of MDM2-p53 antagonists, Nutlin-3/RG7112/RG7388, and PARP inhibitor, 
rucaparib, as single agents and in combination with cisplatin or together were investigated on 
a panel of ovarian cancer cell lines. Sensitivity was measured by growth inhibition, clonogenic 
cell survival assay, apoptosis assays including caspase 3/7 activity and flow cytometry. The 
effect on the p53 molecular pathway and p53-regulated candidate gene expression were 
investigated by western blotting and Quantitative Reverse-Transcription Polymerase Chain 
Reaction (qRT-PCR) respectively.  
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Results: Patients from the ICON3 clinical trial treated with carboplatin whose tumours harbour 
wild-type TP53 had a significantly better overall survival based on both univariate and 
multivariate analysis compared to those with mutant TP53 regardless of sequencing method. 
Adding paclitaxel to the platinum-based treatment showed a trend in favour of greater benefit 
for those with mutant TP53, although this failed to reach statistical significance (p>0.05). 
Overexpression of p53 has potential prognostic value for overall survival of ovarian cancer 
patients. 
Ovarian cancer cell lines with wild-type TP53 were sensitive to MDM2-p53 antagonists, 
Nutlin-3/RG7112/RG7388, while those with mutant TP53 were resistant to MDM2 inhibitors. 
Among the individual cell lines, A2780 and MDAH-2774 were sensitive and other cell lines 
(IGROV-1, OAW42, CP70, MLH1-corrected CP70+ and SKOV-3) were resistant to rucaparib 
regardless of BRCA1/BRCA2 status or deficiencies in HRR reported for these cell lines. 
Combination of Nutlin-3/RG7388 with cisplatin or rucaparib has synergistic and/or dose 
reduction potential dependent on cell genotype and the type of MDM2-p53 antagonist. 
Combined treatments using Nutlin-3/RG7388 and cisplatin led to greater levels of p53 
stabilisation and upregulation of p21WAF1 and MDM2, and higher expression of p21WAF1 was 
associated with a greater synergistic effect for growth inhibition. In combination treatment with 
rucaparib and Nutlin-3/RG7388, rucaparib showed no increase in the effect of MDM2 
inhibitors on the p53 pathway, indicating that the mechanism of observed synergy does not 
involve enhancement of p53 pathway activation by MDM2 inhibitors. Nutlin-3/RG7388 in 
combination with cisplatin or rucaparib resulted in changes in cell cycle distribution, SubG1 
events and caspase 3/7 activity in a cell type, time and compound-dependent manner. 
The fold changes in expression of candidate genes in response to MDM2 inhibitors were less 
in A2780 cells than IGROV-1 and OAW42. The balance of activity between growth 
inhibitory/pro-survival and pro-apoptotic genes dominates a small increase in the expression 
of several DNA repair genes as an explanation for the synergy observed for treatment with 
cisplatin and MDM2 inhibitors. 
Conclusions: The genomic and functional status of TP53 have potentially important prognostic 
and predictive values in ovarian cancer. Targeting the interaction between MDM2 and p53 
using MDM2-p53 antagonists is a promising therapeutic strategy for ovarian cancer patients 
with wild-type TP53 tumours, and combination treatment with them and cisplatin or rucaparib 
has synergistic and/or dose reduction potential dependent on cell genotype.   
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Chapter 1: Introduction 
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1.1 Ovarian cancer 
 Incidence and mortality 
Ovarian cancer is the most lethal of all gynaecological malignancies and was reported to be 
responsible for approximately 152,000 death worldwide in 2012. “It is the seventh most 
common cancer worldwide for females, and the eighteenth most common cancer overall, with 
nearly 239,000 new cases diagnosed in 2012.” (Ferlay J, 2013; Narod, 2016). In the UK, 
ovarian cancer is the sixth most common cancer in British women which accounts for 4% of 
all new cancer cases in females. The incidence rate is greatly influenced by age with the highest 
frequency in older females. More than half of the cases diagnosed in 2011-2013 in the UK were 
aged 65 and over (CRUK, 2016). With the exception of Japan, the highest incidence of ovarian 
cancer is found in developed countries, Europe, the USA and Israel (Hennessy et al., 2009). 
The lifetime risk of developing ovarian cancer is one in fifty two for women in the UK (CRUK, 
2016) and one in seventy two worldwide (Zhan et al., 2013). In terms of ethnicity, rates for 
white females with ovarian cancer range from 17.4 to 18.1 per 100,000 which is significantly 
decreased for Asian, 9.2 to 15.5 per 100,000, and Black women, 6.6 to 12.1 per 100,000 
(CRUK, 2016). Overall, the rate of ovarian cancer incidence has increased for most age 
categories in the UK since the late 1970s to 2013, with the exception of women aged 50-59 
(Figure 1-1) (CRUK, 2016). 
 
Figure 1-1: European Age-Standardised Incidence Rates per 100,000 Population, by Age, 
Females, Great Britain. 
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 Symptoms and diagnosis 
The symptoms of epithelial ovarian cancer are non-specific and early-stage disease is 
asymptomatic. The most common symptoms are increased abdominal size, persistent pelvic 
bloating, abdominal discomfort and pain, loss of appetite with low grade nausea, and inability 
to eat proper meals owing to feeling of fullness. Back pain, fatigue, irritable bowel syndrome, 
urinary burning, shortness of breath due to pleural effusion and menopausal symptoms are 
other clinical presentations of ovarian cancer (Bast et al., 2009;  Lokadasan et al., 2016).  
Diagnosis of ovarian cancer is challenging because of the similarity between its symptoms and 
many more prevalent gastrointestinal, genitourinary and other gynaecological conditions. Up 
until now, no diagnostic technique has been introduced in order to detect disease at initial stage. 
In most cases, the disease is diagnosed at advanced stage with metastasis beyond the ovary, at 
which point response to treatment is not favourable (Bast et al., 2009; Bauerschlag et al., 2010; 
Coleman, 2016; Lokadasan, et al., 2016). In order to detect ovarian cancer at early stages, use 
of multimodal screening including transvaginal sonography and serum CA125 measurement 
are likely to be effective. A combination of the two modalities has a higher specificity than 
either technique alone even though it is not considered as a gold standard for early detection 
(Bast et al., 2009; Colombo et al., 2010). CA125 is a glycoprotein which has been used as a 
biomarker for specific types of cancer, such as ovarian cancer due to its increased level in the 
blood of patients. The utility of serum CA125 to detect early disease is questionable due to its 
elevation only in about 50% of patients with FIGO stage I disease. It is also raised in about 
85% of ovarian cancer patients with FIGO advanced stages. CEA (Serum carcinoembryonic 
antigen) and CA19-9 levels (Cancer antigen 19-9), CA125/CEA ratio and a number of 
morphological variables are sometimes used in specific situations. There are more tests which 
may be performed following the first diagnosis to determine how far the cancer has extended. 
Computerised tomography (CT) scans are used to evaluate the extent of disease and aid surgical 
planning, and chest CT or chest X-ray can be used to determine pleural effusion. Laparoscopy, 
laparotomy and removing abdominal fluid are other tests which may be performed. Magnetic 
Resonance Imaging (MRI) scan is not routinely used (Ledermann et al., 2013; CRUK, 2016).   
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 Risk factors 
The identified risk factors can be divided into two categories, familial and non-familial. The 
former includes a history of ovarian or breast cancer in two or more first-degree relatives, which 
raises the risk of ovarian cancer. Acquiring mutated BRCA1 or/and BRCA2 leads to an 
increased risk of ovarian cancer, though germline mutations (BRCA1, BRCA2, and HNPCC) 
influence ovarian cancers in no more than 10%-15% of cases (Bast et al., 2009; Ledermann et 
al., 2013). More than 90% of ovarian cancers arise  in the absence of germline mutations. The 
latter includes infertility, polycystic ovarian syndrome, raised body mass index (BMI) in 
premenopausal women, use of hormonal replacement treatment and talcum powder, having 
endometriosis, smoking and rising age (Ledermann et al., 2013; CRUK, 2016). Older studies 
showed a link between using fertility drugs and an increased risk of ovarian cancer while more 
recent research found no strong evidence to support this (CRUK, 2016). Although some studies 
considered early menarche and late menopause as risk factors (Ledermann et al., 2013), others 
found no significant association between those and risk of ovarian cancer (Modugno et al., 
2012). 
In contrast, breastfeeding, pregnancy, multiparity, tubal ligation and oral contraceptives 
decrease the risk of ovarian cancer (Modugno et al., 2012; Ledermann et al., 2013). There is 
mounting evidence that steroid hormones have significant impact on the risk of ovarian cancer 
(Modugno et al., 2012). Pregnancy and oral contraceptives protect against ovarian cancer by 
two mechanisms; induction of progestin-mediated apoptosis and association with anovulation. 
Progestins induce apoptosis, while androgens raise the level of risk by stimulatory effects on 
ovarian epithelium (Ho, 2003).  
 Histological subtypes 
Ovarian cancer is a heterogeneous disease including different types of tumours. From the 
histological point of view, most tumours of the ovary are derived from one of three major cell 
types: surface epithelial cells, sex cord stromal cells (including granulose, theca, and hilus 
cells), and germ cells (oocytes). Since Epithelial Ovarian Carcinoma (EOC) is the major form 
of the disease, accounting for about 90% of ovarian tumours, it is a major focus of studies 
(Colombo et al., 2010; Jelovac and Armstrong, 2011; Zhan et al., 2013; CRUK, 2016). Based 
on the molecular genetic distinctive markers as well as morphologic and clinical differences, 
EOC can be categorised into two groups, type I and type II. Also, tumours in each cell type are 
subcategorized into benign, borderline and malignant groups. In clinical and molecular terms, 
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tumours presenting at low stage, are inactive, confined to the ovary and somewhat genetically 
stable are designated type I, including low grade serous carcinoma (LGSC), low-grade 
endometrioid, clear cell, mucinous and transitional carcinomas. Conversely, type II tumours 
are more aggressive and almost always present in advanced stage. Type II tumours include 
high-grade serous carcinoma (HGSC), high-grade endometrioid and undifferentiated carcinomas. 
Also, patients with type I disease present with different mutations to those suffering from type II 
tumours (Figure 1-2). For instance, TP53 mutations, CCNE1 (encoding cyclin E1) 
amplification, and mutation or promoter methylation of BRCA1/2 are frequently been seen in 
type II tumours. On the other hand, type I tumours present with KRAS, BRAF, ERBB2, PTEN, 
CTNNB1, and PIK3CA gene abnormalities, which target specific cell signalling pathways (Kim 
et al., 2012; Zhan et al., 2013; Cobb et al., 2015; Skirnisdottir et al., 2015). Although clear cell 
and mucinous cancers are included in type I, they have a worse prognosis than type II when 
they are not detected early (Cobb et al., 2015). The frequency distribution of HGSC is 60-80% 
of ovarian epithelial carcinoma (Li et al., 2012). It is 10-20%, 3-10%% and 5-20% of epithelial 
ovarian cancers which are comprised of endometrioid, clear cell and mucinous tumours 
respectively (van Niekerk et al., 2011). LGSC is uncommon and accounts for 3% of epithelial 
ovarian cancer (Chris M.J. Conklin, 2013). 
 
 
Figure 1-2: Histological subtypes of ovarian cancer and associated mutations/molecular 
alterations. MMR, Mismatch repair; *, CHK2, BARD1, BRIP1, PALB2, RAD50, RAD51C, 
ATM, ATR, EMSY and Fanconi anemia genes (Banerjee and Kaye, 2013).   
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 Staging 
According to the staging system called the FIGO (International Federation of Gynaecological 
Oncologists) system , ovarian cancer is distinguished into four categories at the time of surgery 
(Table 1-1). Due to current hypotheses that consider epithelial ovarian, peritoneal and tubal 
cancers represent a spectrum of disease originating in the Müllerian compartment, the FIGO 
staging classification was revised (Table 1-2) (Zeppernick and Meinhold-Heerlein, 2014; Cobb 
et al., 2015). 
 
Table 1-1: FIGO (1986) staging system for ovarian cancer.  
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Table 1-2: FIGO (2013) staging system for ovarian cancer. 1, It is impossible to have stage 
I peritoneal cancer; 2, Dense adhesions with histologically proven tumour cells justify 
upgrading apparent stage I tumours to stage II; 3, Extra-abdominal metastases include 
transmural bowel infiltration and umbilical deposits.
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 Theories of ovarian carcinogenesis and molecular pathogenesis 
It has been previously thought that epithelial ovarian tumour originates from ovarian surface 
epithelium, a single layer of epithelium covering the ovarian germ and stromal cells 
(Zeppernick et al., 2015). Mounting evidence recently indicates that type I as well as type II 
epithelial ovarian tumours arise from outside the ovary, encompassing it secondarily. 
Furthermore, their development individually occurs as a result of alterations in various 
molecular pathways (Kurman and Shih, 2011; Tagawa et al., 2012).  
Ongoing investigations strongly indicate that the precursor of HGSC is fallopian tube 
epithelium rather than ovarian surface epithelium as formerly thought (Walton et al., 2016). 
This hypothesis was suggested by a group of Dutch investigators in 2001. Piek et al. described 
existence of “serous tubal intraepithelial carcinomas (STICs)” and early invasive HGSC in the 
fallopian tube occurs in both familial and 50% to 60% of sporadic ovarian carcinoma (Kurman 
and Shih, 2011; Zeppernick et al., 2015). STICs are also present in the majority of peritoneal 
(67%) and all tubal carcinomas (100%) (Cobb et al., 2015). They are recognised by 
morphological characteristics such as disorganized, pleomorphic, hyperchromatic, and 
enlarged epithelial cells with highly atypical nuclei (Kurman and Shih, 2011; Zeppernick et 
al., 2015). The lesions were almost always distinguished in the fimbria, suggesting that early 
malignant alterations initiate in secretory-type cells. There is some convincing evidence that 
supports this proposal. For example, the similarity of genes expressed in HGSC compared to 
fallopian tube is much more than to ovarian surface epithelium. Also, immunohistochemistry 
(IHC) staining shows expression of a Müllerian marker, PAX8, in HGSC which is different 
from Calretinin, a mesothelial marker (ovarian surface epithelium has a mesothelial not a 
Müllerian morphologic phenotype) (Figure 1-3). Moreover, coexpression of p53, p16, FAS, 
Ki-67 and cyclin E1 appear not only in STICs but also in HGSC. Lastly, some research has 
recently confirmed the existence of short telomeres in STIC lesions which is comparable with 
other precancerous lesions (Kurman and Shih, 2011; Zeppernick et al., 2015). As previously 
mentioned, STICs are detectable in 50% to 60% of cases and there are other probabilities for 
remaining cases with no evidence of tubal involvement. Missing small STICs, disappearing 
STICs by overgrowth of invasive carcinoma and development from ovarian cortical inclusion 
cysts are other possibilities. The formation of these cysts occurs during ovulation while the 
fimbriae have close connections with the ovary and tubal epithelial cells become embedded 
within the disrupted ovarian surface (Figure 1-4). It seems that ovulation has a likely effect on 
 8 
 
early ovarian carcinogenesis by the release of follicular fluid, producing free radicals and 
inflammation, which is consistent with the protective effects of pregnancy and the use of oral 
contraceptive pills (Kurman and Shih, 2011). 
Endometriosis is the originator of endometrioid and clear cell carcinomas, but the origin of 
mucinous and transitional tumours is obscure. It seems that these arise from transitional 
epithelial nests placed in paraovarian locations at the tuboperitoneal junction. Confirmation of 
this concept would suggest that only gonadal stromal and germ cell tumours derive from 
ovaries (Kurman and Shih, 2010; Kurman and Shih, 2011; Cobb et al., 2015). LGSC develops 
from spread of presumed fallopian tube epithelial stem cells into the ovulation site where those 
stem cells form surface inclusion cysts. Those cysts are likely to grow into serous cystadenomas 
and develop into serous borderline tumours representing the precursor lesions of LGSC 
(Figure 1-5) (Cobb et al., 2015). 
 
Figure 1-3: The comparison of IHC staining pattern for ovarian epithelium 
(mesothelium), normal fallopian tube epithelium, and HGSC. PAX8 is a marker of 
Müllerian-type epithelium, such as fallopian tube epithelium, and Calretinin is a marker 
of mesothelium (Kurman and Shih, 2010). 
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Figure 1-4: Development of a cortical inclusion cyst from tubal epithelium (Kurman and 
Shih, 2011). 
 
Figure 1-5: (A) Proposed development of LGSC and HGSC from tubal epithelium by way 
of a cortical inclusion cyst and cystadenoma or an intraepithelial carcinoma (STIC) 
implanting directly on the ovary developing into a HGSC. APST, atypical proliferative 
serous tumor. (B) A schematic representation of direct dissemination or shedding of STIC 
cells onto the ovarian surface (Kurman and Shih, 2011).
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 Survival 
The rate of patient survival depends on many variables such as detection time, stage of disease, 
histological subtype, TP53 status, effective surgery and response to treatment. Earlier diagnosis 
correlates with more survival; however, only about 20% of all recorded patients are diagnosed 
in the early stages. The overall 5-year survival is nearly 30% or less because of detection in 
advanced stages, which involve distant metastasis (Yasmeen et al., 2011). The stage of disease 
has a huge impact on the survival as five-year relative survival ranges from 90% at stage I to 
4% at stage IV (CRUK, 2016). Mutant and hence non-functional TP53 is associated with 
resistance to present treatments and shorter survival. Complete cytoreduction where possible 
and treatment with optimized combinations of cytotoxic therapeutic drugs, greatly improve 
survival (Bast et al., 2009; Kurman and Shih, 2010; Kim et al., 2012). 
1.2 Treatment of ovarian cancer 
The treatment procedure is influenced by several issues, such as general health, fertility, type 
of ovarian cancer, disease stage and grade, and primary status or relapsed disease (CRUK, 
2016). Nevertheless, standard therapy is cytoreductive surgery to remove the bulk of tumour, 
and a combination of platinum-and taxane-based chemotherapy (Banerjee and Kaye, 2013; 
CRUK, 2016). 
 Primary treatment 
Combination of cytoreductive surgery and platinum-based chemotherapy is standard treatment 
for newly diagnosed disease. Debulking surgery decreases the size of tumour, which in theory 
results in having more access to the supply of oxygen and nutrient for the remained tumour 
cells and permits them to enter a proliferating phase and become much more sensitive to 
chemotherapy. Another advantage of surgical cytoreduction is eliminating or reducing existing 
resistant tumour cells, which may postpone the relapse. Due mainly to the fact that surgery 
alone is not completely curative, it must be followed by chemotherapy (Hennessy et al., 2009; 
Colombo et al., 2010; CRUK, 2016).  
The aim of chemotherapy is to reduce the risk of relapse and/or to shrink the cancer. The 
chemotherapy may be performed before surgery if the tumour is large, in order to shrink the 
cancer and make it easier to remove. The surgery is likely to be curative for women who present   
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with borderline ovarian tumour or a very early cancer which is low stage (stage 1a) and grade 
(CRUK, 2016). In general, the treatment includes six cycles of platinum-based chemotherapy 
following primary debulking surgery or three cycles of neoadjuvant chemotherapy followed 
by interval debulking surgery and a further three cycles of chemotherapy. 
 Treatment of recurrent disease 
Although up to 80% of patients with primary disease respond to first-line chemotherapy, 
relapse and resistance to treatment is prevalent, leading to lack of long-term benefit from 
treatment (Kim et al., 2012). Platinum-based chemotherapy, platinum combinations, targeted 
therapies including angiogenesis inhibitors and poly-ADP ribose polymerase (PARP) 
inhibitors or addition of those to chemotherapy would be choices of treatment in relapsed 
platinum-sensitive ovarian cancer patients (defined as disease recurring ≥ 6 months) (Luvero 
et al., 2014). The ICON4/OVAR 2.2 randomised trials showed significantly longer overall 
survival and progression free survival in combination of platinum and paclitaxel to platinum 
alone for platinum-sensitive patients with relapsed ovarian cancer (Parmar et al., 2003). 
Platinum-resistant patients consist of different categories with various biological behaviour. 
Further treatment of a dose-dense schedule of platinum alone or in combination with etoposide 
or paclitaxel, paclitaxel, topotecan, gemcitabine or targeted therapy are the choices of treatment 
for platinum-resistant patients. Interval debulking surgery would be other choice of treatment 
in recurrent ovarian cancer (Luvero et al., 2014). 
 The molecular mechanism of platinum-based treatment 
Cisplatin (cis-diamminedichloroplatinum) was the first FDA-approved platinum compound for 
cancer treatment in 1978. Among several thousand analogues synthesised to enhance the 
therapeutic index, about 13 of those have been entered in clinical trials, with only carboplatin 
(1,1-cyclobutanecarboxylato) showing a definite advantage over cisplatin with reduced side 
effects (Figure 1-6) (Dasari and Tchounwou, 2014). Platinum drugs are used for treatment of 
different types of cancer including tumours of bone, blood vessels, and soft tissue and solid 
tumours such as ovarian cancer. They are genotoxic therapeutic agents interacting with DNA, 
RNA and protein. The uptake of platinum drugs occurs via passive diffusion and active 
transport through the copper transporters CTR1 and CTR2 (Johnstone et al., 2014; Nasma et 
al., 2014). The efflux ATPases, MRPs and ATP7A/B, solute carrier importers, AQP2/9, and 
MDR1, the ATP-binding cassette transporter known as P-glycoprotein, are reported as 
transporters of platinum drugs as well (Dasari and Tchounwou, 2014). They are intracellularly 
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activated by a series of equation reactions including replacement of one or both cis-chloro 
groups with water molecules in the cytoplasm due to relatively low concentration of chloride 
ions. The hydrolysed products are potent electrophiles with the ability to react with any 
nucleophile compounds such as sulfhydryl groups on proteins or nitrogen donor atoms on 
nucleic acids (Galluzzi et al., 2012; Dasari and Tchounwou, 2014). These drugs exert their 
cytotoxicity after their activation via interacting with N7-sites of purine residues in DNA, 
causing crosslinking of DNA as 1, 2-intrastrand (90%), 1, 3-intrastrand (5-10%), or interstrand 
(1-2%) crosslinks (Wang et al., 2011). These adducts result in cessation of DNA replication 
and transcription, and are recognized by particular proteins involved in Nucleotide Excision 
Repair (NER) and Mismatch Repair (MMR) (Tanida et al., 2012; Johnstone et al., 2014). These 
DNA damage recognition proteins transmit DNA damage signals to downstream signalling 
pathways including p53, MAPK and p73 leading to induction of apoptosis (Figure 1-7). 
Platinum drugs also induce S- and G2/M phase arrest while their effect on the G0/G1 phase 
arrest is a later event and accumulation of cells in G0/G1 phase is rarely observed following 
platinum drug treatment (Tanida et al., 2012). More than 90% of cisplatin-damaged DNA is 
repaired by the NER pathway associated with cisplatin resistance (Wang et al., 2011), whereas 
apoptosis is triggered by the MMR pathway (Ataian and Krebs, 2006; Tanida et al., 2012). The 
interstrand crosslinks induced by cisplatin are repaired via homologous recombination repair 
(HRR) (Wang et al., 2011). In addition to DNA damage, oxidative stress is also induced after 
platinum-based treatment triggering cell death through apoptosis, necrosis and autophagy 
(Dasari and Tchounwou, 2014). 
 
Figure 1-6: The chemical structure of (A) Cisplatin and (B) Carboplatin.
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Figure 1-7: Overview of the molecular mechanisms of the platinum-based drug, cisplatin, 
in cancer treatment (Dasari and Tchounwou, 2014).   
 
 The p53 and DNA damage response to platinum-based treatment 
Platinum-based drugs exert their cytotoxic effects by both p53-dependent and p53-independent 
pathways. Following exposure to platinum-based drugs, ATM and ATR phosphorylate several 
proteins including Chk1, Chk2 and p53. The phosphorylated Chk1 and Chk2 further phosphorylate 
p53 resulting in stabilisation and activation of p53. Activated p53 in turn trans-activates genes 
involved in cell cycle arrest, apoptosis and DNA repair (Tanida et al., 2012; Wang, 2015).   
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 The mechanisms of resistance to platinum-based chemotherapy 
Different mechanisms are involved in resistance to cisplatin, referred to as pre-target or 
intrinsic resistance, on-target resistance, post-target resistance and off-target resistance 
(Galluzzi et al., 2012). Increased drug efflux via multidrug resistance-associated proteins and 
copper transporting P-type ATPase protein, decreased drug uptake through inactivation or 
down regulation of uptake transporters and drug inactivation by thiol-containing molecules 
such as glutathione are examples of pre-target resistance. Enhanced DNA repair inhibits 
apoptosis progression because persistence of DNA adducts resulting from platinum treatment 
induces apoptosis. Therefore, NER and HRR proficiency result in on-target resistance to 
cisplatin (Galluzzi et al., 2012; Tanida et al., 2012; Nasma et al., 2014). Inhibition of the 
dissemination of DNA damage signals to apoptotic pathways or deficiency in genes in 
downstream pathways involved in response to platinum drugs such as TP53, BIRC5 (Survivin), 
BAX and BCL-2 can also confer resistance to platinum drugs (post-target resistance) (Galluzzi 
et al., 2012; Tanida et al., 2012). Cisplatin resistance can be induced by alterations in signalling 
pathways not directly targeted by cisplatin such as autophagy (Bao et al., 2015) and heat shock 
proteins (off-target resistance) (Galluzzi et al., 2012). It was also reported that BIN1, a tumour 
suppressor nucleocytoplasmic adaptor protein, directly interacts with the c-Myc oncoprotein 
and inhibits its transcriptional activity and cell transformation. It also sensitizes cells to 
cisplatin through directly interacting with PARP1 and inhibiting its activity. Deficiency in the 
BIN1 gene, suppression of BIN1 expression and restoration of PARP1 activity following 
overexpression of c-Myc are novel mechanisms reported to mediate cisplatin resistance 
(Tanida et al., 2012). 
1.3 Targeted therapy in ovarian cancer 
The treatment of ovarian cancer remains a challenge in spite of advances in debulking surgery 
and changes in both chemotherapy schedules and routes of administration (Coward et al., 
2015). Platinum agents used to treat ovarian cancer have major adverse side effects including 
nephrotoxicity, ototoxicity, myelosuppression and gastrointestinal disorders (Pabla and Dong, 
2012). Although chemotherapy prolongs survival, most patients with advanced disease 
experience relapse and eventually develop platinum resistance and die from treatment resistant 
progressive disease (Ledermann et al., 2013; Luvero et al., 2014). Cancer therapy has recently 
been improving with the introduction of targeted therapies to achieve greater specificity and 
less cytotoxicity (Yuan et al., 2011).   
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The potential success of targeted therapy was first recognised in 1998 by FDA approval of a 
monoclonal antibody trastuzumab to treat breast cancer patients harbouring HER-2 positive 
metastasis. In contrast to chemotherapy affecting both cancer and normal rapidly dividing cells, 
targeted therapy has the potential for lower toxicity and greater selectivity by targeting 
molecular abnormalities specific to the cancer (Huang et al., 2014). 
Epithelial ovarian cancer is a heterogeneous disease with different histological subtypes 
representing distinct molecular aberrations, but are nonetheless all treated with the same 
conventional chemotherapy. The identification of deficiencies in distinct molecular pathways 
of individual subtypes and exploitation of them in targeted therapy offers the promise of 
improved clinical outcome in ovarian cancer (Banerjee and Kaye, 2013). Over the last few 
years, molecular targeted therapy of ovarian cancer as single agents or in combination with 
chemotherapy has been showing promising and encouraging results (Banerjee and Kaye, 2013; 
Luvero et al., 2014). However, targeted therapy is challenged by identification of the correct 
population to treat, occurrence of drug resistance (Banerjee and Kaye, 2013; Huang et al., 
2014), marginal response rate across an unselected patient population (10-20%), short-lived 
clinical responders (6-12 months) and disease progression (Huang et al., 2014). To overcome 
targeted therapy resistance, it is suggested that targeted therapies are likely to be most effective 
in combination with standard chemotherapeutic agents or other targeted therapeutic drugs. 
1.4 Combined treatment 
Intrinsic or acquired resistance is the major limitation of targeted cancer therapy. Design of 
strategies to overcome intrinsic resistance and delay acquired resistance to targeted therapy is 
crucial to benefit from the treatment. One strategy is use of more effective drug combinations 
to completely block the oncogenic signalling pathway or activate the tumour suppressor 
signalling pathways (Groenendijk and Bernards, 2014). Dose and toxicity reduction, resistance 
minimisation or delay, and achieving synergistic therapeutic effects are the main objectives of 
drug combination.This is because multiple drugs may affect various targets and/or 
subpopulations. Also, one single target may be targeted with different drugs with varied 
mechanisms of action (Chou, 2006; Chou, 2010; Foucquier and Guedj, 2015). Potentiation or 
enhancement are defined when in the combination of two drugs one has no effect and the effect 
of combination is greater than that of the effective drug. The effect of combination is defined 
as synergism, additive or antagonism if both drugs have an effect on their own, and can be 
defined by Combination Index (CI) values. The synergism and antagonism are defined as 
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greater or less effects than an additive effect. For cancer therapy, synergism at high effect levels 
(ED90, ED95) is more desirable than at low levels of effect (ED50) (Chou, 2006).  
1.5 The tumour suppressor TP53 gene  
The tumour suppressor TP53 gene, discovered by David Lane in 1979, localized on 
chromosome 17p13.1 is referred to as the most often mutated or deleted gene in human cancers. 
It has been substantially established that p53, acting as a genome guardian, protects cells 
against environmental and intra-cellular stressful stimuli by playing important roles in 
regulating cell cycle control, differentiation, apoptosis, DNA repair and proliferation (Levine 
and Oren, 2009; Wade et al., 2013). 
 The structure of p53  
The p53 protein, a 53kDa nuclear phosphoprotein, contains five conserved domains 
(Figure 1-8) which are responsible for performing specific functions including: 
1. A transcriptional activation domain (TAD) is located within the N-terminus portion 
(residues 1-42) required for transcriptional activity. It is also necessary for interaction 
with some proteins including transcription factors, and several TATA box binding 
protein associated factors (TAFs), and mediates interaction with the E3 ubiquitin ligase 
MDM2 and histone acetyltransferases CBP/P300 (Kamada et al., 2015).   
2. A proline- rich region (PRD) is located in the N-terminus region (residues 61-94) 
playing a role in p53 stability, transcriptional activity, and induction of transcription 
independent apoptosis (Kamada et al., 2015). 
3. The central DNA-binding domain (DBD) (residues 101-300) is targeted by 90% of p53 
mutations in different cancers. It has sequence specific DNA binding activity within 
the nucleus and directly binds to a consensus DNA binding site (Kamada et al., 2015).  
4. The C-terminal tetramerization domain (TD) (residues 326-356) plays a role in 
reversible formation of p53 tetramers, regulates p53 oligomeric status and includes a 
Nuclear Export Signal (NES) as well (Kamada et al., 2015).  
5. An autoinhibitory domain (residues 364-393) is localized on the C-terminus of p53 
which has been implicated in downregulation of the DNA binding domain (Kamada et 
al., 2015).   
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Figure 1-8: The p53 structure, its functional domains and location of tumour-associated 
mutation hotspots (Vousden and Lu, 2002). 
 
 Tetramer formation, post-translational modifications and functional regulation of 
p53 
Formation of p53 tetramers is required for its site-specific DNA binding, post-translational 
modifications and protein-protein interactions. It also blocks the NES leading to inhibition of 
p53 nuclear export. The p53 response element consists of four pentanucleotide repeats and each 
repeat is recognised by one p53 DBD (Kamada et al., 2015). In normal cells with wild-type 
p53, p53 is activated following a variety of stresses such as DNA damage, oncogene 
expression, starvation and oxidative stress. Stabilization and increased transcriptional activity 
of p53 result from diverse post-translational modifications, particularly phosphorylation, 
acetylation, and deubiquitination which are introduced into its N-terminus and C-terminal 
regulatory domains (Dai and Gu, 2010). The first crucial step of p53 stabilisation is 
phosphorylation of serine residues within the N-terminal p53 transactivation domain (Kruse 
and Gu, 2009; Cristiana, 2014). The tetrameric form of p53 is ubiquitinated and regulated by 
Pirh2 indicating regulation of the protein turnover of the p53 active form by Pirh2. The 
oligomeric status of p53 affects the MDM2-mediated poly-ubiquitylation of p53, whereas its 
proteasome degradation is only slightly affected by its tetramerization (Kamada et al., 2015).  
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 p53 function 
The tumour suppressor protein p53, known as the guardian of genome, is located at the 
crossroad of a complex network of signalling pathways playing an essential role in cell growth 
regulation, senescence and apoptosis induced by genotoxic and non-genotoxic stresses 
(Figure 1-9) (Mandinova and Lee, 2011; Soussi, 2012; Kamada et al., 2015; Su et al., 2015). 
Other cellular processes of p53 are modulation of autophagy (Rosenfeldt et al., 2013; Cristiana, 
2014; Kamada et al., 2015; Su et al., 2015), inhibition of cell migration and metastasis 
(Kamada et al., 2015; Su et al., 2015), regulation of metabolism (Maddocks et al., 2013; 
Cristiana, 2014; Kamada et al., 2015) and angiogenesis (Cristiana, 2014), moderation of innate 
immune responses through its antagonism of nuclear factor κB signalling (Kamada et al., 2015) 
and sensitisation of cells to ferroptosis (a non-apoptotic form of cell death) (Jiang et al., 2015; 
Kamada et al., 2015). It also targets and regulates the expression of specific microRNAs 
(miRNAs) such as miR-34a inducing cell cycle arrest, senescence and cell death, and miR-192 
and miR-215 promoting p21WAF1 expression (Cristiana, 2014). 
In normal cells under normal conditions, the cellular levels of p53 are low due to a very short-
life ranging from 5 to 30 minutes (Teoh and Chng, 2014). Following exposure to genotoxic or 
non-genotoxic stresses, upstream mediators distinguish and respond to the signals via 
stabilization of p53, as a result of posttranslational modifications of p53 and its regulators such 
as MDM2 and MDMX proteins. The downstream pathways involve p53 transcriptional 
transactivation events and interactions between proteins. The p53 protein regulates expression 
of its downstream transcriptional targets through both DNA binding and transactivation 
domains by binding to responsive DNA sequences and repressing or transactivating these target 
genes. The final outcome of p53 activation is either cell cycle arrest and DNA repair or 
apoptosis (Mandinova and Lee, 2011; Soussi, 2012).  
The cellular reaction to different stresses is completely different based on the tissue and cell 
type, nature and strength of stress, genomic damage and the environment of the cell (Murray-
Zmijewski et al., 2008; Hanahan and Weinberg, 2011; Cristiana, 2014). Other variables 
affecting the p53 response to stress include p53 level, existence of p53 regulator and affinity 
of sites binding to p53. The promoters of genes halting proliferation and genes inducing 
apoptosis comprise high and low affinity sites respectively. The high affinity sites will be 
activated first and then at higher p53 concentrations the low affinity sites would become 
occupied. This would suggest the apoptosis sites should be of a lower affinity. Cell cycle arrest   
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and/or apoptosis are biological end-points of stress (Meek, 2004; Kitayner et al., 2006; Hoe et 
al., 2014). Induction of p53 expression at different levels using a doxycycline-regulated 
inducible p53 expression system in the hepatocellular carcinoma (HCC) cells showed that 
apoptosis and cell cycle arrest were induced at high and low levels of p53 expression 
respectively (Lai et al., 2007). Furthermore, cell fate outcome after p53 activation is influenced 
by the expression levels of anti-apoptotic proteins in target cells, post-translational 
modification of p53 and its regulatory proteins, overexpression of iASPP (inhibitor of 
apoptosis-stimulating of p53 protein) (Hoe et al., 2014), and the influence of other signalling 
pathways which are activated or inhibited (Valente et al., 2013). 
 
Figure 1-9: The p53 signalling pathway (www.tocris.com).
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 p53-mediated cell cycle arrest 
p53-dependent cell cycle arrest in the G0/G1, G2/M, and S-phases occurs through 
transcriptional activation of the CDKN1A encoded cyclin-dependent kinase inhibitor p21WAF1, 
GADD45 (Growth arrest and DNA-damage-inducible 45) and 14-3-3σ genes. The p53-induced 
cell cycle arrest at G0/G1 and G2/M phases is considered to allow time for the cells to repair 
genomic damage before entering the DNA synthesis and mitosis stages respectively (Zhu and 
Bai, 2006). 
The p21WAF1 protein, the best characterised mediator of p53-dependent cell cycle arrest, 
regulates both G1-S and G2-M checkpoints and prevents G1 to S and G2 to M progression 
leading to G0/G1 and G2/M cell cycle arrest. It directly binds to Cyclin/Cdk (Cyclin-dependent 
kinase) complexes such as Cyclin E/Cdk2 and Cyclin B/Cdk1 and induces G0/G1 and G2/M 
cell cycle arrest respectively. Induction of G0/G1 arrest via blockade of Cyclin E/Cdk2 is 
mediated by inhibition of Rb phosphorylation, a process required to release E2F transcription 
factor from Rb and promote expression of genes essential for progression from G1 to the S-
phase (Zhu and Bai, 2006;  Wang, 2007; Valente and Strasser, 2013). Furthermore, p21WAF1 
binds to proliferating-cell nuclear antigen (PCNA) which is required for DNA synthesis and 
DNA repair resulting in G2/M arrest ( Wang, 2007;  Piccolo and Crispy, 2012).  
The GADD45 and 14-3-3σ genes are transcriptionally induced and upregulated by p53, and 
both proteins inhibit the G2/M transition and participate in G2/M arrest. GADD45 exerts its 
effect through binding to Cdc2 (cdk1) and subsequent inhibition of the cyclinB/Cdc2 
interaction and kinase activity. The scaffold protein 14-3-3σ induces G2 arrest via sequestration 
of the cdk1 in the cytoplasm, blockade of cyclin B/cdk1 complex formation, and inhibition of 
Cdk1 activity (Zhu, 2006; Shulin Wang, 2007; Liz J Valente, 2013).  
 p53-mediated cellular senescence 
Senescence, irreversible cell cycle arrest, is another mechanism by which p53 activation can 
result in removal of tumour cells, mediated by the promyelocytic leukemia (PML), 
plasminogen activator inhibitor-1 (PAI-1), deleted in esophageal cancer 1 (DEC1) and p21WAF1 
proteins (Qian and Chen, 2010; Valente and Strasser, 2013) and association of ‘eat me’ 
(opsonisation) signal leading to senescence-induced phagocytosis and killing of the senescent 
cells (Hoe et al., 2014). PML, a direct p53 target, and p53 form a positive regulatory feedback 
loop during cellular senescence. PAI-1, is transcriptionally regulated by p53 and considered as   
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a marker of replicative senescence. It exerts its inhibitory effect on cell proliferation and 
induction of senescence through its physical association with uPA which is a promoter of G1/S 
transition. DEC1 is a target gene of p53 implicated in cell cycle regulation, differentiation, 
apoptosis and p53-dependent cellular senescence. The cell cycle inhibitor p21WAF1 plays an 
important role in p53-dependent cellular senescence; however, it is not essential and lack of 
p21WAF1 reduces DNA damaged-induced premature senescence in tumour cells but does not 
abolish it (Qian and Chen, 2010). Due to the impact of mTOR (mammalian target of rapamycin) 
on the senescence program and inhibition of mTOR following p53 activation, it was reported that 
p53 acts as a suppressor of senescence and converts it into quiescence (reversible cell cycle arrest) 
(Demidenko et al., 2010). However, more research indicated that the status of the mTOR 
pathway can partly determine the selection between senescence and quiescence in p53-
activated cells (Lioubov G. Korotchkina, 2010; Liz J Valente, 2013). 
 p53-mediated apoptosis 
There are two major pathways by which p53-regulated apoptosis is induced, named the 
intrinsic mitochondrial and extrinsic death receptor pathways. The intrinsic mitochondrial 
pathway is primarily used in p53-mediated apoptosis, while the extrinsic pathway is utilised to 
enhance the apoptosis response. The end point of both pathways is caspase activation and 
apoptosis (Zhu, 2006).  
Following exposure to apoptotic stimuli and p53 activation, the intrinsic mitochondrial 
pathway is activated and dominated by BCL-2 family proteins, including anti-apoptotic 
proteins BCL-2 and MCL-1, multi-BH domain pro-apoptotic proteins BAX and BAK, and pro-
apoptotic “BH3-only” proteins BID, BAD, NOXA and BBC3 (known as PUMA). PUMA has 
the ability to bind to anti-apoptotic proteins BCL-2, BCL-W, MCL-1, BCL-2A1 and BCL-XL, 
whereas NOXA can only bind to MCL-1 and BCL-2A1 proteins (Zhu, 2006; Liz J Valente, 
2013; Hoe et al., 2014). Apoptotic stimuli are followed by transcriptional, post-transcriptional 
and/or post-translational activation of the pro-apoptotic BH3-only proteins. These activated 
proteins bind to anti-apoptotic BCL-2 proteins resulting in activation and formation of BAX 
and BAK homo-oligomers and their localisation on the mitochondria which induce production 
of mitochondrial outer membrane permeabilisation (MOMP) and subsequent cytochrome c 
release. Then, formation of the apoptosome complex is promoted by apoptotic protein 
activating factor-1 (Apaf-1) and caspase 9 (Zhu, 2006; Valente, 2013).  
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In the death receptor-mediated extrinsic pathway, another p53-regulated class of pro-apoptotic 
genes is upregulated including the death receptor gene products such as FAS/CD95, DR4 and 
DR5 located at the plasma membrane, and some other gene products implicated in this 
apoptotic pathway. These p53-upregulated receptors suppress Inhibitors of Apoptosis Proteins 
(IAPs) and induce caspase-mediated apoptosis (Zhu, 2006; Joana D, 2010; Valente, 2013). 
Apoptosis may also be triggered by p53 through a non-transcriptional mechanism, an 
alternative cytosolic p53-mediated apoptosis. In this pathway, p53 can shuttle to the outer 
mitochondrial membrane where it directly interacts with the members of BCL-2 protein family 
such as BCL-XL/BCL-2 to displace BAX or BH3 domain-only pro-apoptotic proteins, and 
induce their oligomerisation. The final outcome is production of MOMP, release of cytochrome 
c and consequently activation of the caspase cascade and apoptosis (Zhu, 2006; Kruse and Gu, 
2009; Joana D, 2010; Liz J Valente, 2013; Hoe et al., 2014).  
 Regulation of the p53 cellular levels 
Tumour suppressor p53 has the potential to induce apoptosis and cell cycle arrest and that is 
why the cellular levels of this protein are maintained at a low level  in normal cells (Teoh and 
Chng, 2014). Different mechanisms are involved in regulation of the cellular levels of p53.  
The mouse double minute-2 homolog (MDM2) protein, also named HDM2 in human, is the 
main negative regulator of p53. The formation of an autoregulatory feedback loop between p53 
and MDM2 regulates their cellular levels. MDM2 not only binds to the N-terminus domain of 
p53 to inhibit its transcriptional activity but also interacts with the DNA binding domain to 
promote its proteasomal degradation. The p53 protein is ubiquitylated by the MDM2 RING 
Finger and E3-ubiquitin ligase enzymatic activity of MDM2 to transfer the MDM2-p53 
complex to the cytoplasm and target it for proteasome degradation in the cellular 26S 
proteasome (Figure 1-10) (Wade et al., 2010; Pant et al., 2011; Rew et al., 2012; Rew and Sun, 
2014; Teoh and Chng, 2014).  
In line with the role of MDM2 as the main negative regulator of p53, MDM2 regulator proteins 
can indirectly regulate p53 cellular levels. For example, deregulation of p14ARF (Alternative 
Reading Frame, a negative regulator of MDM2) (Teoh and Chng, 2014), and WIP1 (wild-type 
p53-induced phosphatase, a protein which dephosphorylates MDM2) affects the stability and 
levels of MDM2 and consequently the stability and activity of p53 (Kruse and Gu, 2009). 
RBEL1A, a novel Rab-like GTP-binding protein, is predominantly GTP bound and functions   
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as a GTPase and is overexpressed in primary breast and colon cancer samples. Its direct 
interaction with both MDM2 and p53 proteins augments MDM2-dependent p53 ubiquitylation 
and degradation. RBELIA also exerts its inhibitory effect on p53 through inhibition of the 
transactivation potential of p53 and suppression of p53 activation (Lui et al., 2013). 
 
Figure 1-10: Regulation of p53 by MDM2 (Chene, 2003). 
 
Another negative regulatory protein of p53 is MDMX which has a high sequence and structural 
similarity to MDM2. MDMX binds to p53 at the N-terminal transcriptional activation domain 
of p53 and inhibits its transactivation activity. MDMX has no intrinsic ubiquitination activity; 
however, interaction between MDMX and MDM2 via their C-terminal RING finger domains 
results in formation of an MDM2-MDMX heterodimer and subsequent activation of the E3 
ligase activity of MDM2 in a dose-dependent manner (Pei et al., 2012; Tollini and Zhang, 
2012; Teoh and Chng, 2014). 
Restoration of normal p53 levels after stress response is also induced by some ubiquitin E3-
ligases other than MDM2 which promote p53 degradation including Pirh2, COP1 (Kruse and 
Gu, 2009; Collavin et al., 2010) and Arf-BP1 (Kruse and Gu, 2009). WWP1, a member of 
NEDD4-like ubiquitin ligases, recognises proline-rich sequences on p53. WWP1 interacts with 
p53 producing a mono-ubiquitinated form of p53, retaining it in the cytoplasm and inhibiting 
its transcriptional activity (Collavin et al., 2010).  
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Epigenetic regulation of TP53 can also regulate cellular levels of p53. One such mechanism is 
deregulation of miRNAs. miRNAs are a set of small noncoding RNA sequences of 19 to 25 
nucleotides playing a critical role in regulating gene expression by binding to the 3'-
untranslated regions (3'-UTR) of specific mRNAs. They degrade or destabilise the gene target 
coding mRNA and repress efficient translation of the mRNA into proteins. miR-125b and miR-
504 are reported negative regulators of p53 in human cell lines (Teoh and Chng, 2014).  
1.6 The role of p53 and its transcriptional targets in ovarian cancer 
 p53 and ovarian cancer 
The frequency of TP53 mutation in ovarian cancer is different based on the clinicopathological 
data, including stage of disease, histological subtype and grade of differentiation (Kmet et al., 
2003; Bauerschlag et al., 2010; Rechsteiner et al., 2013) ranging from 34% (Leitao et al., 2004) 
for epithelial ovarian cancer regardless of histological subtype to (97%) for HGSC (Ahmed et 
al., 2010). Accumulation of p53 is a frequent event in ovarian cancer occurring in 4% of 
borderline to 50% of advanced ovarian cancers. Inactivated p53 accumulates in either the 
nucleus or cytoplasm depending on the type of mutation even though the most common p53 
abnormalities in ovarian cancer lead to nuclear accumulation of overexpressed p53 detectable 
by staining (M. Sharon Stack, 2009). In terms of correlation between TP53 status/p53 
overexpression and overall survival (OS) or progression free survival (PFS), the results are 
controversial and are explained in more detail later in chapter 3.5.2, 4.5.3 and 5.5.1. 
 p21WAF1 and ovarian cancer 
The p21WAF1 protein, a member of the cyclin dependent kinase inhibitor (CDKI) superfamily, 
is encoded by the CDKN1A gene located on chromosome 6p21.2. It plays a dual role as a 
tumour suppressor through cell cycle arrest or oncogene via anti-apoptotic function based on 
its subcellular localisation cellular context and circumstances (Abbas and Dutta, 2009; Xia et 
al., 2011; Maria Teresa Piccolo1, 2012). The p21WAF1 has the ability to switch from a nuclear 
tumour suppressor to a cytoplasmic oncogene through the PI3K/Akt signalling pathway (Xia 
et al., 2011; Lu, 2016). Post-translational modification of p21WAF1 mediated by various kinases 
on its threonine and serine residues strongly impacts on its cellular localisation and its specific 
function as a negative regulator of cell cycle arrest. In fact, phosphorylation of p21WAF1 on the 
specific residues Thr145 and Ser153, relocalizes p21WAF1 to the cytoplasm inhibiting the 
interaction of p21WAF1 with Cyclin/Cdk complexes or PCNA and induces its anti-apoptotic 
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function (Maria Teresa Piccolo1, 2012). The p21WAF1 protein mediates its anti-apoptotic role 
through cell cycle arrest, suppression of pro-apoptotic genes regulated by E2F and its 
interaction with different pro-apoptotic proteins such as procaspase 3, caspase 8 and caspase 
10 (Abbas and Dutta, 2009; Maria Teresa Piccolo1, 2012). 
Recent studies indicated that cytoplasmic p21WAF1 is significantly correlated with cisplatin 
resistance in ovarian cancer (Xia et al., 2011; Lu, 2016). p21WAF1 relocation from the nucleus 
to the cytoplasm is induced by Act-mediated phosphorylation. Transfection of cisplatin-
resistant ovarian cancer cell lines with Act2 shRNA led to inhibition of cytoplasmic p21WAF1 
translocation and enhanced their sensitivity to cisplatin (Xia et al., 2011).  
Controversial results were reported in relation to the correlation between p21WAF1 expression 
and overall or progression free survival in ovarian cancer, which is described in more detail 
later in chapter 3.5.3 and 5.5.4. 
 MDM2 and ovarian cancer 
The MDM2 protein is encoded by the MDM2 gene located on chromosome 12q14-15, which 
is amplified or overexpressed in many cancers (Forslund et al., 2008). Due to the role of 
overexpressed and/or amplified MDM2 as an alternative mechanism to inactivate p53, it is 
important to identify cancer types with overexpressed- or amplified-MDM2. The frequency of 
MDM2 amplification in ovarian cancer is 3.1% (Mancini, 2012) and reported MDM2 
overexpression varies from 17% to 47% (Foulkes et al., 1995; Bast et al., 2009; Mancini, 
2012). Also, it was reported that different MDM2 polymorphisms affect the risk of ovarian 
cancer in BRCA-1 related ovarian cancer. For example, MDM2 SNP309 and SNP285C were 
reported to be associated with an increased and decreased the risk of ovarian cancer in BRCA-
1 related ovarian cancer respectively (Bjørnslett et al., 2012). For the association between 
overexpression of MDM2 and overall or progression free survival, there is no consistency 
between reported results, and are explained in more detail later in chapter 3.5.6 and 3.5.7.  
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 The PPM1D (WIP1) phosphatase and ovarian cancer 
The protein phosphatase magnesium/manganese-dependent 1D (PPM1D), also known as wild-
type p53 inducible phosphatase (WIP1), is a member of the type 2C phosphatase family 
encoded by the PPM1D gene located on chromosome 17q23.2. It preferentially 
dephosphorylates phosphoproteins containing SQ/TQ or TXY motifs (Ali et al., 2012). WIP1 
elicits its action through dephosphorylation of p53, ATM, Chk2 and γ-H2AX involved in DNA 
damage response, and leads to inactivation of these proteins (Han et al., 2009; Yin et al., 2016). 
PPM1D amplification and/or overexpression is correlated with poor prognosis, especially in 
hormone-regulated cancers including ovarian cancer. The oncogenic effect of WIP1 is due to 
dephosphorylation of p53, p38, Chk1 and Chk2 and subsequent inhibition of cellular G1-S and 
G2-M checkpoint activities in response to DNA damage (Han et al., 2009). Amplification 
and/or overexpression of WIP1 was reported in ovarian clear cell adenocarcinoma (Hirasawa 
et al., 2003; Tan et al., 2009; Emelyanov and Bulavin, 2015) confering cisplatin resistance (Ali 
et al., 2012). Despite the oncogenic role of WIP1 reported in many carcinomas, one recent 
study demonstrated an antitumour action of WIP1 by involving suppression of  ovarian cancer 
metastasis in xenograft animal models mediated by regulation of the ATM/Akt/Snail signalling 
pathway (Yin et al., 2016). No study has previously been published to evaluate the correlation 
between amplified/overexpressed WIP1 and overall or progression free survival in ovarian 
cancer patients.  
1.7 p53 as a target for cancer therapy 
 p53 and cancer 
Inactivation of the p53 tumour suppressor protein is a frequent event in the development of 
most human cancers with TP53 mutation in more than 50% of many different cancers (Stegh, 
2012). Most of TP53 mutations occur within the DNA binding domain that result in disruption 
of p53 structure and/or abrogation of its DNA contact. The TP53 mutations are usually 
followed by loss of heterozygosity (LOH) during tumour progression leading to inactivation 
of the remaining wild-type TP53 allele (Bo Hong, 2014). Due to the crucial role of p53 in 
induction of cell cycle arrest, response to DNA repair and apoptosis, p53-deficient cells are 
prone to increased genomic instability, malignant transformation, metastasis, resistance to 
chemotherapy and radiotherapy, and poor survival (Lane et al., 2010; Wade et al., 2013; Bo 
Hong, 2014).  
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 p53 and cancer therapy 
The multi-functional transcription activity and anti-cancer effect of p53 in addition to frequent 
loss of  its function in most types of tumour, motivated an enormous effort to develop new 
cancer treatments based on p53-targeted therapy (Lane et al., 2010; Wang and Sun, 2010; 
Stegh, 2012; Hoe et al., 2014). Numerous strategies and biologic approaches have been 
developed to correct p53 dysfunction and restore its activation, including gene therapy, 
development of oncolytic viruses and siRNA/antisense RNA against negative regulators of 
p53, p53-based vaccines, small molecules activating p53 (Lane et al., 2010; Wang and Sun, 
2010; Stegh, 2012; Bo Hong, 2014) and chaperone-like drugs binding to mutant p53 to restore 
its function (Stegh, 2012; Hoe et al., 2014). 
 The pros and cons of p53-targeted cancer therapy 
In spite of potential advantages of p53-targeted therapy including less harm to normal cells, 
fewer side effects, improved effectiveness and life quality, it has its potential drawbacks as 
well (di Iasio and Zauli, 2013). Over 65000 papers have been published on p53; however, none 
of those provide specific predictive biomarkers by which to identify cancer patients who are 
most likely to respond to p53-targeted cancer therapy with the best therapeutic index (di Iasio 
and Zauli, 2013). The therapeutic index is based on the relative sensitivity of both tumour and 
normal tissues towards p53 activating drugs. Resistance development and causing toxic on- or 
off-target side effects are other current challenges for p53-targeted cancer therapy. Another key 
issue in relation to p53 activation is the type of response, cell cycle arrest or cell death, and the 
magnitude of effect in tumour cells compared to normal cells. In terms of the cell fate after 
treatment, it is strongly dependent on the intrinsic properties and microenvironment of tumours 
(Hoe et al., 2014). Furthermore, p53-targeted therapy may result in selection of p53-therapy 
resistant tumours and acquisition of somatic mutations in TP53 gene (Aziz et al., 2011; Bo 
Hong, 2014). Other biological processes influenced by activated p53 such as metabolism, 
angiogenesis, metastasis and age further complicate therapeutic targeting of the p53. However, 
development of predictive biomarkers in response to these therapeutic agents, combination 
therapy and optimisation of p53 restoration therapy (intermittent dosing regimens of drugs) are 
new opportunities to solve the challenges (Bo Hong, 2014).   
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1.8 Small molecule MDM2-p53 binding antagonists as p53-targeted therapeutic agents 
Targeting interactions between MDM2 and p53 with small molecule inhibitors is an attractive 
strategy to activate wild-type TP53 and its growth inhibitory and pro-apoptotic function.  
 MDM2-p53 binding antagonists as non-genotoxic activators of p53  
Mutation of p53 occurs in about 50% of both sporadic and familial cancer cases. It seems that 
in the remaining malignancies, p53 function is inhibited through other mechanisms and 
reactivation of p53 is considered as a therapeutic target. When the TP53 gene is not mutated, 
it may be possible to activate the growth inhibitory and pro-apoptotic functions of p53 by 
preventing the protein-protein binding interaction between p53 and its negative regulators 
MDM2 and MDMX. Recently, synthetic small molecule inhibitors have been developed which 
target a small hydrophobic pocket on MDM2 to which p53 normally binds (Rew and Sun, 
2014).  
One of the attractive features of these agents is their non-genotoxic mechanism of action 
compared with current chemotherapy (Aziz et al., 2011; di Iasio and Zauli, 2013). Another 
potential use of MDM2-p53 binding antagonists is as probes for testing the functional status of 
p53 and its downstream signalling pathways, not only as potential biomarkers for response to 
MDM2-p53 antagonists, but also as indicators of responsiveness to established therapeutic 
agents that act through a p53-dependent mechanism. These compounds have shown promise 
as therapeutic agents in a number of preclinical studies and have entered early phase clinical 
trials.  
 The MDM2-p53 binding site 
The MDM2-p53 interactions is primarily mediated by the N-terminus domains of both proteins 
(Michelsen et al., 2012; Anil et al., 2013). Recently, some studies indicate that it is likely parts 
of MDM2 outside the N-terminal domain (Arkin et al., 2014) or alterations in the C-terminus 
of p53 (Nag et al., 2013) also play a role in the binding interaction. 118 amino acids at the N-
terminal transactivation domain of MDM2 and a 15-residue transactivation domain of p53 
(residues 15-29) (Chene, 2003; Anil et al., 2013) (residues 17-29) (Fu et al., 2012) are involved 
in MDM2-p53 interaction. Based on genetic and biochemical studies as well as the crystal 
structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue 
transactivation domain of p53, MDM-2 has three hydrophobic clefts (Rew et al., 2012) binding 
to three critical amino acid residues of p53 namely Phe19, Trp23, and Leu26 (Figure 1-11A)   
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(Anil et al., 2013;  Tovar et al., 2013; Rew and Sun, 2014). Residues 19-25 of the p53 binding 
domain form an α-helix and residues 17, 18 and 26-29 take a more extended conformation. In 
addition, Thr18 plays an important role in the stability of the helix and regulation of the 
MDM2-p53 interaction via phosphorylation (Chene, 2003; Fu et al., 2012). Both hydrogen 
bonds and van der Waals interactions are involved in the formation of the MDM2-p53 complex 
with Trp23 of p53 forming a strong hydrophobic interaction (Shangary and Wang, 2009; Fu et 
al., 2012). 
 MDM2-p53 binding antagonists 
Using small molecule inhibitors to target protein-protein interactions is challenging owing to 
the large and flat surfaces involved in these interactions causing difficulties for their disruption 
(Ding et al., 2013; Nag et al., 2013; Arkin et al., 2014; Corbi-Verge and Kim, 2016). However, 
it is not a certain obstacle for the MDM2-p53 interaction due to the involvement of only three 
crucial amino acids for the binding of these proteins (Nag et al., 2013). In the case of the 
MDM2-p53 interface, 70% of the atoms are non-polar resulting in a hydrophobic interface, and 
therefore having lipophilic groups is essential for MDM2-p53 inhibitors. Although the 
presence of lipophilic groups usually improves the binding energy, highly lipophilic inhibitors 
are poorly soluble and have limited bioavailability (Chene, 2003).  
Different classes of small molecules inhibitors were designed mimicking the MDM2-p53 
interaction (Figure 1-11B) and developed through combinatorial library screening such as 
Nutlins, Spiroxindoles, Isolindones and Chalcone derivatives with varied potency and 
selectivity (Nag et al., 2013; Arkin et al., 2014). The first published potent and selective 
MDM2-p53 antagonists were the cis-imidazoline compounds, named Nutlins, among which 
the most studied is Nutlin-3 (Shen and Maki, 2011; Ding et al., 2013). RO5503781, 
SAR405838 and HDM201 are more potent and pharmacologically suitable MDM2 inhibitors 
subsequently developed and entered into clinical trials (Burgess et al., 2016).  
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Figure 1-11: (A) MDM2-p53 complex and the three crucial amino acid residues of p53 at 
the MDM2-p53 binding site (Zhao et al., 2015). (B) The MDM2 antagonists mimic the 
MDM2-p53 interaction. MDM2 surface is coloured in blue for hydrophilic areas and grey 
for hydrophobic areas ( Ribeiro et al., 2016). 
 Nutlins 
Nutlins are analogues of cis-imidazoline including Nutlin-1, Nutlin-2 and Nutlin-3. They 
selectively target and bind a small hydrophobic pocket on MDM2, to which p53 normally 
binds, by competing with p53 and imitating the molecular interactions of the three crucial 
amino acid residues from p53 (Nag et al., 2013). Disruption of the interaction between MDM2 
and p53 inhibits ubiquitination and export of p53 by MDM2, leading to p53 stabilization, p53 
nuclear accumulation and upregulation of p53 downstream transcriptional targets involved in 
cell cycle arrest and/or apoptosis, including genes encoding p21WAF1, BAX and PUMA (Hu et 
al., 2006; Mir et al., 2013). Nutlin-1 and Nutlin-2 are racemic mixtures and Nutlin-3a 
(Figure 1-12) is the active enantiomer of Nutlin-3 disrupting the MDM2-p53 interaction with 
IC50 values of 260 nM, 140 nM and 90 nM respectively (Shangary and Wang, 2009; Zhao et 
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al., 2015). Nutlins have the ability to sensitise the cancer cells to conventional chemotherapies 
with the potential for synergistic effect (Mir et al., 2013; Chen et al., 2015). Nutlin-3 
demonstrated the mechanistic proof-of-concept for inhibition of the MDM2-p53 interaction 
and continues to be a useful reference tool compound; however, its pharmacological properties 
are suboptimal for clinical use due to poor pharmacokinetic, bioavailability, solubility and 
permeability (Vu et al., 2013; Ribeiro et al., 2016). 
 RG7112 
RG7112, an advanced member of the Nutlin family (Figure 1-12), is the first clinically tested 
small-molecule inhibitor of MDM2, with ability to displace p53 from the surface of MDM2 
with an IC50 value of 18 nM (Tovar et al., 2013; Vu et al., 2013). Its pharmacologic properties 
have been improved over the early Nutlins, with structural changes to prevent its oxidation, 
reduce molecular weight with the same efficacy, improve MDM2 binding (Yujun Zhao, 2013) 
and inhibit metabolic conversion to the inactive imidazole form (Tovar et al., 2013). RG7112 
has been evaluated in early phase clinical trials as a single agent in adult advanced solid 
tumours, haematological neoplasms and liposarcomas and in combination with cytarabine in 
Acute Myeloid leukaemia (AML) or doxorubicin in soft tissue sarcoma (Hoe et al., 2014). The 
results of the phase I trial of RG7112 in patients with relapsed/refractory Leukemia showed 
clinical activity in correlation with baseline expression levels of MDM2 and provided proof-
of-concept that RG7112 can generate clinical response in hematologic malignancies (Andreeff 
et al., 2016). 
Initial testing of RG7112 by the Paediatric Preclinical Testing Program has confirmed tumour 
regression in wild-type TP53 solid tumours, and showed strong antitumour activity against 
infant acute lymphoblastic leukaemia (ALL), including MLL-rearranged xenografts, 
encouraging further evaluation of RG7112 in both research and clinical trial in the paediatric 
setting (Carol et al., 2013).  
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 RG7388 
RG7388, a Nutlin-3 analogue and a second generation MDM2 inhibitor (Figure 1-12) (Deben 
et al., 2015), was subsequently developed with superior potency, selectivity and oral 
bioavailability suitable for clinical development with a cell-free IC50 value of 6 nM (Lu et al., 
2014). Initial studies have investigated the effect of RG7388 on neuroblastoma cell lines (Chen 
et al., 2015; Lakoma et al., 2015) and established human SJSA-1 osteosarcoma xenografts in 
nude mice (Ding et al., 2013) and confirmed that RG7388 showed all the expected 
characteristics of a MDM2-p53 inhibitor with high affinity and specificity for activating the 
p53 signalling pathway. RG7388 has currently been used as a monotherapy or in combination 
with cytarabine in phase 1 clinical trial in patients with acute myelogenous leukemia, and in 
patients with refractory solid tumour malignancies in combination with posaconazole (Lakoma 
et al., 2015). These studies support further research and clinical investigation of RG7388, 
which is ongoing. 
 
Figure 1-12: The chemical structures of Nutlin-3a, RG7112 and RG7388.
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 Adverse side effects of small molecule inhibitors of the MDM2-p53 interaction 
A concern of p53 reactivating therapies is their effects on the normal cells. Cytotoxicity of 
MDM2 inhibitors to normal tissues was compared to radiotherapy in xenograft mice. Although 
both radiation and chemotherapy induced apoptosis in radiosensitive tissues such as small-
intestine crypts and thymus, MI-219 caused no apoptosis or damage in normal mouse tissue. 
Furthermore, radiation and chemotherapy caused profound accumulation of p53 in intestinal 
crypts and thymus while MI-219 induced p53 activation in normal cells with minimal p53 
accumulation (Shangary and Wang, 2009). However, such studies are flawed because the 
MDM2 inhibitors are optimised against human MDM2 and are much less potent against mouse 
MDM2 and mouse cell lines. 
The most common side effects reported following use of RG7112 in clinical trials are 
gastrointestinal and haematological toxicities, including grade 3 and 4 febrile neutropenia and 
thrombocytopenia (Burgess et al., 2016). Treatment with JNJ-26854165, an oral MDM2 
inhibitor, was well tolerated in patients with advanced solid tumours even though frequent 
adverse grade 1-2events were observed, including nausea, vomiting, fatigue, insomnia, 
electrolyte imbalance and mild renal/liver function impairment (Yuan et al., 2011). Due to 
ubiquitination of other proteins other than p53 such as steroid hormone receptors, androgen 
receptor and Rb via MDM2, other potential off-target effects of MDM2 inhibitors should be 
considered and may even be beneficial. However, no clinical relevance of these potential off-
target effects have been reported in the current early phase trials (Burgess et al., 2016). Overall, 
the most common side effect of small molecule inhibitors of MDM2 reported in clinical trials 
are dose-limiting haematological toxicities and thrombocytopenia (Ray-Coquard et al., 2012; 
Zhao et al., 2015; Andreeff et al., 2016). 
It has also been argued that inhibition of MDM2 may exert a selective pressure on small clonal 
subpopulations of cancer cells harbouring mutant TP53, leading to relapsed tumours resistant 
to p53-dependent chemotherapy and radiotherapy (Zhao et al., 2015; Burgess et al., 2016). 
This issue is discussed and explained in more detail later in general discussion, chapter 9.6.  
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 Gene signatures to predict the response to MDM2-p53 inhibitors 
As MDM2 inhibitors have recently entered into clinical trials, identification of genetic 
biomarkers to potentially predict sensitivity to these agents would be clinically beneficial. The 
main indicator for sensitivity to MDM2 inhibitors is wild-type TP53 which is essential but not 
sufficient because not all wild-type TP53 cells respond to these anti-cancer agents to the same 
extent. Therefore, prediction of sensitivity to MDM2 inhibitors via detection of a p53 target 
gene signature would be helpful to stratify patients who are likely to gain benefit from these 
therapeutic agents (Jeay et al., 2015; Sonkin, 2015; Telfer, 2015).  
A significant correlation was reported between high basal expression of MDM2, XPC, PUMA  
and low expression of CDKN2A genes, and sensitivity to MDM2 inhibitors (Telfer, 2015). In 
a separate study, the Novartis team compared basal levels of p53 downstream gene expression 
in a panel of cancer cell lines which were sensitive or insensitive to MDM2 inhibitor NVP-
CFC218. They identified a minimal set of 13 known p53 target genes as a gene signature 
reflecting the presence of partially activated p53 pathway in the wild-type TP53 sensitive cell 
lines. These genes are involved in negative (MDM2) or positive (ZMAT3, RPS27L) p53 
regulation, cell cycle arrest (CDKN1A, SESN1, CCNG1), apoptosis (AEN, BAX, FDXR, 
TNFRSF10B), oxidative stress (SESN1) and DNA repair (DDB2, RRM2B, XPC) (Espinosa and 
Sullivan, 2015; Jeay et al., 2015). However, another study (Sonkin, 2015) reanalysed the 
validation of TP53 status in the same cell lines used by the Novartis team and found that nearly 
a quarter of them were mistakenly taken  as wild-type TP53 cell lines, thus calling into doubt 
their proposed gene signature as a predictive biomarker for response to MDM2 antagonists. 
Further research is required to define a gene signature set to predict which patients may benefit 
from MDM2 inhibitors. 
 The mechanisms of resistance to MDM2-p53 binding antagonists 
Identification of intrinsic mechanisms of resistance towards MDM2 inhibitors is crucial to 
identify patients who are responsive to the treatment. The most important indicator of 
resistance to MDM2 inhibitors is mutant TP53, which is consistent with the mechanism of 
action (Long et al., 2010; Shaomeng Wang, 2012; Hoe et al., 2014). Strong induction of p53 
with no response to MDM2 inhibitors is indicative of defective p53 protein function or 
deficiencies in other genes involved in the p53 pathway (Long et al., 2010; Shaomeng Wang, 
2012). Intrinsic resistance to apoptosis including mutation in pro-apoptotic genes or high 
cellular levels of anti-apoptotic genes may also play an important role in resistance to MDM2   
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inhibitors as well. ARF inactivation in a mouse model of glioblastoma resulted in development 
of resistance to p53-mediated growth inhibitory effect of Nutlin-3 (Hoe et al., 2014). High 
cellular levels of MDMX have also been reported to render resistance to MDM2 inhibitors such 
as Nutlin-3 and MI drugs (Hoe et al., 2014). However, sensitivity to Nutlin-3 was remained in 
AML cells with naturally high levels of MDMX (Tan et al., 2014). 
Persistent exposure to MDM2 inhibitors is likely to select for tumours with mutant TP53 which 
are resistant to p53-dependent cancer therapies (Shaomeng Wang, 2012). However, TP53 
mutant cell lines are not resistant to a wide range of both targeted and non-targeted agents, apart 
from MDM2 inhibitors according to the COSMIC database (http://www.cancerrxgene.org). One 
study recently published showed that MDM2 inhibitors have the potential to select TP53 
mutations present in tumours at low frequency with resistance to MDM2 antagonists. 
Nevertheless, these tumours are responsive to ionising radiation (Drummond et al., 2016). 
Overall, TP53 mutant tumours selected following treatment with MDM2 inhibitors may remain 
responsive to alternative therapies. 
 MDM2-p53 antagonists in ovarian cancer 
In comparison to type II epithelial ovarian cancer which presents with a high frequency of 
TP53 mutation, type I tumours have mutations in genes other than TP53 such as KRAS, BRAF 
and PTEN (Coward et al., 2015). For most patients with type I epithelial ovarian cancer and 
those left from type II harbouring wild-type TP53, p53 targeted therapy such as MDM2 
inhibitors are likely to be beneficial. 
Limited previous studies have demonstrated that wild-type TP53 ovarian cancer cell lines are 
sensitive to Nutlin-3 (Mir et al., 2013; Erin K. Crane 2015). Nutlin-3 alone and in combination 
with resveratrol induced apoptosis in A2780 cells (Marimuthu et al., 2011). Based on this 
limited prior research, the tool compound Nutlin-3 induces both cell proliferation and apoptosis 
in ovarian cancer cell lines encouraging further studies with clinically relevant inhibitors.  
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1.9 PARP inhibitors and their application in ovarian cancer 
 The Poly ADP Ribose Polymerase (PARP) enzymes and DNA repair 
PARP, a family of nuclear enzymes, consists of 17 enzymes including PARP-1 and PARP-2 
which play a critical role in DNA Base Excision Repair (BER) pathway. Following exposure 
to DNA damage, PARP-1 and PARP-2 are activated and catalyse the cleavage of Nicotinamide 
Adenine Dinucleotide (NAD+) to form Poly ADP-Ribose (PAR) polymer. These PAR 
polymers are added to DNA, histones and DNA repair proteins including PARP, and recruit 
the repair machinery to repair DNA damage (Weil and Chen, 2011; Yuan et al., 2011). 
 PARP inhibitors and synthetic lethality 
Synthetic lethality is a cellular phenomenon in which the function of two different genes are 
simultaneously lost causing cell death, whereas cell death does not occur due to loss of either 
gene function alone. Dysfunctional HRR pathway and inhibition of PARP lead to synthetic 
lethality in cells (Weil and Chen, 2011; Yuan et al., 2011; Curtin, 2013; Stordal et al., 2013). 
Different types of PARP inhibitors such as olaparib, veliparib, niraparib and rucaparib inhibit 
PARP enzyme activity and hinder DNA repair via the BER pathway, resulting in multiple 
double-strand breaks normally repaired by the HRR pathway. The tumour cells with BRCA1/2 
mutation or BRCAness status cannot efficiently repair these double-strand breaks, leading to 
cell death (Figure 1-13) (Turner and Ashworth, 2011; Lupo and Trusolino, 2014; Michels et 
al., 2014). Another mode of action for PARP inhibitors is to trap PARP proteins at sites of 
DNA damage, which is highly toxic to cells due to blockade of DNA replication and induction 
of a replication stress response. Research indicates that these trapped PARP-DNA complexes 
are more toxic than blocking PARP enzyme activity (Turner and Ashworth, 2011; Murai et al., 
2012; Lupo and Trusolino, 2014; Livraghi and Garber, 2015). PARP inhibitors are cytotoxic 
and proficiently result in synthetic lethality in tumour cells with BRCA1/2 deficiencies or 
BRCAness more than normal cells (Underhill et al., 2010; Weil and Chen, 2011).  
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Figure 1-13: The role of PARP inhibitors in synthetic lethality. Molecular pathways underlying PARP/BRCA synthetic lethality. Red 
dotted lines indicate processes impaired by PARP blockade in HR-defective cells. In the presence of PARP inhibitors, SSB repair is 
precluded and either PARP is trapped onto DNA (A) or unrepaired SSBs are converted to DSBs by collision with the replication machinery 
(B). In both cases, resultant replication fork damage requires operational HR for efficient restart (C). HR-deficient BRCA mutant cells 
redirect to alternative, error-prone DNA repair pathways (D), undergoing genomic instability and cell death (Lupo and Trusolino, 2014). 
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 Predictive biomarkers for response to PARP inhibitors 
Up to now, several studies have investigated and highlighted the mutation and epigenetic 
modification of genes implicated in sensitivity to PARP inhibitors. Although germline 
mutations of BRCA1/BRCA2 (Breast Cancer 1/2 tumour suppressor genes) were considered as 
robust predictive biomarkers of PARP inhibitor sensitivity, results of clinical trial have shown 
that the clinical efficacy of PARP inhibitors is not restricted to these genes (Yuan et al., 2011; 
Brown et al., 2016). A BRCAness phenotype, a biomarker of sensitivity to PARP inhibitors, is 
a defective HRR status due to epigenetic hypermethylation of the BRCA1 promoter, somatic 
mutation of BRCA1/2 or dysfunctional mutations in other HRR pathway genes 
(Konstantinopoulos et al., 2010; Michels et al., 2014; Bowtell et al., 2015). Defects in PTEN 
(Turner and Ashworth, 2011; Stordal et al., 2013), deficiency or low expression of RAD51, 
ATM, ATR, EMSY genes (Weil and Chen, 2011; Ihnen et al., 2013) as well as mutation and 
reduced expression of YH2AX (Brown et al., 2016) are proposed as markers of BRCAness 
status. Furthermore, amplification of AURKA and EMCY genes (Sourisseau et al., 2010; Ihnen 
et al., 2013), overexpression of Aurora kinase A and post-translational protein modification 
can also be considered as conferring a BRCAness phenotype (Michels et al., 2014). Low 
expression of genes involved in HRR and response to platinum-based chemotherapy was also 
reported to be associated with sensitivity to rucaparib (Ihnen et al., 2013). 
In regard to PTEN gene, controversial results have been reported amongst which some 
demonstrated no statistically significant association between PTEN mutation and sensitivity to 
PARP inhibitors (Ihnen et al., 2013), whereas others showed PTEN mutations sensitize tumour 
cells to PARP inhibitors through downregulation of RAD51 and impaired HRR (Mendes-
Pereira et al., 2009; Turner and Ashworth, 2011; Weil and Chen, 2011; O'Sullivan et al., 2014). 
The EMCY gene plays a role in HRR as a BRCA2-binding partner and its amplification may 
result in inactivation and silencing of the BRCA2 pathway in sporadic ovarian cancer (Ihnen 
et al., 2013; Michels et al., 2014). Furthermore, amplification or overexpression of the AURKA 
gene is implicated to be associated with sensitivity to rucaparib due to inhibition of RAD51 
recruitment to DNA double-strand breaks (Ihnen et al., 2013). Another protein reported to be 
involved in response to PARP inhibitors is FANCF protein which is an adaptor protein 
stabilising the interaction between FANCC/FANCE and FANCA/FANCG subcomplexes and 
plays a critical role in the correct assembly of Fanconi anemia, FA, core complex. The FA core 
complex is necessary for FANCD2 monoubiquitination localized with BRCA1, RAD51 and 
other DNA repair proteins (Taniguchi et al., 2003). It was also suggested that aberrant 
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expression of ETS transcription factors shown in different cancers may repress BRCA1/2. 
Moreover, interaction of PARP1 binding protein PARPBP, known as PARI, with RAD51 at 
replication forks may result in inhibition of HRR (Michels et al., 2014). Due to the greater 
toxicity of trapping PARP-DNA complexes compared to inhibition of PARP enzymatic 
activity and clinical importance of PARP trapping, PARP expression levels or baseline activity 
of PARP may be considered as a biomarker for PARP inhibition (Brown et al., 2016). 
 Resistance to PARP inhibitors  
Development of resistance to PARP inhibitors occurs through different mechanisms. 
Secondary mutations reversing the BRCA deficiency from a mutated reading frame to a normal 
sequence reading frame leads to resistance to PARP inhibitors. Reversion of mutation is a 
phenomenon occurring following selective pressure of drug treatment. Aberrant expression and 
activity of PARP, upregulation of efflux transporters such as p-glycoprotein, and loss of 53BP1 
are other mechanisms implicated in resistance to PARP inhibitors (Weil and Chen, 2011; Lupo 
and Trusolino, 2014; Frey and Pothuri, 2015). Acquired resistance to PARP inhibitors resulting 
from a secondary mutation has been confirmed to occur in patients (Weil and Chen, 2011).  
 PARP inhibitors in ovarian cancer 
Deficiencies in HRR occur in  up to 50% of epithelial ovarian cancers (Mukhopadhyay et al., 
2012). BRCA1/2 mutations are present in the germline of 70-85% of patients with inherited 
ovarian cancer regardless of histological subtypes, and account for 23% of HGSC. The rate of 
BRCA1/2 mutation in sporadic ovarian cancer is low and low expression levels of BRCA1/2 is 
likely to be an important characteristic of non-inherited ovarian cancer (Weil and Chen, 2011). 
Some studies have identified impaired HRR pathway status in ovarian cancer cell lines, 
indicating the possible sensitivity of ovarian cancer patients bearing deficiencies in the HRR 
pathway other than only BRCA1/2 mutation to PARP inhibitors (Weil and Chen, 2011; Yuan 
et al., 2011; Rigakos and Razis, 2012; Ihnen et al., 2013; Stordal et al., 2013; Michels et al., 
2014). Amplification of the EMSY gene is present in about 20% of cases with HGSC and the 
FANCF methylation was reported in 21% of ovarian cancer (Rigakos and Razis, 2012).  
PARP inhibitors are now undergoing clinical trials as targeted therapy for different types of 
cancer including ovarian cancer. Rucaparib is currently evaluated as a monotherapy in phase 
II clinical trials for patients with BRCA-associated ovarian cancer and in combination with 
chemotherapy for advanced solid tumours. The use of olaparib and veliparib as single agents 
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and in combination with chemotherapy is undergoing phases I and II clinical trials for patients 
with different types of cancer, including ovarian cancer (Anwar et al., 2015; Frey and Pothuri, 
2015). ARIEL2, a phase II trial of rucaparib in platinum sensitive, relapsed HGSC, and 
ARIEL3, a phase II clinical trials of rucaparib maintenance therapy following a platinum 
treatment in relapsed HGSC and endometrioid ovarian cancer, are ongoing to define a 
molecular signature of HR dysfunction in ovarian cancer patients (Frey and Pothuri, 2015). 
Niraparib, CEP-9722 and E7016 are other new PARP inhibitors currently undergoing clinical 
trials as single agents and in combination with chemotherapy in advanced solid tumours 
(Anwar et al., 2015).  
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1.10 Hypothesis and Aims 
Hypothesises: 
1. The genomic and functional status of TP53 are prognostic biomarkers in ovarian cancer 
patients. 
2. The genomic status of TP53 affects the response to MDM2-p53 antagonists, and MDM2-
p53 binding antagonists have the potential for synergistic effects in combination with 
platinum drugs or PARP inhibitors in ovarian cancer. 
Aims: 
1.  To establish whether immunohistochemical staining for p53, p21WAF1, MDM2 and 
WIP1 provide additional predictive value for overall survival in the OVCA1-4 patient 
cohort. 
2. To establish whether genomic status of TP53, and immunohistochemical staining for 
p53, and p21WAF1 provide additional predictive value for chemotherapy outcome in the 
ICON3 patient clinical trial. 
3. To test a panel of established ovarian carcinoma cell lines for their response to MDM2-
p53 binding antagonists, and examine the relationship of this response to the genotype 
of the cells. 
4. To assess the combined effect of MDM2-p53 antagonists with cisplatin. 
5. To evaluate the combined effect of MDM2-p53 antagonists with the PARP inhibitor 
rucaparib. 
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2.1 Tissue Microarray (TMA)  
 Tissue microarray (TMA) 
TMA is a powerful molecular biology technique with the ability of arraying up to 1000 samples 
into a single paraffin block, which allows simultaneous assessment of gene product on a large 
number of specimens (Jawhar, 2009; Gately et al., 2011). Several variables including antigen 
retrieval, incubation times, washing procedures and reagent concentration can also be 
standardized by TMA via analysing the whole cohort at the same time. One of the main 
drawbacks of TMA is that due to tumour heterogeneity one core may not be representative of 
the entire tumour (Jawhar, 2009; Barrette et al., 2014). This problem can be overcome using 
IHC on more than one core, duplicate/triplicate, taken from different areas in the original 
samples. Efficient and useful application of IHC on TMA has been proven by a study showing  
good concordance between TMA core staining and whole-slide immunohistochemical data 
which is approximately 96% (Barrette et al., 2014). Several studies also validated ovarian 
carcinoma tissue microarray as a reliable technique to analyse the expression of markers 
including p53 (Rosen et al., 2004; Hecht et al., 2008). 
 Development of TMA and collection of specimens 
Ethical approval and specific consent were obtained for the collection and analysis of clinical 
material. Two sets of TMAs were used in this study. The first set consists of 167 patient 
samples assembled on TMA and labelled as OVCA 1 to OVCA 4. The second set collected 
and labelled as ICON3-1 to ICON3-6 consists of 260 patient samples. There are two cores from 
each tumour sample in the TMA to maximise the tumour area represented, and based on the 
reported studies indicating two cores are comparable to whole tissue section in the analysis of 
more than 95% of cases (Camp et al., 2000) or in more than 96% of cases (Rosen et al., 2004). 
The samples were in formalin fixed paraffin embedded (FFPE) blocks and cores taken only 
included tumour areas that were marked by a histopathologist. Histological analysis and grades 
of differentiation of the primary tumour specimens were determined according to the FIGO 
Cancer Committee. 
 TMA design 
A TMA layout was designed and prepared for each set of TMAs. The TMA includes a marker, 
duplicates of the patient tissue samples and duplicates of normal human tissues such as prostate 
and spleen as control tissues. The cores were labelled with a number related to the patient 
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according to the numbers on the spreadsheet of patient data. The tissue core was taken from 
original histopathological blocks, known as donor blocks, and placed in an empty recipient 
block. The size of the cores was 1 mm in diameter and 4 mm in depth. A standard microtome 
and water bath were used to prepare paraffin sections.  
2.2 Immunohistochemistry (IHC) 
 Principles and methods 
Immunohistochemistry is the application of immunologic techniques to detect antigens in 
tissue sections using labelled antibodies. Cut sections of 3 to 4 micron thickness from paraffin-
embedded blocks were used for immunohistochemistry analysis. Optimisations were 
performed using three different dilutions of primary anti-p21WAF1 and anti-p53 antibodies 
(1:25, 1:50 and 1:100) and primary anti-MDM2 and anti-WIP1 antibodies (1:50, 1:100, 1:250 
and 1:500), various incubation times (40, 50 and 60 minutes), different buffers including 
Citrate (10 mM Sodium citrate, 0.05% Tween 20, 1 litre deionized water, pH=6) and Tris (1M 
Tris, 1 litre deionized water, pH=9) and different antigen retrieval methods (microwave and 
decloaker). Finally, the best outcomes were used for experiments (Table 2-1). Slides were 
dewaxed in xylene for 5 minutes to remove paraffin and hydrated with graded ethanol (100%, 
95%, and 75%) for 5 minutes. Antigen retrieval was performed as illustrated in Table 2-1. 
These antigen retrieval reagents break the protein cross-links formed by formalin fixation and 
uncover hidden antigenic sites, thereby enhancing staining intensity obtained with antibodies. 
To block endogenous peroxidase activity, sections were treated with 0.5% hydrogen peroxide 
(Fisher Scientific) for 10 minutes at room temperature. Slides were incubated at room 
temperature for primary antibodies. After rinsing in the 10X TBS Tween 20 buffer (0.5M Tris 
base, 9% NaCl, 1 litre deionized water, 0.5% Tween 20, pH=8.4) to wash away any unbound 
primary antibody, sections were exposed to the appropriate horseradish peroxidase (HRP) 
(MenaPath, UK) conjugated anti-rat/mouse/rabbit IgG secondary antibody for 30 minutes. This 
kit enhances signals produced by interaction between antigen and antibody for the detection of 
low concentrations of antigens, or for increased staining intensity in compensation for low titer 
primary antibodies. For primary mouse antibodies, universal probe (MenaPath, UK) was 
applied for 20 minutes before this stage, which increases staining sensitivity 10 to 40 times for 
mouse monoclonal antibodies. Then, they were rinsed in water to remove excess reagent and 
3, 3’ diaminobenzidine (DAB, Sigma) was added, for 10 minutes for p53, MDM2, WIP1 and 
5 minutes for p21WAF1. This reagent is a precipitating substrate which produces a brown 
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formazan stain according to the amount of HRP activity and hence is indirectly a measure of 
the degree of primary antibody binding. This precipitate is insoluble in the presence of alcohol 
and xylene.  
Dehydration of the sections was performed in graded alcohol and xylene, and distyrene, 
plasticizer and xylene (DPX) mounting (Sigma) used in order to preserve stain. Slides not 
incubated in primary antibody were used as an antibody negative control to test for specificity 
of staining. 
 
 
Table 2-1: The antigen retrieval method and antibody dilution used for different proteins. 
 
 Immunohistochemistry Scoring 
Images of the stained slides were used for scoring and visualised via the Aperio ScanScope® 
CS, an automated digital scanner (Aperio Technologies, Bristol, UK) technology and 
Spectrum™ image management software. A modified H-Score was applied for 
immunoscoring, in which each specimen was scored by multiplying the intensity (no 
staining=0, weak=1, intermediate=2 and strong=3) by the proportion of staining (1=1-14%, 
2=15-24%, 3=25-39%, 4=40-59%, 5=60-79% and 6=80-100%). Scores ranged from 0 up to 
18. Score was considered 0, negative, where there was no staining and positive where there 
was nuclear or cytoplasmic staining. To consider the heterogeneity within the tumour and 
maximise the tumour area represented, 2 cores from different areas of tumour were scored, 
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which are comparable to whole tissue section in the analysis of more than 95% of cases (Camp 
et al., 2000) or in more than 96% of cases (Rosen et al., 2004). For each core with different 
intensity, several areas including 100 cells were chosen, scored and the average was calculated 
as the final score for each core. For example, if 20% of a core includes more cells stained weak, 
60% includes more cells stained intermediate and 20% was negative, 1 part of area including 
weak and 3 parts of area including intermediate were chosen, scored and the average was 
considered as the final score for that core. A mean of two scores was used for the final score 
of duplicate TMA samples. The score of the remaining core was used where a core loss 
occurred. The samples were scored only by Maryam Zanjirband twice at two different times to 
avoid bias; however, it is a limitation of this study. 
2.3 Tissue Culture 
 Characteristics of ovarian cancer cell lines investigated  
The panel of ovarian cancer cell lines used in this study, is listed below and the histological 
subtype of the tumours from which they were derived and TP53 status are summarised in 
Table 2-2.  
A2780 cell line harbouring wild type TP53 was derived from tumour tissue from an untreated 
patient. Cells grow as a monolayer including cell clusters of different sizes without any signs 
of differentiation (Pizao et al., 1992).  
IGROV-1 was established from tumour tissue from an untreated 47-year-old woman suffering 
from a stage III ovarian carcinoma. Histologically, this cell line was diagnosed with multiple 
differentiations with endometrioid for the major part of the tumour and some clear cells and 
undifferentiated foci. The IGROV-1 cells grow as a monolayer and indicate the presence of 
two cellular clones including one pseudodiploid with 46 chromosomes and the other 
hypotetraploid with 92 chromosomes with increased number of the tetraploid cells following 
increased number of subcultures (Bénard et al., 1985). As information on the TP53 status of 
IGROV-1 in the literature was contradictory, sequencing was performed and no mutation was 
detected. 
OAW42 cell line with wild-type TP53 was derived from an ascitic fluid sample of a 46-year-
old woman with recurrent disease after a complete response to six courses of cis-platinum 
(Wilson et al., 1996). The cell line was established from a serous cystadenocarcinoma. It grows   
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as a monolayer and cells have an intermediate morphology, neither as small round cells nor as 
large polygonal cells (Hills et al., 1989).  
CP70 is a resistant clone derived from A2780 by selection for growth in cisplatin. The CP70 
cell line harbours a heterozygous TP53 mutation (c.514 G->T, p.Val172Phe) (Lu et al., 2001). 
The CP70 cell line is an MMR-deficient variant of the A2780 cell line with deficiency in the 
MLH1 gene (Curtin et al., 2004). 
MLH1-corrected CP70+ is a chromosome 3 transferrant of the CP70 cells (Curtin et al., 2004) 
and retains the heterozygous TP53 mutation (c.514 G->T, p.Val172Phe) (Lu et al., 2001).  
MDAH-2774 was derived from a patient with endometrioid epithelial ovarian cancer growing 
as a monolayer (Dai et al., 2009). MDAH-2774 harbours a TP53 mutation located in exon 8 
(c.818G->A, p.Arg273His). The mutant p53 is overexpressed and results in intense nuclear 
staining with p53 antibodies. This cell line also has a mutated KRAS gene, involving activation 
of the MAPK signalling pathway (Dai et al., 2009).  
SKOV-3 was stablished from an ascetic fluid sample from a patient with ovarian 
adenocarcinoma. It grows as a monolayer with colonies containing large polygonal cells. This 
cell line is one of the most resistant ovarian cancer cell lines to chemotherapy agents such as 
cisplatin and carboplatin (Hills et al., 1989). Due to inconsistent information on the TP53 status 
of SKOV-3 in the literature, sequencing was performed and a frame shift deletion (c.265delC, 
p.Pro89fsX33) was confirmed.  
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Table 2-2: The ovarian cancer cell lines and their Histotype and mutational TP53 status. 
EC, Endometrioid carcinomas; CCC, Clear cell carcinomas; UD, Undifferentiated.
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 Cell line authentication 
The cell lines were authenticated by short tandem repeat (STR) DNA profiling using 
hypervariable DNA microsatellite regions, which are very small (3-6bp) long repeated DNA 
motifs ( Dr. Claire Hutton) (McLaren et al., 2013). All cell lines were regularly tested for 
Mycoplasma infection using a PCR based method by Elizabeth Matheson. The mutational 
status of TP53 for IGROV-1, MDAH-2774 and SKOV-3 cell lines was analysed using a Sanger 
sequencing method and the results are presented in chapter 6.4.2.2. The MLH1 status was tested 
for the MLH1-corrected CP70+ cell line using western blot and comparison with A2780 as a 
MLH1-proficient cells (positive control) and CP70 as a MLH1-deficient cell line (negative 
control) (Curtin et al., 2004). The results are shown in chapter 6.4.1. 
 Cell culture 
All cell lines were grown and maintained as monolayers. A2780, IGROV-1, OAW42 and CP70 
were cultured in RPMI-1640 (Sigma) supplemented with 10% (volume/volume, v/v) Foetal 
Bovine Serum (FBS) (Gibco) and 5% (v/v) penicillin/streptomycin (Sigma). The MLH1-
corrected CP70+ cell line was grown in RPMI-1640 supplemented with 10% (v/v) FBS and 
Hygromycin B (200 µg/ml: Life Technologies, Inc.) (Curtin et al., 2004) for the selection and 
maintenance of the cells containing the Hygromycin resistance gene. MDAH-2774 and SKOV-
3 cell lines were cultured in DMEM supplemented with 10% and 5% (v/v) FBS and 
penicillin/streptomycin respectively. All cells were routinely cultured in either 75 cm2 or 25 
cm2 sterile tissue culture flasks and incubated at 370C in a humidified atmosphere of 5% carbon 
dioxide. To routinely passage adherent cells when they reached 70-80% confluence, culture 
medium from the flask was removed by aspiration; the monolayer was washed with 5-10 ml 
(according to the size of flask) phosphate buffered saline (PBS without cations and pH 7.2, 
Gibco) and cells were detached with 0.5-2 ml 1x (for OAW42 cells 1-3 ml 2.5x ) trypsin/EDTA 
(10X, Sigma) in PBS. Trypsin enzymatically detaches adherent cells from tissue culture plates 
for passaging. Divalent cations such as calcium and magnesium, which are often present in the 
cell culture environment, inhibit this action. EDTA sequesters these ions and thus boosts the 
efficacy of trypsin. Then, cells were incubated at 370C for a few minutes until the cells lift off 
and 5-10 ml culture medium was added to neutralise the trypsin. Finally, an appropriate volume 
of cell suspension was dispensed into a fresh sterile flask. Due to use of concentrated 
trypsin/EDTA for OAW42 cells, the cells with medium was centrifuged, the medium removed 
and then the cells with fresh medium were split to sterile flasks. The cells were seeded at a low   
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density for routine cell culture and high density for an experiment within the next 3-4 days. All 
experimental cell manipulations and subculturings were performed using sterile equipment and 
reagents within a class II safety cabinet (Biomat, Medair Technologies, MA, USA) at all times. 
 Cryogenic storage of cell lines and revival of the cells 
In order to store the cell lines, exponentially growing cells were detached, centrifuged, extra 
medium was aspirated and the pellet resuspended in freezing medium containing each cell 
line’s appropriate growth media with 10% FBS (v/v) and 10% (v/v) DMSO (Sigma #276855). 
DMSO was added as a cryoprotectant to inhibit the formation of ice crystal within the cells at 
low temperature, which otherwise would disrupt the cell membrane. Aliquots of 1ml were 
retained in cryotubes (NUNCTM, Rochester, NY, USA) and frozen slowly at -800C overnight. 
Cryotubes were then transferred to liquid nitrogen for long-term storage. To grow cells from 
stored liquid nitrogen stocks, the vials were quickly thawed in a water bath at 370C. Then, cells 
were suspended in growth media, centrifuged at 1000rpm to remove DMSO from the solution 
and resuspended in fresh medium for transfer into culture flasks or plates for growth. 
2.4 Drugs and specificities 
 Cis-diamino-dichloro-platinum (CDDP or cisplatin)  
Cisplatin (Cl2H6N2Pt+2, MW=300.05104 g/mol), a DNA damaging agent, was purchased from 
Merck Millipore (Watford, UK). It was solubilised in distilled water at a final concentration of 
2mM stocks and stored at -20ºC. 
 MDM2-p53 antagonists 
Nutlin-3 (C30H30Cl2N4O4, MW=581.5 g/mol), a 1:1 racemic mixture of the active 
enantiomer Nutlin-3a and the inactive enantiomer Nutlin-3b, was purchased from NewChem 
Technologies Limited (#548472-68-0) in solid form (Newcastle, UK). DMSO was used as 
solvent to solubilise the powder at a final concentration of 10mM and smaller aliquots were 
stored at -20ºC. The interaction of MDM2 and p53 is inhibited by Nutlin-3 with cell free assay 
IC50 value of 90 nM. 
RG7112 (C38H48Cl2N4O4S, MW= 727.78 g/mol), the first clinical small molecule inhibitor 
of MDM2-p53, and RG7388 (C31H29Cl2F2N3O4, MW= 616.48 g/mol), with more potency 
and selectivity, were kindly provided by Professor Herbie Newell and made available by the 
Newcastle Anticancer Drug Development Initiative. Both were dissolved in DMSO to a final   
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concentration of 1mM and the stocks stored as explained above. They inhibit the MDM2-p53 
interaction with an IC50 value of 18 nM for RG7112 and 6 nM for RG7388. 
 Rucaparib 
Rucaparib (C19H18FN3O.H3PO4, MW=421.36 g/mol) is the first PARP inhibitor that was 
entered into clinical trial as a chemopotentiator. It is one of a series of tricyclic benzimidazole 
carboxamide PARP inhibitors with Ki of 1.4 nM for PARP1 in a cell-free assay. It was kindly 
supplied by Professor Nicola Curtin, and prepared as described above in 10mM stocks 
solubilised in DMSO. 
2.5 Cell counting 
A Neubauer haemocytometer (Hawksley, Sussex, UK) was used to estimate cell densities. A 
1:1 dilution of the suspension in 0.4% trypan blue dye (Biorad, #145-0021) or 10µl of cell 
suspension were added to each side of the haemocytometer, which was prepared based on the 
manufacturer’s instructions. Each grid has a total volume of 0.1mm3 (1mm2 (area) x 0.1 mm 
(depth)) and therefore n counts/grid are representative of n×104 cells/ml. The average cell 
counts/grid of at least two grids on each side of the haemocytometer were calculated and 
multiplied by 104 or 2 x 104 in the case of 1:1 dilution with the 0.4% trypan blue before loading. 
Following exposure to trypan blue, dead/dying cells with damaged membrane integrity are 
stained blue whereas viable cells remain clear with intact plasma membrane. The absolute or 
proportion of viability can be measured by this method even though the cells must be counted 
quickly during 5 minutes after adding the dye, due to staining of viable cells after 5 minutes.  
2.6 Sulforhodamine B (SRB) assay 
 Principles of SRB assay 
SRB assay is a rapid, sensitive and inexpensive method to estimate the number of cells in 96-
well microtiter plates for drug screening developed by Skehan et al. SRB is a purple anionic 
protein dye which binds to the basic amino acid residues in proteins under mild acidic 
conditions. The optical density of SRB is measured at 564nm with a signal to noise ratio of 1.5 
with 1000 cells/well (Skehan et al., 1990). The intensity of the staining depends on the amount 
of cellular protein and can be used as a measure of cell number and hence culture growth.  
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 SRB assay method 
The cells in 96-well plates were fixed by adding 25 µl Carnoy's fixative (three parts methanol 
plus one part concentrated acetic acid) at appropriate time-points, stored at 40C for at least 1 
hour up to 2 weeks, washed 5 times in tap water and dried at 600C or room temperature. After 
fixation, adherent cells were stained with 0.4% (w/v) SRB dissolved in 1% (v/v) acetic acid for 
30 minutes. The staining was followed by 5 washes with 1% (v/v) acetic acid to remove 
unbound stain, drying at 600C or room temperature, and solubilising the bound stain in 
100µl/well of 10mM Tris buffer (pH 10.5) with gentle mixing for 20 minutes. Lastly, the 
absorbance of the redissolved stain was read at 570nm using a multi-well spectrophotometer 
(BioRad, Model 680). 
2.7 Growth curves 
Growth curves for all cell lines were established to measure the doubling times of the cell lines. 
Exponentially growing cells were detached, transferred to a sterile universal tube and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was aspirated, the pellet was gently re-
suspended in 10 ml of medium, and the cells were counted by a Haemocytometer. Five different 
dilutions of cells, (2.4 x 105, 1.2 x 105, 6 x 104, 3 x 104, and 1.5 x 104 ml-1) were established 
and seeded into six 96-well plates by adding 100 µl of cells in each of 6 wells per plate for each 
density. To compensate for the edge effect due to evaporation, 100 µl medium was added to 
the outer rows and columns of the six 96-well plates. The cells were observed under a 
microscope to check their viability and confluence. One plate on each subsequent day after 
seeding was fixed by adding 25 µl Carnoy's fixative and stored at 40C. Then, the SRB assay 
was used as described above to estimate cell density in each well and growth curves were 
constructed by using GraphPad Prism statistical analysis software version 5.04.  
2.8 Growth inhibition assay and calculation of GI50 values 
Based on the growth curve previously done, a suitable seeding density of cells was chosen for 
plating which during the assay period resulted in growth of the culture which had negligible 
lag phase, a short doubling time, and did not reach plateau phase within the course of the 
experiment. This was then used for constructing growth inhibition curves and measuring 
concentrations of drugs required to achieve 50% growth inhibition (GI50). The cell densities 
chosen were 4.5 x 104 (ml-1) for A2780, 6 x 104 (ml-1) for IGROV-1 and SKOV-3, 3 x 104 (ml-
1) for OAW42, CP70, and MLH1-corrected CP70+ and 2.25 x 104 (ml-1) for MDAH-2774. The 
optimal number of exponentially growing cells were seeded in 96-well plates, and incubated at   
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370C for 24 hours to attach. Each column was then treated with a range of drug concentrations 
as detailed in the specific materials and methods section of the relevant chapters. For each 
treatment, the drug solvent was also used as a control. A Day 0 control was plated and 
immediately fixed by Carnoy’s solution after 24 hours of attachment. The treatment plates were 
incubated with the mentioned concentration of drugs for 72 hours, fixed and were then stored 
at 40C for at least 1 hour. The relative amounts of cells were determined by SRB assay as 
described in 2.6.2. The SRB data from the spectrophotometer readings was transferred and 
interpreted by using Microsoft Excel software. The average plate Day 0 absorbance values 
were subtracted from the treatment plate values, and calculation of means and standard 
deviations of optical densities from >3 independent experiments were made. These figures 
were analysed and plotted by using GraphPad Prism 5.04 to plot the dose dependent growth 
inhibition curves and measure the interpolated GI50 values.  
2.9 Clonogenic cell survival assay 
To evaluate whether any of the treatment regimens led to reduction of colony formation ability 
of the cells, clonogenic assays were performed by the modified method in which the cells are 
not trypsinised after attachment. Based on the drug concentration and sensitivity of cell lines, 
100 to 100,000 exponentially growing cells were seeded into triplicate six-well plates. After 
24 hours, cells were treated with media, solvent and different concentrations of drugs for 48 
hours. Then, the media including drug was removed and free-drug media was added. The cells 
were incubated for 1 to 3 weeks to form colony for counting (a colony was defined as a focus 
of ≥50 cells). After that, the plates were washed with PBS, fixed with Carnoy’s fixative and 
stained with 0.4% (w/v) crystal violet for a few minutes. Plates were again washed and then 
left at room temperature to dry. The cloning efficiency in control samples treated with 
appropriate volumes of drug solvent alone, DMSO or distilled water, was calculated using 
cloning efficiency formula (colonies counted/cells seeded) x 100. The percentage survival at 
each data-point was calculated using the specific formula (drug treated cell cloning 
efficiency/control cell cloning efficiency) x 100. The LC50 values, the dose of drug leads to 
50% loss of colony formation, were calculated using GraphPad Prism statistical analysis 
software version 5.04.  
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2.10 Combined treatment and median-effect analysis 
 Growth inhibition in response to combined treatment 
For combination treatments, the appropriate densities of wild-type TP53 cell lines were seeded 
for 24 hours and then treated for 72 hours with each agent alone and in combination 
simultaneously at constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x, and 4x their respective GI50 
concentrations. They were fixed and stained by SRB assay as outlined previously. The fraction 
of cells affected following treatment was calculated using GraphPad Prism 5.04. Median-effect 
analysis was used to calculate Combination Index (CI) and Dose Reduction Index (DRI) values 
using CalcuSyn software v2 (Biosoft, Cambridge, UK). The DRI values>1 are favourable and 
CI<1, CI=1 and CI>1 are indicators of synergism, additivity and antagonism respectively 
(Chou, 2006; Chou, 2010). More detail for interpretation of CI and DRI are described within 
the chapters where relevant. 
2.10.1.1 Clonogenic cell killing assay in response to combined treatment 
Based on the drug concentration and sensitivity of cell lines, appropriate numbers of 
exponentially growing cells were seeded into triplicate six-well plates. Cells were treated with 
each drug alone and in combination at constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x and 4x or 0.25x, 
0.5x and 1x their respective LC50 concentrations, depending on the cell line and its single agent 
LC50 values, for 48 hours. The colonies were fixed and stained as described in section 2.9. DRI 
and CI values were calculated and interpreted as explained above. 
2.11 Western blotting 
 Principles of western blotting 
Western blot analysis is a powerful technique applied to measure relative amounts of proteins 
in a sample of tissue homogenate or cell extract, according to the immunoreactivity between 
antigen and antibody. It is a practical method used to estimate protein sizes in kDa by directly 
comparing with a set of standard size marker proteins or ladder. Gel electrophoresis is used to 
separate denaturated proteins according to size. They are then transferred to a specific 
membrane (normally nitrocellulose or PVDF) to probe with antibodies to target specific 
proteins. Lastly, the labelled probes bound to the protein of interest are visualised by different 
methods including chemiluminescent detection. The technique contains several main stages as 
explained below.  
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 Lysate (Cellular protein mixture) preparation 
Exponentially growing cells were detached, counted and 3 mL of appropriate cell densities 
were used to seed into 70 mm tissue culture dishes as described in specific materials and 
methods where relevant. The cell cultures were incubated at 370C for 48 hours before drug 
treatment. After 48 hours, the medium was aspirated; 3ml medium, 3ml 1% solvent (Distilled 
water or DMSO), or 3ml of prepared drugs was added to the tissue culture dishes, which were 
then incubated at 370C for four hours before harvesting the cells and preparing lysates for 
Western blot analysis. At the end of each treatment the media was removed, the cells were 
washed with 40C PBS and 40µl of lysis buffer (0.0625M Tris-HCl pH 6.8, 2% w/v SDS 
(Sigma), 10% v/v Glycerol (Sigma)) was added to each well. The buffer contains SDS, which 
disrupts non-covalent bonds in the proteins and coats them with negative charge, denaturing 
them so that they migrate according to molecular weight during subsequent gel electrophoresis. 
Then, cells were scraped, the lysate was transferred into microfuge tubes (Eppendorfs), the 
samples were heated at 1000C for 10 minutes and sonicated at 23KHz using a Soniprep 150 
plus (MSE) for 10 sec (Amplitude set at 6.0) three times. A combination of sonication and lysis 
buffer was used to enhance protein extraction and reduce the viscosity of the samples by 
breaking up the DNA. 
 Measurement of protein concentration (bicinchoninic acid assay, BCA) 
The concentration of protein in the cell lysates was estimated by using a bicinchoninic acid 
(BCA) assay to determine the volume of lysate that should be loaded on the gel for equal 
quantities of protein. BCA is a detergent containing two reagents A and B mixed with the ratio 
50 portions of BCA reagent A to 1 part of BCA reagent B (Thermo Scientific; Prod. No: 23227) 
to produce a suitable dilution. Standard concentrations of 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 mg/ml 
bovine serum albumin (BSA) and lysate sample dilutions of 1 in 10 were prepared. Aliquots 
of 10µl of standard or sample were added per well of a 96-well plate. Then, 190µl of the BCA 
mixture was added to each well and mixed up and down using a multi-channel pipette. The 
plate was wrapped in Clingfilm, incubated at 370C for 30 minutes and the absorbance read at 
570nm using a spectrophotometer (Spectramax 250 Molecular Devices). 
The BCA assay is a biochemical assay, indicating the protein concentration by changing colour 
of the sample solution from green to purple in proportion to protein concentration which can 
be measured by using colorimetric techniques. The A stock BCA solution contains sodium 
carbonate, sodium bicarbonate, sodium tartrate, bicinchoninic acid and cupric sulfate pentahydrate 
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in a highly alkaline solution with a pH 11.25. This method includes two reactions. In the first 
one, reduction of Cu2+ ions to Cu+, which in the presence of proteins (a temperature dependent 
reaction) leads to chelation of copper with the protein and formation of a pale green complex. 
In the second one, two molecules of BCA react with Cu+ ions; to form a purple-coloured 
product that strongly absorbs light at a wavelength of 562 nm. It seems that formation of colour 
with BCA is influenced by protein structure, quantity of peptide bonds and existence of some 
specific amino acids such as cysteine, tryptophan and tyrosine. The protein concentration of 
the samples were calculated based on a BSA standard curve, and were multiplied by 10 to 
account for the dilution factor of the samples. 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Novex® 4-20% Tris-Glycine 12- or 15-well polyacrylamide gradient gels (Invitrogen) were 
used in the study. The polyacrylamide gels were placed in Invitrogen Mini-Cell gel 
electrophoresis tanks and filled with 1x electrode buffer (144g Glycine, 30g Tris base, 10g 
SDS, 800ml distilled water, the volume was brought to 1L).  
According to the calculation from the protein estimation assay, a required volume of lysate was 
added to SDS loading buffer to achieve a final volume which contained 30μg of protein in 
30μl. SDS loading buffer contains 0.4g SDS, 2ml glycerol, 1ml 0.1% bromophenol blue, 1ml 
ßeta-mercaptoethanol, 2.5ml 0.5M Tris/HCL and 13.5ml distilled water. The samples were 
heated at 1000C for 10 minutes, loaded into the wells of the gel and electrophoresis carried out 
at 180V for 45 minutes to separate the proteins. SeeBlue® Plus2 Pre-Stained Standard 
molecular weight markers (Invitrogen) were used in the flanking wells of each gel. 
 Transfer  
The separated proteins were transferred by perpendicular electrophoresis to a nitrocellulose 
HybondTM C membrane (Amersham, Buckinghamshire, UK). The transfer electrophoresis tank 
was set up according to the manufacturer’s instructions and was filled with transfer buffer (3g 
Tris base, 14.14g glycine, 200ml methanol and distilled water was added to make the volume 
up to 1L). All Hybond™C membrane, filter paper and fibre pads were immersed for 10 minutes 
in transfer buffer. Cassettes were set up in this order: black side first, fibre pad, filter paper 
(Whatman 3MM, Kent UK), gel, HybondTMC membrane, filter paper, fibre pad. The cassettes 
were closed and placed in transfer tanks, with the black side of the cassette facing the black 
anode, and electrophoretic transfer performed at 100V for 30 minutes.  
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 Blocking 
The HybondTMC membrane now carrying the immobilised proteins was placed into a 50ml 
Falcon tube (BD Biosciences, San Jose, CA, USA) filled with 5% w/v non-fat milk or bovine 
serum albumin (BSA) dissolved in 1x TBS Tween-20 (Fisher BioReagents) pH 7.6 and washed 
by gentle shaking and rolling at room temperature for an hour. This step was carried out to 
block non-specific binding which otherwise produces a high background staining on the 
nitrocellulose membrane. The membrane was cut into strips according to molecular weight 
ranges estimated from the marker proteins in order to probe with appropriate antibodies. 
 Primary and secondary antibodies 
The strips were incubated with specific primary antibodies added to 3 ml 5% w/v non-fat 
milk/1x TBS Tween or 5% BSA/1x TBS Tween according to specified antibody supplier 
guidelines as stated in Table 2-3. Then, the Falcon tubes were placed on the rolling mixer for 
1 hour at room temperature or overnight at 40C. Finally, strips were washed three times with 
1x TBS/Tween to remove unbound primary antibodies and to get ready for the next stage.  
Horseradish peroxidase (HPR) conjugated goat anti-mouse IgG and goat anti-rabbit IgG 
secondary antibodies (1:1000) (DakO, Denmark) diluted in TBS Tween/5% milk or TBS 
Tween/5% BSA were applied for between 45 to 60 minutes at room temperature. Following 
that, the filter strips were washed for 4 minutes seven times in 1x TBS/Tween on the platform 
shaker. 
 Enhanced chemiluminescence protein detection 
An Enhanced Chemiluminescence (ECL) kit (Amersham) was used for protein detection. 
Washed filters were exposed for 1 minute to a mixture of ECL1 and ECL2, which is a 
chemilominescent substrate used for chemilominescence-based immunodetection of HRP on 
western blot membranes. ECL contains two reagents; one is the luminol substrate and the other 
functions as an enhancer, used in equal volumes to attain the most intense light emission. The 
antibody-conjugated HRP converts the luminol substrate to triplet carbonyl and its decay to 
singlet carbonyl leads to emission of light. The membrane was covered by a clear film and 
placed in an autoradiography cassette (Genetic Research Instrumentation, Essex, UK). A sheet 
of X-ray film (Kodak) was placed on the membrane in the dark room and the exposed film was 
subsequently developed and fixed using a Mediphot 937 (Colenta, Austria) automated film 
processor.   
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Table 2-3: The primary and secondary antibodies used for western blotting. HRP, Horseradish peroxidase. 
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2.12 Polymerase Chain Reaction (PCR) 
PCR is an in vitro biochemical technique with the ability to rapidly and accurately amplify a 
few copies of specific sequences of DNA developed in 1983 by Kary Mullis and optimised in 
its present form by Saiki (Bartlett, 2003).  
 Principles of PCR 
The PCR technique is based on thermal cycling, which typically includes 20-40 cycles of 
repeated heating and cooling of the reaction for DNA melting and DNA enzymatic replication. 
A variety of parameters including the concentration of divalent ions and deoxyribonucleic acids 
(dNTPs), melting temperature (Tm) of the primers and the DNA polymerase used for DNA 
synthesis impact the temperatures and the length of time they are applied in each cycle.  
An initialisation step consisting of heating the reaction to a temperature of 94-960C held for 1-
9 minutes is required for DNA polymerases. There are three steps after the initialisation step 
to a PCR reaction including denaturation, primer annealing and elongation. Denaturation at 94-
980C for 20-30 seconds causes DNA melting of the DNA template by disrupting the hydrogen 
bonds between complementary bases, which produces single-stranded DNA. During the 
annealing step, specific primers (short complementary oligonucleotides of single stranded 
DNA about 20 base pairs long) flank the target region on the template DNA and serve as a 
starting point for DNA synthesis. Then, they prime a DNA polymerisation reaction in the 
presence of thermostable DNA polymerase (eg. from Thermus aquaticus or Pyrococcus 
furiosus), the deoxyribonucleic acids dATP, dTTP, dCTP and dGTP, an appropriate co-factor 
such as MgCl2, and buffer solution. Primer annealing occurs at a lower temperature (between 
50-650C for 20-40 seconds) to allow specific hybridisation of primers to the complementary 
part of the template strand. Finally, there is an elongation step during which a new DNA strand 
complementary to the DNA template strand is synthesised in a 5' to 3' direction at 720C. A 
suitable chemical environment for optimum activity and stability of the DNA polymerase is 
essential and provided by the buffer solution. Magnesium acts as a cofactor and catalyser, 
increasing productivity of Taq DNA polymerase.  Following the last PCR cycle, the final single 
elongation is performed at 70-740C for 5-15 minutes to fully extend any remaining single-
stranded DNA.  
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 DNA extraction  
Genomic DNA was extracted using a QIAamp DNA Mini Kit (Qiagen, UK) as described by 
the manufacturer. The quality of DNA and its concentration were estimated using 
NanoDropTM ND-1000 Spectrophotometer and sample type DNA-50 (NanoDrop 
Technologies, Inc. Wilmington, DE, USA). A blank measurement of the appropriate solvent 
devoid of sample was used before sample measurement, and the pedestals were cleaned with 
distilled water between each measurement. The absorbance for nucleic acids is at 260nm, for 
protein or phenol contaminants at 280nm and for carbohydrate or solvent contamination at 
230nm. Hence, the ratio of 260:280 or 260:230 can be used as a measure of sample purity. A 
ratio of 260:230 is higher than the ratio of 260:280 for a given sample, which normally is 1.8-
2.2. The purity of DNA was determined by the ratio of 260nm:280nm, which is around 1.8 for 
good quality of DNA (Figure 2-1).  
 
Figure 2-1: The absorbance spectra pertaining to a DNA sample  
 
 PCR protocol  
All reagents needed for the PCR experiment were prepared at the appropriate concentration 
(the final concentration of DNA should be at least 100ng) and kept on the ice throughout the 
experiment (Table 2-4). The mixture of reagents was set up at the PCR station and the PCR 
tubes were placed into the thermal cycler (GeneAmp PCR Systems, AB Applied Biosystems) 
run based on the Touchdown programme (Table 2-5). The TP53 exon 4 sequence was split into 
two partially overlapping amplicons due to its large size. The purification of PCR products was   
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carried out for subsequent analysis using the purelink PCR purification kit (Qiagen, UK) in 
accordance with the manufacturer’s protocol. 
 
Table 2-4: The reagents and their volumes used for PCR. *, The concentration of DNA 
should be measured; **, the volume depends on the DNA concentration. SN, Sense; ASN, 
Antisense, dH2O, Distilled water.  
 
 
Table 2-5: The PCR programme used to amplify exons 4.1, 4.2, 5, 8 & 9. *, The 
temperature decreases by 0.50C each cycle. 
 
 DNA gel electrophoresis  
DNA gel electrophoresis was used to separate and identify DNA fragments based on the 
amplicon size. The loading buffer (G1881, Promega, UK) was added to the PCR products to 
visualize and load the samples into the wells, and to determine how far the samples have 
migrated during the run. The 100bp DNA Ladder (Life Technologies) was diluted in 1/10 with 
Tris 10mM and used as a DNA ladder. DNA gel electrophoresis was performed using 2% 
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agarose gel (Bp1356-500, Fisher Scientific) (w/v, 0.5x TBE) with 100 voltage for around 45 
minutes. To prepare 0.5x TBE, 100 ml of 5x TBE (1.1M Tris; 900mM Borate; 25mM EDTA; 
pH 8.3) was added to 900mL of deionized water and mixed well. Then, DNA was visualised 
using Biorad image software under UV light on a transilluminator and digitally photographed 
(Figure 2-2). The length of amplicon was calculated applying the BioEdit v 7.2 software. 
 
 
Figure 2-2: The PCR product for TP53 exon 5 with the amplicon size of 294 bp (base 
pairs). 
 
2.13 Quantitative real-time PCR  
 Principles of qRT-PCR 
qRT-PCR is a molecular technique monitoring amplification of a targeted cDNA molecule 
during the PCR in real time. qRT-PCR was performed using SYBR® green RT-PCR master 
mix (Life technologies) on an ABI 7900HT sequence detection system. SYBR green is a 
fluorescent dye binding to the minor groove of double-stranded DNA, dsDNA, with an 
excitation wavelength of ~ 485nm and an emission wavelength of ~ 524nm. The intensity of 
fluorescent signal measured by a detector directly associates with double-stranded DNA 
quantity. Therefore, the amount of PCR double-stranded DNA products can be measured after   
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every elongation step in real time. The fold changes in the expression of the target gene in 
relation to internal reference genes is determined for relative quantification.  
 RNA extraction  
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Germany) as described by the 
manufacturer. RNA purity and concentration were estimated with an ND-1000 
spectrophotometer and sample type RNA-40 as stated in section 2.12.2 (NanoDrop 
Technologies, Thermo Scientific, UK). The purity of RNA was determined by the ratio of 
260nm:280nm, which is approximately 2.0 for good quality of RNA.  
 cDNA synthesis 
Total messenger RNA was converted to cDNA using the thermal cycler (GeneAmp PCR 
Systems, AB Applied Biosystems) in accordance with the manufacturer’s guidelines 
(Table 2-6). PCR reactions were performed using cycling parameters (Stage 1: 42 ˚C for 1 
hour, Stage 2: 95 ˚C for 5 min) for only 1 cycle. 
 Primer validation 
All primers used were validated by preparing a serial dilution of the genomic DNA template 
and using SYBR Green Master Mix and SDS 2.3 software (Applied Biosystems) as described 
by the manufacturer (Figure 2-3). Validated primers used (Sigma-Aldrich UK) are listed in 
Table 2-7 and Table 2-8. 
 qRT-PCR protocol 
PCR reactions with 50 ng/μl of the cDNA samples per 10μl final reaction volume, were 
performed using standard cycling parameters (Stage 1: 50˚C for 2min, Stage 2: 95˚C for 10min, 
then 40 cycles of 95˚C for 15 Sec and 60˚C for 1 min) on an ABI 7900HT sequence detection 
system. GAPDH was used as endogenous control due to its almost constant level of expression, 
and the DMSO solvent control sample used as the calibrator for each independent repeat. Data 
analysis using the ΔΔCt Method was carried out using SDS 2.3 software (Applied Biosystems). 
Data were presented as mean ± standard error of mean (SEM) relative quantities (RQ) of ≥3 
independent repeats.  
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Table 2-6: The reagents and their volumes used for q-RT-PCR. *, The concentration of 
RNA should be measured; **, the volume depends on the RNA concentration and the 
final concentration of RNA should be 500ng. 
 
 
Figure 2-3: The results of primer validation.   
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Table 2-7: The primers and their sequences used for qRT-PCR experiments for DNA 
repair genes. F, Forward; R, Reverse. 
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Table 2-8: The primers and their sequences used for qRT-PCR experiments for the pro-
apoptotic, anti-apoptotic, cell cycle arrest and GAPDH genes. F, Forward; R, Reverse.
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2.14 Analysis of cell cycle distribution and apoptosis via flow cytometry 
The DNA content in the distinct cell cycle phases is different with diploid (2N) for G0/G1 
phase cells, 2N>n<4N for the cells in S-phase and tetraploid (4N) for those in G2/M phases. 
The distribution of a population of cells into different phases of the cell cycle can be estimated 
through measuring the DNA concentration by Flow cytometry. Induced changes in the cell 
cycle distribution following exposure to drug may also provide information to understand 
underlying mechanisms of drug function. 
 The principles of FACS  
For cell cycle analysis by flow cytometry, the plasma membrane of the cells must permeablised 
by using a buffer containing a detergent such as Triton-X. The cells should also be treated with 
RNase A to remove RNAs from the cells and eliminate artefacts distorting the results when the 
cells are stained with dyes binding to both DNA and RNA. The last step is quantitatively 
staining the DNA with a fluorescent dye such as propidium iodide (PI). PI is an intercalating 
dye binding to both double-stranded DNA and RNA with an excitation wavelength of ~ 535nm 
and an emission wavelength of ~ 617nm when bound to DNA. Following staining and putting 
the cell suspension through the FACSCalibur, the cells were sucked through a narrow sample 
injection tube by a vacuum. The cells and their PI stained nucleus intercept the 488-nm argon 
ion laser beam causing transmission and scattering of the light which is detectable via a 
forward-scattered (FSC) diode and a side-scattered (SSC) diode. FSC and SSC give 
information about the volume and granularity of cells respectively. The scattered light can be 
detected by photodetectors and fluorescent light emitted from PI is reflected on to the FL-2 
585/42 detectors by dichromic mirrors at right angles to the beam of light whereas other 
wavelengths of light are transmitted for other detectors to pick up. Detectors are 
photomultipliers with the ability to amplify signals from single photons so that they can 
electronically be recorded.   
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 FACSCalibur instrument setting and gating 
The instrument settings have to be optimised to detect, record and analyse events with size and 
complexity characteristic of mammalian cells rather than other objects that intercept the light. 
To optimise instrument setting, the scatter plots of SSC-H vs. FSC-H and FL2-A vs. FL2-W 
were set up using CellQuest software (Beckton Dickinson) and an untreated control sample of 
each cell line. Furthermore, a histogram of counts vs. FL2-H was set up where the G0/G1 and 
G2/M peaks were set to 200 and 400 on a linear scale respectively. Therefore, the events which 
have a FL2-A intensity below diploid cells known as SubG1 events are detectable. For each 
sample, data acquisition was collected at 10000 events and saved. 
 Flow cytometry protocol 
Based on the type of cells and their growth rate, the appropriate density of cells was seeded in 
a 6-well plates (Corning) or small cell culture flask (25 cm) and treated as described in specific 
materials and methods of the relevant chapters. Harvested cells, both floating and adherent, 
were washed with PBS and resuspended in 500 μL PBS and incubated at room temperature for 
around 20 minutes. Then, they were diluted 1:1 in a PI solution with 1mg/mL sodium citrate 
(Sigma, St Louis, MO), 100 µg/mL propidium iodide (Sigma), 200 µg/mL RNAse A (Sigma) 
and 0.3% Triton-X (Sigma) to stain. The samples were analysed on a FACSCalibur flow 
cytometer using CellQuest Pro software (Becton Dickinson, Oxford, UK) after three times 
syringing to remove any clumps of cells. It is an essential step because an aggregation of two 
G0/G1 cells can mistakenly be counted as a G2/M cell.  
 FACS data analysis 
The CellQuest software was used to analyse acquired FACS files and generate representative 
2D and 3D histograms of control and treated sample cell cycle distribution. The Cyflogic v 
1.2.1 software (CyFlo Ltd, Turku, Finland) was applied to manually gate the population of 
events in different phases of cell cycle and gate-out the SubG1 events on the FL2-A histogram 
plots. The proportion of events in S-phase and the percentage of those in each of peaks 
corresponding to G0/G1 and G2/M was calculated and plotted on the grouped bar charts using 
GraphPad Prism 6 software. The proportion of SubG1 events, a surrogate marker of apoptosis, 
was calculated as a percentage of total events and represented as separate bar charts 
(Figure 2-4).   
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Figure 2-4: Cell cycle distribution and apoptotic endpoints of control (untreated) and 
treated samples in which the events were manually gated. 
2.15 Caspase 3/7 activity 
The Caspase-Glo® 3/7 Assay is a luminescent assay which includes a proluminescent caspase 
3/7 substrate containing the tetrapeptide sequence DEVD. In the presence of caspase 3 and 
caspase 7 activities, the substrate is cleaved resulting in release of aminoluciferin which is a 
substrate of luciferase used in the production of luminescent light.  
Caspase 3/7 activity was measured using a Caspase-Glo® 3/7 Assay (Promega, Southampton, 
UK) following the manufacturer’s instructions. The cells were seeded at the appropriate 
densities and treated as outlined in specific materials and methods of the relevant chapters.The 
luminescence was measured using a Fluostar Omega Plate Reader (BMG LABTECH) and 
luminescence readings were normalized and plotted relative to the control.  
2.16 Statistical analysis 
All statistical tests presented were carried out using the SPSS 22.0 software package for 
windows (SPSS Inc., Chicago, USA) or GraphPad Prism version 5.04 software. The type of 
statistical tests used are specified in the individual materials and methods sections for each 
chapter. A p-value of <0.05 was considered to be statistically significant. 
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Chapter 3: An investigation of ovarian cancer tumour samples for p53, 
p21WAF1, MDM2 and WIP1 expression using tissue microarrays (TMA) 
of OVCA1-4 cohort 
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3.1 Introduction 
Mutation and overexpression of the TP53 gene is one of the most frequent genetic 
abnormalities in ovarian cancer. Overexpression of p53 occurs in 51% of ovarian cancer, and 
the reported rate of TP53 mutation ranges from 30% up to 80% (Reles et al., 2001; Kmet et 
al., 2003; Ling and Wei-Guo, 2006; Bast et al., 2009). p21WAF1, MDM2 and WIP1 are p53 
downstream targets playing a critical role in cell cycle arrest, the p53 negative autoregulatory 
loop and dephosphorylation of p53 respectively (Abbas and Dutta, 2009; Le Guezennec and 
Bulavin, 2010; Wade et al., 2013). Given the controversial results about the importance of p53, 
p21WAF1 and MDM2 as prognostic biomarkers in ovarian cancer and the important role of WIP1 
in dephosphorylation and inactivation of p53, this part of the study focussed on the 
investigation of the roles of these proteins as prognostic and predictive biomarkers in ovarian 
cancer (Sengupta et al.; Kmet et al., 2003; Dogan et al., 2005; Han et al., 2009; Bauerschlag 
et al., 2010; Le Guezennec and Bulavin, 2010; Ali et al., 2012; Skirnisdottir and Seidal, 2013). 
 p53 as a guardian of the genome and cellular gatekeeper 
The tumour suppressor p53 responds to intrinsic and extrinsic stress signals. Following 
exposure to stress, p53 stabilization, sequence-specific DNA binding, and transcriptional 
activation of target genes occur to protect cells against environmental and intra-cellular stress 
stimuli (Wade et al., 2013). The p53 pathway can be divided into two parts; upstream pathway 
and downstream pathway. Upstream mediators distinguish and respond to stress signals to 
increase stabilisation of p53 largely as a result of post-translational modifications of p53 and 
its regulators such as the MDM2 and MDMX proteins. The downstream pathway involves p53 
transcriptional transactivation events and interactions between proteins. The p53 protein 
regulates expression of its downstream transcriptional targets including upregulation of the 
growth inhibitory WAF1 gene, proapoptotic genes such as BAX and PUMA, the MDM2 
autoregulatory p53 inhibitor, as well as inactivation of prosurvival BCL2 family members. In 
summary, the final outcome of p53 activation is either cell cycle arrest and DNA repair, 
senescence or apoptosis (Vassilev, 2007; Mandinova and Lee, 2011). The role of p21WAF1 in 
cell proliferation control, and the importance of MDM2 and WIP1 as negative regulators of 
p53 are described in chapter 1.5.4, 1.5.7 and 1.6.4 respectively.  
Due to importance of p53 and its downstream targets, p21WAF1, MDM2 and WIP1, it was set 
out to investigate the role of these proteins in ovarian cancer and their correlation with survival.  
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3.2 Hypothesis and Objectives 
Hypothesis:  
1. p53 and its downstream targets, p21WAF1, MDM2 and WIP1 can be considered as 
prognostic biomarkers for overall survival in ovarian cancer. 
Objectives: 
1.  To establish whether tumour sample immunohistochemical staining for p53, p21WAF1 
and MDM2 has prognostic value in the OVCA1-4 patient cohort. 
2.  To evaluate whether immunohistochemical staining for WIP1 provides additional 
predictive value for overall survival in the OVCA3-4 patient cohort.
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3.3 Specific Materials and Methods 
The first part of this study was performed using IHC on TMA samples collected from ovarian 
cancer patients from the North East of England, who had been referred to the Queen Elizabeth 
Hospital Gateshead Newcastle (QE).  
 TMA and patient characteristic 
Ovarian cancer patients who underwent primary surgery between 1995 and 2000 were detected 
using the Queen Elizabeth Hospital pathology department database. Among the samples 
collected between these years, cases with minimum 5 years of clinical and survival data were 
selected and a collection of 167 of primary epithelial ovarian cancer was detected based on the 
all histology reports. All patient data including surgery, pathological and survival data were 
collected, entered into an anonymous databases and stored in a secure server in accordance to 
clinical laboratory practice guidelines. 
 Developing an ovarian cancer TMA 
TMA design is described in chapter 2.1.3. All samples were immunostained with Cytokeratin 
to map the tumour areas which were determined by a pathologist (Dr Paul Cross). There was 
no pathology review to update the diagnosis of these archival samples. Sample cores were 
taken from individual tumour FFPE blocks to construct 4 TMA blocks representing all the 
patient’s tumour specimens, with duplicate cores on each block. Four TMAs, OVCA1-4, were 
produced using a manual tissue microarray (TMA I, Beecher Instruments) by members of the 
ovarian cancer group, including Dr. Ali Kucukmentin, Dr. Ahmed Elattar and Dr. Richard 
Edmondson and with the help of Dr. Paul Cross (consultant pathologist at Queen Elizabeth 
Hospital, Gateshead).  
As mentioned in most studies, a standard 1mm diameter core of tissue was taken from the 
marked area and used for these TMAs (Eckel-Passow et al., 2010; Kim et al., 2013). Following 
arraying of all the cores, the completed TMA block was incubated face down on to a normal 
glass slide at 37 0C for 30 minutes. This process was done to warm the paraffin which provides 
stability for the cores. Sections were cut from the TMA blocks and mounted on four slides 
labelled as OVCA1, OVCA2, OVCA3 and OVCA4. Immunohistochemical (IHC) staining was 
carried out on the TMA slides for p53, p21WAF1, MDM2 and WIP1 proteins. There was 
appropriate ethical approval to analyse the samples and patient details obtained from hospital   
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records. Clinicopathological data had been recorded for histological subtype, stage, residual 
disease, CA125 and grade. Incomplete data were recorded as lost (Table 3-1). 
 Antibody specificity and optimization 
Monoclonal Mouse Anti-Human p53 (Clone DO-7, Dako, 1:100), MDM2 (OP46, Calbiochem, 
1:50), WIP1 (F-10, Santa Cruz Biotechnology, 1:500) and Monoclonal Rabbit Anti-Human 
p21WAF1 (2947S, Cell Signalling, 1:50) proteins were used for IHC staining. Validation of 
MDM2 antibody was performed using paraffin-embedded pellets of MDM2 inhibitor treated 
(10 µM Nutlin-3) SJSA and its Nutlin-3 resistant daughter cell line SN40R2 (Bo et al., 2014; 
Esfandiari et al., 2016) as positive and negative control respectively. Due to cross reactivity 
between monoclonal anti-MDM2 clone SMP14 and cytokeratin 6, 14 or 16 causing a problem 
when working with epithelial cells (www.abcam.com/MDM2-antibody-SMP-14-ab3110; 
www.emdmillipore.com/.../Anti-MDM2-Antibody), we investigated the expression of these 
cytokeratins in the ovarian adenocarcinomas to be sure there is no cross-reactivity. Based on 
the literature, there is no expression of K6, K14 and K16 in ovarian carcinoma, whereas a 
K7+/K20- expression is characteristic of ovarian adenocarcinomas (Karantza, 2011). 
The paraffin-embedded pellets of MDM2 inhibitor treated (5 µM Nutlin-3) MCF7 cells was 
used as a positive control and DMSO treated SJSA cell line as a negative control to validate 
the WIP1 antibody (Figure 3-1). The SJSA and MCF7 cell lines are amplified for MDM2 
(Arkin et al., 2014) and PPM1D (Parssinen et al., 2008) genes respectively. The antibodies 
were optimized as described in chapter 2.2.1 and the best outcomes were used for experiments 
(Figure 3-2).   
 Staining, scoring and categorising 
IHC was carried out based on the details explained in section 2.2.1, and slides stained omitting 
the primary antibody were used for negative control (Burry, 2011). The H-score is a method to 
evaluate the extent of immunoreactivity, which is obtained according to the intensity of IHC 
staining and the percentage area stained. More detail for scoring is provided in section 2.2.2. 
Receiver Operating Characteristic (ROC) curve analysis was used to examine the relationship 
between sensitivity and specificity for immunohistochemical staining scores. The ROC curve 
(Cao et al., 2014) or distribution of H-score values (Madjd et al., 2011) were used to categorise 
the samples into two groups of high and low expression for p53, p21WAF1, MDM2 and WIP1 
proteins.  
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 Statistical analysis 
The statistical significance of observed differences in patient survival was analysed by the 
Kaplan-Meier method using a Log-rank test. For differences in the distribution of 
immunohistochemistry scores between subsets of patient samples an Analysis of variance 
(ANOVA) test was used. The Mann-Whitney and Kolmogorov-Smirnov tests were used to 
compare probability distribution in two samples. All statistical tests presented were carried out 
using the SPSS 22.0 software package for windows (SPSS Inc., Chicago, USA) or GraphPad 
Prism version 5.04 software. A p-value of <0.05 was considered to be statistically significant.  
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Table 3-1: Clinicopathological data for 167 samples of ovarian cancer on TMA 1-4. 
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Figure 3-1: Image demonstrating validation of WIP1 (F-10, 1:500) and MDM2 (OP46, 
1:1000) antibodies using FFPE pellets of MDM2 inhibitor or DMSO treated SJSA, MCF7 
and SN40R2 cells.
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Figure 3-2: Image demonstrating optimization of p53, p21WAF1, MDM2 and WIP1 
antibodies on samples of tissue cores from the ovarian cancer TMA 1 to 4 slides. Images 
were captured and viewed by ScanScope® CS (Aperio Technologies, Bristol UK) at 10X 
magnification.
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3.4 Results 
 Overall Survival (OS) 
Overall disease related survival is the time for which people in a study or treatment category 
are alive, measured from date of diagnosis to the last time the patients were seen or their date 
of death as a result of disease, excluding deaths unrelated to disease (Bewick et al., 2004). 
Kaplan-Meier analysis is a standard way to analyse survival when there is a variable follow-up 
time. This involves calculating the fraction of individuals surviving for a certain length of time 
after therapy in spite of variable follow-up times and loss to follow-up of some subjects (Rich 
et al., 2010). Kaplan-Meier survival plots were applied to determine the relationship of 
variables to survival. Comparison between the survival curves was made by Log-rank test, 
employing logarithms of the ranks of the data and calculating a p-value to confirm whether or 
not the overall differences amongst survival curves are statistically significant. 
In this cohort, 104 (62%) women died of ovarian cancer, 4 (2%) died because of other reasons, 
10 (7%) were alive with disease recurrence, 38 (23%) were alive without disease and 11(6%) 
cases did not follow after surgery. 
A Kaplan-Meier survival analysis was performed according to the clinicopathological data. 
The overall five year disease specific survival was 32% which is comparable to other studies 
with the overall 5-year survival about 30% (Agarwal and Kaye, 2003; Dogan et al., 2005; 
Witham et al., 2007; Corney et al., 2008; Yasmeen et al., 2011) (Figure 3-3). The median 
disease specific survival was 26.6 months in the range of 0-116 months (CI=95%).  
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Figure 3-3: Kaplan-Meier graph showing 32% five-year overall survival for the TMA 1-
4 patient cohort.  
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 Histological tumour subtype and patient survival 
The incidence in diverse histological subtypes was 66 cases (39%) HGSC, 51 cases (30%) 
endometrioid, 18 cases (11%) mucinous, 16 cases (10%) clear cell, 13 cases (8%) LGSC and 
3 cases (2%) adenocarcinoma, with a total n=167. The observed differences among survival 
curves in relation to different histological subtypes were statistically significant X2=14.61, 
p=0.01). None of the patients suffering from adenocarcinoma survived to 5 years, although the 
numbers were small. Individuals with clear cell (20%) and HGSC (20%) had the worst 5 year 
specific survival, whilst patients with endometrioid (46%), LGSC (45%) and mucinous (39%) 
tumour histologies were in a better prognosis group (Figure 3-4). These results were consistent 
with the fact that clear cell and HGSC are known to be more aggressive types of ovarian cancer 
and help to validate the cohort. 
 
 
Figure 3-4: The survival times in relation to histological subtypes (p=0.01).
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 Stage and relationship with survival 
The frequency distribution for different disease stages was 28 (17%), 14 (8%), 90 (54%) and 
18 (11%) at I, II, III, IV stages respectively and 17 (10%) cases were missed, which give a total 
of n=150. Statistical analysis indicated that the stage of disease was a highly significant 
prognostic factor for survival (X2=56.81, p< 0.0001). Diagnosis at an earlier stage of disease 
was associated with increased 5 year specific survival with 75%, 64%, 21%, and 0% for stages 
I, II, III and IV respectively (Figure 3-5). 
 
 
Figure 3-5: The survival times in relation to disease stage (p< 0.0001).
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 Tumour grade and patient survival 
In the TMA 1-4 study cohort, 80 cases (48%) were recorded with grade III tumours (poorly 
differentiated), 45 cases (27%) were grade II (intermediate differentiation) and 42 (25%) were 
grade I (well differentiated) (n=167). Statistical analysis showed the grade to be a significant 
prognostic variable (X2=6.93, p=0.03). The 5 year survival probability was 47%, 27% and 25% 
for well (I), intermediate (II) or poorly differentiated (III) tumours respectively (Figure 3-6). 
 
 
Figure 3-6: The survival times in relation to tumour grade (p=0.03).
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 Residual disease and patient survival 
Malignant cells or neoplasia remaining after surgery is referred to as residual disease and the 
surgical outcome is categorised into three groups; complete, optimal and suboptimal. There is 
no remaining visually observable malignant tissue in the complete surgical cytoreduction 
category, whereas less and more than 1 centimetre nodules left at the end of surgery define 
optimal and suboptimal cytoreduction groups respectively. 
54 (32%) of patients from the cohort had complete surgical removal of disease. 30 cases (18%) 
were grouped in the optimal and 64 (39%) in the suboptimal surgical cytoreduction categories 
(n=148) and 19 (11%) cases were lost. Residual disease was a highly significant prognostic 
factor (X2=60.02, p<0.0001), and the 5 year survival probabilities were 66% for complete, 29% 
for optimal and less than 6% for suboptimal groups (Figure 3-7). 
 
 
Figure 3-7: The survival times in relation to residual disease (p<0.0001).
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 CA125 and relationship with survival 
CA125 is a glycoprotein, which has been used as a biomarker for specific types of cancer, such 
as ovarian cancer, due to increased level in the blood of patients. However, the role of it as a 
predictor is controversial because of lack of sensitivity and specificity.  
In order to analyse the relationship of survival to available CA125 measurements on blood 
samples, the subjects were divided into two categories based on the median value of CA125 
which was 480 within the range of 6 to 14465. Two groups were ≤ 480 CA125 level (71, 42%) 
and > 480 CA125 level (68, 41%), and data was missing for 28 (17%) cases with a total n=139. 
As the graph shows, individuals with a low level of CA125 appeared to have improved survival 
in comparison with the high CA125 group, but the difference according to the Log-rank test 
(X2=2.92, p=0.08) was not significant at the 95% confidence level (Figure 3-8). 
 
 
Figure 3-8: The survival times in relation to CA125 (p=0.08).  
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 The p53 staining distribution, scores, categories and correlation with survival 
From a total of 167 patients, 12 (7%) cores were lost because of processing or not having 
tumour cells. The staining was predominantly nuclear and ranged from negative to strongly 
positive (Figure 3-9). This observation is consistent with IHC results reporting nuclear staining 
of p53 in ovarian cancer tissue samples (Dogan et al., 2005; Psyrri et al., 2007; Corney et al., 
2008; Bauerschlag et al., 2010). ROC curve analysis was used to determine a cut-off value and 
categorise the samples into high and low expression groups (Figure 3-10). The area under the 
ROC curve, AUC, showing the accuracy of the test was 0.66 and the p-value was 0.002. From 
a total of 155 samples, 2 (1%) were negative (H-score=0) and 153 (99%) of patients were 
positive (H-score>0) categorised as 95 (61%) low (H-score ≤9) and 60 (39%) high (10≤H-
score≤18) (Figure 3-11). 
The analysis of Kaplan-Meier survival in relation to p53 expression shown in Figure 3-12 
indicates that the differences between two groups based on the H-score values of p53 
expression are statistically significant. Individuals with tumours showing high staining for p53 
had a worse survival probability compared with the low p53 staining groups (X2=11.55, 
p=0.001) confirming p53 as a highly significant prognostic variable. The 5 year survival 
probabilities were 15% for high score, 43% for low score. The median disease specific survival 
was 37 months (in the range 0-116) for patients with tumour showing low expression of p53 
compared to 19 months for those with tumour expressing high levels of p53. 
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Figure 3-9: Image demonstrating p53-stained samples of tissue cores with different 
staining intensities and H-scores from the ovarian cancer TMA 1-4 slides.  
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Figure 3-10: The ROC curve in relation to p53 expression demonstrating the area under 
the curve (AUC=0.66, P=0.002), and the optimal categorisation cut-off point for patient 
samples based on the p53 expression. 
 
 
 
Figure 3-11: The p53 H-score distribution in samples from 155 patients. The horizontal 
black line represents the median, which equals to the optimal cut-point value gained by 
ROC curve.
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Figure 3-12: The survival times in relation to low (H-Score≤9) and high (10≤H-score≤18) 
expression of p53 (p=0.001). 
 Univariate analysis of p53 H-score and corresponding clinicopathological data 
The Kruskal-Wallis one-way ANOVA test was used to determine whether there are any 
significant relationships between the level of p53 expression and prognostic variables shown 
in univariate analysis to be associated with poor survival, including grade, histological subtype, 
residual disease and stage (Figure 3-13). The results showed that generally p53 staining was 
higher in groups which are known to have a poor prognosis on the basis of other factors 
(Figure 3-13). The expression of p53 in patients at low stages of ovarian cancer (I & II) was 
lower than those at advanced stages (III & IV) (X2=13.30, p=0.004). Both Mann-Witney and 
Kolmogorov-Smirnov tests are nonparametric tests which compare two unpaired groups of 
data. However, Mann-Whitney test is mostly sensitive to changes in the median. The Mann-
Whitney (p=0.0002) and Kolmogorov-Smirnov (p=0.0008) tests both showed that the stage 
III p53 H-score was significantly higher than for stage I. However, there was no significant 
difference between stage I and stage II or IV. Also, on average individuals with complete 
debulking surgery had low expression of p53 compared to other groups (X2=12.80, p=0.002). 
Based on the Mann-Whitney (p=0.001) and Kolmogorov-Smirnov (p=0.005) tests, p53 
staining in patients with complete cytoreductive surgery was significantly lower compared to 
those with optimal cytoreduction. In comparison, only the Mann-Whitney test (p=0.019) 
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showed that individuals with completely cytoreductive surgery have lower expression of p53 
compared to patients with suboptimal cytoreduction. Furthermore, well differentiated tumours 
had lower expression of p53 (X2=20.13, p<0.0001). The Mann-Whitney (p=0.0006, p<0.0001) 
and Kolmogorov-Smirnov (p=0.014, p=0.0006) tests both indicated that the well differentiated 
tumours p53 H-score was significantly lower than for moderately and poorly differentiated 
tumours respectively. The p53 H-scores were also significantly different between histological 
subtypes (X2=30.85, p<0.0001). The p53 immunostaining H-scores were significantly higher 
in HGSC than mucinous, (Man-Whitney p=0.0003 and Kolmogorov-Smirnov p=0.014), clear 
cell (Man-Whitney p=0.0001 and Kolmogorov-Smirnov p=0.001) and endometrioid (Man-
Whitney p=0.02). The Mann-Whitney test also showed a statistically significant difference in 
p53 staining between mucinous and endometrioid (p=0.018) or LGSC (p=0.035) 
(Figure 3-13). 
 
Figure 3-13: Statistical analysis of the relationship between p53 H-score and prognostic 
variables. Grade (p<0.0001), Residual disease (p=0.002), Stage (p=0.004) and Histological 
subtype (p<0.0001) (Kruskal-Wallis test).
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Table 3-2: Univariate analysis of p53 H-score and corresponding clinicopathological data. 
p53 H-score ranged from 0 to 18. Significant p-values are highlighted (Kruskal-Wallis 
test). *, p<0.05; **, p<0.01; ***, p<0.001.
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 The p21WAF1 staining distribution, scores, categories and relationship to survival  
From a total of 167 patients, 11 (7%) cores were missing during processing and 156 (93%) 
remained to analyse. The staining was confined to the nucleus and ranged from negative to 
strong positive which is consistent with other IHC staining of p21WAF1 on ovarian cancer 
showing nuclear staining (Anttila et al., 1999; Schmider et al., 2000; Rose et al., 2003a; Bali 
et al., 2004; Skirnisdottir and Seidal, 2013) (Figure 3-14). To determine the cut-off value and 
categorise the samples based on the p21WAF1 expression, the ROC curve analysis was used. 
The AUC and p-value were 0.53 and 0.56 for p21WAF1 immunohistochemical staining 
indicating no significant relationship of p21WAF1 expression to survival (Figure 3-15). The 
frequency distribution for p21WAF1 staining was 13 (8%) negative and 143 (92%) positive with 
total cases N=156. Based on the frequency distribution of p21WAF1 scoring and the median, 
p21WAF1 scores were grouped as low (H-Score=0-2) and strong (H-Score=3-11) (Figure 3-16). 
These values were applied to determine relationship of p21WAF1 protein expression with 
survival. 
The analysis of Kaplan-Meier survival in relation to p21WAF1 expression shown in Figure 3-17. 
The statistical analysis indicated that the p21WAF1 expression was not prognostic variable for 
survival (X2=0.22, p=0.64). 
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Figure 3-14: Example images of p21WAF1-stained tissue cores from OVCA 1-4 slides. The 
images were captured using spectrumTM software. 
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Figure 3-15: The ROC curve for p21WAF1 expression in relation to the prognostic value 
for patient survival (AUC=0.53, p=0.56). No clear optimal cut-point was evident. 
 
 
 
Figure 3-16: The p21WAF1 H-score distribution for tumour samples from 156 patients. 
The horizontal black line represents the median.
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Figure 3-17: The survival times in relation to low (H-Score<2) and high (3≤H-score≤11) 
p21WAF1 expression (p=0.64). 
 
 Univariate analysis of p21WAF1 H-score and corresponding clinicopathological 
data 
A scatter plot of the overall relationship between p53 and p21WAF1 expression, showed there 
was no overall inverse relationship between the expression of p53 and p21WAF1 in this dataset 
(Figure 3-18).  
The relationship between p21WAF1 H-score and stabilised prognostic variables was examined 
by the Kruskal-Wallis test. The results showed no significant difference in p21WAF1 H-scores 
amongst the three grades (p=0.8). The p21WAF1 immunostaining H-scores were not 
significantly different between different histological subtypes (p=0.07) with one missing case 
(0.6%). No significant difference was observed between the three residual disease sub-groups 
(p=0.5) (with 18 lost cases, 11.5%) or for the four tumour stages (p=0.2) (with 15 missing 
cases, 9.6%) (Figure 3-19).  
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Figure 3-18: A scatter plot showing the lack of correlation between p53 and p21WAF1 H-
scores. 
 
 
Figure 3-19: The statistical analysis of the relationship between p21WAF1 H-score and 
prognostic variables. Grade (p=0.80), Residual disease (p=0.57), Stage (p=0.21) and 
Histological subtype (p=0.07) (Kruskal-Wallis test). For stage II, low grade serous and 
endometrioid, the median of H-scores is equal to 25% percentile. 
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 Concomitant expression of p53 and p21WAF1 and correlation with survival 
To study the relationship between concomitant expression of p53 and p21WAF1 and survival, 
the samples were grouped into four categories based on the level of H-scores for both proteins 
(Table 3-3). As shown in the Figure 3-20, there was a significant difference between the four 
categories based on the combination H-score values of p53 and p21WAF1 in relation to survival 
(X2=11.92, p=0.01). However, the effect is related to the p53 expression levels not p21WAF1 
status. No significant difference was observed between tumours with p53 high expression and 
p21WAF1 low expression compared to those with p53 high expression and p21WAF1 high 
expression (X2=0.20, p=0.66). There was also no significant difference between patients with 
tumours expressing p53 low and p21WAF1 high or p53 low and p21WAF1 low (X2=0.005, 
p=0.94). This indicates that the significant difference is related to the expression of p53, and 
p21WAF1 status does not add anything (Figure 3-20). 
 
 
Table 3-3: Concomitant expression of p21WAF1 and p53 based on the H-score data.
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Figure 3-20: The survival times in relation to concomitant expression of p21WAF1 and p53 
(p=0.01).   
 
 The MDM2 staining distribution, scores, categories and correlation to survival 
The MDM2 IHC showed nuclear staining ranging from negative to strongly positive 
(Figure 3-21). This pattern of staining was consistent with other IHC findings for MDM2 on 
ovarian cancer tissue (Baekelandt et al., 1999; Sengupta et al., 2000; Dogan et al., 2005). Of 
the 167 patients, 22 (13%) cases were lost because of processing or not having tumour cells. 
The ROC curve analysis gave an AUC=0.56 and p=0.24, which indicates no significant 
relationship between MDM2 expression and survival (Figure 3-22). Overall, 21 (14%) of 
patients had tumours that were negative and 124 (86%) were positive for MDM2 expression 
from a total of n=145 cases. The median H-score value was used to categorise the dataset into 
low (H-Score=0-2) and high (H-Score=3-11) groups to examine whether there was any 
relationship to patient survival (Figure 3-23).  
The Kaplan-Meier survival analysis in relation to MDM2 expression (Figure 3-24) showed no 
significant correlation between MDM2 expression and survival times (X2=0.94, p=0.33). 
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Figure 3-21: Example images of MDM2-stained tissue cores with different intensities 
from the OVCA1-4 microarray slides. 
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Figure 3-22: The ROC curve analysis for the survival prognostic value of MDM2 
expression (AUC=0.56, p =0.24) showing no clear optimal cut-off level.  
 
 
Figure 3-23: The frequency distribution of MDM2 H-score in samples from 145 patients. 
The horizontal black line represents the median. 
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Figure 3-24: The survival times in relation to low (H-Score<2) and high (3≤H-score≤11) 
MDM2 expression (p=0.33).   
 
 Univariate analysis of MDM2 H-score and corresponding clinicopathological 
data 
In the TMA data presented here, there was no significant difference in MDM2 H-scores 
amongst the six different histological subtypes (p=0.59), three grades (p=0.63), three residual 
disease groups (p=0.18) with 15 (10%) lost cases or the four stage groups (p=0.36) with 13 
(9%) missing cases (Figure 3-25). 
 Concomitant expression of p53 and MDM2 and correlation to survival 
To investigate the relationship of concomitant expression of p53 and MDM2 with survival, the 
samples were grouped into four categories based on the H-score data for both proteins. 
(Table 3-4). The Kaplan-Meier graph showed a significant difference among the four 
categories based on the combined H-score values of p53 and MDM2 in relation to survival 
(X2=10.06, p=0.018) (Figure 3-26). The survival probability was significantly better in patients 
with low expression of p53 and high expression of MDM2 with the highest 5 year probability, 
46%, and median disease free survival of 45 months versus individuals with high expression 
of both p53 and MDM2 who had the worst survival with a 19% 5 year survival probability and 
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median disease free survival of 14 months (p=0.02). Patients with low expression of both p53 
and MDM2 had a significantly better overall survival than those with high expression of both 
p53 and MDM2 (p=0.04). There was also a significant difference in overall survival between 
individuals with low expression of p53 and high expression of MDM2 compared to patients 
with low expression of MDM2 and high expression of p53 (p=0.02).  
 
 
Figure 3-25: Statistical analysis of the relationship between MDM2 H-score and Grade 
(p=0.63), Residual disease (p=0.19), Stage (p=0.36) and Histological subtype (p=0.59) 
(Kruskal-Wallis test). For intermediate differentiated, optimal cytoreduction and stage 
III the median of H-scores is equal to 25% percentile.
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Table 3-4: Concomitant expression of MDM2 and p53 based on the H-score data. 
 
 
Figure 3-26: The survival times in relation to concomitant expression of MDM2 and p53 
(p=0.018). 
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 WIP1 staining, distributions, scores, categories and correlation to survival 
The WIP1 IHC showed mostly nuclear and occasionally cytoplasmic staining on the OVCA3-
4 slides, ranging from weak to strongly positive (Figure 3-27). From a total of 69 patients, 7 
(10%) of WIP1 stained cores were lost due to processing or not having tumour cells. No 
significant correlation of WIP1 expression to survival was indicated by the ROC curve analysis 
(AUC=0.56, p=0.48) (Figure 3-28). WIP1 IHC positive staining was observed for all samples 
(n=62). The median WIP1 H-score was used to categorise samples as low (H-Score=4-8), and 
high (H-Score=9-13) (Figure 3-29). These values were applied to examine the relationship of 
WIP1 protein expression to patient survival. 
The Kaplan-Meier graph showed no significant difference in survival between the two groups 
of individuals based on WIP1expression (X2=0.47, p=0.49) (Figure 3-30). The 5 year survival 
was 35% for the high score group and 40% for the low score group, with a median disease 
specific survival of 31 months for both categories.
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Figure 3-27: Example images showing WIP1-stained samples of tissue cores with 
different intensities from the OVCA3-4 TMA slides. 
 106 
 
 
Figure 3-28: The ROC curve for the survival prognostic value of WIP1 expression 
(AUC=0.56, p=0.48) showing no clear optimal cut-off levels based on the WIP1 
expression. 
 
 
Figure 3-29: The frequency distribution of WIP1 H-score in samples from 62 patients. 
The horizontal black line represents the median.
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Figure 3-30: The survival times in relation to low (4≤H-score≤8) and high (9≤H-score≤13) 
WIP1 expression (p=0.49).   
 
 Univariate analysis of WIP1 H-score and corresponding clinicopathological data 
No significant difference in WIP1 H-scores was observed between the six groups based on 
histological subtypes (p=0.26). A significant difference was shown neither for the four stage 
groups (p=0.37) with 6 missing cases (10%) nor for the three residual disease groups (p=0.46) 
with 8 lost cases (13%). The only significant difference in WIP1 IHC H-scores was amongst 
the three grades (X2=6.61, p=0.03) with one missing case (2%). The Mann-Whitney test 
indicated that the well differentiated tumours WIP1 H-score was significantly higher than that 
of  poorly differentiated tumours (p=0.001) while the difference between the well differentiated 
tumours WIP1 H-score and that of intermediately differentiate tumours was marginally 
significant (p=0.05) (Figure 3-31).  
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Figure 3-31: The statistical analysis of the relationship between WIP1 H-score and Grade 
(p=0.03), Residual disease (p=0.46), Stage (p=0.37) and Histological subtype (p=0.12) 
(Kruskal-Wallis test). For poorly differentiated, the median of H-scores is equal to 25% 
percentile. 
 
 Concomitant expression of p53 and WIP1 and relationship to survival 
The H-scores for both proteins were categorised into four groups to study the relationship 
between concomitant expression of p53 and WIP1 with survival (Table 3-5). As shown in 
Figure 3-32, no significant differences were found among the four groups based on the H-score 
values of both proteins in relation to survival (X2=1.78, p=0.62).  
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Table 3-5: Concomitant expression of p53 and WIP1 based on the H-score values. 
 
 
Figure 3-32: The survival times in relation to concomitant expression of p53 and WIP1 
(p=0.62). 
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 Multivariate cox regression analysis of survival 
A forward stepwise multivariate analysis was then performed including variables shown to be 
significant predictors of survival difference on univariate analysis including grade, residual 
disease, stage, histological subtype, p53 and coexpression of p53 and p21WAF1 or MDM2. In 
multivariate analysis, stage (p=0.002), histological subtype (p=0.04) and residual disease 
(p=0.01) were identified as independent prognostic variables for patients with ovarian cancer, 
with stage as the most significant indicator. In contrast grade (p=0.47), p53 (p=0.23), and 
concomitant expression of p53 and p21WAF1 (p=0.22) or p53 and MDM2 (p=0.06) do not 
appear as independent prognostic variables in multivariate analysis (Table 3-6). 
 
 
Table 3-6: Univariate and multivariate Cox regression analysis of p53/its downstream 
targets and survival. Histological subtype, stage and residual disease retain significance 
as independent prognostic variables for the OVCA 1-4 cohort. *, p<0.05; **, p<0.01; ***, 
p<0.001.
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3.5 Discussion 
Ovarian cancer is the fifth leading cause of cancer-related death in women (Zhan et al., 2013). 
Although several prognostic variables including serum CA125 levels, stage, residual disease 
and histological subtype have been used to detect and define risk categories in ovarian cancer, 
identification of new prognostic markers is necessary to gain benefit from effective therapies 
(Dogan et al., 2005; Huang et al., 2010). A number of studies have examined the correlation 
between expression of p53, p21WAF1, and MDM2 and survival in ovarian cancer; however, the 
findings are controversial (Anttila et al., 1999; Baekelandt et al., 1999; Schmider et al., 2000; 
Harlozinska et al., 2002; Dogan et al., 2005; Psyrri et al., 2007; Bartel et al., 2008). 
Given the central role of a functional p53 signalling pathway in cell cycle arrest, apoptosis, and 
response to chemotherapy and the previously reported controversial results, the first part of the 
study set out with the aim of assessing the importance of p53 and its downstream targets 
including p21WAF1, MDM2 and WIP1 as biomarkers to forecast the likely overall survival. This 
is the first study to investigate WIP1 expression as a potential prognostic variable in ovarian 
cancer.  
 Overall survival and established prognostic variables 
A comparison to previously published cohorts was performed to evaluate and validate the 
clinicopathological data for the cohort of patients used for the OVCA 1-4 TMA set. The five 
year overall survival was 32% for the cohort in this study which is in line with those of previous 
studies, 25% (Bartel et al., 2008), 29% (Corney et al., 2008), 30% (Agarwal and Kaye, 2003), 
30.6% (Zhan et al., 2013) and 35% (Dogan et al., 2005). In terms of histological subtypes, 
serous is the most common subtype in ovarian cancer accounting for up to 80%, compared to 
10-20% of endometrioid/mucinous and 5-10% of clear cell tumours (Colombo et al., 2010; 
Wang et al., 2012; Ledermann et al., 2013; Sung et al., 2014). 
In the present study, the serous histological subtype (47%) represented the highest proportion 
of samples, whereas the adenocarcinoma (2%) were the lowest proportion of samples. The 
proportion of mucinous (11%) and clear cell (10%) was in accordance with other studies 
although the frequency of endometrioid (30%) was higher and HGSC was lower than 
previously reported studies. The frequency distribution of HGSC is 60-80% of ovarian 
epithelial carcinoma (van Niekerk et al., 2011; Di Leva and Croce, 2013; Hua et al., 2016) and 
it is 10-20% for endometrioid (Cho and Shih, 2009;  Niekerk et al., 2011). The higher frequency   
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of endometrioid and lower frequency of serous particularly for HGSC than what expected 
might be because of not performing pathology review to update the diagnoses of these archival 
samples. Another possible explanation is that the detection of HGSC from high grade 
endometrioid can be very difficult as some pathologists classify high grade endometrioid as 
HGSC with endometrioid features or as a mixture of HGSC and high grade endometrioid 
(Kurman and Shih, 2011). Therefore, it might be due to pathological misclassification. 
Univariate analysis of overall survival indicated residual disease, FIGO stage, histological 
subtype and grade as significant prognostic factors (p<0.05). The subjects with HGSC and clear 
cell tumour had the worst 5-year specific survival, which is consistent with the established 
knowledge that these subtypes are more aggressive than others. Also, patients with advanced 
stages of disease, poorly differentiated tumour and incompletely resected residual disease had 
the worst 5-year specific survival, which is comparable to other studies (Reles et al., 2001; 
Ding et al., 2013). CA125 was not a significant prognostic variable in this study (p>0.05) 
consistent with data obtained by Osman (2008). The results of multivariate analysis confirmed 
stage, histological subtype and residual disease as independent prognostic variables while 
grade was not retained as an independent prognostic variable, as also found by other studies 
(Colombo et al., 2010; Braicu et al., 2011; Bamias et al., 2012). The consistency with 
established observations serves to validate the clinicopathological data for the cohort of 
patients used for the OVCA 1-4 TMA set. 
 The p53 expression and relationship to survival and other prognostic variables 
In this TMA study, the p53 H-scores were categorised into low and high groups based on the 
ROC curve analysis. From a total of 155 patients, 95 (61%) and 60 (39%) had low and high 
expression of p53 respectively. Interestingly, the observed differences in survival rates of 
patients with tumours showing low or high p53 expression was statistically significant 
(p=0.001), and supports p53 expression in univariate analysis as a prognostic factor in ovarian 
cancer. Individuals with tumours expressing a high level of p53 experience worse survival with 
15% five year disease specific survival compared to patients with low p53 expression having 
a 44% rate of survival.  
These results are in agreement with other studies which found a significant better overall 
survival (Schuyer et al., 2001; Nakayama et al., 2003; Dogan et al., 2005; Bartel et al., 2008; 
Leffers et al., 2008; Vartiainen et al., 2008; Skirnisdottir and Seidal, 2013) or marginally 
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significant better overall survival (Reles et al., 2001; Darcy et al., 2008) for patients whose 
tumours have low expression of p53 compared to those with high expression of p53. 
In contrast, other studies indicated no significant association between p53 expression levels 
and overall survival (Shahin et al., 2000; Sagarra et al., 2002; Havrilesky et al., 2003; Gadducci 
et al., 2006; Green et al., 2006; Tomsova et al., 2008; Rechsteiner et al., 2013). This 
inconsistency may be due to various options applied to classify the samples, sample size, type 
or histology of cancer and stage of disease. Darcy et al. (2008) investigated the prognostic 
value of p53 expression in two different cohorts named GOG-157 and GOG-111 including 
patients with high risk early stage or advanced stage epithelial ovarian cancer respectively. As 
the results of these cohorts illustrated in Table 3-7, advanced stages of disease decreased the 
significance of p53 expression. 
The p53 Meta-analysis study was performed including 53 studies on the prognostic value of 
p53 expression. The results indicated that p53 protein expression have a modest effect on 
prognosis and overall survival despite the presence of heterogeneity between studies. 
Nevertheless p53 protein expression is unlikely to be useful as a predictive biomarker in 
clinical practice (de Graeff et al., 2009). This study also showed that homogeneity patients in 
different subgroups such as patients with a particular differentiation grade or disease stage is 
important for biomarker analysis. For example, FIGO stage distribution affects study outcome 
using Meta-regression analysis. The p53 lost its significance prognostic value when the meta-
analysis was limited to studies reporting results for stage III/IV tumours. In addition to this 
meta-analysis study, several studies performed on patients at advanced disease stages showed 
no significant association between p53 expression status and overall survival (Table 3-7). 
Antonia et al. (2002) stained ovarian carcinoma sections with three different primary antibodies 
against p53 protein (DO-7, PAb240, and PAb1620). The intensity of staining and percentage 
of reactive cells depended on the antibody used, and were higher with DO-7 antibody than 
other antibodies. 
The observed differences between varying levels of p53 expression and clinicopathological 
prognostic indicators are very interesting. They demonstrate how p53 staining is higher in 
groups which are known to have a poor prognosis on the basis of other factors. Overall, the 
present findings indicate that the tumours with high p53 expression are more aggressive, thus 
tumours from patients with advanced stages of disease (III and IV), incompletely cytoreductive 
surgery, HGSC and poorly differentiated tumours are more likely to express high levels of p53.   
 114 
 
It is somewhat surprising that there was no statistically significant difference between stage I 
and stage IV in relation to p53 expression. A possible explanation for this might be the small 
number of subjects in the stage IV group (17 out of 140, 12%). 
Another interesting exception is the low level of p53 staining for the clear cell histological 
subtype, since this group was found to have a poor survival. This result is not surprising because 
clear cell morphology is known as an aggressive subtype of ovarian cancer with infrequent 
TP53 mutation (Shih-Chu Ho et al., 2001; Amikura et al., 2006). 
These observations are in accord with other studies showing a positive correlation between p53 
high expression and established prognostic variables. Shahin et al. (2000), Sagarra et al. (2002) 
and Kmet et al. (2003) found that the incidence rates of p53 high expression among serous 
histological subtype, late stage and grade III differentiated tumours are clearly higher than other 
histological subtypes, early stage and grade I differentiated tumours. Another study by Reles 
et al. (2001) showed that high expression of p53 is associated with poor differentiation and late 
stage tumours. In another report in which clinicopathological correlations with p53 expression 
were examined, there was only a correlation between high level of p53 and loss of 
differentiation (Baekelandt et al., 1999; Nakayama et al., 2003). Moreover, Lihong et al. 
(2012) have demonstrated that there is a close relationship between the level of p53 protein and 
degree of malignancy (metastasis and recurrence) and prognosis of ovarian cancer. In contrast, 
Antonio et al. (2002) and Malamou et al. (2007) reported no significant correlation between 
p53 expression and histology, stage and grade of ovarian carcinoma (p>0.05). As explained 
above, the discrepancy observed between studies may be related to the type of antibody, the 
type of sample used for IHC staining, and how the samples were categorized. 
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Table 3-7: The results of studies on the prognostic value of p53 expression. FFPE, Formalin fixed paraffin embedded; OVCA, Ovarian 
cancer; EOVCA, Epithelial ovarian cancer; Platinum-based, Platinum plus cyclophosphamide, paclitaxel, doxorubicin or etoposide; CAP, 
Cyclophosphamide, doxorubicin and cisplatin; *, Irrespective of intensity; **, In regard to intermediate or strong nuclear staining; ***, 
Samples collected from a clinical trial.
 116 
 
 The p21WAF1 expression and its correlation with survival and prognostic indicators  
According to the frequency distribution of p21WAF1 H-scores, the samples were grouped into 
low and high expression categories. The pattern of staining was quite different to that observed 
for p53 and generally the H-scores were much lower. No significant difference was observed 
in survival rates on a log-rank test for patients with tumours exhibiting low or high expression 
of p21WAF1. These results support previous studies performed by Skirnisdottir et al. (2013) and 
Sengupta et al. (2000), but they are not consistent with those of Anttila et al (1999) and Rose 
et al. (2003) who observed that positive or high p21WAF1 expression conferred an overall 
survival advantage. Rose et al. (2003) used fresh, snap-frozen or paraffin-embedded samples, 
applied the WAF1/CIP1 monoclonal antibody, and categorised the samples into negative 
(54%) and positive (46%) groups. Anttila et al. (1999) observed negative p21WAF1 expression 
in 26%, low p21WAF1 expression (<10% of the tumour nuclei was positive) in 44% and high 
p21WAF1 expression (>10% of the tumour nuclei was positive) in 30% of FFPE samples with 
the p21WAF1-specific mouse monoclonal antibody (NCL-WAF1). Different types of sample and 
antibody used may partly explain this inconsistency.  
In terms of the relationship between p21WAF1 expression and clinicopathological data, the 
p21WAF1 immunostaining H-scores were not significantly different amongst various groups 
according to histological subtype, grade, stage and cytoreductive surgery (p>0.05). Another 
study by Harlozinska et al. (2002) found no significant correlation between p21WAF1 and 
histology, grade and stage, supporting the results in the current study. However, these findings 
differ from some published studies Anttila et al (1999) observed a significant statistical 
difference between low p21WAF1 expression and histological subtype (p<0.00005), high grade 
of tumour (p=0.0005), advanced stage (p=0.001) and primary residual tumour (p=0.0001). 
Rose et al. (2003) also indicated that positive p21WAF1 staining significantly correlated with 
lower stage tumours (p=0.003), tumours of clear cell histology (p=0.001) and those optimally 
cytoreduced (p=0.02); however, there was no relationship between positive p21WAF1 and 
tumour grade. Moreover, Skirnisdottir et al. (2013) found only a significant correlation 
between p21WAF1 status and histological subtype (p=0.016), not with grade, stage and 
cytoreductive surgery. As mentioned earlier, different types of antibody applied to stain and 
various techniques used to categorise data sets into two groups may explain discrepancies.   
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 The correlation between p53 expression and p21WAF1 expression 
The present results showed no correlation between p53 and p21WAF1 expression. Most studies 
have failed to observe a clear relationship between p53 and p21WAF1 expression and concluded 
that p21WAF1 is induced by both p53-dependent and p53-independent mechanisms. This has 
been concluded from frequently observed lack of inverse correlation between the expression 
of p53 and p21WAF1. In particular, p21WAF1 has been reported to be induced more by p53-
independent mechanisms in ovarian cancer (Sengupta et al.; Phalke et al., 2012).   
 The relationship of concomitant expression of p53 and p21WAF1 with survival 
In the present study, patients with p53 high expression and p21WAF1 low expression had worse  
survival, with 14% five year disease specific survival, compared with individuals with p53 low 
expression and p21WAF1 high expression, who had the best survival, with a 46% rate of survival. 
However, the significant difference was not better than on the basis of p53 IHC status alone 
and was completely similar with 15% five year disease specific survival for patients with high 
expression of p53 compared to 44% five year disease specific survival for individuals with low 
expression of p53. Therefore, the observed effect is related to p53 expression status other than 
p21WAF1 expression status. Anttila et al. (1999) and Skirnisdottir et al. (2013) found a 
significant relationship between concomitant expression of p53 and p21WAF1 and survival with 
a worse disease free survival for the subgroup of patients with concomitant p53 positive and 
p21WAF1 negative tumours compared to other subgroups.  
 The MDM2 expression and its correlation with survival and prognostic indicators  
The present findings indicated no significant difference in survival rates for patients with 
tumours showing high or low expression of MDM2. A number of studies have previously 
investigated the relationship of MDM2 expression to survival in patients with ovarian cancer 
(Baekelandt et al., 1999; Sengupta et al., 2000; Dogan et al., 2005). Baekelandt et al. (1999) 
found no statistically significant difference between patients with tumours showing low or high 
expression of MDM2. Sengupta et al. (2000) categorised the samples two ways, including low, 
intermediate and high MDM2 expression or negative and positive MDM2 expression. In both 
cases, they did not observe any significant difference in survival rates for patients. They also 
used two different antibodies (clone SMP14 and clone IF2) for MDM2 protein staining. The 
pattern of staining was dependent on the antibody used, which was six times more positive 
when the clone IF2 was used. However, the study by Dogan et al. (2005) is in contrast with 
these findings. These authors used NeoMarker (291P906, USA) antibody for MDM2 protein 
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staining and observed patients with tumours positive for MDM2 expression (<1% indices were 
accepted as negative, and the remaining were accepted as positive) had worse survival 
compared to individuals with negative MDM2 expression (p<0.01). As mentioned earlier, 
various options used to categorise the samples and different types of antibodies applied may 
explain this inconsistency.  
In the current study, the MDM2 immunostaining H-scores were not significantly different 
amongst different groups of histological subtype, grade, stage and cytoreductive surgery 
(p>0.05). These results support previous studies indicating no significant relationship of 
MDM2 expression to histological subtype, stage and residual disease while showing 
conflicting results in terms of the correlation between MDM2 expression and tumour grade. 
Sengupta et al. (2000) found an association between MDM2-positive tumours and whether the 
tumours were well differentiated (p=0.022) but not with other clinicopathological variables, 
whereas Dogan et al. (2005) observed a correlation between positivity for MDM2 expression 
and poor differentiation (p<0.05) but not to other prognostic variables. 
 The relationship between coexpression of MDM2 and p53 with survival 
The relationship between coexpression of p53 and MDM2 and survival rates was statistically 
significant in this cohort (X2=10.06, p=0.018). Across all four categories, patients with low 
expression of both p53 and MDM2 had a significantly better overall survival than those with 
high expression of both p53 and MDM2 (p=0.04). The survival probability was significantly 
better in patients with low expression of p53 and high expression of MDM2 versus individuals 
with high expression of both p53 and MDM2 (p=0.02). There was also a significant difference 
in overall survival between individuals with low expression of p53 and high expression of 
MDM2 compared to patients with low expression of MDM2 and high expression of p53 
(p=0.02). Another study by Dogan et al (2005) categorised concomitant expression of p53 and 
MDM2 into two groups as positive or negative (cut-off levels were stratified at 10% for p53 
and 1% for MDM2 indices) to examine the relationship to patient survival indicating 
coexpression of p53 and MDM2 was significantly related to poor outcome (p<0.05).   
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 The WIP1 expression and its relationship with survival and prognostic indicators 
This is the first study to investigate the correlation of WIP1 expression with survival using IHC 
in patients with ovarian cancer. A number of studies have recently investigated the mRNA 
expression levels of PPM1D (the gene for WIP1) in primary ovarian cancer tumours and/or a 
panel of established ovarian clear cell adenocarcinomas, confirming higher levels of PPM1D 
mRNA expression in the clear cell histological subtype (Hirasawa et al., 2003; Tan et al., 
2009b; Ali et al., 2012; Richter et al., 2015). Contrary to expectations, this study did not find 
a significant difference in survival rates for patients with tumours showing low or high levels 
of WIP1 protein (p=0.49). A possible explanation for this unexpected result might be the 
relatively small number of clear cell adenocarcinoma samples in this study (6 out of 62, 9.6%).  
In the present study, a significant relationship between WIP1 expression and tumour grade was 
observed with higher expression of WIP1 in well-differentiated tumours compared to poorly- 
and intermediately-differentiated tumours (p=0.03), but not with other prognostic indicators. 
Although no statistically significant difference was found between WIP1 expression and 
different histological subtypes (p=0.26), a higher number of clear cell adenocarcinomas 
tumours are needed for a stronger statistical comparison to be made.  
 The correlation between coexpression of p53 and WIP1 to survival 
In this study, the observed differences amongst various categories of concomitant expression 
of p53 and WIP1 in relation to survival were not statistically significant (p=0.62). As shown 
in Table 3-5, the number of samples in each group is small and that limits the statistical 
analysis. Overall, a higher number of sample in each category, mainly in II, III and IV, is 
required to make a stronger statistical comparison. 
 Multivariate cox regression analysis of survival 
A multivariate Cox regression analysis was applied to variables shown to be significant 
predictors of survival difference on univariate analysis, including grade, residual disease, stage, 
histological subtype, expression of p53, and coexpression of p53 and p21WAF1, or p53 and 
MDM2 to compare survival rates. Stage, histological subtype and residual disease retained 
their significance in multivariate analysis as independent prognostic variables, while grade, 
p53, concomitant expression of p53 and p21WAF1 or p53 and MDM2 did not retain significance 
as independent prognostic variables. Numerous studies have performed multivariate analysis 
based on the variables shown to be significant prognostic factors in univariate analysis.   
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Regardless of how many variables were used to perform multivariate analysis, stage retained 
significance as an independent prognostic and predictive factor for survival (Baekelandt et al., 
1999; Sengupta et al., 2000; Reles et al., 2001; Sagarra et al., 2002; Dogan et al., 2005; Zhang 
et al., 2014).  
3.6 Conclusion and further work 
The frequency distribution of histological subtypes and prognostic indicators for survival 
validates the cohort in the present study as representative of ovarian cancer patient populations. 
The findings in this research confirm p53 as a potential prognostic marker of survival in 
patients with ovarian cancer, demonstrating that high expression of p53 is more prevalent in 
patients with more aggressive types of the disease at advanced stages (III/IV) with higher grade 
and serous histology subtype. These observations also indicate that coexpression of p53 and 
MDM2 has more potential as a prognostic factor compared to the expression of MDM2 alone. 
However, further work with larger sample sizes for high expression of both is needed to give a 
clear picture of MDM2 as a predictive marker of survival. Survival data show no significant 
correlation with WIP1 expression in two different categories though this requires further 
studies with a higher number of clear cell adenocarcinomas.  
Although high expression of p53 is often considered as indicative of mutation, the expression 
may be elevated for other reasons, including increased transcription followed by translation, 
stabilization or resistance to degradation (Reles et al., 2001; Havrilesky et al., 2003; 
Bauerschlag et al., 2010). To give a more accurate picture of p53 as a predictive marker in 
ovarian cancer, it is more pertinent to study the relationship between TP53 gene status and p53 
expression with survival in tumours from the same cohort of patients. 
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Chapter 4: TP53 mutation analysis of ICON3 trial samples using Sanger 
and Next Generation Genomic DNA sequencing  
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4.1 Introduction 
For ovarian cancer patients, earlier platinum-based chemotherapy has been superseded by a 
standard first-line treatment consisting of taxane-platinum based combination therapy. 
However, this is more costly, neurotoxic, and has no effect on 20 to 30% of patients 
(Kupryjanczyk et al., 2008). Although most patients respond to the standard treatment, relapse 
with drug-resistant disease is prevalent. Given the critical role of the TP53 gene in response to 
DNA damaging agents, a number of studies have explored the importance of TP53 gene status 
in ovarian cancer (Canevari et al., 2006; Gadducci et al., 2006; Yang-Hartwich et al., 2015). 
There is evidence supporting the hypothesis that patients harbouring wild-type TP53 have a 
higher response rate to platinum-based chemotherapy and a better OS and/or PFS compared to 
those with mutant TP53. However, the role of TP53 status in response to chemotherapy and 
determining resistance is controversial (Table 4-1). It is very important to improve the ability 
to predict and identify patients who are most likely to benefit from treatment. Our 
understanding of the role of TP53 may help to predict sensitivity to chemotherapy and allow 
individualisation of treatment, thereby reducing morbidity and side effects whilst maintaining 
response rate in ovarian cancer.  
 
Table 4-1: Association between OS and/or PFS and TP53 status according to treatment. 
OS, Overall survival; PFS, Progression-free survival; Platinum-based chemotherapy, 
Cisplatin or carboplatin plus cyclophosphamide or paclitaxel; ND, Not determined.
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 The rate of TP53 mutation in ovarian cancer 
A number of studies have reported the rate of TP53 mutation in ovarian cancer to range from 
34% to 96% (Table 4-2). This discrepancy amongst the results may be attributed to different 
techniques used to detect mutations and variation in the grades or stages of disease in the 
sample populations investigated. It may also be related to whether the most commonly mutated 
exons (exons 4-9), the entire coding region of TP53 (exons 2-11) or the whole gene were 
sequenced. Furthermore, some confusion is based on whether TP53 mutations are being 
reported in ovarian cancer generally, specifically epithelial ovarian cancer or for different 
histological subtypes, in particular serous or HGSC (de Graeff et al., 2009; Ahmed et al., 2010).  
 DNA sequencing as a gold standard method for mutation detection 
There are different molecular methods used to identify mutations based on the type of nucleic 
acid and specimen, number of mutations and reliability of the method (Mahdieh and Rabbani, 
2013). DNA sequencing is a powerful technique considered as a gold standard for mutation 
detection. Sanger sequencing and Next Generation Sequencing (NGS) represent the most 
extensively used techniques for DNA sequencing ( Highsmith, 2006; Mahdieh and Rabbani, 
2013). In some studies pre-screening by Single-strand conformation polymorphism (SSCP) 
was used and those DNA samples which showed mobility shifts on SSCP gels were sequenced. 
4.1.2.1 Sanger sequencing 
The dideoxynucleotide sequencing method, known as Sanger sequencing, is based on the 
selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during 
in vitro DNA replication and was introduced by Frederick Sanger and colleagues in 1977 ( 
Highsmith, 2006; Hutchison, 2007). PCR-based Sanger sequencing is a multistep process 
starting with amplification of target DNA by PCR to increase sensitivity and specificity of the 
sequencing reaction. The next crucial step is removal of unused primers at the end of the 
amplification reaction to avoid noisy sequencing data (W. Edward Highsmthh, 2006; SenGupta 
and Cookson, 2010). Then, double stranded DNA is converted to single stranded DNA which 
is used for the sequencing reaction. We generated the exon PCR products here and sent the 
PCR samples off for sequencing. In the dye-terminator Sanger sequencing method used for this 
study, each of the four ddNTP chain terminators is labelled with a different fluorescent dye 
emitting light at different wavelengths in one reaction leading to greater efficiency and speed 
for automated sequencing. Different fluorescent colours are sequentially detected during 
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capillary electrophoresis to build up the sequence of the nucleotides as an chromatogram image 
(Highsmith, 2006). 
4.1.2.2 Next Generation Sequencing (NGS) 
The NGS techniques, known as high-throughput sequencing, include Roche 454, 
Illumina/Solexa, SOLiD, Ion Torrent, Pacific Biosciences/Single Molecule Sequencing and 
Intelligent Bio Systems improving both speed and cost at the expense of shorter read lengths 
compared to Sanger sequencing. They are capable of sequencing the whole genome, chromatin 
immunoprecipitation and genome wide RNA for mammalian and human tissue transcriptomes. 
A major development in NGS technology occurred with advances in library preparation 
methods. Large numbers of libraries can simultaneously be pooled and sequenced during a 
single sequencing run by multiplexing using bar-coding to sequence many samples for a given 
target sequence at the same time. It is hugely more efficient and for large numbers of samples 
can be more cost-effective. The high speed, high throughput, versatility and cost-effectiveness 
of NGS has resulted in NGS becoming the dominant genome sequencing technique. However, 
Sanger sequencing is considered as a “gold standard“ technique to validate smaller studies and 
the only method widely used to sequence long read-lengths of DNA, up to 1,000 nucleotides 
in length (Ledergerber and Dessimoz, 2011; Mestan et al., 2011). 
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Table 4-2: The frequency of TP53 mutation in ovarian cancer reported in different studies. OVCA, Ovarian cancer; EOVCA, Epithelial 
ovarian cancer; HGSC, High grade serous carcinoma; SSCP, Single-strand conformation polymorphism; Platinum-based chemotherapy, 
Cisplatin or carboplatin plus cyclophosphamide or paclitaxel; *, A mutation was associated with a short-term advantage in OS; however, 
there was no longer any improvement in survival for patients with mutant TP53 tumours after 2.5 years from primary diagnosis; **, A 
mutation was associated with advantage in OS. 
. 
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Table 4-2 (Continued): The frequency of TP53 mutation in ovarian cancer reported in different studies. OVCA, Ovarian cancer; EOVCA, 
Epithelial ovarian cancer; HGSC, High grade serous carcinoma; HGPSC, High grade pelvic serous carcinoma; SSCP, Single-strand 
conformation polymorphism; Platinum-based chemotherapy, Cisplatin or carboplatin plus cyclophosphamide or paclitaxel; NGS, Next 
generation sequencing; *, Null mutation compared to wild-type TP53; **, A mutation was associated with advantage in OS. The Cancer 
Genomic Atlas Research (2011) and Wong et al (2013) used the same cohort. 
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4.2 Hypothesis and Objectives 
Hypothesis:  
1. Patients whose tumours have wild-type TP53 are more sensitive to platinum-based 
chemotherapy than those with mutant TP53, therefore they survive longer as a result of 
response to treatment. 
2. Patients with mutant TP53 tumours gain benefit from addition of paclitaxel to 
treatment, while those with wild-type TP53 do not benefit. 
Objectives: 
1.  To study the role of TP53 status as a prognostic factor for overall survival and 
progression-free survival in the ICON3 patient cohort. 
2. To correlate TP53 status with response to chemotherapy, and assess it as a predictive 
marker of disease outcome in the ICON3 patient cohort. 
3. To evaluate the efficacy of paclitaxel plus carboplatin or CAP (cyclophosphamide, 
doxorubicin and cisplatin) with a control of either CAP or carboplatin alone with 
respect to TP53 status. 
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4.3 Specific Materials and Methods 
 Patient characteristics 
A total of 260 patient samples taken from ICON3 randomized clinical trial. The samples were 
collected at primary surgery between February, 1995, and October, 1998 with median follow-
up of 11.9 years. From a total of 260 patient samples 207 samples were from UK and 53 were 
from Italy. There was a pathology review to update the diagnosis of these archival samples that 
was performed by Paul Cross, the pathologist at the Queen Elizabeth Hospital in Gateshead. 
The review was based on a single slide per case (as this was all we had) but at least that was 
taken from the exact block from which the DNA was extracted, which obviously minimises 
the effect of any heterogeneity. In fact, the review was limited to a single H&E slide but was 
carried out by an extremely experienced gynae pathologist. The pathologist was unable to 
perform any immunohistochemistry which is accepted as a part of the assessment of these 
tumours which is mentioned as a limitation of this study. 
The aim of ICON3 was to compare the safety and efficacy of paclitaxel plus carboplatin with 
a control of either carboplatin alone or CAP. Patients had received no previous treatment likely 
to affect the outcomes, and patients requiring treatment were randomly assigned to paclitaxel 
plus carboplatin or control treatment, which was single agent carboplatin or CAP. The 
randomization was performed in a ratio of 2:1 in favour of the control group. Appropriate 
ethical approval was obtained to analyse the samples. Overall survival and progression-free 
survival were evaluated as primary and secondary outcomes. No evidence of a difference in 
OS between paclitaxel plus carboplatin and control was observed indicating single agent 
carboplatin and CAP are as effective as paclitaxel plus carboplatin as first line treatment. 
The role of the TP53 gene in determining resistance remains controversial although there is 
increasing evidence to support the hypothesis that patients with wild-type TP53 tumours have 
high response rates to platinum-based treatment and may gain no benefit from addition of 
paclitaxel. Therefore, it was proposed to examine the samples for mutations of the TP53 gene 
and correlate this with subsequent outcome (Figure 4-1). 
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Figure 4-1: Diagram of the samples taken from ICON3 randomised clinical trial. 
 TP53 mutation analysis 
For the Sanger sequencing, the samples were macro-dissected using areas outlined by Paul 
Cross (a pathologist). The DNA extraction and exon PCR was performed in NICR (by Dr. 
Claire Hutton and Dr. Jennifer Houniet) and the PCR products were sent to DBS Genomics 
(Durham, UK) for sequencing. For the NGS, FFPE blocks were supplied to NewGene 
(Newcastle, UK) and whole tissue sections were used for DNA extraction and purified PCR 
products were used for sequencing. The proportion of tumour cells in the samples used for 
sequencing was around 90%. The general primer design rules or Primer 3Plus design 
(www.bioinformatics.nl/primer3plus) were used to design sequence specific PCR primers and 
https://secure.ngrl.org.uk/SNPCheck/ was applied to filter and check for the presence of SNPs. 
PCR primers used are presented in Table 4-3. The TP53 exon 4 sequence was split into two 
partially overlapping amplicons due to its large size. Sequencing of all coding regions and 
adjacent splice sites (+/- 10bp) of the TP53 gene (exon 2 to 11) was carried out using both 
Sanger sequencing and NGS.  
NGS was performed using a Roche 454 system and was based on amplicon libraries. In total, 
the TP53 region of interest was covered by 11 sequence specific primer pairs, each flanked by 
MID-labelled Primer A and Primer B sequences to barcode the samples. In each NGS 
experiment, a total of 88 amplicons, corresponding to the TP53 region of interest of 8 distinct 
patients, were amplified from genomic DNA using a high fidelity Taq polymerase (FastStart 
High fidelity PCR System, Roche Diagnostics). The Agencourt AMPure XP beads (Beckman 
Coulter) and the Quant-iT PicoGreen dsDNA kit (Invitrogen) were used to individually 
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purified and quantified PCR products respectively. Each of the amplicons in combination with 
an equimolar ratio for each patient sample was applied to generate corresponding patient-
specific amplicon pools. 
The pools were diluted to a concentration of 1×106 molecules per μl and processed using the 
GS Junior Series Lib-A method (Roche Diagnostics). 5,000,000 beads per emulsion oil tube 
was used to perform forward (A beads) and reverse (B beads) reactions. The copy per bead 
ratio used was 1.1:1. The workflow recommended by the manufacturer was used to amplify 
reaction, break the emulsions and enrich the beads carrying amplified DNA. Lastly, the 
obtained amplicon library was loaded on a PicoTiterPlate (PTP) and subjected to NGS on the 
Genome Sequencers, GS-FLX or Junior instruments (454 Life Sciences).The commercially 
available software packages Amplicon Variant Analysis (AVA) (454 Life Sciences) and 
NextGene (Softgenetics) were used for data processing.  
Amplicon coverage information was generated using AVA software by identifying primer 
sequences in de-multiplexed reads. Information on the forward and reverse reads was extracted 
using an in-house designed Perl program script for each barcode multiplex identifier (MID). 
The covered amplicons with less than 30 reads were insufficient, therefore they were re-
amplified and sequenced in a separate run. Mapping to reference sequence NM_000546.5 and 
variant calling was performed by NextGene software v2.3.3 through to v2.3.4.4. The .sff files 
were converted to quality .fna files. Any reads with maximum number of uncalled bases >1, 
called base number of each read<100 and median score threshold <15 were rejected. 
Based on the MID barcodes, all reads of adequate quality were sorted and assigned to a specific 
sample. To remove any artificial nucleotide strings (e.g. residual primer sequence in 
overlapping regions) that can interfere with the mapping process, the sequences were further 
trimmed by 27nt. Default settings for the Roche454 SNP/Indel discovery application were used 
for mapping with mutation filters, mutation percentage of 5%, SNP allele count of 3 and total 
coverage count of 5. It means that any variant with mutant allele frequency of at least 5% 
observed at least 3 times with at least 5 reads was retained in the filtered variant table. The 
average depth of sequencing of different amplicons was 265. Please see Appendix I for more 
information about the average depth of sequencing of each exon. 
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 Statistical analysis 
The sequencing and statistical analysis were performed independently, with the clinical data 
held by the MRC Clinical Trials Unit. The statistical analysis was carried out by Wendi Qian 
from the Medical Research Council (MRC) Clinical Trials Unit. The Kaplan-Meier method 
and log-rank test were used to analyse whether or not the observed differences in survival times 
were statistically significant. The clinical data with respect to TP53 status were tested using a 
chi-squired test, Mann-Whitney test or t-test. The prognostic value of TP53 status on platinum-
based chemotherapy was evaluated by fitting Cox proportional hazards regression models or 
flexible models to PFS and OS. Both univariate and multivariate analyses were performed 
including TP53 status and clinical baseline data. Analysis of the interaction between TP53 
status and addition of paclitaxel to platinum-based chemotherapy was performed in an 
exploratory manner due to small sample size and Cox proportional hazards regression models 
were used. All hypotheses were tested using two-sided p-values, and p-values of <0.05 were 
considered to be statistically significant.  
 132 
 
 
Table 4-3: The primer sequences used for amplifying different exons of TP53. F, 
Forward; R, Reverse.  
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4.4 Results 
 Mutational analysis of TP53 
The TP53 sequence analysis was performed for exons 2-11 in a set of 260 FFPE ovarian cancer 
samples from the ICON3 cohort using both Sanger and NGS techniques. In addition, results 
are shown for analyses based on combined datasets; firstly in which a sample is registered as 
mutant if detected by either technique and secondly is only registered as mutant if detected by 
both techniques. The results showed differences between Sanger sequencing and NGS data. 
(Table 4-4).  
Sanger sequencing data demonstrated that 131 tumour samples had mutations on a single exon, 
and fourteen samples had mutations on two different exons. Based on the NGS, 139 tumour 
samples exhibited mutations on one exon, 22, 4 and 1 samples showed mutations on two, three 
or four distinct exons respectively. The rate of TP53 mutation was 72% based on the mutations 
detected by either Sanger or NGS method, and it was 47% according to the mutations detected 
by both methods. Both Sanger and NGS showed the majority of mutations occur in exons 5-8 
of TP53 (70%-80%) encoding the highly conserved DNA-binding domain.TP53 mutations 
were detected in all exons by NGS; however, there were no TP53 mutations in exon 2, 3 and 
11 detected by the Sanger sequencing method. In addition, results are shown for analyses based 
on combined datasets; firstly in which a sample is registered as mutant if detected by either 
technique and secondly in which it is only registered as mutant if detected by both techniques. 
 
 
Table 4-4: The frequency distribution of wild-type and mutant TP53 based on the Sanger, 
NGS, either or both methods from 260 patients of ICON3 cohort. NGS, Next generation 
sequencing.
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 Results based on the Sanger sequencing 
The TP53 mutational status determined by Sanger sequencing was correlated with the 
clinicopathological data. The overall survival time of patients with wild-type TP53 treated with 
single agent carboplatin or CAP was compared to those with mutant TP53 treated with 
carboplatin or CAP. Also, additional analysis was carried out to analyse the efficacy of 
paclitaxel with carboplatin compared to a control of either CAP or carboplatin alone according 
to Sanger TP53 status. The analyses were also performed for the subset of patients with serous 
histology. Lastly, a multivariate analysis was performed, which included Sanger TP53 status 
and established clinicopathological prognostic variables known to be associated with OS in 
ovarian cancer. 
4.4.2.1 Distribution of TP53 status detected by Sanger sequencing 
Data for a total of 253 tissue samples from patients was available, because seven patients 
received no chemotherapy treatment. TP53 mutations were detected in 140 of the 253 samples 
(55%) and 113 tumour samples had wild-type TP53 (45%). The frequencies of insertion, 
deletion, transversion and transition were 4%, 12%, 20% and 64% respectively. The highest 
frequency of substitution mutations was G>A (42%) (Figure 4-2A & B). The substitution 
mutations cover TP53 hotspot mutations at codon 175, 237,248, 273 and 282, with a strong 
predominance at codon 237 (Figure 4-2C).   
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Figure 4-2: (A) Distribution of TP53 mutations and (B) Distribution of TP53 substitution 
mutations from 253 samples of the ICON3 cohort detected by Sanger sequencing. (C) 
Distribution of the TP53 mutations in p53 residues from 253 samples of the ICON3 cohort 
detected by Sanger sequencing. 
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4.4.2.2 Distribution of clinicopathological variables according to Sanger TP53 status 
Table 4-5 summarizes the characteristics of both wild-type and mutant TP53 groups for 253 
patients with respect to histological subtypes, FIGO stage, residual disease and differentiation 
grade.  
The largest histological group was recorded as HGSC, with a distribution of 159 (63%). Lower 
frequencies were observed for LGSC with 26 cases (10%), clear cell with 25 cases (10%), 
endometrioid with 21 cases (8%), undifferentiated with 17 (7%) and mucinous with 5 cases 
(2%). HGSC was the major histological subtype in both categories with 53% for wild-type 
TP53 tumours and 71% for mutant TP53 tumours (Table 4-5). Distribution of histological 
subtypes was different in regard to the mutational status of TP53, and the rate of TP53 mutation 
was significantly higher for patients with HGSC than those with LGSC (p=0.03) or other 
histological subtypes (clear cell, endometrioid, mucinous and undifferentiated) (p=0.03). 
From a total of 253 patients, there were 42 (17%) with FIGO disease stage I/II, 169 (66%) with 
stage III and 42 (17%) with stage IV (Table 4-5). There was no significant difference in the 
proportion of tumours from patients within each FIGO stage between those with wild-type 
TP53 compared to those with mutant TP53 (X2=1.31, p=0.52). 
60 (24%) of individuals from the cohort had complete cytoreductive surgery, 51 (20%); and 
142 (56%) had <2 cm and ≥2 cm residual bulk disease respectively. Statistical analysis showed 
no significant difference in the frequency of residual bulk disease between the two TP53 status 
groups (X2=1.03, p=0.60) (Table 4-5). 
The frequency distribution for differentiation grade was 155 cases (62%) grade 3 (poorly 
differentiated), 76 cases (30%) grade 2 (intermediate differentiation) and 20 cases (8%) grade 
1 (well differentiated) (Table 4-5). The presence of mutant TP53 was significantly associated 
with poor differentiation (X2=13.22, p=0.001).  
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Table 4-5: Distribution of clinicopathological data with respect to Sanger TP53 status for 
253 samples from patients in the ICON3 cohort.
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4.4.2.3 Sanger TP53 status and Overall Survival/Progression-Free Survival  
Survival curves were constructed based on the mutational status of TP53 using the Kaplan-
Meier analysis method. The log-rank test was applied to compare the differences between 
survival curves to establish whether or not the observed differences are statistically significant. 
As shown in Figure 4-3, there was a significant difference in survival time between patients 
whose tumours have wild-type TP53 and those harbouring mutant TP53 (X2=6.91, p=0.008).  
PFS was defined as the length of time between the first day of treatment and the date of 
recurrence, last follow-up, or death. The Kaplan-Meier plot showed that the PFS probability 
was significantly better in individuals with wild-type TP53 compared to patients with mutant 
TP53 (X2=4.20, p=0.04) (Figure 4-4).  
 
Figure 4-3: Overall survival for all patients in relation to Sanger TP53 status (p=0.008).  
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Figure 4-4: Progression-free survival for all patients in relation to Sanger TP53 status 
(p=0.04). 
 
 
4.4.2.4 Survival following treatment with carboplatin alone in relation to Sanger TP53 
status 
The Kaplan-Meier plot and univariate analysis showed the presence of wild-type TP53 was 
significantly correlated with better survival probability for patients treated with single agent 
carboplatin (X2=6.32, p=0.01) (Figure 4-5). For multivariate analysis of overall survival for 
patients treated with single agent carboplatin, the mutational status of TP53 (p=0.0007), stage 
III (p=0.04), residual bulk ≥2 cm (p=0.003) and endometrial histology (p=0.01) were all 
retained as independent prognostic variables with the most significant variable being the TP53 
status (Table 4-6). 
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Figure 4-5: Overall survival for patients treated with carboplatin alone in relation to 
Sanger TP53 status (p=0.01).  
 
 
Table 4-6: Multivariate analysis of overall survival for patients treated with carboplatin 
alone. *, p<0.05; **, p<0.01; ***, p<0.001. Significant p-values are highlighted.
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4.4.2.5 Survival following treatment with either single agent carboplatin or CAP in 
relation to Sanger TP53 status 
In the case of individuals treated with either single agent carboplatin or CAP, there was a 
significant difference in median survival time between women with wild-type and mutant TP53 
tumours (X2=5.99, p=0.01) (Figure 4-6). The multivariate analysis for the group of patients 
who received either carboplatin or CAP demonstrated that TP53 mutational status (p=0.002), 
residual disease <2 cm (p=0.04) and residual disease ≥2 cm (p=0.002) retained prognostic 
significance (Table 4-7). These results demonstrate that TP53 mutational status defined by 
Sanger sequencing is an independent prognostic variable and individuals with wild-type TP53 
tumours survive longer as a result of this treatment. 
 
 
Figure 4-6: Overall survival for patients treated with either carboplatin or CAP in 
relation to Sanger TP53 status (p=0.01). 
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Table 4-7: Multivariate analysis of overall survival for patients treated with either 
carboplatin or CAP. *, p<0.05; **, p<0.01. Significant p-values are highlighted.  
 
4.4.2.6  Analysis of survival for patients with serous histology tumours following 
treatment with carboplatin alone in relation to Sanger TP53 status  
Due to the previously reported high proportion of TP53 mutations in HGSC (Ahmed et al., 
2010; Kurman, 2013), the most aggressive histological subtype of ovarian cancer, subgroup 
survival analysis was performed in relation to TP53 status and treatment options for 90 patients 
with serous histology. The Kaplan-Meier analysis showed a highly significant association 
between the mutational status of TP53 and OS (X2=8.59, p=0.003) (Figure 4-7). Based on the 
multivariate analysis for this subgroup, TP53 (p=0.0002), stage III (p=0.03), residual disease 
<2 cm (p=0.02) and residual disease ≥2 cm (p=0.005) were retained as independent prognostic 
variables (Table 4-8).  
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Figure 4-7: Overall survival for treatment with carboplatin alone for patients with serous 
histology tumours in relation to Sanger TP53 status (p=0.003).  
 
 
Table 4-8: Multivariate analysis for overall survival following treatment with carboplatin 
alone for patients with serous histology tumours. *, p<0.05; **, p<0.01; ***, p<0.001. 
Significant p-values are highlighted.
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4.4.2.7 Analysis of survival for patients with serous histology tumours following 
treatment with either carboplatin or CAP in relation to Sanger TP53 status 
As shown in Figure 4-8, the women with serous histology and wild-type TP53 tumours who 
received carboplatin or CAP had significantly better survival times compared to those with 
mutated TP53 (X2=8.84, p=0.003). Also, mutational status of TP53 (p=0.0001), residual 
disease <2 cm (p=0.03) and residual disease ≥2 cm (p=0.001) retained their significance as 
independent prognostic variables on multivariate analysis (Table 4-9). 
 
 
Figure 4-8: Overall survival following treatment with either carboplatin or CAP, for 
patients with serous histology tumours in relation to Sanger TP53 status (p=0.003). 
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Table 4-9: Multivariate analysis for overall survival following treatment with carboplatin 
or CAP, for patients with serous histology tumours. *, p<0.05; **, p<0.01; ***, p<0.001. 
Significant p-values are highlighted.   
 
4.4.2.8 The effect of paclitaxel addition on overall survival for treatment with either 
carboplatin or CAP, according to tumour Sanger TP53 status 
The survival times for patients treated with platinum-based chemotherapy versus those 
additionally treated with paclitaxel, were analysed by TP53 status. As can be seen in Figure 4-9, 
addition of paclitaxel showed a trend for improved overall survival, which was greater in the 
TP53 mutated subgroup, particularly for patients with serous tumours, however this did not 
reach statistical significance (p=0.11).  
4.4.2.9 The effect of paclitaxel addition on overall survival for treatment with CAP alone, 
according to tumour Sanger TP53 status 
To study whether women whose tumours have wild-type TP53 gain benefit from addition of 
paclitaxel to carboplatin compared to CAP, the survival times were analysed in relation to TP53 
status. There was no significant difference in survival between patients treated with CAP 
compared to those received carboplatin and paclitaxel by TP53 status (p=0.08) (Figure 4-9).  
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4.4.2.10 The effect of paclitaxel addition on overall survival for treatment with 
carboplatin alone, according to tumour Sanger TP53 status 
As shown in Figure 4-9, no significant difference was observed in survival for patients treated 
with carboplatin compared to those treated with addition of paclitaxel to carboplatin in respect 
to TP53 status (p=0.57). 
4.4.2.11 The effect of paclitaxel addition on survival for treatment with carboplatin or 
CAP for patients with serous histology tumours, according to tumour Sanger 
TP53 status 
In terms of patients with serous histological subtype, women treated with addition of paclitaxel 
appeared to be associated with better overall survival compared to individuals treated with 
either carboplatin or CAP, in particular for those with mutant TP53, nevertheless this difference 
was marginally significant (p=0.06) with an odds ratio of 0.66 (0.44-1.00) (Figure 4-9). 
4.4.2.12 The effect of paclitaxel addition on survival for treatment with CAP alone for 
patients with serous histology tumours, according to tumour Sanger TP53 status 
In the case of individuals with serous histology tumours who received addition of paclitaxel, 
no significant difference in survival was observed irrespective of TP53 status (p=0.12) 
(Figure 4-9). 
4.4.2.13 The effect of paclitaxel addition on survival for treatment with carboplatin alone 
for patients with serous histology tumours, according to tumour Sanger TP53 
status 
As can be seen in Figure 4-9, patients with serous histology tumours gain no benefit from 
addition of paclitaxel to carboplatin (p=0.28) (Figure 4-9).  
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Figure 4-9: The effect of paclitaxel addition on overall survival for patients treated with 
platinum-based chemotherapy, in relation to Sanger TP53 status (p>0.05). All patients in 
this context refers to CAP or carboplatin as control. 
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 Results based on the Next Generation Sequencing (NGS) 
4.4.3.1 Distribution of TP53 status detected by NGS 
162 (64%) out of 253 patients had tumours with mutant TP53, 89 (35%) showed wild-type 
TP53 and 2 cases (1%) were lost. NGS detected a higher incidence of mutant TP53 cases 
compared to Sanger sequencing, 64% versus 55%. The frequencies of insertion, deletion, 
transversion and transition mutations were 7%, 14%, 14% and 65% respectively. The highest 
frequency of substitution mutations was C>T (37%) (Figure 4-10A & B). The substitution 
mutations cover TP53 hotspot mutations at codon 175, 237, 248, 273 and 282, with a 
predominance in codon 273 (Figure 4-10C). This difference compared to the Sanger 
sequencing (Figure 4-2C) could be due to the low success rate for exon 7 sequencing by NGS. 
4.4.3.2 Distribution of clinicopathological variables according to NGS TP53 status 
Table 4-10 illustrates the frequency distribution of TP53 mutations in regard to 
clinicopathological data including histological subtypes, residual disease, FIGO stage and 
differentiation grade. The overall differences between the frequency distribution of different 
histological subtypes with respect to mutational status of TP53 was statistically significant 
(X2=24.06, p=0.0002).  
The distribution of different disease stages was associated with genomic status of TP53 
(X2=11.03, p=0.004), which is in contrast with Sanger sequencing data (X2=1.31, p=0.52). 
Consistent with Sanger sequencing data, there was no significant difference in the frequency 
distribution for each category of residual disease based on the mutational status of TP53 
(X2=4.10, p=0.13). Furthermore, the presence of mutant TP53 was significantly associated with 
poor differentiation (X2=17.75, p=0.0001) (Table 4-10).   
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Figure 4-10: (A) Distribution of TP53 mutations and (B) Distribution of TP53 substitution 
mutations from 253 samples of the ICON3 cohort detected by NGS. (C) Distribution of 
the TP53 mutations in p53 residues from 253 samples of the ICON3 cohort detected by 
NGS.
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Table 4-10: Distribution of clinicopathological data with respect to NGS TP53 status for 
253 samples from patients in the ICON3 cohort.
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4.4.3.3 NGS TP53 status and Overall Survival/Progression-Free Survival  
The Kaplan-Meier analysis method was used to construct survival curves based on the NGS 
TP53 status. In contrast with the Sanger sequencing data, there was no significant difference 
in OS (X2=2.14, p=0.14) and PFS (X2=1.08, p=0.30) times between patients with wild-type 
TP53 compared to individuals with mutant TP53 tumours (Figure 4-12 & Figure 4-12). 
 
 
Figure 4-11: Overall survival for all patients in relation to NGS TP53 status (p=0.14).
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Figure 4-12: Progression-free survival for all patients in relation to NGS TP53 status 
(p=0.30). 
 
4.4.3.4 Survival following treatment with carboplatin alone in relation to NGS TP53 
status  
As shown in Figure 4-13, the survival probability was significantly better for patients with 
wild-type TP53 tumours who received carboplatin than those with mutant TP53 tumours 
(X2=3.98, p=0.04). The TP53 (p=0.003), residual bulk ≥2 cm (p=0.004) and endometrioid 
histology (p=0.02) were all retained as independent prognostic variables on multivariate 
analysis, with the most significant variable being the TP53 mutational status (Table 4-11).
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Figure 4-13: Overall survival for patients treated with carboplatin alone in relation to 
NGS TP53 status (p=0.04). 
 
 
Table 4-11: Multivariate analysis of overall survival for patients treated with carboplatin 
alone. *, p<0.05; **, p<0.01. Significant p-values are highlighted.
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4.4.3.5 Survival following treatment with either carboplatin or CAP in relation to NGS 
TP53 status 
In contrast with the Sanger sequencing data, survival times were not significantly different 
between women treated with either single agent carboplatin or CAP with respect to NGS TP53 
status (X2=1.62, p=0.20) (Figure 4-14). The only significant predictor of survival which was 
retained as an independent variable on multivariate analysis was residual disease ≥2 cm 
(p=0.004) (Table 4-12).  
 
 
Figure 4-14: Overall survival for patients treated with either carboplatin or CAP in 
relation to NGS TP53 status (p=0.20).
 155 
 
 
Table 4-12: Multivariate analysis of overall survival for patients treated with either 
carboplatin or CAP. **, p<0.01. Significant p-values are highlighted. 
 
4.4.3.6 Analysis of survival for patients with serous histology tumours following 
treatment with carboplatin alone in relation to NGS TP53 status 
As can be seen in Figure 4-15, survival times were not associated with TP53 status for patients 
with serous histology tumours treated with carboplatin alone (X2=2.01, p=0.16). Cox 
regression multivariate analysis identified the TP53 status (p=0.006), residual bulk <2 cm 
(p=0.04) and residual disease ≥2 cm (p=0.009) as independent prognostic factors (Table 4-13).  
4.4.3.7  Analysis of survival for patients with serous histology tumours following 
treatment with either carboplatin or CAP in relation to NGS TP53 status 
No significant difference was observed in survival time between patients with serous histology 
and wild-type TP53 tumours treated with carboplatin or CAP compared to those with mutant 
TP53 (.X2=0.55, p=0.46) (Figure 4-16). The only variable which retained its significance as an 
independent prognostic factor on multivariate analysis was residual disease ≥2 cm (.X2=6.84, 
p=0.009) (Table 4-14).  
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Figure 4-15: Overall survival for treatment with carboplatin alone, for patients with 
serous histology tumours in relation to NGS TP53 status (p=0.16). 
 
 
Table 4-13: Multivariate analysis for overall survival following treatment with 
carboplatin alone for patients with serous histology tumours. *, p<0.05; **, p<0.01. 
Significant p-values are highlighted.
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Figure 4-16: Overall survival following treatment with either carboplatin or CAP, for 
patients with serous histology tumours in relation to NGS TP53 status (p=0.46). 
 
 
Table 4-14: Multivariate analysis for overall survival following treatment with either 
carboplatin or CAP for patients with serous histology tumours. **, p<0.01. 
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4.4.3.8 The effect of paclitaxel addition on overall survival for treatment with either 
carboplatin or CAP, according to tumour NGS TP53 status 
The overall survival was analysed for patients treated with either carboplatin or CAP compared 
to those who received paclitaxel plus carboplatin in relation to NGS TP53 status. As shown in 
Figure 4-17, no significant impact on survival was observed by addition of paclitaxel (p=0.12). 
4.4.3.9 The effect of paclitaxel addition on overall survival for treatment with CAP alone, 
according to tumour NGS TP53 status  
Individuals treated with a combination of carboplatin and paclitaxel appeared to be associated 
with better long-term survival compared to those received CAP alone, in particular for patients 
with mutant TP53 tumours even though this difference did not reach statistical significance 
(p=0.07) (Figure 4-17) 
4.4.3.10  The effect of paclitaxel addition on overall survival for treatment with carboplatin 
alone, according to tumour NGS TP53 status  
As can be seen in Figure 4-17, paclitaxel addition had no significant impact on survival for 
patients who received single agent carboplatin, irrespective of mutational status of TP53 
(p=0.62). 
4.4.3.11 The effect of paclitaxel addition on survival for treatment with either carboplatin 
or CAP for patients with serous histology tumours, according to tumour NGS 
TP53 status 
For patients with serous histology tumours, there was no significant difference in survival time 
between women treated with either carboplatin or CAP compared to those treated with an 
addition of paclitaxel to carboplatin irrespective of TP53 status (p=0.07) (Figure 4-17).  
4.4.3.12 The effect of paclitaxel addition on survival for treatment with CAP alone for 
patients with serous histology tumours, according to tumour NGS TP53 status 
The statistical analysis showed no significant difference in survival between patients with 
serous histology tumours treated with CAP alone compared to those who received carboplatin 
and paclitaxel, regardless of TP53 status (p=0.11) (Figure 4-17).  
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4.4.3.13 The effect of paclitaxel addition on survival for treatment with carboplatin alone 
for patients with serous histology tumours, according to tumour NGS TP53 
status 
No significant difference in survival was observed between patients with serous histology 
tumours treated with carboplatin alone versus those treated with a combination of carboplatin 
and paclitaxel by TP53 mutational status (p=0.28) (Figure 4-17). 
 
 
Figure 4-17: The effect of paclitaxel addition on overall survival for patients who treated 
with platinum-based chemotherapy, in relation to NGS TP53 status (p>0.05). All patients 
in this context refers to CAP or carboplatin as control.
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 Analysis of hypotheses in regard to Sanger sequencing, NGS, either Sanger or NGS, 
and both techniques 
4.4.4.1 Overall survival and progression-free survival 
Table 4-15 summarises the log-rank test p-values for the observed differences between OS or 
PFS times in relation to TP53 mutational status. The results for patients with serous histology 
are also summarised. The summary results are shown for individual analyses using TP53 
mutation data detected by Sanger sequencing, NGS, either Sanger or NGS, and both 
techniques. The analysis based on the Sanger sequencing indicated that mutational status of 
TP53 is a significant prognostic biomarker for all patients and for the subgroup with serous 
histology tumours. The TP53 status retained its significance for overall survival when the data 
were analysed based on detection by both techniques. However, for PFS, significant differences 
in survival were only observed according to TP53 status detected using Sanger sequencing. 
 
 
Table 4-15: Summary overall survival and progression-free survival for all patients and 
patients with serous histology tumours in relation to TP53 mutational status detected by 
different techniques. *, p< 0.05; **, p< 0.01. NGS, Next generation sequencing. Significant 
p-values are highlighted. 
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4.4.4.2 Analysis of the first hypothesis for all patients 
We hypothesised that patients with wild-type TP53 are more sensitive to carboplatin than those 
with mutant TP53 and survive longer as a result of this treatment. 
Regardless of the sequencing method or combinations of datasets (Either or Both), patients 
whose tumours harboured wild-type TP53 were more sensitive to single agent carboplatin than 
those with mutant TP53 (p< 0.05). Furthermore, TP53 genomic status was also retained as an 
independent predictive variable in multivariate analysis including age, disease stage (I/II and 
III), residual disease, grade of differentiation (poor and intermediate differentiation), histology 
and TP53 mutational status (p<0.01) (Table 4-16).  
TP53 mutational status detected by Sanger sequencing or defined by the combination of both 
Sanger and NGS had prognostic significance in both univariate and multivariate analyses for 
all patients who received either single agent carboplatin or CAP (Table 4-16).  
For PFS, the TP53 status was not significantly associated with survival for patients in response 
to all treatment options with the exception of those treated with carboplatin, in relation to 
mutational status of TP53 detected by either Sanger sequencing or NGS. Interestingly, TP53 
status was an independent prognostic factor in multivariate analysis for patients treated with 
carboplatin irrespective of sequencing method or TP53 status dataset combination (Table 4-17). 
4.4.4.3 Analysis of the first hypothesis for patients with serous histology tumours 
For patients with serous histology tumours treated with single agent carboplatin, individuals 
with wild-type TP53 detected by Sanger sequencing and by both sequencing techniques had a 
better OS compared to those with mutant TP53. The TP53 status was significant as a prognostic 
biomarker in multivariate analysis irrespective of sequencing technique. Furthermore, the 
prognostic value of TP53 retained significance for patients with serous histology tumours 
treated with carboplatin or CAP for both univariate and multivariate analysis based on the 
Sanger sequencing and on detection by both sequencing methods (Table 4-18).  
No significant difference was observed in PFS for patients with serous histology tumours by 
TP53 status irrespective of sequencing method. However, the TP53 status was significant in 
the Cox multivariate regression analysis model for treatment with carboplatin alone (Table 4-19).  
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Table 4-16: Univariate and Multivariate Cox regression analysis of overall survival for 
patients treated with carboplatin alone, either carboplatin or CAP in relation to TP53 
status. *, p< 0.05; **, p< 0.01; ***, p< 0.001; NGS, Next generation sequencing. Significant 
p-values are highlighted. 
 
 
Table 4-17: Univariate and Multivariate Cox regression analysis of progression-free 
survival for patients treated with carboplatin alone, either carboplatin or CAP in relation 
to TP53 status. *, p< 0.05; **, p< 0.01; NGS, Next generation sequencing. Significant p-
values are highlighted.
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Table 4-18: Univariate and Multivariate Cox regression analysis of overall survival 
following treatment with carboplatin alone, either carboplatin or CAP for patients with 
serous histology tumours in relation to TP53 status. *, p< 0.05; **, p< 0.01; ***, p< 0.001; 
NGS, Next generation sequencing. Significant p-values are highlighted. 
 
 
Table 4-19: Univariate and Multivariate Cox regression analysis of progression-free 
survival following treatment with carboplatin alone, either carboplatin or CAP for 
patients with serous histology tumours in relation to TP53 status. *, p< 0.05; **, p< 0.01; 
NGS, Next generation sequencing. Significant p-values are highlighted.    
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4.4.4.4 Analysis of the second hypothesis, patients whose tumours have mutant TP53 may 
benefit from the addition of paclitaxel to carboplatin while those with wild-type 
TP53 do not benefit 
Overall, at the 95% confidence level, addition of paclitaxel had no statistically significant benefit 
for ovarian cancer patients irrespective of TP53 genomic status and sequencing techniques or 
combination datasets used, with a few exceptions listed in Table 4-20 & Table 4-21. 
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Table 4-20: Kaplan-Meier and Log-rank test analysis of overall survival for patients treated with platinum-based versus addition of 
paclitaxel to carboplatin in regard to TP53 mutational status.*, p<0.05. Significant p-values are highlighted. 
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Table 4-21: Kaplan-Meier and Log-rank test analysis of progression-free survival for patients treated with platinum-based versus addition 
of paclitaxel to carboplatin in regard to TP53 mutational status.*, p<0.05. Significant p-values are highlighted. 
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4.5 Discussion 
The optimum treatment for ovarian cancer still remains challenging despite large and well-
designed clinical trials. One of the major determinants of outcome in ovarian cancer is 
sensitivity and response to chemotherapy. The role of the TP53 gene in resistance to treatment 
is controversial even though many studies show the mutational status of TP53 is a significant 
determinant of response to chemotherapy (Havrilesky et al., 2003; Canevari et al., 2006; 
Gadducci et al., 2006; Bast et al., 2009; Gadducci et al., 2009). A body of experimental 
evidence suggests the hypothesis that patients with wild-type TP53 are more sensitive to 
platinum-based chemotherapy than those with mutant TP53, and that patients with mutant 
TP53 tumours may gain greater benefit from a combination treatment of platinum-based 
chemotherapy and paclitaxel. The identification of determinants of tumour response to 
chemotherapy and development of laboratory techniques to determine sensitivity to 
chemotherapy prior to treatment help physicians to optimise and individualise patients’ 
treatment and avoid more normal tissue toxicity.  
 Limitations of FFPE tissues for DNA sequencing 
Recently, cancer therapy has been improved by using molecularly targeted therapies which 
have greatly increased the clinical request for detection of actionable mutations (A subset of 
driver mutations that have significant diagnostic, prognostic, or therapeutic implications in 
subsets of cancer patients and for specific therapies) in cancer patients. In fact, precision 
medicine depends on accurate detection of these actionable mutations (Do and Dobrovic, 
2015). 
FFPE tissue is one of the most widely used methods to preserve nucleic acid and protein for 
disease diagnosis and research although use of FFPE tissue for detection of actionable 
mutations is challenging (Do and Dobrovic, 2015; Gagan and Van Allen, 2015; Arreaza et al., 
2016). The FFPE process results in different types of DNA damage including DNA 
fragmentation because of hydrolysis of phosphodiester bounds, formaldehyde-induced 
crosslinks, generation of a basic sites and deamination of cytosine base leading to C-> T 
mutations which can be considered as direct or indirect sources of sequence artifacts. The 
amount of amplifiable templates available for PCR amplification is significantly reduced by 
extensive fragmentation of DNA. Another issue for working with FFPE tissue is insufficient 
and limited quantity of DNA extracted from FFPE samples which results in poor uniformity 
sequencing data and inhibits the power of mutation detection (Munchel et al., 2015). Despite   
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these limitations, the results of DNA sequencing data sets from 13 pairs of matched FFPE and 
fresh-frozen tissue samples indicated high rate of concordant calls between those at reference 
and variant position in three commonly used sequencing approaches including whole genome, 
whole exome and targeted exon sequencing. Furthermore, statistical approaches and 
bioinformatics have been developing to decrease the background mutations, improve the 
sensitivity of sequencing and eliminate false-positive calls (Munchel et al., 2015).  
 Analysis of TP53 mutation  
In this study, 260 tumour samples were examined for TP53 status by genomic DNA sequencing 
of the coding exons, 2-11, using Sanger sequencing and NGS techniques. The prevalence of 
TP53 mutations wad 47%, 56%, 64% and 72% according to the mutations detected by both 
techniques, Sanger, NGS and either Sanger or NGS respectively. The results from Sanger and 
NGS are comparable to most previous studies that have sequenced the full coding exons of 
TP53 in ovarian cancer (Wen et al., 1999; Shahin et al., 2000; Reles et al., 2001) or in the 
serous histological subtype of ovarian cancer (Bernardini et al., 2010). However, it was lower 
than the rate of TP53 mutation in exons 2-11 for patients with serous ovarian cancer reported 
by Havrilesky et al. (2003) (75%), women with high grade pelvic serous ovarian cancer 
reported by Ahmed et al. (2010) (97%), or those with HGSC reported by The Cancer Genomic 
Atlas Research (2011) (96%). 
Also, the frequency of ovarian cancer TP53 mutation was higher than other studies which 
sequenced only exons 5-8 (Fallows et al., 2001; Schuyer et al., 2001; Amikura et al., 2006; 
Bartel et al., 2008; Rechsteiner et al., 2013). These results indicate that sequencing only exons 
5-8 misses some mutations located in exons 2-4 and 9-11. Both Sanger and NGS identified the 
majority of TP53 mutations to be located in exons 5-8 which is consistent with other studies 
(Fallows et al., 2001; Reles et al., 2001; Havrilesky et al., 2003; Ahmed et al., 2010). From a 
total of 159 patients with HGSC, 99 (62%) and 112 (71%) had mutant TP53 by Sanger status 
and NGS status respectively. These results differ from two published studies which reported a 
very high frequency of TP53 mutation in HGSC (>95%) (Ahmed et al., 2010; The Cancer 
Genome Atlas Research, 2011; Wong et al., 2013). Given the fact that exons 2-11 of TP53 was 
sequenced by NGS in above studies, this inconsistency is not due to different techniques used 
or exons sequenced in these studies. From a total of 25 patients with clear cell ovarian cancer, 
10 (40%) and 7 (28%) had mutant TP53 by Sanger and NGS status respectively. This is 
unlikely that the lower frequency of TP53 mutation in HGSC and higher frequency of TP53 
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mutation in clear cell and endometrioid histological subtypes is due to misclassification of the 
samples. Diagnoses from the historical ICON3 clinical trial were reviewed and updated in early 
2012 by an extremely experienced gynae pathologist. when the classification changed the 
percentages in each group also changed and the up to date classification correlates with the 
current publications representing 60-80% of epithelial ovarian cancer as HGSC (Li et al., 2012; 
Devouassoux-Shisheboran and Genestie, 2015; McCluggage et al., 2015) and 5-10% as clear 
cell ovarian cancer (Devouassoux-Shisheboran and Genestie, 2015; Levitan, 2016). However, 
the frequency of LGSC (10%) was slightly higher than previously reported studies, 3% (Chris 
M.J. Conklin, 2013) and 6-8% (Rachel N. Grisham, 2016). Moreover, if the proportion of 
HGSC is considered as the percentage reported by more currently published studies (70%) 
(Devouassoux-Shisheboran and Genestie, 2015; McCluggage et al., 2015) which is 8% higher 
than the presented results in this study (62%), the TP53 mutation rate of HGSC would be 70% 
(62% + 8%) and 79% (71% + 8%) by Sanger status and NGS status respectively. Furthermore, 
low rates of allele frequency may be responsible in some way for the observed differences in 
the rate of TP53 mutation in our study compared to others. An interesting paper indicates that 
p53 mutations can be found in anyone (including women without cancer) if you look hard 
enough (Krimmel et al., 2016) 
The most prominent mutations were substitution/missense, which is consistent with other 
studies (Reles et al., 2001; Schuyer et al., 2001; Yemelyanova et al., 2011; Rechsteiner et al., 
2013).  
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 Relationship of TP53 status to clinicopathological variables 
In the current study, analysis of the relationship between clinicopathological variables and 
Sanger TP53 status did not show significant differences amongst different disease stages and 
residual bulk groups in regard to Sanger TP53 status. In contrast, the presence of mutant TP53 
was significantly correlated with poor differentiation and high grade serous histology. These 
results are in accord with other studies that found no association between TP53 status and 
disease stage (Bauerschlag et al., 2010; Kim et al., 2014) and other findings that patients with 
mutant TP53 are more likely to be associated with increasing tumour grade (Kmet et al., 2003; 
Bauerschlag et al., 2010; Rechsteiner et al., 2013).  
TP53 status by NGS indicated that TP53 mutations were significantly associated with 
histological subtype, advanced FIGO stage and poor differentiation, while no association 
between residual disease and NGS TP53 status was shown. Two previous studies by Kemet et 
al. (2003) and Rechsteiner et al. (2013) also reported significant associations between TP53 
status and clinicopathological data. However, some other studies reported no significant 
association between the presence of TP53 mutation and some clinical pathological data 
(Fallows et al., 2001; Rose et al., 2003). Literature differences can be explained in part 
bydifferent sequencing methods, different sequenced exons, study design and size of samples 
in various studies. 
 The relationship between TP53 status and overall survival or progression-free 
survival regardless of treatment in the ICON3 study 
The data from Sanger sequencing for all patients and the subgroup of patients with serous 
ovarian cancer showed TP53 mutational status as a significant prognostic factor for OS and/or 
PFS. Mutational status defined by detection using both sequencing techniques also indicated a 
significant association between TP53 mutation and OS but not with PFS. Several studies 
support these results and found a clear trend with longer OS and/or PFS for patients with wild-
type TP53 tumour compared to those harbouring mutant TP53 tumour (Reles et al., 2001; 
Schuyer et al., 2001; Nadkarni et al., 2013; Rechsteiner et al., 2013). Gadducci et al. (2006) 
found a clear trend for better OS and PFS for ovarian cancer patients with wild-type TP53 
tumour compared to those with mutant TP53, although the observed differences did not reach 
statistical significance. Some other studies have reported no significant association between 
TP53 mutation and OS and/PFS (Laframboise S, 2000; Fallows et al., 2001; Bartel et al., 2008;   
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Ahmed et al., 2010; Bauerschlag et al., 2010). However, HGSC cases with a high rate of TP53 
mutation, 96.7%, were used in the study performed by Ahmed et al.  
In contrast, no significant correlation was observed in OS and PFS with respect to NGS TP53 
status and mutations defined in a combination dataset by the detection by either Sanger or NGS 
methods. In fact, the increased frequency of mutations in the combined dataset led to a decrease 
in the prognostic value of TP53. These results indicate that the inclusion of samples with a low 
percentage of mutant reads, because of the higher sensitivity and lower accuracy of the NGS 
method, may lead to the inclusion of samples as mutant when only small TP53 mutant 
subclones are present, which are likely not to have the same impact on response to treatment 
and patient survival time. This suggests it would be interesting to perform a ROC curve analysis 
based on the percentage of mutant allele reads to see if it is possible to define an optimal cut-
point for what is a prognostically significant percentage of mutant reads. This might explain 
the difference between the Sanger and NGS results. The potential for FFPE-induced artefacts 
such as cytosine deamination which induce C>T changes can be considered as another possible 
explanation for the observed differences in Sanger sequencing and NGS data. Another reason 
for these differences may be due to the issues related to exon 7 sequencing by NGS. As 
illustrated above and in Table 4-2, the frequency distribution of TP53 mutation and its 
correlation with survival in patients with ovarian cancer have been the subject of several studies 
even though the results are inconsistent. This inconsistency in findings might be related to 
different DNA sequencing techniques, the number of exons sequenced, various sample sizes 
and study design, diverse chemotherapy treatment options and dose. The significance of TP53 
status as a prognostic biomarker in the present study was dependent on the sequencing methods 
used to detect mutation.  
It has been suggested that the classification of mutations based on their impact on p53 structure 
and function could further refine the prognostic accuracy of TP53 mutational status, with 
distinct types of mutations resulting in differing impact on patient survival (Canevari et al., 
2006; Liu et al., 2010; Brachova et al., 2015). Several studies analysed correlation between 
TP53 status and OS and/or PFS in regard to type of mutation. Shahin et al. (2000), Rose et al. 
(2003) and Nadkarni et al. (2013) analysed the impact of TP53 status on overall survival 
according to the type of TP53 mutation, demonstrating a significant association between null 
TP53 and OS, while the presence of missense mutant TP53 was not significantly correlated 
with OS. Another study investigated the association between TP53 mutation and survival in 
patients diagnosed with advanced serous ovarian cancer and reported significantly worse PFS   
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in patients with “oncomorphic” TP53 mutation, in which the mutations lead to both the 
elimination of wild-type TP53 function and conferment of dominant oncogenic function, 
compared to patients with tumours harbouring mutations not categorised as oncomorphic 
(Brachova et al., 2015). An additional study demonstrated that patients with HGSC grouped 
according to structural classes of TP53 mutations have different survival outcomes for OS and 
PFS (Seagle et al., 2015). In contrast, Ahmed et al. (2010) and Wang et al. (2004) reported no 
indication of significant association between the type of TP53 mutation (missense versus non-
missense) and OS or PFS. This is a possible avenue to explore in further analysis of the current 
study dataset.    
Surprisingly, a few studies have reported that patients with advanced HGSC and mutant TP53 
had significantly better OS and/or PFS than those with wild-type TP53 tumour (Ueno et al., 
2006; Wong et al., 2013).  
 Patients from the ICON3 study with wild-type TP53 tumours treated with single 
agent carboplatin have better overall survival than those with mutant TP53  
This is the first time that carboplatin single agent is compared with combination plus paclitaxel 
by TP53 mutational status in a randomized controlled clinical trial. For the primary objective 
in the present study, TP53 mutational status was a significant predictor of OS following 
treatment with single agent carboplatin, regardless of the sequencing method, and retained 
independent prognostic significance on multivariate analysis alongside established 
clinicopathological prognostic factors. For PFS and treatment groups other than single agent 
carboplatin, the significance of TP53 status as a predictive biomarker in the present study was 
dependent on the sequencing methods used to detect mutation.  
For patients with serous histology, TP53 retained its significance in response to treatment 
according to the data collected by Sanger or both sequencing methods in univariate analysis, 
but in multivariate analysis based on all sequencing data, Sanger sequencing, NGS, either 
Sanger or NGS, and both Sager and NGS data. A possible explanation for decreased predictive 
significance of TP53 for patients with serous histology might be that the rate of TP53 mutation 
is higher in serous ovarian cancer compared to other histological subtypes (Ahmed et al., 2010). 
These results are consistent with other studies which described a better response to platinum-
based chemotherapy and longer OS for patients whose tumours have wild-type TP53 than 
individuals harbouring mutant TP53 (Reles et al., 2001; Gadducci et al., 2006). However, they   
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are not part of a controlled clinical trial and not testing carboplatin as a single agent versus 
carboplatin plus paclitaxel.  
Reles et al. (2001) investigated the relationship between TP53 genomic status and OS for 
patients who received cisplatin plus cyclophosphamide, carboplatin plus cyclophosphamide or 
other chemotherapy regimens. They reported a better OS for patients whose tumours harbour 
wild-type TP53 than those with mutant TP53 tumours. Gadducci et al. (2006) found a clear 
trend for longer OS and PFS for ovarian cancer patients with wild-type TP53 tumours who 
received paclitaxel plus carboplatin-based chemotherapy compared to those with mutant TP53 
tumours. A significant association between TP53 mutational status and OS was shown for 
patients with advanced epithelial ovarian cancer who received platinum-based chemotherapy 
(Havrilesky et al., 2003). 
In contrast, other authors reported no significant relationship between TP53 genomic status and 
response to platinum-based chemotherapy and overall survival (Fallows et al., 2001; Wang et 
al., 2004; Bauerschlag et al., 2010). As mentioned above, none of these studies are part of a 
controlled clinical trial. 
 Patients from the ICON3 study whose tumours have mutant TP53 gain benefit from 
addition of paclitaxel to carboplatin, while those with wild-type TP53 do not 
benefit 
Overall, for the current cohort taken from the ICON3 trial, the whole patient group did not gain 
statistically significant benefit from a combined treatment with paclitaxel and carboplatin 
compared to those treated with carboplatin alone or CAP alone irrespective of TP53 status and 
serous histology. However, there was a statistical trend for the inclusion of paclitaxel to confer 
greater survival benefit for the TP53 mutant subgroup compared with patients who had wild-
type TP53 tumours.  
These results differ from a few previous studies which have been previously performed to 
evaluate the efficacy of taxane-platinum versus platinum-based therapy in regard to TP53 
status in ovarian cancer (Smith-Sørensen et al., 1998; Kupryjanczyk et al., 2008). Smith et al. 
(1998) assessed the effect of paclitaxel and cisplatin versus cyclophosphamide and cisplatin in 
tumours from 45 randomized patients with ovarian cancer in relation to TP53 status detected 
by direct DNA sequencing. In terms of relapse free survival, patients with mutant TP53 treated 
with paclitaxel plus cisplatin had a significantly better survival than those with mutated TP53 
treated with cyclophosphamide and cisplatin (p=0.002). Kupryjanczyk et al. (2008) assessed   
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effectiveness of taxane-platinum therapy compared to platinum-based therapy with respect to 
TP53 status estimated by immunohistochemistry in non-randomized ovarian cancer patients 
with stage IIB-IV. 10% staining was considered as the optimal cut-off value for separation of 
tumours with or without a missense mutation in TP53 gene. The results showed that OS and 
PFS were not affected by the type of treatment in patients whose tumours stained by less than 
10%. In contrast, individuals with tumours stained more than 10% gained benefit from addition 
of paclitaxel to platinum-based chemotherapy and survived longer (p=0.008). As explained 
before, these differences can partly be explained by the size, study design, mixed histological 
subtypes, grades and stages, and different methods used to identified the genomic status of 
TP53 gene of the various studies. 
 Conclusion and further work 
This study evaluates for the first time the effect of TP53 genomic status on OS or PFS for 
ovarian cancer patients from a controlled clinical trial, ICON3, who received single agent 
carboplatin or CAP as a control versus those treated with a combination of paclitaxel with 
carboplatin. The results of current study clearly show predictive value of TP53 genomic status 
in response to single agent carboplatin for ovarian cancer patients regardless of sequencing 
method. Using ROC curve analysis to determine the optimal cut-off value for the number of 
reads in NGS may give a better result in relation to mutational status of TP53 as predictive and 
prognostic biomarker in ovarian cancer. 
Studies have clearly indicated that ovarian cancer is a complex series of distinctly different 
diseases with different aetiologies and heterogeneity at the molecular level (Wang et al., 2004; 
Bast et al., 2009; Ahmed et al., 2010; Le Page et al., 2010; Prat, 2012). This suggests that 
development of reliable and consistent prognostic biomarkers must be specific to 
histopathological subtype and in the case of TP53 mutation should investigate differences 
between mutation subclasses. Also, functional evaluation of the p53 pathway may provide 
added value, rather than looking at TP53 mutation alone in order to predict response to 
chemotherapy, individualisation of treatment and survival outcome in patients with ovarian 
cancer. 
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Chapter 5: An investigation of ovarian cancer tumour samples for p53 and 
p21WAF1 expression using tissue microarrays (TMA) from the ICON3 
cohort 
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5.1 Introduction 
The most frequent genetic event in ovarian cancer is alteration of the TP53 gene, involving 
mutation and either absence of expression or overexpression due to stabilisation of mutant 
forms. Although numerous studies have previously been performed to evaluate the predictive 
value of TP53 alterations in ovarian cancer, the outcomes are ambiguous.  
Truncating mutations such as nonsense mutations, deletions and insertions are missed by 
immunohistochemistry staining, and overexpression of TP53 is not necessarily a signature of 
mutation. Several studies have assessed both TP53 gene status and its protein expression status 
together as predictive biomarkers in relation to survival outcomes (Reles et al., 2001; Schuyer 
et al., 2001; Wang et al., 2004; Gadducci et al., 2006; Bartel et al., 2008; Rechsteiner et al., 
2013) and a few have correlated the combined status of TP53 alteration with both response to 
chemotherapy and survival (Shahin et al., 2000; Bartel et al., 2008). Assessing the expression 
and functional status of p53 as well as TP53 genomic status may be more informative for 
predicting response to treatment. 
5.2 Hypothesis and Objectives 
Hypothesis:  
1.  There is an association between the presence of TP53 mutation and immunohistochemistry 
staining results. 
2.  The expression and functional status of the TP53 gene can add prognostic value to predict 
survival outcomes in ovarian cancer patients. 
Objectives: 
1.  To establish whether immunohistochemical staining for p53 can be considered as an 
additional prognostic variable in the ICON3 patient cohort. 
2. To correlate immunohistochemical staining patterns of p53 expression with TP53 
mutational status.  
3. To evaluate the role of combined status of TP53 genomic alterations, p53 expression and 
functional status for their combined prognostic value in ovarian cancer. 
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5.3 Specific Materials and Methods 
 TMA and patient characteristic 
The patient cohort characteristics were described in chapter 4.3.1. The tumour FFPE blocks 
were used to take sample cores and construct 6 TMA blocks which represented all patients 
tumour specimens with duplicate cores on each block. Six TMAs, ICON3-1 to ICON3-6 were 
produced by Dr. Jennifer Houniet with a standard 1 mm diameter core as suggested by other 
researchers (Eckel-Passow et al., 2010; Kim et al., 2013). Then, sections were cut from the 
TMA blocks and mounted on six slides labelled as ICON3-1 to ICON3-6. The slides were used 
to perform immunohistochemistry staining for p53, and p21WAF1 as a downstream 
transcriptional target of p53. 
 Antibody specificity and optimization 
The antibodies used, their dilution and optimisation are provided in section 2.2.1 and 3.3.2. 
 Staining, scoring and categorising 
The slides were stained and the samples scored and categorised as described in section 3.3.3. 
 DNA sequencing 
The TP53 gene, exons 2-11, was sequenced as explained in section 4.3.2. 
 Statistical analysis 
The Kaplan-Meier method and log-rank test were used to analyse the statistical significance of 
observed differences in patient survival. The relationship between TP53 mutational status and 
p53 H-scores was analysed using the Mann-Whitney and Kolmogorov-Smirnov tests. The 
LIFETEST Procedure was applied to compute the homogeneity of strata due to the importance 
of biomarker analysis in homogeneous sub-groups of patients. The Chi-square test was used to 
analyse differences on a contingency table with 2 columns and 3 or more rows. All statistical 
tests presented were performed using the GraphPad Prism version 5.04 software and a p-value 
of <0.05 was considered to be statistically significant. 
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5.4 Results 
 The p53 staining distribution, scores, categories and correlation with survival 
A total of 253 tissue samples from the 260 patients were used; seven patients with no treatment 
cycles were omitted. 22 (9%) cores were lost due to processing or no tumour cells in the patient 
sample. The p53 staining pattern was nuclear, ranging from negative to strongly positive. The 
distributions of immunohistochemical staining found are shown in Figure 5-1. ROC curve 
analysis was used to identify whether there was an optimal prognostic cut-off point to 
categorise the samples for subsequent Kaplan-Meier analysis; however, the area under the ROC 
curve, AUC, was 0.53 and no clear cut-point was evident (data not shown). From a total of 231 
samples, 30 (13%) were negative (H-score=0), and 201 (87%) of patients were positive (H-
score>0). The samples were categorised based on the LIFETEST procedure in three groups 
including 82 (35%) tumour samples having low expression of p53 (0≤H-score≤3), 64 (28%) 
tumour samples with an intermediate level of p53 (4≤H-score≤7), and 85 (37%) of tumours 
expressing high level of p53 (8≤H-score≤16). The Kaplan-Meier survival curves in relation to 
these three categories of p53 expression are shown in Figure 5-2. Although intermediate 
expression of p53 appeared to be associated with better overall survival compared to other two 
groups, this difference did not reach statistical significance on a log-rank test (X2=5.66, 
p=0.06).  
 
 
Figure 5-1: The p53 H-score distribution in samples from 231 patients. The horizontal 
black line represents the median.  
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Figure 5-2: The survival times in relation to low (0≤H-score≤3), intermediate (4≤H-
score≤7), and high expression (8≤H-score≤16) of p53 (p= 0.06).  
 
 Correlation of TP53 status and p53 protein expression 
This part of the study set out to investigate whether p53 immunohistochemical analysis can be 
used as a robust method for inferring the presence of TP53 mutation in ovarian carcinoma. 
Overall, there was a significant correlation between strong immunohistochemical staining for 
p53 and TP53 mutation detected by Sanger sequencing and NGS. 
5.4.2.1 Results based on the Sanger TP53 status 
A scatter plot comparison of the p53 immunohistochemistry H-score between TP53 wild-type 
(N=100) and mutant (N=131) sample sub-groups was constructed based on the Sanger 
sequencing data (Figure 5-3). The Mann-Whitney (p=0.01) and Kolmogorov-Smirnov 
(p=0.009) tests both showed that the distributions are significantly different in shape and 
median. The Mann-Whitney test confirmed that the median H-score is significantly higher for 
the TP53 mutant group (Median of H-score=7) than the TP53 wild-type category (Median of 
H-score=4) (Figure 5-3). A ROC curve analysis showed the sensitivity and specificity of 34% 
and 81% respectively for optimal predictive values of p53 immunohistochemistry as a 
surrogate for TP53 mutation (AUC=0.6, P=0.04).   
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From a total of 131 TP53-mutated samples, 110 cases (84%) were positive and 21 cases (16%) 
were completely negative for p53 staining. In the wild-type TP53 sub-group, 91 cases (91%) 
were positive and 9 cases (9%) were negative for p53 staining (Table 5-1). The distributions 
of negative and strong expression of p53 was higher in tumours with mutant TP53 compared 
to those with wild-type TP53. Conversely, there was a higher proportion of samples with low 
expression of wild-type TP53 compared to those with low expression of mutant TP53 
(Figure 5-4). The observed differences between different groups are statistically significant 
(X2=4.67, p=0.03) based on a Chi-square test.  
 
Figure 5-3: The distribution of p53 H-scores in relation to Sanger TP53 status. The 
horizontal line represents the median (Mann-Whitney (p=0.01), Kolmogorov-Smirnov 
(p=0.009).  
 
 
Table 5-1: The frequency distribution of p53 H-scores in relation to Sanger TP53 status 
(X2 = 4.67, p=0.03). IHC, Immunohistochemical staining; No, Number. 
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Figure 5-4: The proportion of p53 H-score in different categories in regard to Sanger 
TP53 status. Low (0≤H-score≤3); Intermediate (4≤H-score≤7); High expression (8≤H-
score≤16) (X2=4.67, p=0.03). 
 
5.4.2.2 The association between p53 immunohistochemistry staining and type of Sanger 
TP53 mutation 
Immunohistochemical analysis of p53 was evaluated in relation to the type of TP53 mutation 
(missense or nonsense/frameshift) based on the Sanger data. The most common type of 
mutations were missense mutations affecting 95 (73%) cases included, and this group included 
the highest proportion of high p53 expression cases. From a total of 36 tumour samples with 
nonsense, deletion or insertion mutation, 10 samples were negative for IHC staining. 
(Table 5-2). A Chi-square test confirmed that the observed differences in the frequency of p53 
IHC staining with respect to type of TP53 mutation was statistically significant (X2=14.02, 
p=0.003) (Figure 5-5). More statistical analysis using the Poisson distribution test indicated 
that accumulation of p53, high expression of p53, is significantly higher for patients whose 
tumours harbour missense mutation compared to those with nonsense or frameshift mutation 
(p<0.0001, Poisson distribution test). Furthermore, no significant difference was observed in 
the proportion of negatively stained tumours between missense and nonsense or frameshift 
mutation groups (p=0.1, Poisson distribution test).  
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Table 5-2: The frequency distribution of p53 immunohistochemistry staining in relation 
to the type of Sanger TP53 mutation. Negative (H-score=0); Low (1≤H-score≤3); 
Intermediate (4≤H-score≤7); High expression (8≤H-score≤16) (X2=14.02, p=0.003); No, 
Number. 
 
 
 
Figure 5-5: The frequency distribution of p53 immunohistochemistry staining in relation 
to the type of Sanger TP53 mutation. Negative (H-score=0); Low (1≤H-score≤3); 
Intermediate (4≤H-score≤7); High expression (8≤H-score≤16) (X2=14.02, p=0.003). Del, 
deletion; Ins, insertion.  
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5.4.2.3 Results based on the NGS TP53 status 
The frequency distribution of p53 immunohistochemistry H-score between wild-type TP53 
(N=80) and mutant (N=150) sample sub-groups was compared based on the NGS results (no 
result for one tumour sample) (Figure 5-6). The frequency distribution of p53 H-scores in 
relation to TP53 status was significantly different according to both Mann-Whitney (p=0.005) 
and Kolmogorov-Smirnov (p=0.003) tests. The median H-score is significantly higher for the 
TP53 mutant group (Median of H-score=7) than the TP53 wild-type category (Median of H-
score=4) (Figure 5-6). The sensitivity and specificity of predictive values of p53 immunohistochemistry 
as a surrogate for TP53 mutation were 35% and 88% respectively based on the ROC curve 
analysis (AUC=0.61, P=0.04). Of the cases with mutant TP53, 24 (16%) showed negative 
staining for p53 and 126 (84%) showed positive staining. Of tumours with wild-type TP53, 6 
cases (7%) and 74 cases (93%) were negative and positive for p53 staining respectively 
(Table 5-3). Figure 5-7 shows that the distributions of tumours with negative and high 
expression of mutant TP53 was higher than those with negative and high expression of wild-
type TP53 demonstrating the relationship between TP53 mutation and no expression or high 
expression of p53. . In contrast, the frequency distribution of samples with low expression of 
wild-type TP53 was higher than those with low expression of mutant TP53. The Chi-Square 
test analysis confirmed that the observed differences between different categories are statistically 
significant (X2=5.82, p=0.01).   
 
 
Figure 5-6: The distribution of p53 H-scores in relation to NGS TP53 status. The 
horizontal line represents the median (Mann-Whitney (p=0.005), Kolmogorov-Smirnov 
(p=0.003)).
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Table 5-3: The frequency distribution of p53 H-scores in relation to NGS TP53 status 
(X2=5.82, p=0.01). IHC, Immunohistochemical staining; No, Number. 
 
 
Figure 5-7: The proportion of p53 H-score in different categories in regard to NGS TP53 
status. Negative (H-score=0); Low (1≤H-score≤3); Intermediate (4≤H-score≤7); High 
expression (8≤H-score≤16) (X2=5.82, p=0.01). 
 
5.4.2.4 The association between p53 immunohistochemistry staining and type of TP53 
mutation 
Immunohistochemical analysis of p53 was evaluated in relation to the type of TP53 mutation 
(missense or truncated) based on the NGS data. Missense mutations were the most common, 
with 128 (85%) cases included, and this group included the highest proportion of high p53 
expression cases. From a total of 22 tumour samples with nonsense, deletion or insertion 
mutation, negative staining was the predominant pattern of IHC staining (Table 5-4). A Chi-  
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square test confirmed that the observed differences in the frequency of p53 IHC staining with 
respect to type of TP53 mutation was statistically significant (X2=29.96, p<0.0001) 
(Figure 5-8). More statistical analysis using the Poisson distribution test indicated that 
accumulation of p53, high expression of p53, is significantly higher for patients whose tumours 
harbour missense mutation compared to those with truncating mutation (p<0.0001, Poisson 
distribution test). Furthermore, no significant difference was observed in the proportion of 
negatively stained tumours between missense and nonsense/frame shift mutation groups 
(p=0.1, Poisson distribution test). 
 
Table 5-4: The frequency distribution of p53 immunohistochemistry staining in relation 
to the type of NGS TP53 mutation. Negative (H-score=0); Low (1≤H-score≤3); 
Intermediate (4≤H-score≤7); High expression (8≤H-score≤16) (X2=29.96, p<0.0001); No, 
Number. 
 
Figure 5-8: The frequency distribution of p53 immunohistochemistry staining in relation 
to the type of NGS TP53 mutation. Negative (H-score=0); Low (1≤H-score≤3); 
Intermediate (4≤H-score≤7); High expression (8≤H-score≤16) (X2=29.96, p<0.0001). Del, 
deletion; Ins, insertion.
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 Combined status based on TP53 mutation and p53 protein expression: correlation 
with survival 
To study the association between combined status of TP53 alterations and survival outcomes, 
231 patient samples were categorised according to their combined TP53 mutational and protein 
expression status into six groups. In terms of p53 protein expression, each sub-group of wild-
type TP53 or mutant TP53 was divided into three categories as low expression (0≤H-score≤3), 
intermediate (4≤H-score≤7) and high expression (8≤H-score≤16).  
5.4.3.1 Results based on the Sanger TP53 status 
231 samples were grouped into six categories including mutant and low expression (39, 17%), 
mutant and intermediate expression (31, 14%), mutant and high expression (61, 26%), wild-
type and low expression (43, 19%), wild-type and intermediate expression (33, 14%) and wild-
type and high expression (24, 10%). Kaplan-Meier survival analysis represented in Figure 5-9 
shows a significant difference in patient survival across the sub-groups. The survival 
probability was significantly better in patients with intermediate p53 expression and wild-type 
TP53 genomic status compared to other groups (X2=11.67, p=0.04). 
Further analysis was separately carried out for sub-groups of patients whose tumours had wild-
type or mutant TP53. From a total of 100 patients whose tumours harboured wild-type TP53, 
43 cases (43%), 33 cases (33%) and 24 cases (24%) were categorised as low, intermediate and 
high expression respectively. There was again a significant difference in survival, and patients 
with intermediate expression and wild-type TP53 genomic status had a longer survival time 
compared to those with low or high expression and wild-type TP53 (X2=7.26, p=0.03) 
(Figure 5-10). In contrast, when patients with mutant TP53 were categorised into three groups 
based on the levels of p53 expression as low (39, 30%), intermediate (31, 24%) and high 
expression (61, 46%), no significant difference in survival time was observed in the analysis 
between patients with mutant TP53 with respect to p53 protein expression status (X2=1.20, 
p=0.5) (Figure 5-11).  
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Figure 5-9: The survival times in relation to combined Sanger TP53 tumour mutational 
and p53 protein expression status (p=0.04). 
 
 
Figure 5-10: The survival times in relation to tumour p53 protein expression status for 
the wild-type Sanger TP53 tumour genomic status sub-group (p=0.03).
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Figure 5-11: The survival times in relation to tumour p53 protein expression status for 
the mutant Sanger TP53 tumour genomic status sub-group (p=0.5). 
 
5.4.3.2 Results based on the NGS TP53 status 
A majority of women had tumours with mutant TP53 (150, 65%) with a distribution of 45 
(19.5%) low expression, 36 (16%) intermediate expression and 69 (30%) high expression. The 
frequency distribution for expression levels of wild-type TP53 (80, 34.5%) was 37 cases (16%) 
low expression, 28 cases (12%) intermediate expression and 15 cases (6%) high expression. 
Also, there was 1 (0.5%) missing case with no result for NGS TP53 status, which gives a total 
of n=231. As shown in Figure 5-12, there was no significant difference in survival between 
patients in relation to combining the NGS TP53 mutational and protein expression status 
(X2=8.13, p=0.3). When the data were separately analysed for patients with wild-type or mutant 
TP53, no significant difference was observed in relation to p53 protein expression levels. In 
the wild-type NGS TP53 sub-group, although high p53 immunostaining appeared to be 
associated with worse patient survival compared to those with intermediate or low tumour p53 
immunostaining, this difference did not reach statistical significance on a Log-rank test 
(X2=4.43, p=0.1) (Figure 5-13). The Kaplan-Meier analysis in Figure 5-14 shows no significant 
relationship between survival time and p53 immunostaining in the mutant NGS TP53 sub-
group (X2=2.58, p=0.3).  
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Figure 5-12: The survival times in relation to combining the NGS TP53 mutational and 
p53 protein expression status (p=0.2). 
 
 
Figure 5-13: The survival times in relation to p53 IHC score in the wild-type NGS TP53 
sub-group (p=0.1).
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Figure 5-14: The survival times in relation to p53 IHC score in the mutant NGS TP53 
sub-group (p=0.3). 
 
 The p21WAF1 staining distribution, scores, categories and correlation with survival 
From a total of 253 samples, 21 (8%) cores were missing during processing or contained no 
tumour cells in the patient sample, and 232 (92%) remained to analyse. The staining was limited 
to nuclei and ranged from negative (H-score=0) to positive (1≤H-score≤10) (Figure 5-15). The 
area under the curve from ROC curve analysis for p21WAF1 IHC staining was 0.52 
demonstrating the correlation of p21WAF1 expression to survival was weak. The frequency 
distribution for p21WAF1 staining was 52 (22%) negative and 180 (78%) positive. Fifty-two 
samples (22%) were negative (H score = 0), 121 samples (52%) showed low expression (H 
score = 1), and 59 samples (26%) showed intermediate or high expression (H score between 1 
and 10). As shown in Figure 5-16, the p21WAF1 expression was not a prognostic variable for 
survival (X2=0.49, p=0.8).  
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Figure 5-15: The p21WAF1 H-score distribution in samples from 232 patients. The 
horizontal black line represents the median. 
 
 
Figure 5-16: The survival time in relation to p21WAF1 expression (p=0.8).
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 Relationship between of TP53 status and p21WAF1 protein expression 
The CDKN1A gene encoding p21WAF1 is a downstream transcriptional target of p53, but can 
also be upregulated by p53-independent pathways. To study the relationship between p21WAF1 
expression and mutational status of TP53, a scatter plot was constructed indicating the 
frequency distribution of p21WAF1 immunostaining H-scores in relation to TP53 mutational 
status.  
5.4.5.1 Results based on the Sanger TP53 status 
The expression levels of p21WAF1 were compared between wild-type TP53 (N=100) and mutant 
(N=132) sample sub-groups according to the Sanger sequencing results (Figure 5-17). Neither 
Mann-Whitney (p=0.9) nor Kolmogorov-Smirnov (p=0.99) tests showed a significant 
difference in the distributions of p21WAF1 H-scores in relation to Sanger TP53 status. For the 
mutant TP53 sub-group, most of the samples were categorised as low expression with a 
distribution of 73 (55%). Lower frequencies were observed for tumour samples grouped as 
negative with 29 cases (22%) and intermediate or high expression with 30 cases (23%). In 
comparison, 23 (23%) of patients with wild-type TP53 had no p21WAF1 expression, 48 (48%) 
and 29 (29%) of those were grouped as low and intermediate or high expression respectively 
(Table 5-5) (Figure 5-18). The Chi-square test confirmed no significant difference between 
various categories (X2=0.32, p=0.6).  
 
 
Figure 5-17: The frequency distribution of p21WAF1 H-scores in relation to Sanger TP53 
status (Mann-Whitney (p=0.9), Kolmogorov-Smirnov (p=0.99)). The horizontal line 
represents the median.
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Table 5-5: The frequency distribution of p21WAF1 H-score in relation to Sanger TP53 
status (X2=0.32, p=0.6). IHC, Immunohistochemical staining; No, Number.  
 
 
 
Figure 5-18: The proportion of p21WAF1 H-score in different categories in regard to 
Sanger TP53 status. Negative (H-score=0); Low (H-score=1); Intermediate or high (2≤H-
score≤10) (X2=0.32, p=0.6). 
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5.4.5.2 Results based on the NGS TP53 status 
Figure 5-19 compares the distributions of p21WAF1 immunohistochemistry H-score between 
wild-type TP53 and mutant sub-categories based on the NGS results. Neither Mann-Whitney 
(p=0.05) nor Kolmogorov-Smirnov (p=0.31) tests showed a significant difference in the 
distributions of p21WAF1 H-scores in relation to NGS TP53 status. From a total of 151 patients 
with mutant TP53, 40 (26%) of tumour samples had no expression of p21WAF1, 78 (52%) of 
those were grouped with low expression and 33 (22%) had intermediate or high expression. 
For patients with TP53 wild-type tumour, 12 (15%) were categorised as negative, 42 (53%) 
had low expression and 26 (32%) were grouped as intermediate or high expression (Table 5-6) 
(Figure 5-20). One sample had no NGS result (H-score=1). Consistent with the Sanger 
sequencing data, the Chi-square test indicated no significant difference in the proportion of 
TP53 mutant cases between different p21WAF1 H-score sub-groups (p=0.07).  
 
 
Figure 5-19: The frequency distribution of p21WAF1 H-scores in relation to NGS TP53 
status (Mann-Whitney (p=0.05), Kolmogorov-Smirnov (p=0.31). The horizontal line 
represents the median. 
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Table 5-6: The frequency distribution of p21WAF1 H-score in relation to NGS TP53 status 
(X2=5.40, p=0.07). IHC, Immunohistochemical staining; No, Number. 
 
 
 
Figure 5-20: The proportion of p21WAF1 H-score in different categories in regard to NGS 
TP53 status. Negative (H-score=0); Low (H-score=1); Intermediate or high (2≤H-
score≤10) (X2=5.40, p=0.07).
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 The relationship between p21WAF1 expression and survival in regard to TP53 
mutational status 
232 patient samples were categorised according to their combined TP53 mutation and p21WAF1 
protein expression status into six groups. Each sub-group of wild-type TP53 or mutant was 
divided into three categories as negative (H-score=0), low expression (H-score=1), and 
intermediate or high expression (2≤H-score≤10). The data was also analysed separately in 
regard to either wild-type TP53 or mutant TP53 group. 
5.4.6.1 Results based on the Sanger TP53 status 
232 tumour samples were grouped into six categories with respect to p21WAF1 H-score and 
Sanger TP53 status, and association between the groups with survival was studied. The Kaplan-
Meier survival analysis represented in Figure 5-21 shows no significant difference in survival 
times between different categories (X2=4.4, p=0.5). Further analysis was performed to evaluate 
the relationship between p21WAF1 expression and survival in relation to either wild-type TP53 
or mutant TP53 (Figure 5-22 & Figure 5-23). The Kaplan-Meier plots and statistical analysis 
showed that survival data were not correlated with changes in p21WAF1 staining with respect to 
wild-type TP53 (X2=0.57, p=0.8) or mutant TP53 (X2=0.03, p=1.0). 
 
Figure 5-21: The survival times in relation to combining the Sanger TP53 status and 
p21WAF1 expression (p=0.5). 
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Figure 5-22: The survival times in patients with wild-type Sanger TP53 tumour in relation 
to p21WAF1 expression (p=0.8). 
 
 
Figure 5-23: The survival times in patients with mutant Sanger TP53 tumour in relation 
to p21WAF1 expression (p=1.0). 
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5.4.6.2 Results based on the NGS TP53 status 
231 tumour samples were categorised into six categories with respect to p21WAF1 expression 
and NGS TP53 status, and relationship between the groups with survival was studied. Overall, 
no significant difference was observed in survival rate for patients with tumours showing 
different levels of p21WAF1 expression in relation to NGS TP53 status (Figure 5-24) (X2=6.16, 
p=0.4). Of patients with wild-type TP53 tumour, survival data were not correlated with 
changes in p21WAF1 expression in three different groups (Figure 5-25) (X2=2.90, p=0.2). For 
individuals with mutant TP53 tumours, there was no significant difference in survival amongst 
different groups in relation to p21WAF1 expression (Figure 5-26) (X2=2.88, p=0.2). 
 
 
Figure 5-24: The survival times in relation to combining the NGS TP53 status and 
p21WAF1 expression (p=0.4). 
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Figure 5-25: The survival times in patients with wild-type NGS TP53 tumour in relation 
to p21WAF1 expression (p=0.2). 
 
 
Figure 5-26: The survival times in patients with mutant NGS TP53 tumour in relation to 
p21WAF1 expression (p=0.2).
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5.5 Discussion 
Although there are established prognostic variables in ovarian cancer, including stage of 
disease, histological subtype, residual disease and tumour differentiation, more additional 
predictive biomarkers are necessary to further refine the predicted efficacy of response to 
treatment and survival outcomes (Schuyer et al., 2001). Prior studies which have evaluated the 
association between p53 protein expression levels and/or TP53 mutational status with survival 
outcomes have found inconsistent results on whether TP53 status or p53 protein expression 
can be considered as significant predictive and prognostic variable for ovarian cancer patients. 
It is suggested that the status of p53 alterations (combining the mutational and protein 
expression status) might be more helpful than either gene status or protein status alone (Shahin 
et al., 2000; Bartel et al., 2008). Therefore, this part of the study concentrated on evaluation of 
combined mutational and protein expression status of p53 as a prognostic biomarker in ovarian 
cancer. 
 The p53 staining distribution and correlation with overall survival 
In the current study, 87% (201 of 231) of patients were positive for p53 expression, which is 
nearly in keeping with the finding of other studies which also categorised tumours with no p53 
protein expression as a negative staining (66% in Havrilesky et al. (2003); 70% in 
Yemelyanova et al. (2011)). However, it is higher than the 45% of tumours with positive p53 
expression reported by Leitao et al. (2004). Most studies have categorised tumours with >10% 
stained cells as positive and those with ≤10% stained cells as negative. 
The p53 H-scores were categorised into low, intermediate and high expression groups, and the 
difference in survival time between all groups was only marginally significant (X2=5.66, p= 
0.06). Although these results differ from some published studies which indicated a worse 
survival time for patients with high expression of p53 protein (Schuyer et al., 2001; Nakayama 
et al., 2003; Bartel et al., 2008), they are consistent with other reported studies which showed 
no significant association between p53 protein expression and survival outcome (Shahin et al., 
2000; Reles et al., 2001; Havrilesky et al., 2003; Gadducci et al., 2006; Rechsteiner et al., 
2013). A meta-analysis of 53 studies on the prognostic value of p53 expression indicated that 
p53 protein expression has a modest effect on prognosis and overall survival despite the 
presence of heterogeneity between studies, but nevertheless it is unlikely to be useful as a 
predictive biomarker in clinical practice (de Graeff et al., 2009).  
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This limitation, as described in section 3.5.2, can be explained in part by small sample size, 
sub-optimal design of some studies, different antibodies and cut-offs, alterations of other genes 
encoding proteins associated with p53 protein expression or regulation (Shahin et al., 2000; 
Canevari et al., 2006). It may also be due to the different treatment options (Levesque et al., 
2000), immunohistochemical methods (de Graeff et al., 2009; Rechsteiner et al., 2013), time 
of follow-up and histological subtypes of the tumours analysed in diverse series (Havrilesky et 
al., 2003; Gadducci et al., 2006). Also, Graeff et al. (2009) found FIGO stage distribution 
affects study outcome using meta-regression analysis.  
 TP53 gene mutation and relationship with immunohistochemical staining 
In this study, a significant correlation between the TP53 mutational status and protein 
expression of p53 was found regardless of sequencing technique used (p≤0.01). The results 
showed higher incidence of high p53 protein accumulation as well as cases of no p53 
expression in tumours with mutant TP53 compared to those with wild-type TP53. One 
mechanism through which p53 protein accumulates at high levels in the presence of TP53 
mutation is the inability of mutant p53 protein to transactivate wild-type TP53 target genes 
including MDM2. Therefore, reduced MDM2 protein levels result in decreased p53 
degradation (Wiman, 2007; Oren and Rotter, 2010). Also, PTEN expression increases mutant 
p53 protein levels through MDM2 inactivation or possibly direct binding to mutant p53 protein 
(Li et al., 2008). Stabilisation of mutant p53 protein can also probably occur via contribution 
of heat-shock proteins (Wiman, 2007). The mechanisms involved in accumulation of wild-type 
TP53 are not completely understood (Leitao et al., 2004) but nonetheless there are some 
possible explanations for this abnormal stability. Deregulation of MDM2 and p14ARF, high 
expression of p14ARF and low expression of MDM2, could result in the accumulation and 
stability of p53 protein. It is also suggested that the expression of MDM2 splice variants which 
are short variants of MDM2 protein acting as dominant negative inhibitors to the activity of 
full-length MDM2 or those variants lacking the p53 binding domain may affect the stability of 
wild-type p53 protein (Wang et al., 2005; Bartel et al., 2008). Furthermore, PTEN confers p53 
protection from MDM2 degradation via inhibition of P13K/AKt signalling enhancing MDM2 
nuclear translocation (Vlachostergios et al., 2012). Negative immunohistochemistry staining 
results from nonsense mutations, deletions and insertions (Nakayama et al., 2003; Bartel et al., 
2008; Yemelyanova et al., 2011) or through MDM2 degradation (Oren and Rotter, 2010). The 
results of this study are consistent with other research which found a significant association 
between TP53 mutation and the pattern of immunohistochemical detection of p53 expression   
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(Lavarino et al., 2000; Reles et al., 2001; Schuyer et al., 2001; Wang et al., 2004; Yemelyanova 
et al., 2011; Rechsteiner et al., 2013). Leitao et al. (2004) found a relationship between p53 
expression and TP53 mutation and suggested that sensitivity, specificity and predictive values 
of p53 immunoreactivity can be used modestly as an approximate surrogate indication of TP53 
mutation. In contrast to these findings; however, no evidence of sufficient specificity and 
sensitivity of immunohistochemistry data for surrogate detection of TP53 mutation was 
concluded by Singer et al. (2005), Gadducci et al. (2006) and Bartel et al. (2008).  
In terms of correlation between p53 expression and type of TP53 mutation, our results showed 
a significant relationship between different patterns of p53 expression and the type of TP53 
mutation, which was mainly an association of p53 high expression with missense mutation 
(88% based on the Sanger sequencing and 97% according to NGS). In comparison, only 48% 
of protein-truncating TP53 mutations were reflected by negative immunohistochemistry 
staining and this did not significantly differ from the percentage of negative p53 staining 
identified in the missense TP53 mutation group (52%). These results support previous research 
into this area which link missense mutations in the TP53 gene with stable p53 protein resulting 
in high p53 expression. In fact, optimised p53 IHC assay interpreted correctly can be used as a 
surrogate for the TP53 mutational status, and use of both IHC and sequencing techniques can 
be considered as a gold standard to predict the functional status of p53 (Kobel et al., 2016) 
Leitao et al. (2004) found positive p53 expression in 72% of tumours with missense TP53 
mutation. Reles et al. (2001), Schuyer et al. (2001) and Rechsteiner et al. (2013) also reported 
that missense TP53 mutations were significantly associated with high expression of p53 in 
epithelial ovarian cancer. Moreover, Yemelyanova et al. (2011) found overexpression or 
complete absence of p53 was closely correlated with a TP53 mutation.  
 The functionality of TP53 and correlation with survival 
It can be argued that combining TP53 mutational status and p53-dependent protein expression 
as an indication of the functional status of p53 may have greater prognostic value than either 
TP53 gene status or p53 protein expression alone. This part of study set out to investigate the 
relationship between functionality of TP53 and overall survival.  
The results based on the Sanger TP53 status showed that patients with wild-type TP53 and 
intermediate levels of p53 protein expression have a better OS compared to other groups with 
altered TP53 (p=0.04). For patients with wild-type TP53 tumours, p53 protein expression 
retained its significance and patients with intermediate p53 protein expression showed a longer 
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OS than those with low or high p53 protein expression (p=0.03). In contrast, for patients with 
mutant TP53 tumours p53 protein expression was not significantly associated with differences 
in survival (p=0.5). 
According to NGS TP53 data, no significant association was observed in survival time between 
patients categorised based on combining the TP53 mutational and protein expression status 
(p=0.2). p53 expression levels had no significant relationship to survival for patients with either 
wild-type (p=0.1) or mutant (p=0.3) TP53 tumours. 
A few studies have evaluated the correlation of TP53 functionality with survival outcome. One 
of these studies indicated that a combination of both TP53 mutations and overexpression of 
p53 is a stronger predictive biomarker than either alone (Wen et al., 1999). Shahin et al. (2000) 
found wild-type TP53 immunonegative groups had a slightly worse survival than those with 
wild-type TP53 immunopositive tumours. Bartel et al. (2008) categorised the patient samples 
into four groups including patients with overexpressed (>10 % p53 staining) or not expressed 
(≤10% p53 staining) wild-type TP53 and those with overexpressed or no expressed mutant 
TP53. They found individuals with overexpression of wild-type TP53 had the worst survival 
time compared to other groups; however, the difference was only marginally significant 
(p=0.08). When p53 protein expression levels were compared between patients with wild-type 
TP53, the difference in survival time reached statistical significance (p=0.02).   
 The p21WAF1 staining distribution and correlation with survival 
The samples were categorised into three groups including 52 (22%) cases negative, 121 (52%) 
cases with low expression (H-score=1) and 59 (26%) with intermediate or high expression 
(2≤H-score≤10). No significant difference in survival was observed in analysis between 
patients whose tumours had no p21WAF1 expression, low p21WAF1 expression or 
intermediate/high expression of p21WAF1 (p= 0.8). Prior studies which evaluated the correlation 
of p21WAF1 protein expression with survival time have found inconsistent results. Green et al. 
(2006) grouped 169 tumour samples into two low (p21WAF1 staining<3%) and high expression 
(3%≤ p21WAF1 staining) categories. Survival data were correlated with changes in p21WAF1 
staining in two different groups and patients with low p21WAF1 expression had a median 
survival time less than those with high p21WAF1 expression (p= 0.03). Rose et al. (2003) 
categorised 267 tumour samples into two groups with negative (<2%) and positive (≥2%) 
staining There was a significant difference in OS between patients with positive and negative 
p21WAF1 staining, with an OS advantage for patients whose tumours had positive p21WAF1 
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staining (p= 0.02). Two further studies categorised patients into groups with negative (p21WAF1 
staining<10%) and positive (10%≤ p21WAF1 staining) p21WAF1 expression and found significant 
difference in survival between two categories (Bali et al., 2004; Terauchi et al., 2005). In 
contrast to these previous studies, some published studies which are consistent with our results 
indicated that the survival probability was not significantly better in patients with positive or 
high expression of p21WAF1 compared to those with negative or low expression of p21WAF1 
(Levesque et al., 2000; Geisler et al., 2001; Skirnisdottir and Seidal, 2013). As previously 
mentioned in part 5.5.1, this discrepancy may partly be explained by different sample size, sub-
optimal design of some studies, different antibodies and cut-off values, different treatment 
options and immunohistochemical methods used in various studies.  
 Correlation of TP53 status and p21WAF1 protein expression 
The correlation between frequency distribution of p21WAF1 H-scores and TP53 mutational 
status was examined using Mann-Whitney and Kolmogorov-Smirnov statistical tests. No 
significant association was observed in distribution of p21WAF1 H-scores in regard to either 
Sanger TP53 status or NGS TP53 status (p≥0.05).  
Some studies have included p21WAF1 protein expression with p53 protein expression, some of 
which found no statistically significant associations between p53 protein expression and 
p21WAF1 protein expression (Levesque et al., 2000; Harlozinska et al., 2002; Skirnisdottir and 
Seidal, 2013). In contrast, other researchers found a significant inverse relationship between 
p53 and p21WAF1 expression (Anttila et al., 1999; Geisler et al., 2001; Bali et al., 2004). A 
possible explanation for this inconsistency might be no uniform definition of how to describe 
and categorise immunohistochemistry stained samples as negative and positive p53/ p21WAF1 
staining (Rose et al., 2003). 
A few studies have investigated the association between TP53 mutational status and p21WAF1 
protein expression. Rose et al. (2003) evaluated p21WAF1 expression as a function of sequenced 
TP53 gene mutation (exons 4-10, Sanger technique). The frequency distribution of positive 
p21WAF1 nuclear staining (2%≤p21WAF1 staining) in wild-type TP53 ovarian tumours was 
significantly higher than tumours with either missense or null TP53 mutations (p=0.04). One 
more study has noted an inverse correlation between p21WAF1 expression and overexpression 
of mutant TP53 (Bowtell, 2003).   
 205 
 
 The correlation of p21WAF1 expression to survival in regard to TP53 mutational 
status 
In this study, tumour samples were split into 6 categories based on the both p21WAF1 expression 
levels and TP53 mutational status, and the differences in survival time between different groups 
were analysed. Overall, the difference in survival time between various sub-groups did not 
reach statistical significance on a log-rank test irrespective of the techniques for sequencing 
TP53 (p>0.05).  
Rose et al. (2003) categorised 267 tumours based on the p21WAF1 expression and TP53 
mutational status (Sanger sequencing method). There was a trend toward a survival advantage 
for patients with p21WAF1-positive tumours when only wild-type TP53 tumours were assessed 
(p=0.06). For patients whose tumours had missense mutant TP53, survival data were not 
correlated with changes in p21WAF1 staining in different groups. However, significant 
difference in survival was detected in the analysis between individuals with TP53-null and 
p21WAF1-negative stained tumours and those with TP53-null and p21WAF1-positive stained 
tumour, with a survival advantage for the former group (p=0.005). The difference between our 
results and this study can be explained in part by use of different cut-off value and consideration 
of the type of TP53 mutation in the analysis by Rose et al. (2003). 
 Conclusion and further work 
In summary, the combined evaluation of TP53 mutation and protein expression provides 
additional information compared to either TP53 mutation or p53 protein expression alone, 
particularly in those patients with wild-type TP53. As explained in chapter 4, using ROC curve 
analysis to determine the optimal cut-off value for the number of reads in NGS may give a 
better result in relation to mutational status of TP53 as predictive and prognostic biomarker in 
ovarian cancer. Generally speaking, p53 immunohistochemistry staining can be informative as 
a surrogate indication for TP53 mutation, especially with high expression of p53 for missense 
TP53 mutation, but it is unlikely to be accurate enough on its own for clinical practice. Also, 
evaluation of other genes/proteins involving in the p53 pathway may be more informative 
compared to TP53 mutational and/or protein expression status alone and can provide functional 
insight.  
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Chapter 6: An investigation of the effect of MDM2-p53 binding antagonists 
as single agents on ovarian cancer cell lines 
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6.1 Introduction 
The treatment of ovarian cancer remains challenging due to relapse and resistance to 
chemotherapy, leading to lack of long-term benefit from treatment. For this reason, molecular 
alterations in tumours, particularly those involved in growth signalling pathways, cell cycle 
progression and apoptosis are being investigated to potentially exploit for targeted therapy 
(Agarwal and Kaye, 2003; Bast et al., 2009; Huang et al., 2010). This chapter set out to 
investigate the role of p53 in response to MDM2-p53 antagonists Nutlin-3, RG7112 and 
RG7388 as single agents in a panel of ovarian cancer cell lines. The chemical structures of 
MDM2-p53 antagonists and their mechanism of action are described in chapter 1.8. 
 Inactivation of p53 in ovarian cancer 
TP53 mutation is the most common cause of p53 inactivation in ovarian cancer occurring in 
30% up to 80% of cases (Reles et al., 2001; Kmet et al., 2003; Ling and Wei-Guo, 2006; 
Metindir et al., 2008; Bast et al., 2009). In the remaining malignancies, p53 function is held in 
check through other mechanisms and reactivation of p53 is a potential therapeutic strategy 
(Ling and Wei-Guo, 2006). Other mechanisms of p53 inactivation in ovarian cancer include 
MDM2 amplification/overexpression and p14ARF deficiency. A few reports indicated negative 
expression or genetic alterations of p14ARF (Havrilesky et al., 2003; Nam and Kim, 2008) in 
epithelial ovarian cancer. The p14ARF protein is a negative regulator of MDM2, binding to 
MDM2 and sequestering it into the nucleus resulting in activation of p53 (Nam and Kim, 2008; 
Creighton et al., 2010). There is a lack of evidence to confirm significant association of 
p14ARF expression and survival or clinicopathological features in epithelial ovarian cancer 
(Nam and Kim, 2008).  
Regulation of the p53 cellular level is discussed in detail in chapter 1.5.7. Given the important 
role of MDM2 in degradation and inactivation of p53, inhibition of the MDM2-p53 binding 
interaction has been considered as a promising therapeutic target for malignancy with wild-
type TP53.   
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6.2 Hypothesis and Objectives 
Hypothesis: 
1. Wild-type TP53 ovarian cancer cell lines are sensitive to the growth inhibitory and/or 
apoptotic effects of the MDM2-p53 antagonists Nutlin-3, RG7112 and RG7388, 
whereas mutant TP53 cell lines are resistant.  
Objectives: 
1. To test a panel of established ovarian carcinoma cell lines for their response to MDM2-
p53 antagonists Nutlin-3, RG7112 and RG7388, and evaluate the relationship of this 
response to the genotype of the cells.  
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6.3 Specific Materials and Methods 
 Cell lines 
Three wild-type TP53 and four mutant TP53 epithelial ovarian carcinoma cell lines used in this 
study were sourced from the NICR authenticated cell bank and regularly tested for 
mycoplasma. The wild-type TP53 cell lines used were A2780, IGROV-1, OAW42 and the 
mutant TP53 cell lines were CP70, MLH1-corrected CP70+, MDAH-2774 and SKOV-3. More 
details of these cell lines and their cell culture are provided in chapter 2.3.1, 2.3.2 and 2.3.3.  
 Growth curves and growth inhibition assays 
The SRB assay was used to generate growth curves, growth inhibition curves for 72 hours, and 
calculate GI50 values as described in chapter 2.7 and 2.8. Based on the growth curves, the 
appropriate cell densities were chosen for cells to be in the exponential phase of growth. 
 PCR 
Genomic DNA was extracted from a pellet of IGROV-1, MDAH-2774, or SKOV-3 including 
1 x 106 cells, using a QIAamp DNA Mini Kit (Qiagen, UK) as described in general materials 
and methods (2.12.2). The quality of the DNA and its concentration were estimated using a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE, 
USA). The purity of DNA was determined by the ratio of 260nm:280nm, which is around 1.8 
for good quality of DNA. The DNA extracted from IGROV-1 was amplified for TP53 exon 5, 
from MDAH-2774 for TP53 exon 8 and from SKOV-3 for TP53 exon 4 and exon 5 (Table 6-1).  
Purification of PCR products was carried out for subsequent analysis using the Purelink PCR 
purification kit (Qiagen, UK) in accordance with the manufacturer’s protocol previously 
explained (2.12.3). Agarose gel electrophoresis was performed using a 2% agarose gel with 
100 volts for approximately 45 minutes. Then, DNA was visualised using a Biorad Gel 
Documentation System under UV light trans-illumination and digitally photographed. The 
purified DNA was sent to DBS Genomics (Durham, UK) for Sanger Dideoxy DNA 
sequencing.  
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Table 6-1: The primers and their sequences used for PCR-based sequencing for different 
exons of TP53 gene. F, Forward; R, Reverse. 
 
 Western blot 
2 x 105 cells were seeded per 35mm diameter well in 6-well tissue culture plates (Corning 
Corp) for western blot analysis and left for 48 hours to adhere and grow. To study the effect of 
Nutlin-3/RG7388 on the functional p53 pathway, cells were treated with 0.2, 1 and 5 µM 
Nutlin-3 or 0.02, 0.1 and 0.5 µM RG7388 and lysates were extracted after 4 hours. For time 
course analysis, the cells were treated with 2x GI50 Nutlin-3, RG7388 or cisplatin and  lysates 
were prepared after 0.5, 1, 2, 4, 6, 8 and 24 hours. Medium, distilled water and DMSO treated 
cells were used as control. The antibodies used and their details are provided in chapter 2.11.7. 
 Flow cytometry 
Flow cytometry was performed to analyse cell cycle distribution changes and induced 
apoptosis over 24 hours treatment, as described in chapter 2.14.3. The A2780 and IGROV-1 
cell lines were seeded at 1.7 x 105 cells/well in 6-well plates and the OAW42 cell line at 1.3 x 
105 per small flask. Cells were treated with cisplatin, Nutlin-3, and RG7388 at 1x GI50 
concentration for 24 hours. Adherent and non-adherent cells were harvested to analyse the cell 
cycle distribution and SubG1 apoptotic cells by propidium iodide (PI) staining. Harvested cells 
were washed with PBS and re-suspended in 500 μL PBS with 1mg/mL sodium citrate (Sigma, 
St Louis, MO), 100 µg/mL propidium iodide (Sigma), 200 µg/mL RNAse A (Sigma)   
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and 0.3% Triton-X (Sigma). Samples were analysed on a FACSCaliburTM flow cytometer using 
CellQuest Pro software (Becton Dickinson, Oxford, UK). Cell cycle distribution was 
determined using Cyflogic (CyFlo Ltd, Turku, Finland). 
 Clonogenic cell survival assay 
Clonogenic survival assays were performed for the panel of 6 ovarian cancer cell lines as 
described in chapter 2.9. 
 Caspase 3/7 activity assay 
The Caspase-Glo® Assay (Promega, Southampton, UK) was used to measure the caspase-3 
and -7 activities in cultures of cells. The A2780 and IGROV-1 cell lines were seeded at 4.5 x 
104 cells/well and OAW42 cell line at 3 x 104 cells/well in white-welled 96-well plates 
(Corning, UK) for 24 hours. The cells were treated with 1x GI50 concentration of cisplatin, 
Nutlin-3 and RG7388 for 24 hours. The Caspase 3/7 kit was defrosted, the buffer was added 
and allowed to reach room temperature. A 1:1 volume of caspase reagent was added to each 
well and the plates covered with aluminum foil and incubated for 1 hour at room temperature. 
Following exposure to caspase reagent, cells lyse and release activated caspase to cleave the 
substrate resulting in a ‘glow-type ‘luminescence. The resulting lysates were analyzed on a 
microplate luminometer (Berthold Technologies, Herefordshire, UK) after the incubation 
period. Luminescence readings were normalized and plotted relative to the control. 
 Statistical analysis 
The statistical paired t-test was used to compare the mean of 3 or more paired biological repeats 
and p-values <0.05 were considered statistically significant.  
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6.4 Results 
 Determination of the growth characteristics of 7 ovarian cancer cell lines 
Growth curves were constructed for A2780, IGROV-1, OAW42, CP70, MLH1-corrected 
CP70+, MDAH-2774 and SKOV-3 cell lines, as described in chapter 2.7 (Figure 6-1). The cell 
densities and doubling time for each cell line were determined based on the growth curves as 
described in section 2.7 (Table 6-2). Overall, all cell lines used in this study grow well with the 
exception of SKOV-3 which grows relatively slowly. There was difficulty detaching OAW42 
cells, which was solved by using 2.5x Trypsin/EDTA and 10 minutes incubation time. To 
validate the MLH1-corrected CP70+ cell line by western blot analysis, A2780, the MMR-
proficient cell line, and CP70, its MLH1-deficient variant, were used as positive and negative 
controls respectively (Curtin et al., 2004) (Figure 6-2)   
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Figure 6-1: Growth curves to determine the cell density used for growth inhibition assays. 
The curves and seeding densities chosen for growth inhibition assays are shown as red 
lines. For A2780 and MDAH-2774, the average of two densities was used.
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Table 6-2: The seeding densities of cells used for growth inhibition assays and doubling 
time calculated for each cell line.  
 
 
Figure 6-2: Western blot analysis showed the expression of MLH1 protein in the MLH1-
corrected CP70+ cell line. A2780, the MMR-proficient cell line, and CP70, its MLH1-
deficient variant, were used as a positive and negative control respectively. 
 
 Sequencing of TP53 exon 5 in the IGROV-1, TP53 exon 8 & 9 in the MDAH-2774 
and TP53 exon 4 and 5 in the SKOV-3 cell lines 
Due to contradictory information on the TP53 status of IGROV-1 and SKOV-3 cell lines in the 
literature and to check the reported TP53 mutation for MDAH-2774 cell line, DNA was 
extracted and PCR-based sequencing of the TP53 gene in these cell lines was carried out. Based 
on the Sanger website Cosmic database, there are an insertion (c.267_268insC) and a 
substitution mutation (c.377 A->G) in the IGROV-1 cell line. However, some studies cited 
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IGROV-1 as a wild-type TP53 cell line (Le Moguen et al., 2006). A frame shift deletion 
(c.267delC) based on the Sanger website and a substitution mutation (c.179 A->G) (O'Connor 
et al., 1997) were reported in the SKOV-3 cell line. Furthermore, a substitution mutation 
(c.818G->A) was reported in MDAH-2774 (Dai et al., 2009). 
6.4.2.1 Determination of extracted DNA concentration and PCR amplification 
DNA purity and concentration were estimated and good quality DNA was used for PCR 
amplification of TP53 exon 5 for IGROV-1, TP53 exon 8 for MDAH-2774 and TP53 exon 4 
and exon 5 for SKOV-3 cell lines. The 2% agarose gel electrophoresis showed the 
amplification of the expected amplicons, which were 261 bp for exon 4.1, and 241 bp for exon 
4.2, 294 bp for exon 5, and 443 bp for exon 8 & 9. 
6.4.2.2 Sequencing results  
The results of PCR-based Sanger sequencing of the TP53 exon 5 confirmed the wild-type TP53 
status of the IGROV-1 cell line (Figure 6-3). The results also indicated that MDAH-2774 
harbours a TP53 mutation located in exon 8 (c.818G->A, p.Arg273His) (Figure 6-4). A frame 
shift deletion (c.265delC, p.Pro89fsX33) (Figure 6-5) was confirmed in TP53 exon 4 and no 
substitution mutation (c.179 A->G) was detected in TP53 exon 5 for the SKOV-3 cell line 
(Figure 6-6). This frameshift deletion results in premature termination and dysfunctional p53 
protein. 
 
Figure 6-3: Exon 5 DNA sequencing of the IGROV-1 cell line. Neither an insertion 
(c.267_268insC) nor a substitution mutation (c.377 A->G) was confirmed by Sanger 
sequencing. 
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Figure 6-4: Exon 8 & 9 DNA sequencing of the MDAH-2774 cell line. A substitution 
mutation (c.818 G->A, p.Arg273His) in exon 8 of TP53 was detected by Sanger 
sequencing.  
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Figure 6-5: Exon 4 DNA sequencing of SKOV-3 cell line. A frame shift deletion 
(c.265delC, P.pro89fsX33) was detected by Sanger sequencing. 
 
 
 
Figure 6-6: Exon 5 DNA sequencing of the SKOV-3 cell line. No substitution mutation 
(c.179 A->G) was detected by Sanger sequencing.   
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 Wild-type TP53 ovarian cancer cell lines are sensitive to the growth inhibitory effect 
of MDM2-p53 antagonists, Nutlin-3, RG7112 and RG7388 
Both wild-type and mutant TP53 cell lines were treated with different concentrations of 
cisplatin (0-16 µM) and Nutlin-3 (0-30 µM). Wild-type TP53 cells were treated with lower 
concentrations of RG7112 or RG7388 (0-5 µM) and mutant cells treated with higher 
concentrations of RG7112 or RG7388 (0-30 µM). Growth inhibition assays and the GI50 values 
were calculated following 72 hours exposure to drugs (Table 6-3). The results (Figure 6.7 and 
6.8) show clear resistance to MDM2-p53 antagonists in mutant TP53 cell lines. The GI50 values 
were significantly lower in wild-type TP53 cell lines compared to mutant, which is consistent 
with their mechanism of action. Both Mann-Whitney (p<0.0001) and Kolmogorov-Smirnov 
(p<0.0001) tests showed the observed differences are highly statistically significant (Table 6-3 
and Figure 6.8). The GI50 values for wild-type TP53 cell lines for RG7112 (716.7±165.9 (SEM) 
nM) and RG7388 (253.3±73.1 (SEM) nM) were in the nanomolar range, while for Nutlin-3 
they were in the micromolar range (1.76±0.51 (SEM) µM). In contrast, mutant TP53 cell lines 
had GI50 values greater than 10 μM: 19.7 ± 1.3 μM for RG7112, 17.8 ± 2.9 μM) for RG7388 
and 21.2-˃30 μM for Nutlin-3. Due to the greater potency of RG7388 compared to RG7112 
and clinical interest, other experiments were carried out with Nutlin-3 and RG7388. 
 
Table 6-3: GI50 concentrations of cisplatin, Nutlin-3, RG7112 and RG7388 for the panel 
of ovarian cancer cell lines of varying TP53 status. Data represent the mean of at least 3 
independent experiments ± SEM.
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Figure 6-7: Growth inhibition curves demonstrating the effect of MDM2-p53 antagonists 
compared to cisplatin in a panel of ovarian cancer cell lines. The results clearly show the 
effect of MDM2-p53 antagonists is TP53 dependent. Data represent the mean of at least 
3 independent experiments.
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Figure 6-8: The sensitivity to cisplatin and MDM2 antagonists, Nutlin-3, RG7112 and 
RG7388, in a panel of wild-type and mutant TP53 ovarian cancer cell lines. Wild-type 
TP53 cell lines are significantly more sensitive to growth inhibition by cisplatin (Mann 
Whitney test, p< 0.0001 and Kolmogorov-Smirnov test p=0.001), Nutlin-3, RG7112 and 
RG7388 (Mann Whitney and Kolmogorov-Smirnov tests, p< 0.0001) treatment for 72 
hours compared to mutant TP53 cell lines. Data shown are the average of at least three 
independent experiments and error bars represent SEM. 
 
 Functional activation of the p53 pathway in wild-type TP53 cell lines in response to 
Nutlin-3/RG7388 
The p53-dependent response to Nutlin-3/RG7388 assessed by western blotting showed that 
Nutlin-3/RG7388 induced stabilization of p53 and upregulation of p21WAF1 and MDM2 protein 
levels four hours after the commencement of treatment in a concentration-dependent manner 
and confirmed functional activation of wild-type p53 by release from MDM2. However, as 
anticipated, it had no effect on p53-dependent gene expression in the TP53-mutant cell lines 
with the delivered dose range of Nutlin-3/RG7388 (Figure 6-9). Interestingly this was despite 
a small increase in stabilization of mutant p53 in response to RG7388 at the doses of 0.1 and 
0.5 µM with the CP70 and MLH1-corrected CP70+ cell lines. This result indicates that some 
forms of mutant p53 are still targeted for degradation by MDM2 even though they have lost 
their transcriptional function. Also, there is a frame-shift deletion in the SKOV-3 cell line 
leading to an absence of detectable p53, p21WAF1 and MDM2 expression. 
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Figure 6-9: Western blot analysis for (A) Nutlin-3 and (B) RG7388 showed stabilization of p53 and upregulation of p53 transcriptional 
target gene protein levels, MDM2 and p21WAF1, four hours after the commencement of treatment in wild-type TP53 cell lines with the 
indicated doses (µM); however, they had no effect on downstream transcriptional targets of p53 in mutant TP53 ovarian cancer cell lines 
with the delivered dose range of MDM2 antagonists despite stabilization of the mutant p53 in the CP70 and MLH1-corrected CP70+ cells. 
TP53 mutant cell lines are highlighted in red colour.
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 Time course western blot analysis of p53, p21WAF1 and MDM2 expression in wild-
type TP53 cell lines treated with cisplatin or Nutlin-3/RG7388 
Time course analysis for the expression of p53, p21WAF1 and MDM2 was carried out using 
three wild-type TP53 cell lines treated with cisplatin, Nutlin-3 or RG7388 at 2x their respective 
GI50 concentrations. Lysates were extracted after 0.5, 1, 2, 4, 6, 8, and 24 hours. What is 
interesting in this data is that MDM2-p53 antagonists, Nutlin-3/RG7388, induced p21WAF1 
upregulation more than cisplatin. The highest levels of induced p53 were 4 hours after 
commencement of Nutlin-3/RG7388 treatment in A2780 and OAW42 compared to 8 and 24 
hours post-treatment of cisplatin in A2780 and OAW42 respectively (Figure 6-10 & 
Figure 6-11). Unexpectedly, no significant upregulation of p21WAF1 was detected in these cell 
lines following cisplatin treatment. With the IGROV-1 cell line, cisplatin and Nutlin-3/RG7388 
treatment increased induction and stabilisation of p53 at the highest levels after 8 and 6 to 8 
hours post-treatment respectively (Figure 6-11). These results indicated that MDM2-p53 
antagonists are more effective at inducing p53 and upregulating its downstream targets, 
p21WAF1 and MDM2, compared to cisplatin in ovarian cancer cell lines; however, the effect is 
cell type and time dependent. 
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Figure 6-10: Western blot analysis showing time course analysis of the p53, p21WAF1 and 
MDM2 expression in the A2780 cell line treated with 2x GI50 concentrations of cisplatin, 
Nutlin-3 or RG7388. Actin was used as a loading control.
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Figure 6-11: Western blot analysis showing time course analysis of the p53, p21WAF1 and 
MDM2 expression in the IGROV-1 cell line treated with 2x GI50 concentrations of 
cisplatin, Nutlin-3 or RG7388. Actin was used as a loading control.
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Figure 6-12: Western blot analysis showing time course analysis of the p53, p21WAF1 and 
MDM2 expression in the OAW42 cell line treated with 2x GI50 concentrations of cisplatin, 
Nutlin-3 or RG7388. Actin was used as a loading control.
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 The effect of Nutlin-3/RG7388 on cell cycle distribution changes and/or apoptosis in 
wild-type TP53 ovarian cancer cell lines 
Wild-type TP53 cell lines were analysed for their cell cycle response to Nutlin-3/RG7388 as a 
single agent compared to DMSO control. Cells were treated with Nutlin-3/RG7388 at 1x their 
respective GI50 concentrations for 24 hours. They were then analysed by flow cytometry for 
cell cycle phase distribution changes and evidence of apoptosis in response to treatment. 
Nutlin-3 increased slightly the proportion of cells in G0/G1 phase. Nutlin-3 also increased the 
percentage of SubG1 events, a surrogate marker of apoptosis, across three cell lines. RG7388 
after 24 hours treatment led to a substantial increase in the proportion of cells in the G0/G1 
phase of the cell cycle across all cell lines compared to Nutlin-3 at the same GI50 doses. RG7388 
induced SubG1 events in all cases, which was more significant in the IGROV-1 ovarian cancer 
cell line (Figure 6-13A & B). 
 The effect of Nutlin-3/RG7388 as a single agent on the Caspase 3/7 activity in wild –
type TP53 ovarian cancer cell lines 
The induction of apoptosis was also evaluated by caspase 3/7 enzymatic assay, which is a 
sensitive and specific indicator of apoptosis (Chen et al., 2015). Wild-type TP53 ovarian cancer 
cell lines were treated for 24 hours with 1x their respective Nutlin-3/RG7388 GI50 
concentrations. No significant increase in the caspase 3/7 activity in response to Nutlin-
3/RG7388 was detected in the A2780 and OAW42 cell lines. With IGROV-1, a significant 
increase in caspase 3/7 activity in response to Nutlin-3/RG7388 compared to DMSO control 
was observed (Figure 6-13C).  
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Figure 6-13: Nutlin-3/RG7388 affects the cell cycle distribution and apoptotic endpoints. 
(A) Nutlin-3/RG7388 increased the proportion of cells in G0/G1 phase compared to 
DMSO control. (B) Flow cytometry for SubG1 events and (C) Caspase 3/7 activity is 
represented as fold change relative to DMSO solvent control. *, p ˂ 0.05; **, P < 0.01; 
***, P < 0.001. Data are shown as the average of at least 3 independent experiments and 
error bars represent SEM. 
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 Nutlin-3/RG7388 alone results in clonogenic cell death in a p53-dependent manner 
Clonogenic survival assays were performed for the panel of six ovarian cancer cell lines. 
Exponentially proliferating cell cultures were counted and seeded at appropriate densities for 
colony formation and treated with different concentrations of cisplatin or Nutlin-3/RG7388. 
The results showed TP53 mutant cell lines were significantly more resistant to Nutlin-3/ 
RG7388, but also demonstrated a wide range of responses for the wild-type TP53 cell lines 
(Figure 6-14 & Table 6-4). Nutlin-3 markedly decreased the clonogenic survival of A2780 cells 
(LC50=1.65±0.7 (SEM) µM); however, IGROV-1 (LC50=11±2.1 (SEM) µM) and OAW42 
(LC50=6.25±0.50 (SEM) µM) were substantially less sensitive to Nutlin-3 (Figure 6-14B).  
RG7388 was much more potent than Nutlin-3, and decreased the clonogenic survival of all the 
wild-type TP53 ovarian cancer cell lines. Consistent with the mechanism of action for MDM2 
antagonists, RG7388 had little or no effect on mutant TP53 cell lines in the 0-2 µM dose range 
(Figure 6-14C). Interestingly, although all three cell lines were sensitive to RG7388, the 
relative sensitivity of the wild-type TP53 cell lines to Nutlin-3 and RG7388 was very different. 
The clonogenic cell survival responses to RG7388 for A2780 and OAW42 were similar, 
whereas for Nutlin-3 their relative responses were quite different, with only A2780 showing 
sensitivity to Nutlin-3. Overall, the clonogenic cell survival assays showed not only that mutant 
TP53 genomic status was a major determinant of resistance to Nutlin-3 and RG7388, but also 
that the relative response of the wild-type TP53 cell lines differed for the two MDM2 inhibitors 
in a way that was not explicable simply by the relative potency of the compounds in cell-free 
MDM2-p53 binding assays. Consistent with growth inhibition assays, MDM2 antagonists 
showed a clearer and more effective p53-dependent response compared to cisplatin.  
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Figure 6-14: Clonogenic survival for the panel of ovarian cancer cell lines. Treatment 
with (A) Nutlin-3 (B) RG7388 and (C) Cisplatin. Clonogenic cell survival LC50 values 
were dependent on the TP53 genomic status. Data are shown as the average of at least 3 
independent experiments and error bars represent SEM. 
 
 
Table 6-4: LC50 concentrations for cisplatin, Nutlin-3 and RG7388 for the panel of 
ovarian cancer cell lines of varying TP53 status. Data represent the mean of at least 3 
independent experiments ± SEM.  
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6.5 Discussion 
Ovarian cancer is the most lethal gynaecological malignancy and in most cases it is diagnosed 
at advanced stage with metastasis beyond the ovary, at which point treatment is not favourable 
(Bauerschlag et al., 2010; Qinglei Zhan et al., 2013). Advanced ovarian cancer treatment 
usually involves a combination of debulking surgery and platinum-based chemotherapy, alone 
or with addition of paclitaxel. Although chemotherapy prolongs survival, most patients with 
advanced disease die from treatment resistant progressive disease (Kim et al., 2012; 
Ledermann et al., 2013). Cancer therapy has recently been improving with the introduction of 
targeted therapies to achieve greater specificity and less cytotoxicity (Munagala et al., 2011; 
Yuan et al., 2011; Nicolas Andre et al., 2012). Due to the crucial role of p53 in tumour 
suppression, it is an attractive target for cancer therapy. Different strategies have been 
developed to restore p53 function including inhibition of the MDM2-p53 interaction as a 
promising therapeutic target for cancer therapy (Wang and Sun, 2010; Hong B et al., 2014). 
This study evaluates for the first time the effect of the MDM2-p53 binding antagonist RG7112 
and RG7388, as a single agent in a panel of ovarian cancer cell lines of defined TP53 genomic 
status. 
 Ovarian cancer cell lines and response to MDM2-p53 antagonists, Nutlin-
3/RG7122/RG7388 
To evaluate the effect of Nutlin-3, RG7122 and RG7388 in TP53 wild-type compared to mutant 
cell lines, growth inhibition assays were performed. Although there is uncertainly underlying 
the subtype classification of some commonly used ovarian cancer cell lines, (Domcke 2013) 
these results need to be discussed. Domcke et al. (2013) analysed a panel of 47 ovarian cancer 
cell lines to identify those that have highest genetic similarity to ovarian tumour according to 
the copy-number changing, mutations and mRNA expression profiles. They reported that 
A2780, SKOV-3 and IGROV-1 cell lines are poorly suited as models for HGSC because of 
having a flat copy-number profile, and A2780 and SKOV-3 have no TP53 mutation. They 
reported IGROV-1 cell line as endometrioid or clear cell rather than HGSC origin. It is 
confusing because many published literatures including the original one reported A2780, 
SKOV-3 and IGROV-1 as undifferentiated, adenocarcinoma and a mixture of endometrioid 
and clear cell lines respectively rather than HGSC (Bénard et al., 1985; Hills et al., 1989; Pizao 
et al., 1992; Anglesio et al., 2013; Stordal et al., 2013). Moreover, SKOV-3 was reported as 
an ovarian cancer cell line with mutant TP53, homozygous deletion (Sonego et al., 2013; 
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Mullany et al., 2015; Zanjirband et al., 2016) rather than an ovarian cancer cell line with wild-
type TP53. 
Within the panel of ovarian cancer cell lines studied, wild-type TP53 cell lines were 
significantly more sensitive to Nutlin-3, RG7112 and the more potent RG7388 compared to 
mutant TP53 cell lines, which is consistent with their mechanism of action. Use of cell lines 
from different subtypes had no impact on the conclusion drawn about the influence of TP53 
status on the biological phenotypes studied. These results are consistent with limited previous 
studies demonstrating that wild-typeTP53 ovarian cancer cell lines are responsive to Nutlin-3 
and extends observations to the second generation MDM2 inhibitor RG7388 currently in early 
phase clinical trials (Mir et al., 2013; Erin K. Crane 2015).  
 Functional activation of the p53 pathway in response to MDM2-p53 antagonists, 
Nutlin-3/RG7388, in TP53 wild-type ovarian cancer 
Nutlin-3 and RG7388 treatment led to more p53 stabilization and induction of p21WAF1 and 
MDM2 in the wild-type TP53 ovarian cancer cell lines. There was no upregulation of p53 
downstream target genes in TP53 mutant ovarian cancer cell lines in response to Nutlin-3 and 
RG7388 treatment. Interestingly, despite the lack of downstream function, there was some 
evidence of mutant p53 stabilization in response to treatment with MDM2 inhibitors in the 
TP53 mutant CP70 and MLH1-corrected CP70+ cell lines. This suggests some mutant forms 
of p53 still show evidence of degradation by MDM2 (Oren and Rotter, 2010) which is 
prevented by the MDM2 inhibitors. For the SKOV-3 cell line, no expression of p53 was 
observed due to a frame shift deletion at codon 89 (c.265delC, P.pro89fsX33) which results in 
production of an undetectable level of truncated protein. These results are in accord with two 
limited recent ovarian cancer cell line studies indicating that Nutlin-3a increased stabilisation 
and induction of p21WAF1 in a wild-type TP53-dependent manner (Mir et al., 2013; Erin K. 
Crane 2015). 
 Time course western blot analysis of the p53, p21WAF1 and MDM2 expression in the 
wild-type TP53 cell lines treated with cisplatin or Nutlin-3/RG7388 
The results of this part of the study demonstrated earlier and stronger response of the p53 
pathway to Nutlin-3/RG7388 treatment compared to cisplatin, indicating that MDM2-p53 
antagonists act in a more specifically p53-dependent manner than cisplatin. These results also 
give some information on how to schedule the order of drugs in sequential combined treatment   
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to gain more p53 stabilisation and p21WAF1 upregulation. Overall, it is expected that treatment 
with cisplatin followed with Nutlin-3/RG7388 four hours after cisplatin treatment might result 
in more synergistic effect. 
 Nutlin-3/RG7388 affects cell cycle arrest and/or apoptosis in wild-type TP53 ovarian 
cancer cell lines 
Nutlin-3 and RG7388 induced cell cycle arrest and/or apoptosis in wild-type TP53 ovarian 
cancer cell lines in a cell-type dependent manner. When cells were treated with the GI50 
isoeffect doses of RG7388 or Nutlin-3, RG7388 had a greater effect on the cell cycle 
distribution, with increased accumulation of cells in G0/G1. There is a consistency between 
Flow cytometry results and the growth inhibitory effect of Nutlin-3/RG7388. The GI50 values 
for RG7388 were lower than those for Nutlin-3 across all wild-type TP53 cell lines which is 
supported by the higher proportion of G0/G1 phase arrest for the cells treated with RG3788 
compared to Nutlin-3. These results are in agreement with those of Mir et al. (2013) who found 
G0/G1 cell cycle phase arrest in TP53 wild-type ovarian cancer treated with Nutlin-3a , and 
Chen et al. (2015) who reported G0/G1 phase arrest in TP53 wild-type neuroblastoma cell lines 
treated with RG7388.  
To further investigate the effect of Nutlin-3/RG7388 on the induction of apoptosis, caspase 3/7 
activity was analysed in wild–type TP53 ovarian cancer cell lines. Significantly increased 
levels of caspase3/7 activity in IGROV-1 cells treated with Nutlin-3/RG7388 compared to 
DMSO control was in agreement with the increased proportion of SubG1 events in Nutlin-
3/RG7388 treated IGROV-1 cells. Furthermore, the lack of a significant increase in caspase3/7 
activity in A2780 and OAW42 cell lines following Nutlin-3/RG7388 treatment is consistent 
with no significant change in the percentage of SubG1 events in these cell lines after treatment. 
Overall, there was a consistent relationship between the detection of SubG1 events on Flow 
cytometry and caspase 3/7 activity; however, cell cycle arrest is not always accompanied by 
the induction of apoptosis (Weng et al., 2001) as seen for OAW42 cells in this study. These 
results are in agreement with those obtained by Chen et al. (2015) that also indicated a 
consistency between increased SubG1 events and higher caspase 3/7 activity in neuroblastoma 
cell lines treated with RG7388.   
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 Nutlin-3/RG7388 alone results in clonogenic cell death in a p53-dependent manner   
The clonogenic cell survival assays also showed TP53 mutant cell lines were much more 
resistant to Nutlin-3 & RG7388, but nevertheless also demonstrated a range of different relative 
single agent responses for the wild-type TP53 cell lines. A possible explanation for this range 
of responses between the wild-type TP53 cell lines might be differences in drug uptake (Chen 
et al., 2014), deficiencies or variation in the expression of p53 target genes involved in 
apoptosis and other mechanisms of cell death, including the pro-apoptotic proteins BAX and 
PUMA and anti-apoptotic proteins BCL-2 and MCL-1 (Haupt et al., 2003; Jeffers et al., 2003). 
 Conclusion and further work 
In conclusion, the present study demonstrates that MDM2-p53 antagonists are potent anti-
cancer compounds in vitro leading to cell cycle arrest and/or apoptosis of wild-type TP53 
ovarian cancer cell lines as a single agent. The findings show that following exposure to 
MDM2-p53 antagonists, different outcomes are obtained due to various downstream 
alterations of the p53 pathway. They clearly indicate that the presence of wild-type TP53 
remains the main predictive biomarker of response to MDM2 inhibitors; however, more 
research is needed to identify other genes and signalling pathways involved as determinants of 
response to MDM2-p53 antagonists in wild-type TP53 tumour cells.  
Using MDM2-p53 antagonists as single-agent therapy has been suggested to be potentially 
limited due to acquisition of resistance through continuous exposure to MDM2 inhibitors 
followed by de novo mutations (Wei et al., 2013; Khoo et al., 2014). It is therefore logical to 
consider using MDM2 antagonists in combination with established therapeutic agents to 
improve treatment, with the possibility of dose reduction and less normal tissue cytotoxicity 
and genotoxicity. In the context of ovarian cancer it is of interest to investigate the combination 
of cisplatin and MDM2 inhibitors, particularly as individually these agents have different dose 
limiting toxicities. 
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Chapter 7: An investigation of the effect of MDM2-p53 antagonists in 
combined treatment with cisplatin on ovarian cancer cell lines 
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7.1 Introduction 
Targeted therapies in ovarian cancer have been investigated to overcome relapse and 
chemoresistance, which is the main challenge for treatment. Different strategies have been 
developed to reactivate p53 in tumours with dysfunctional p53 including inhibition of the p53-
MDM2 interaction. However, some concerns have been expressed that resistance to MDM2-
p53 antagonists may be acquired following repeated treatment with MDM2 inhibitors (Bo et 
al., 2014). For this reason, targeting more than one signalling pathway by combination therapy 
may be a useful approach and is a widely accepted concept in cancer therapy. This study 
evaluates for the first time the effect of the MDM2-p53 binding antagonist RG7388 in 
combination with cisplatin in a panel of wild-type TP53 ovarian cancer cell lines and compares 
this to the combination of Nutlin-3 with cisplatin in the same cell line panel. 
 Combination therapy 
Combination treatment is an approach to improve therapeutic effect, reduce dose and toxicity, 
and minimise and/or delay drug resistance. This is because multiple drugs may affect various 
targets and/or subpopulations. Also, one single target may be targeted with different drugs with 
varied mechanisms of action (Chou, 2006; Chou, 2010). Induction of cell cycle arrest and 
apoptosis following treatment with many types of chemotherapeutic drugs occur through 
activation of the p53 pathway. Therefore, reactivation of the p53 pathway may supplement and 
increase the sensitivity of tumours to a range of conventional chemotherapeutic agents 
(Almazov et al., 2007; Wang and Sun, 2010; Bo et al., 2014). This part of the study was 
designed to investigate the combined effect of Nutlin-3/RG7388 with cisplatin on a panel of 
wild-type TP53 established ovarian cancer cell lines to identify potential improvements in the 
efficacy of therapy for ovarian cancer patients.  
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7.2 Hypothesis and Objectives 
Hypothesis: 
1. The combination of MDM2-p53 antagonists with cisplatin has synergistic potential 
for the treatment of ovarian cancer.  
2. The MDM2-p53 antagonists decrease the expression of DNA repair genes 
implicated in response to cisplatin and capacity for repair of cisplatin induced DNA 
damage leading to a synergistic effect in combined treatment with Nutlin-3/RG7388 
and cisplatin. 
Objectives: 
1. To investigate the effect of combined treatment of Nutlin-3/RG7388 with cisplatin 
on a panel of wild-type TP53 ovarian cancer cell lines and determine the synergistic, 
additive or antagonistic effect of combination. 
2. To investigate possible induced changes in the mRNA expression levels of p53-
regulated genes involved in growth arrest, apoptosis and DNA repair in response to 
cisplatin following exposure to Nutlin-3/RG7388 as a single agent.   
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7.3 Specific Materials and Methods 
 Cell lines 
Three wild-type TP53 ovarian carcinoma cell lines, A2780, IGROV-1 and OAW42 were used 
in this study. More details of these cell lines are provided in chapter 2.3.1 and 2.3.2. 
 Combined treatment of Nutlin-3/RG7388 with cisplatin, SRB assay 
For combination treatment of Nutlin-3 or RG7388 with cisplatin, the wild-type TP53 cell lines 
were treated for 72 hours with each agent alone and in combination simultaneously at constant 
1:1 ratios of 0.25x, 0.5x, 1x, 2x, and 4x their respective GI50 concentrations. Median-effect 
analysis was used to calculate Combination Index (CI) and Dose Reduction Index (DRI) values 
(Chou, 2006) using CalcuSyn software v2 (Biosoft, Cambridge, UK). 
 Western blot 
2 x 105 cells were seeded per 35mm well of a 6-well plate for western blot analysis and left for 
48 hours to adhere and grow. To investigate the effect of combined treatment of Nutlin-
3/RG7388 with cisplatin on the functional p53 pathway, cells were treated with each agent 
alone and in simultaneous combination at constant 1:1 ratios of 1x and 2x their respective GI50 
concentrations.  Lysates were extracted following 4 hours treatment. The antibodies used and 
their details are found in chapter 2.11.7. 
 Flow cytometry 
Flow cytometry was performed to analyse cell cycle distribution changes and induced 
apoptosis over 24, 48 and 72 hours after treatment as described in chapter 2.14.3 and 6.3.5. The 
A2780 and IGROV-1 cell lines were seeded at 1.7 x 105 cells/well in 6-well plates and the 
OAW42 cell line at 1.3 x 105 per small flask, T25. Cells were treated with cisplatin, Nutlin-3, 
and RG7388 alone and with a combination of Nutlin-3 or RG7388 with cisplatin 
simultaneously at constant 1:1 ratios of 1x and 2x (A2780 and IGROV-1) or 0.5x and 1x 
(OAW42) their respective GI50 concentrations for 24, 48 and 72 hours. The samples were 
analysed as described in chapter 6.3.5.  
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 Combined treatment of Nutlin-3/RG7388 with cisplatin, clonogenic cell survival 
assay 
To study the effect of combined treatment on  clonogenic cell survival, cells were treated with 
Nutlin-3, RG7388 and cisplatin alone and in combination at constant 1:1 ratios of 0.25x, 0.5x, 
1x, 2x and 4x or 0.25x, 0.5x and 1x their respective LC50 concentrations, depending on the cell 
line and its single agent LC50 values, for 48 hours. More details are described in chapter 2.9. 
DRI and CI values were calculated using CalcuSyn software v2 (Biosoft, Cambridge, UK). 
(Chou, 2006).  
 Caspase 3/7 activity assay 
The Caspase-Glo® Assay (Promega, Southampton, UK) was used to measure the caspase-3 
and -7 activities in the cultures of cells. The A2780 and IGROV-1 cell lines were seeded at 4.5 
x 104 cells/well and OAW42 cell line at 3 x 104 cells/well in white-welled 96-well plates for 
24 hours. Then, cells were treated with Nutlin-3, RG7388 and cisplatin alone and in 
combination at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations for 24 and 
48 hours. The caspase 3/7 activity assay was performed as described in chapter 6.3.7. 
 Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) 
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Germany). RNA purity and 
concentration were estimated with an ND-1000 spectrophotometer (NanoDrop Technologies, 
Thermo Scientific, UK). The purity of RNA was determined by the ratio of 260nm:280nm, 
which is around 2 for pure RNA. Total messenger RNA was converted to cDNA using the 
Promega Reverse Transcription System (A3500, Promega) as described in chapter 2.12.2. 
More details of validated primers used and qRT-PCR protocol are provided in chapter 2.13.4 
and 2.13.5.  
 Statistical analysis 
The statistical paired t-test was used to compare the mean of 3 or more paired biological repeats 
and the p-values <0.05 were considered statistically significant.  
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7.4 Results 
 Nutlin-3/RG7388 synergise with cisplatin for growth inhibition of wild-type TP53 
ovarian cancer cell lines 
The effect of Nutlin-3/RG7388 in combination with cisplatin was investigated for 3 wild-type 
TP53 ovarian cancer cell lines using median-effect analysis. The sensitivity of these TP53 wild-
type cell lines to growth inhibition during 72 hours exposure to Nutlin-3, RG7388 and cisplatin 
was determined as single agents, and in combination at 5 equipotent concentrations between 
0.25× and 4× their respective GI50 concentrations. The effect of combined treatment was cell 
type and compound dependent. Combination of Nutlin-3/RG7388 with cisplatin at all 
concentrations led to greater growth inhibition compared to either agent alone for the A2780 
cell line. From the data in Figure 7-1, it is apparent that combination treatment of Nutlin-3 with 
cisplatin at concentrations lower than the individual 1x GI50 dose resulted in more growth arrest 
compared to higher than 1x GI50 dose. Combination treatment of OAW42 and IGROV-1 cell 
lines also produced more growth arrest at concentrations equal to or lower than the individual 
1x GI50 dose (Figure 7-1 & Figure 7-2). 
To determine whether the observed differences in growth inhibition were additive or 
synergistic, the data were analysed using median-effect analysis and CI and DRI values 
calculated. CI values for each constant ratio combination and at effect levels of ED50, ED75 and 
ED90 were computed. Also, the average of CI values at ED50, ED75 and ED90 was determined 
(Figure 7-3 & Table 7-1). Across all cell lines, the effect of combination treatment of Nutlin-
3/RG7388 with cisplatin ranged from additive to synergistic based on the CI at ED50. Although 
the effect of combined treatment based on overall CI was synergism for A2780, it was 
antagonism for IGROV-1 and OAW42 (Table 7-1 & Figure 7-3). The data analysis showed 
there was a favourable DRI, which demonstrates how many-fold the dose of each drug in a 
combination treatment may be reduced to achieve a given effect level compared with the doses 
of each drug alone. Both Nutlin-3, and RG7388 had favourable DRI values for combined 
treatment with cisplatin, with most experimental values ranging from 1.1-fold to 6.9-fold dose 
reduction (Table 7-2). These DRI values have clinical implications, demonstrating a significant 
individual drug dose reduction may be achieved for a given combination therapeutic effect, 
compared with the dose of either drug alone as a single agent to obtain the same therapeutic 
effect.  
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Figure 7-1: Growth inhibition curves of three wild-type TP53 cell lines exposed to Nutlin-
3 and cisplatin alone, and in combination at constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x and 
4x their respective GI50 concentrations for 72 hours. Data are shown as the average of at 
least 3 independent experiments and error bars represent SEM.
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Figure 7-2: Growth inhibition curves of three wild-type TP53 cell lines exposed to RG7388 
and cisplatin alone, and in combination at constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x and 4x 
their respective GI50 concentrations for 72 hours. Data are shown as the average of at 
least 3 independent experiments and error bars represent SEM.
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Figure 7-3: The growth inhibition combination index (CI) values  for Nutlin-3/RG7388 in 
combination with cisplatin at ED50 and the average of CI values at effect levels ED50, ED75 
and ED90 in three wild-type TP53 ovarian cancer cell lines. (A) CI values for Nutlin-3 in 
combination with cisplatin. (B) CI values for RG7388 in combination with cisplatin. Data 
are shown as the average of at least 3 independent experiments and error bars represent 
SEM. CI, Combination Index; ED, Effective dose.   
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Table 7-1: Growth inhibition CI values for Nutlin-3/RG7388 in combination with cisplatin for the wild-type TP53 ovarian cancer cell lines. 
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. CI values were 
calculated for each constant ratio combination and at effect levels ED50, ED75 and ED90 from the average of at least three independent 
experiments. CI Ave ED50-90 represents the average of CI values at effect levels of ED50, ED75 and ED90. CI range: < 0.1 very strong 
synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 
1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. 
Synergistic combinations are highlighted in bold font. CI, Combination Index; ED, Effective dose.
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Table 7-2: DRI values for growth inhibition by RG7388/Nutlin-3 in combination with cisplatin for the wild-type TP53 ovarian cancer cell 
lines. The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. DRI values 
were calculated for each constant ratio combination from the average of at least three independent experiments. Favourable DRI values 
are highlighted in bold font. DRI, Dose reduction index.
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 The effect of combination treatment with Nutlin-3/RG7388 and cisplatin on 
activation of the p53 pathway 
Further analysis was performed to investigate the effect of combination treatment on the p53 
molecular pathway using western blotting. Wild-type TP53 cell lines were treated with Nutlin-
3/RG7388 and cisplatin alone, and in combination at constant 1:1 ratios of 1x and 2x their 
respective GI50 concentrations for 4 hours. Western analysis showed that treatment with Nutlin-
3/RG7388 and cisplatin as a single agent and in combination with cisplatin induced p53 
stabilization and upregulation of p21WAF1 and MDM2, confirming functional activation of 
wild-type TP53 (Figure 7-4). Moreover, combination treatment in all cases led to greater levels 
of p53 stabilization, p21WAF1 and MDM2 upregulation compared to cisplatin on its own, and 
in most cases these were greater than those induced or upregulated by Nutlin-3/RG7388 alone. 
Higher expression of p21WAF1 for combined treatment was associated with a greater synergistic 
effect for growth inhibition. However, Nutlin-3 and RG7388 led to little change of BAX 
expression compared to DMSO control, and their combination with cisplatin showed only a 
small increase in the expression of BAX compared to cisplatin on its own. Interestingly, 
cisplatin alone at a GI50 or 2x GI50 dose showed much less p53 pathway induction than Nutlin-
3 or RG7388 alone.   
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Figure 7-4: Combination of Nutlin-3/RG7388 with cisplatin increased stabilization of p53 
and upregulation of its downstream targets, MDM2 and p21WAF1 compared to cisplatin 
on its own. Total levels of p53, p21WAF1, MDM2 (4 hours) and BAX (8 hours) after the 
commencement of treatment with Nutlin-3 and RG7388 alone, and in combination with 
cisplatin at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations analysed 
by western blot in three wild-type TP53 ovarian cancer cell lines.
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 Nutlin-3/RG7388 in combination with cisplatin induces cell cycle distribution 
changes and/or apoptosis in wild-type TP53 ovarian cancer cell lines 
Wild-type TP53 cell lines were treated with Nutlin-3/RG7388 and cisplatin, alone and in 
simultaneous combination at constant 1:1 ratios of 1x and 2x (1/2 x & 1x for OAW42) their 
respective GI50 concentrations for 24, 48 and 72 hours. They were then analysed by flow 
cytometry for cell cycle phase distribution changes and evidence of apoptosis in response to 
treatment.  
7.4.3.1 The effect of Nutlin-3 in combination with cisplatin on cell cycle distribution and 
SubG1 events in wild-type TP53 ovarian cancer cell lines 
Nutlin-3 only showed a modest increase in the proportion of cells in G0/G1 phase in a dose 
and time-dependent manner (Figure 7-5A, Figure 7-6A & Figure 7-7A). Nutlin-3 also 
increased the percentage of SubG1 events, a surrogate marker of apoptosis, in A2780 and 
IGROV-1 cell lines in a treatment time and dose-dependent manner (Figure 7-5B & 
Figure 7-6B). For A2780 and IGROV-1 cells, combination treatment of Nutlin-3 with cisplatin 
led to a dose and time-dependent increase in the proportion of cells in G2/M phase and the 
proportion of SubG1 events compared to cisplatin on its own, particularly for A2780 cells 
(Figure 7-5 & Figure 7-6). Interestingly, combination of Nutlin-3 with cisplatin at 1x GI50 
concentrations led to a significantly increase in G2/M cell cycle arrest compared to cisplatin 
on its own at both 1x and 2x GI50 concentrations after 48 and 72 hours for A2780 and IGROV-
1 cell lines. In terms of OAW42 cell line, combined treatment of Nutlin-3 with cisplatin 
resulted in a decrease in cells in G2/M phase compared to cisplatin on its own (Figure 7-7A). 
Furthermore, combined treatments decreased the proportion of SubG1 events compared to 
cisplatin on its own demonstrating the protective effect of Nutlin-3 against cisplatin in OAW42 
cell line (Figure 7-7B). 
  
  
 
248 
 
Figure 7-5: Combination of Nutlin-3 with cisplatin affects the cell cycle distribution and apoptotic endpoints. A2780 cell line was treated 
for 24, 48 and 72 hours with Nutlin-3 or cisplatin alone and at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations. 
Combination of Nutlin-3 with cisplatin led to an increased proportion of cells in G2/M phase (A) and SubG1 events (B) compared to either 
agent alone in a time and concentration-dependent manner. Nut-3, Nutlin-3; CDDP, Cisplatin; *, p<0.05; **, p<0.01. The red stars 
represent significant increase in SubG1 events compared to DMSO control. Data are shown as the average of at least 3 independent 
experiments and error bars represent SEM. 
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Figure 7-6: Combination of Nutlin-3 with cisplatin affects the cell cycle distribution and apoptotic endpoints. IGROV-1 cell line was 
treated for 24, 48 and 72 hours with Nutlin-3 or cisplatin alone and at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations. 
Combination of Nutlin-3 with cisplatin led to an increased proportion of cells in G2/M phase (A) and SubG1 events, with the exception of 
SubG1 events after 72 hours at 2x GI50 concentration (B) compared to either agent alone in a time and concentration-dependent manner. 
Nut-3, Nutlin-3; CDDP, Cisplatin; *, p<0.05. The red stars represent significant increase in SubG1 events compared to DMSO control. 
Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
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Figure 7-7: Combination of Nutlin-3 with cisplatin affects the cell cycle distribution and apoptotic endpoints. OAW42 cell line was treated 
for 24, 48 and 72 hours with Nutlin-3 or cisplatin alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of Nutlin-3 with cisplatin led to a decreased proportion of cells in G2/M phase (A) and SubG1 events (B) compared to 
cisplatin alone. Nut-3, Nutlin-3; CDDP, Cisplatin. Data are shown as the average of at least 3 independent experiments and error bars 
represent SEM. 
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7.4.3.2 The effect of RG7388 in combination with cisplatin on cell cycle distribution and 
SubG1 events in wild-type TP53 ovarian cancer cell lines 
RG7388 alone after 24 hours treatment led to a higher increase in the proportion of cells in the 
G0/G1 phase of the cell cycle across all cell lines compared to Nutlin-3 at the same GI50 doses 
(Figure 7-8A, Figure 7-9A & Figure 7-10A). RG7388 induced SubG1 events in all cell lines in 
a concentration and time-dependent manner (Figure 7-8B, Figure 7-9B & Figure 7-10B). The 
IGROV-1 cell line showed a higher basal level of SubG1 events on Flow cytometry compared 
to the other cell lines, which was further increased by MDM2 inhibitor or cisplatin treatment. 
In terms of the proportional distribution of cells in G0/G1 or G2/M, the effect of RG7388 
combination with cisplatin was time dependent. Combined treatment for 24 hours led to 
proportionally more cells in the G0/G1 cell cycle phase compared to the effect of cisplatin on 
its own and a higher proportion of cells in the G2/M phase compared to the effect of RG7388 
alone across all 3 cell lines. After 48 and 72 hours treatment, the combination of RG7388 with 
cisplatin led to a greater proportional increase in G2/M phase compared to either agent alone 
for A2780 and IGROV-1, whereas for OAW42 there was a reduction in the proportion of cells 
in G2/M phase (Figure 7-8A, Figure 7-9A & Figure 7-10A). Combined treatment of RG7388 
with cisplatin resulted in increased SubG1 events in A2780 and IGROV-1 cells compared to 
cisplatin on its own, which was treatment time and dose-dependent (Figure 7-8B & 
Figure 7-9B). Interestingly, combined treatment of RG7388 with cisplatin at 1x GI50 
significantly increased SubG1 events compared to cisplatin on its own even at 2x GI50 
concentration in A2780 (after 48 hours) and IGROV-1 (after 24 hours). In contrast, 
combination treatments resulted in decreased SubG1 events after 48 and 72 hours post-
treatment for OAW42 compared to cisplatin on its own, demonstrating a protective effect of 
RG7388 against cisplatin (Figure 7-10B).  
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Figure 7-8: Combination of RG7388 with cisplatin affects the cell cycle distribution and apoptotic endpoints. A2780 cell line was treated 
for 24, 48 and 72 hours with RG7388 or cisplatin alone and at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations. 
Combination of RG7388 with cisplatin led to an increased proportion of cells in G2/M phase (A) and SubG1 events (B) after 48 and 72 
hours post-treatment compared to either agent alone in a time and concentration-dependent manner. RG, RG7388; CDDP, Cisplatin; *, 
p<0.05; **, p<0.01; ***, p<0.001. The red stars represent significant increase in G0/G1 or SubG1 events compared to DMSO control. Data 
are shown as the average of at least 3 independent experiments and error bars represent SEM. 
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Figure 7-9: Combination of RG7388 with cisplatin affects the cell cycle distribution and apoptotic endpoints. IGROV-1 cell line was 
treated for 24, 48 and 72 hours with RG7388 or cisplatin alone and at constant 1:1 ratios of 1x and 2x their respective GI50 concentrations. 
Combination of RG7388 with cisplatin led to an increased proportion of cells in G2/M phase after 48 and 72 hours post-treatment (A) and 
SubG1 events after 24 and 48 hours post-treatment (B) compared to either agent alone in a time and concentration-dependent manner. 
RG, RG7388; CDDP, Cisplatin; *, p<0.05; **, p<0.01. The red stars represent significant increase in G0/G1 or SubG1 events compared 
to DMSO control. Data are shown as the average of at least 3 independent experiments and error bars represent SEM.
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Figure 7-10: Combination of RG7388 with cisplatin affects the cell cycle distribution and apoptotic endpoints. OAW42 cell line was treated 
for 24, 48 and 72 hours with RG7388 or cisplatin alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of RG7388 with cisplatin led to no increased proportion of cells in G2/M phase compared to cisplatin on its own (A) and a 
significant decrease in SubG1 events 72 hours post-treatment compared to cisplatin alone (B). RG, RG7388; CDDP, Cisplatin; *, p<0.05; 
**, p<0.01; ***, p<0.001. The red stars represent significant increase in G0/G1 events compared to DMSO control. Data are shown as the 
average of at least 3 independent experiments and error bars represent SEM. 
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 The effect of Nutlin-3/RG7388 in combination with cisplatin on the caspase 3/7 
activity in wild –type TP53 ovarian cancer cell lines 
The induction of apoptosis was also evaluated by caspase 3/7 enzymatic assay, which is a 
sensitive and specific indicator of apoptosis (Chen et al., 2015). Wild-type TP53 ovarian cancer 
cell lines were treated for 24 and 48 hours with 1x and 2x their respective Nutlin-3/RG7388 
GI50 concentrations as a single agent and in combination with cisplatin. In general, across the 
cell lines there was a positive correlation between the caspase 3/7 activity and accumulation of 
SubG1 events. With IGROV-1, a concentration-dependent increase in the caspase 3/7 activity 
in response to Nutlin-3/RG7388 compared to DMSO control was observed. Furthermore, the 
combination of Nutlin-3/RG7388 with cisplatin led to more caspase 3/7 activity in IGROV-1 
compared to either agent alone with the exception of combination of RG7388 with cisplatin at 
2x GI50 values after 48 hours post-treatment (Figure 7-11 & Figure 7-12). Also no significant 
increase was observed for the combination of Nutlin-3/RG7388 with cisplatin compared with 
the effect of cisplatin alone in the A2780 cells (Figure 7-11 & Figure 7-12). Combination 
treatments led to a decrease in the caspase 3/7 activity in the OAW42 cells, indicating a 
protective effect of Nutlin-3/RG7388 against cisplatin in this cell line (Figure 7-11 & 
Figure 7-12). Taken together, these results demonstrated that the effect of Nutlin-3/RG7388 in 
combination with cisplatin on caspase 3/7 activity is cell type, compound and time dependent. 
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Figure 7-11: Combinations of Nutlin-3 with cisplatin affects caspase3/7 activity. The wild-type TP53 ovarian cancer cells treated at 
constant 1:1 ratios of 1x and 1/2x or 2x their respective GI50 concentrations of Nutlin-3 and cisplatin alone, and in combination for 24 and 
48 hours. Caspase 3/7 activity is represented as fold change relative to DMSO solvent control. Nut-3, Nutlin-3; CDDP, Cisplatin; *, p<0.05; 
**, p<0.01; ***, p<0.001. The red stars represent a significant increase in the caspase3/7 activity compared to DMSO control.
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Figure 7-12: Combinations of RG7388 with cisplatin affects caspase3/7 activity. The wild-type TP53 ovarian cancer cells treated at 
constant 1:1 ratios of 1x and 1/2x or 2x their respective GI50 concentrations of RG7388 and cisplatin alone, and in combination for 24 
and 48 hours. Caspase 3/7 activity is represented as fold change relative to DMSO solvent control. RG, RGB7388; CDDP, Cisplatin; *, 
p<0.05; **, p<0.01; ***, p<0.001. The red stars represent a significant increase in the caspase3/7 activity compared to DMSO control.  
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 Nutlin-3/RG7388 synergises with cisplatin for clonogenic cell killing of wild-type 
TP53 ovarian cancer cell lines 
The reduction in clonogenic survival in response to 48 hours exposure to Nutlin-3, RG7388 
and cisplatin, both as single agents and in combination at 5 equipotent concentrations between 
0.25× and 4× their respective LC50 concentrations was determined for the three wild-type TP53 
cell lines and evaluated by median-effect analysis. Due to the high LC50 for IGROV-1 and 
OAW42 in response to Nutlin-3, 3 equipotent concentrations between 0.25× and 1x their 
respective LC50 concentrations were used to assess the combination effect of Nutlin-3 with 
cisplatin.  
The effect of combined treatment was cell type and compound-dependent (Figure 7-13 & 
Figure 7-14). The combination of Nutlin-3 with cisplatin led to a further decrease in colony 
formation compared to treatment with either agent alone for all three cell lines and was 
particularly marked for IGROV1 (Figure 7-13). Although the combination of Nutlin-3 with 
cisplatin significantly decreased the clonogenic survival of IGROV-1 and A2780 compared to 
either agent alone, the combined treatment of RG7388 with cisplatin at the same LC50 ratios 
only moderately reduced colony formation (Figure 7-14). For the OAW42 cell line, the 
combination treatment of Nutlin-3 with cisplatin reduced the ability of the OAW42 cell line to 
form colonies to a greater extent than either agent on its own. In contrast, there was no 
significant reduction in the clonogenic cell survival of OAW42 following combination 
treatment with RG7388 and cisplatin compared to either agent alone (Figure 7-13 & 
Figure 7-14).  
The data were analysed using median-effect analysis and CI values calculated to evaluate 
whether the observed differences in clonogenic cell survival were synergistic, additive or 
antagonistic. CI values for each constant ratio combination at estimated effect levels of ED50, 
ED75 and ED90 were individually computed, and the average of CI values was also determined. 
Across all three wild-type TP53 cell lines, the effect of combination treatment of Nutlin-3 with 
cisplatin ranged from additive to strongly synergistic (Figure 7-15 & Table 7-3). In addition, 
for combination treatments, both Nutlin-3 and cisplatin had a favourable DRI ranging from 
1.3-fold to 10.9-fold dose reduction (Table 7-4).  
For A2780 and IGROV-1 cell lines a synergistic effect was observed for combination treatment 
with Nutlin-3 and cisplatin, whereas for RG7388 and cisplatin combinations the effect was 
additive to antagonistic. For the OAW42 cell line the combination of RG7388 and cisplatin 
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was antagonistic, suggesting RG7388 had a protective effect against cisplatin (Figure 7-15). 
Although the combined effect of RG7388 with cisplatin ranged from additive to antagonistic, 
there was nevertheless a favourable DRI for the same level of clonogenic cell killing when 
treatments are combined for all RG7388 concentrations and most concentrations of cisplatin 
(Table 7-4). 
 
Figure 7-13: Nutlin-3 has a synergistic or additive effect with cisplatin in clonogenic 
survival assays in wild-type TP53 ovarian cancer cells. Clonogenic survival for three wild-
type TP53 cell lines exposed to Nutlin-3 and cisplatin alone, and in combination at 
constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x and 4x (A2780) and 0.25x, 0.5x, 1x (IGROV-1 & 
OAW42) their respective LC50 concentrations for 48 hours.
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Figure 7-14: RG7388 has an additive or antagonistic effect with cisplatin in clonogenic 
survival assays in wild-type TP53 ovarian cancer cells. Clonogenic survival for three wild-
type TP53 cell lines exposed to RG7388 and cisplatin alone, and in combination at 
constant 1:1 ratios of 0.25x, 0.5x, 1x, 2x and 4x their respective LC50 concentrations for 
48 hours.
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Figure 7-15: The clonogenic survival combination index (CI) values for Nutlin-3 (A) and 
RG7388 (B) in combination with cisplatin at ED50 and, the average of CI values at effect 
levels ED50, ED75 and ED90 in three wild-type TP53 ovarian cancer cell lines. Data are 
shown as the average of at least 3 independent experiments and error bars represent 
SEM. CI, Combination Index; ED, Effective dose.   
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Table 7-3: Clonogenic survival CI values for RG7388/Nutlin-3 in combination with cisplatin for the wild-type TP53 ovarian cancer cell 
lines. The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. CI values 
were calculated for each constant ratio combination and at effect levels ED50, ED75 and ED90 from the average of at least three independent 
experiments. CI Ave ED50-90 represents the average of CI values at effect levels of ED50, ED75 and ED90. CI range: < 0.1 very strong 
synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 
1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. 
Synergistic combinations are highlighted in bold font. CI, Combination Index; ED, Effective dose; ND; Not determined.
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Table 7-4: DRI values for clonogenic cell killing by RG7388/Nutlin-3 in combination with cisplatin in wild-type TP53 ovarian cancer cell 
lines. The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective LC50 concentrations. DRI values 
were calculated for each constant ratio combination from the average of at least three independent experiments. DRI, Dose reduction 
index; ND; Not determined. Favourable DRI values are highlighted in bold font.
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 Nutlin-3/RG7388 induces expression of cell cycle arrest/apoptosis-related genes and 
those implicated in DNA repair in response to cisplatin 
To investigate the mechanistic basis for the observed combination effects, the effect of MDM2 
inhibitor treatment on mRNA expression of candidate genes with potential for influencing the 
response to cisplatin was analysed by qRT-PCR. Changes in the expression of cell 
cycle/apoptosis-related genes as well as those involved in nucleotide excision repair (NER) 
and mismatch repair (MMR) for the three wild-type TP53 cell lines in response to Nutlin-3 and 
RG7388 are shown in Figure 7-16. The cells were treated with 5 (µM) Nutlin-3 and 0.5 (µM) 
RG7388, and total RNA was extracted 6 hours after the commencement of treatment.  
Overall, the fold changes in expression in response to MDM2 inhibitors were less in A2780 
cells than IGROV-1 and OAW42 (Figure 7-16 & Figure 7-17). In the case of the genes involved 
in cell cycle arrest and growth inhibition, Nutlin-3 and RG7388 treatment significantly induced 
CDKN1A, SESN1 and GADD45A gene expression in all three cell lines, with CDKN1A 
consistently showing the highest level of induction (p<0.05) (Figure 7-16). Both treatments 
showed a significant increase in the expression of the pro-apoptotic TNFRSF10B and PUMA 
genes in all three cell lines, with increases of PUMA mRNA being highest in the IGROV-1 cell 
line (p<0.05) (Figure 7-16). The Nutlin-3/RG7388 treatment also increased expression of the 
pro-apoptotic gene TP53INP1 in A2780 and OAW42 cells; however, there was no significant 
induction in IGROV-1. No significant increase was observed for the pro-apoptotic gene BAX 
in any of the cell lines. Although Nutlin-3/RG7388 treatment led to significantly increased 
expression of AEN in IGROV-1, the induction of AEN was not statistically significant for 
A2780 (Figure 7-16). Furthermore, both Nutlin-3 and RG7388 treatments significantly 
increased the expression of the MDM2 gene, the negative regulator of p53, across all three cell 
lines. The treatments led to a statistically significant decrease in the expression of BCL-2 for 
A2780 and IGROV-1 cell lines although the changes were small and unlikely to be biologically 
significant. Also, no significant changes were observed in the expression levels of the anti-
apoptotic BIRC5 and MCL-1 genes (Figure 7-16).  
To study the effect of Nutlin-3 and RG7388 on the expression of genes implicated in the 
response to DNA repair induced by cisplatin, the expression of TP53BP1, DDB2, ERCC1, 
XPC, MLH1, MSH2, RAD51 and RRM2B genes in response to Nutlin-3 and RG7388 was 
investigated. A significant increase was measured in the expression of DDB2 in response to 
Nutlin-3 and XPC in response to both Nutlin-3 and RG7388 for A2780 cells (p<0.05). In the   
 265 
 
 
case of IGROV-1, XPC and MSH2 gene expression levels were significantly induced in 
response to Nutlin-3 and reduced in response to RG7388 respectively (p<0.05). For OAW42 
cells, there was a significant increase in the expression of DDB2 gene and a significant decrease 
in the MLH1 and MSH2 expression levels in response to Nutlin-3 treatment (p<0.05). With 
Nutlin-3 treatment, the TP53BP1 gene expression decreased in all three cell lines, although 
statistically this trend was not significant (p>0.05) (Figure 7-16). 
The mRNA profile found for CDKN1A and BAX genes was consistent with the western blot 
analysis for p21WAF1 and BAX proteins (Figure 7-4). The increased CDKN1A and SESN1 gene 
expression is also in agreement with induced cell cycle arrest and growth inhibition across the 
three cell lines. Furthermore, induction of PUMA and TNFRSF10B is in accordance with the 
induction of apoptosis, SubG1 events and caspase 3/7 activity, in A2780 and IGROV-1 
(Figure 7-5B, Figure 7-6B, Figure 7-8B, Figure 7-9B, Figure 7-11A & Figure 7-12). However, 
in spite of significantly increased PUMA and TNFRSF10B gene expression levels in OAW42, 
no induction of apoptosis was observed in this cell line (Figure 7-7B, Figure 7-10B, Figure 7-11 
& Figure 7-12).  
The increased sensitivity to MDM2 inhibitors and their synergy with cisplatin observed with 
the A2780 cells was not obviously attributable to any individual change in candidate gene 
expression. However, as can be seen in Figure 7-17, the balance of expression between the 
growth arrest genes and the autoregulatory negative feedback MDM2 gene on the one hand 
and the pro-apoptotic and DNA repair genes on the other hand, was somewhat less with the 
A2780 cells (Figure 7-18).  
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Figure 7-16: mRNA expression of genes relating to apoptosis, cell cycle arrest, nucleotide 
excision repair (NER) and DNA mismatch repair (MMR) in response to 5 µM Nutlin-3 
or 0.5 µM RG7388 for 6 hours relative to DMSO solvent control. *, p˂0.05; **, P<0.01; 
***, P<0.001. Data are presented as mean ± standard error of mean (SEM) of three 
independent repeats.
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Figure 7-17: Growth arrest, pro-apoptotic, anti-apoptotic and DNA repair-related gene 
expression changes induced by 5 µM Nutlin-3 or 0.5 µM RG7388 for 6 hours relative to 
DMSO solvent control. Summary data are presented as a combination of three 
independent repeats for Nutlin-3 and three for RG7388.   
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Figure 7-18: Gene expression changes (CDKN1A, MDM2, PUMA and SESN1) induced by 
5 µM Nutlin-3 or 0.5 µM RG7388 for 6 hours relative to DMSO solvent control in one cell 
line against another cell line ( three pairwise comparisons). Summary data are presented 
as a combination of three independent repeats for Nutlin-3 and three for RG7388. (A) 
A2780 versus OAW42 (p<0.05), (B) A2780 versus IGROV-1 (p<0.05) and (C) IGROV-1 
versus OAW42 (p>0.05). 
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7.5 Discussion 
Advanced ovarian cancer treatment usually involves debulking surgery followed by platinum 
based chemotherapy, alone or with the addition of paclitaxel. Although chemotherapy prolongs 
survival, most patients with advanced disease die from treatment resistant progressive disease 
(Kim et al., 2012; Ledermann et al., 2013). Cancer therapy has recently been improving with 
the introduction of targeted therapies to achieve greater specificity and less cytotoxicity 
(Munagala et al., 2011; Yuan et al., 2011; Nicolas Andre et al., 2012). When new agents are 
evaluated against particular cancers they are compared against established treatments and also 
in combination with established treatments, particularly when there is a mechanistic rationale 
to suggest that there may be an additive or synergistic effect of the combination. Platinum 
agents are the standard treatment used for ovarian cancer which induces cell cycle arrest and 
apoptosis through both p53-dependent and p53-independent pathways. Therefore in addition 
to the effect of MDM2-p53 binding antagonists alone, it is of interest to investigate the 
combined effect of these novel agents with cisplatin.  
 Nutlin-3/RG7388 synergises with cisplatin for growth inhibition of wild-type TP53 
ovarian cancer cell lines 
Resistance to MDM2-p53 binding antagonists has been suggested to be acquired by prolonged 
exposure of cells to sub-lethal doses through de novo inactivating TP53 mutations or selection 
of pre-existing subclones of TP53 mutant cells that might be present as a result of cancer cell 
instability and tumour heterogeneity (Shen et al., 2008; Aziz et al., 2011). For this reason, it is 
suggested that MDM2-p53 antagonists are likely be most effective in combination with 
standard existing chemotherapeutic agents or agents that target or limit the potential outgrowth 
of TP53 mutated cells. Platinum agents used to treat ovarian cancer have major adverse side 
effects including nephrotoxicity, ototoxicity, myelosuppression and gastrointestinal disorders 
(Florea and Büsselberg, 2011; Pabla and Dong, 2012). This study set out with the aim of 
assessing the effect combination treatment of Nutlin-3 and RG7388 with cisplatin in a panel of 
ovarian cancer cell lines of known TP53 status.  
Overall, the combination effect of Nutlin-3 and RG7388 with cisplatin varied with synergism 
in A2780 and moderate synergism to antagonism in IGROV-1 and OAW42 cell lines, 
depending on drug concentration. A single limited previous study examined the combination 
of Nutlin-3a with cisplatin in A2780p, A2780cis and the OV90 cell lines. The results showed 
a synergistic effect in A2780p and A2780cis, consistent with our study (Mir et al., 2013). Based   
 270 
 
 
on the CI values at the average of ED50-ED90 and ED50 (Chou, 2006), the combination effect 
of Nutlin-3 and RG7388 with cisplatin ranged from synergism to moderate synergism in A2780 
and moderate synergism to antagonism in IGROV-1 and OAW42 cell lines. Unexpectedly, 
combination of RG7388 with cisplatin resulted in less synergistic or additive effect compared 
to combined treatment of Nutlin-3 with cisplatin across all three cell lines. The reason for this 
is not clear but it may be related to the induction of G0/G1 cell cycle arrest following exposure 
to RG7388 which leads to protection of the cells against cisplatin, since cisplatin is 
preferentially cytotoxic against S-phase cells. Chen et al. (2015) obtained the least degree of 
synergy for cisplatin with RG7388 in neuroblastoma cell lines compared to synergies between 
RG7388 and doxorubicin, topotecan, temozolomide or busulfan. 
The most important clinically relevant finding from the data is favourable DRI values in both 
combination treatment of Nutlin-3 and RG7388 with cisplatin. DRI values represent the 
magnitude (fold) of dose reduction that is achievable in combination for a given degree of 
effect compared with the dose of each drug alone (Chou, 2006; Zhang et al., 2009; Chou, 2010). 
Even in the absence of synergy, combined treatment can nevertheless be of potential clinical 
use, because in most cases a favourable dose reduction for each agent may still be achievable 
for a given level of effect compared with each agent alone (Table 7-2). This is of particular 
potential benefit when the agents in question, in this case MDM2 inhibitors and cisplatin, have 
different dose limiting toxicities. Overall, the effects observed were compound and cell type 
dependent. 
 Combination of Nutlin-3/RG7388 with cisplatin induces functional activation of the 
p53 pathway in TP53 wild-type ovarian cancer cell lines 
The combination treatments increased stabilization of p53 and upregulation of p21WAF1 and 
MDM2 compared to either agent alone, particularly compared to cisplatin in A2780 and 
IGROV-1, which is in agreement with data obtained by Mir et al. (2013) in the A2780p cell 
line, Barbieri et al. (2006) and Koster et al. (2011) in testicular carcinoma cells and Voon et 
al. (2015) in nasopharyngeal carcinoma. However, there was no significant increase in p53 
stabilization and p21WAF1 upregulation with combined treatment of OAW42 cells compared to 
Nutlin-3 and RG7388 as single treatments. These results help to explain the observed 
differences in the effect of combined treatment on growth inhibition between these cell lines. 
These findings are in keeping with functional activation of p53 as a driver of the synergistic 
effects in combination treatment. For growth inhibition the increased upregulation of p21WAF1   
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is consistent with its role in cell cycle arrest (Giono and Manfredi, 2007; Abbas and Dutta, 
2009; Cazzalini et al., 2010). Nutlin-3 and RG7388 led to little change of BAX compared to 
DMSO control and combination of Nutlin-3 with cisplatin at 1x GI50 showed a slight increase 
in the expression of BAX in A2780 and IGROV-1 cell lines compared to cisplatin on its own. 
These results differ from Mir et al. (2013) who found induction of BAX following combined 
treatment of Nutlin-3a with cisplatin compared to cisplatin on its own. A possible explanation 
for this inconsistency might be the high concentration of Nutlin-3a (5 µM) and cisplatin (3.5 
µM) used compared to what has been used in this study.  
 Nutlin-3/RG7388 synergises with cisplatin for cell cycle arrest and/or apoptosis in 
wild-type TP53 ovarian cancer cell lines 
Individually, Nutlin-3 and RG7388 induced cell cycle arrest and/or apoptosis in wild-type 
TP53 ovarian cancer cell lines in a time and dose-dependent manner. Combination treatment 
with Nutlin-3 or RG7388 and cisplatin led to greater G2/M and/or G0/G1 cell cycle phase 
accumulation, more SubG1 events and/or higher levels of caspase 3/7 activity compared to 
either agent alone in a cell type and time-dependent manner. These results are consistent with 
those of Mir et al. (2013) who found more accumulation of cells in G2/M phase in wild-type 
TP53 ovarian cancer cell lines, A2780p and A2780cis, treated with a combination of Nutlin-
3a and cisplatin compared to either agent alone.  
Overall, there was a positive correlation between the detection of SubG1 events on Flow 
cytometry and caspase 3/7 activity; however, cell cycle arrest is not always accompanied by 
the induction of apoptosis  (Weng et al., 2001; Simone Fulda et al., 2010) as seen for OAW42 
cells in this study. The apparent protective effect of Nutlin-3/RG7388 against cisplatin in 
OAW42, indicated by the antagonistic effect of combination, was reflected by fewer SubG1 
events and Caspase 3/7 activity compared to cisplatin on its own (Figure 7-7B, Figure 7-10B, 
Figure 7-11C Figure 7-12C). In terms of A2780 cells, there was a significant increase in SubG1 
events following combination of Nutlin-3/RG7388 with cisplatin even though no significant 
increased caspase 3/7 activity was observed, indicating the involvement of alternative 
pathways implicated in cell death, rather than caspase 3/7 activation. 
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 Nutlin-3/RG7388 affects the response to cisplatin for clonogenic cell killing of TP53 
wild-type ovarian cancer cell lines 
Combined treatment with Nutlin-3 and cisplatin significantly decreased the clonogenic survival 
of wild-type TP53 ovarian cancer cells compared with either agent alone, and the combination 
effect ranged from additive to strong synergy. Nutlin-3 may sensitize wild-type TP53 ovarian 
cancer cell lines to cisplatin via multiple factors including increased p53-dependent apoptosis 
(Arya et al., 2010; Voon et al., 2015). Surprisingly, the combination of RG7388 with cisplatin 
showed no evidence of synergy for reduction of colony forming ability. The clonogenic assay 
results for combination of RG7388 with cisplatin ranged from antagonism for OAW42, 
indicating a protective effect of RG7388 against cisplatin, to additive for A2780 and IGROV-
1. The difference between the results for combination of cisplatin with Nutlin-3 compared to 
the combination with RG7388 may in part be due to different p53-dependent off-target effects 
of these MDM2 inhibitors (Contractor and Harris, 2012; Khoo et al., 2014). A contributory 
factor may be differences in G0/G1 cell cycle arrest with MDM2 inhibitors, since an increased 
G0/G1 cell cycle arrest may protect against agents such as cisplatin which are preferentially 
cytotoxic against S-phase cells (Wagner and Karnitz, 2009). 
 Nutlin-3/RG7388 affects expression of cell cycle arrest/ apoptosis-related genes and 
those involved in response to DNA repair 
Across the three cell lines, Nutlin-3/RG7388 increased CDKN1A and SESN1 expression 
consistent with their essential role in cell cycle arrest and growth inhibition (Budanov and 
Karin, 2008; Abbas and Dutta, 2009). Both Nutlin-3 and RG7388 treatment significantly 
induced the expression of the pro-apoptotic TNFRSF10B and PUMA genes in all three cell 
lines. TNFRSF10B  and its ligand, TRAIL, have been reported to preferentially induce 
apoptosis in transformed and tumour cells even though TNFRSF10B is expressed at a 
significant level in most normal tissues (Ashkenazi and Herbst, 2008; Bossi et al., 2015). This 
may contribute to the generally greater toxicity of MDM2 inhibitors for cancer cells compared 
to normal cells, although some haematopoietic cell lineages also appear to be sensitive, as 
evidenced by the dose limiting thrombocytopenia seen in the early phase clinical trials of 
MDM2 inhibitors (Jiang et al., 2007). There was a positive concordance between the 
expression of these pro-apoptotic genes and the apoptotic endpoints shown by ubG1 signals on 
Flow cytometry and caspase 3/7 activity in A2780 and IGROV-1 cell lines. However, this 
relationship did not extend to the OAW42 cell line, for which increased pro-apoptotic 
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TNFRSF10B, TP53INP1 and PUMA gene expression was not in keeping with low caspase 3/7 
activity and SubG1 FACS signals. Failure to undergo apoptosis in OAW42 cells in response 
to C1311, a new class of imidazoacridinones, has been reported, consistent with our 
observation (Zaffaroni et al., 2001). A possible explanation for the lack of evidence of 
apoptosis in OAW42 might be high levels of anti-apoptotic proteins such as BCL-2, BCL-X 
and MCL-1 or deficiency in downstream factors involved in the apoptosis cascade (Haupt et 
al., 2003; Jeffers et al., 2003). This would imply that OAW42 would be responsive to inhibitors 
of these anti-apoptotic proteins and they would potentiate the effect of MDM2 inhibitors in 
OAW42 in particular. Although BAX is reported to be required for PUMA-induced apoptosis, 
there was no significant increase in BAX expression, either at the mRNA or protein level in 
response to Nutlin-3/RG7388 treatment in any of the cell lines.  
Significantly increased expression of several p53-regulated genes involved in the repair of 
DNA lesions induced by cisplatin, including DDB2, XPC and RRM2B, lead us to reject the 
hypothesis that reduced capacity for repair of cisplatin induced DNA damage leads to a 
synergistic effect in combined treatment with Nutlin-3/RG7388 and cisplatin. Although there 
was some evidence of a reduced expression of the DNA mismatch repair genes, MLH1 and 
MSH2, the changes were very small and unlikely to be biologically significant.  
 Conclusion and further work 
In conclusion, the present study demonstrates that combination treatment with MDM2 
inhibitors and cisplatin has synergistic and/or dose reduction potential dependent on cell 
genotype and compound and merits further investigation. Our study clearly indicates that the 
presence of wild-type TP53 remains the main predictive biomarker of response to MDM2 
inhibitors. However, an additional determinant of response involves the balance of activity 
between growth inhibitory/pro-survival and pro-apoptotic genes and our results indicate that 
this dominates the small changes in the expression of DNA repair genes as an explanation for 
the synergy observed for treatment with cisplatin and MDM2 inhibitors. 
Due to the effectiveness of MDM2-p53 antagonists as single agents in wild-type TP53 ovarian 
cancer cell lines, it was of interest to study the effect of combination of MDM2-p53 antagonists 
with the PARP inhibitor, rucaparib, in ovarian cancer cell lines. Inhibition of PARP might 
promote DNA damage related signalling to the p53 pathway. 
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Chapter 8: An investigation of the combination effect of MDM2-p53 
antagonists Nutlin-3/RG7388 or cisplatin with PARP inhibitor 
rucaparib on ovarian cancer cell lines 
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8.1 Introduction 
This chapter focuses on the effect of combination treatment of MDM2-p53 antagonists Nutlin-
3/RG7388 or cisplatin with rucaparib, a PARP-1 inhibitor also known as AG014699 or PF-
01367338 (McCrudden et al., 2015), in a panel of ovarian cancer cell lines. Due to the high 
rate of BRCA1, BRCA2 mutations and BRCAness, ovarian cancer sensitivity to PARP 
inhibitors has been explored and clinical trials are ongoing (Rigakos and Razis, 2012; Stordal 
et al., 2013; O'Sullivan et al., 2014). Data presented in chapter 6 confirmed the sensitivity of 
wild-type TP53 ovarian cancer cell lines to Nutlin-3/RG7388 as a single agent. 
Mechanistically, rucaparib inhibits the Base Excision Repair pathway (BER) as a result of 
PARP inhibition. Unrepaired single-strand DNA breaks are converted to double-strand breaks 
at fork replication, which do not get repaired accurately in deficient-HRR (Homologous 
Recombination Repair) cells (Underhill et al., 2011; Bai et al., 2015). These unrepaired double 
strand breaks lead to increased levels of p53 due to persistence of unpaired DNA.  
Findings about the interplay between p53 and PARP are controversial (Valenzuela et al., 2002; 
Jelinic and Levine, 2014; Bai et al., 2015). It was hypothesized that following combination 
treatment of Nutlin-3/RG7388 with rucaparib the p53 pathway is activated by inhibition of 
PARP and further induction and stabilisation of p53 via Nutlin-3/RG7388 treatment would 
result in more growth arrest and/or apoptosis in wild-type TP53 ovarian cancer cell lines. 
This chapter set out to evaluate the effect of combined treatment of Nutlin-3/RG7388 or 
cisplatin with rucaparib in a panel of ovarian cancer cell lines in regard to the effect on growth 
arrest, p53 downstream pathway activation and cell cycle progression.  
 Rucaparib (AG014699, PF-01367338) 
Rucaparib is one of a series of tricyclic benzimidazole carboxamide PARP inhibitors with a Ki 
of 1.4 nM for PARP1 in a cell-free assay. It was the first PARP inhibitor to enter into clinical 
trials as a chemopotentiator (Figure 8-1) (Thomas et al., 2007; McCrudden et al., 2015). It was 
successfully granted a license by the FDA in 2015 for use as a monotherapy for patients with 
BRCA1/2 mutant advanced ovarian cancer after at least two prior lines of platinum-based 
chemotherapy. It inhibits DNA BER via both inhibition of PARP enzyme activity and 
formation of trapped PARP-DNA complexes (Brown et al., 2016). It has off-target effects for 
9 protein kinases in the 1.2-18 micromolar range, demonstrating less selectivity compared to 
olaparib as a PARP inhibitor (Antolín and Mestres, 2014). 
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Figure 8-1: Chemical structure of rucaparib.
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8.2 Hypothesis and Objectives 
Hypothesis: 
1. Combined treatment of MDM2-p53 antagonists Nutlin-3/ RG7388 or cisplatin with 
rucaparib increases growth inhibition and/or apoptosis in ovarian cancer cell lines 
compared to either agent alone.  
Objectives: 
1.  To test a panel of established wild-type TP53 ovarian carcinoma cell lines for their 
response to combination treatment of Nutlin-3/RG7388 with rucaparib and determine 
the synergistic, additive or antagonistic effect of combination. 
2.  To investigate the effect of combined treatment of cisplatin with rucaparib on a panel 
of wild-type TP53 ovarian cancer cell lines and determine the synergistic, additive or 
antagonistic effect of combination. 
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8.3 Specific Materials and Methods 
 Cell lines 
The same panel of cell lines described in chapter 6.3.1 was used for the experiments in this 
chapter. 
 Growth inhibition assay and combined treatments 
Growth inhibition curves for 72 hours were constructed using SRB assay and GI50 values were 
calculated as described in general Materials and Methods (2.8). Based on the growth curves, 
the appropriate cell densities were chosen when cells were in exponential phase of growth and 
treated with different concentrations of rucaparib (0.4-25 µM). 
Combination treatment of Nutlin-3/RG7388 or cisplatin with rucaparib was performed as 
described in chapter 7.3.2. 
 Western blot 
2 x 105 cells were seeded in a small dish T25 for western blot analysis and left for 48 hours to 
adhere and grow. To investigate the effect of combined treatment of Nutlin-3/RG7388 or 
cisplatin with rucaparib on the p53 pathway, cells were treated with each agent alone and in 
simultaneous combination at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations. The lysates were extracted following 4 hours treatment. The antibodies used 
and their details are found in chapter 2.11.7. 
 Flow cytometry 
Flow cytometry was performed to analyse cell cycle distribution changes and induced 
apoptosis over 24, 48 and 72 hours after treatment as described in general Materials and 
Methods (2.14.3 & 2.14.4) and chapter 7.3.4. 
 Clonogenic cell survival assay 
Clonogenic survival assays were performed for the panel of 6 ovarian cancer cell lines as 
described in section 2.9. 
 Statistical analysis 
The statistical paired t-test or Mann-Whitney test was used to compare the mean of 3 or more 
paired biological repeats and the p-value <0.05 were considered statistically significant. 
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8.4 Results 
 The growth inhibitory response of ovarian cancer cell lines to rucaparib 
The cells were treated with a wide range of rucaparib concentrations (0.4-25 µM) for 72 hours 
to construct growth inhibition curves and calculate the GI50 values. The GI50 values 
significantly varied showing a range of responses, with A2780 (3.26±0.47 µM) and SKOV-3 
(> 25 µM) as the most sensitive and resistant cell lines respectively (Figure 8-2). Across mutant 
TP53 cell lines, there was a direct correlation between cisplatin sensitivity and response to 
rucaparib (Table 8-1). The results of this study showed no relationship between the status of 
TP53 and response to rucaparib (Mann-Whitney, p>0.05) (Figure 8-3).  
 
 
Table 8-1: GI50 concentrations of rucaparib and cisplatin for the panel of ovarian cancer 
cell lines of varying TP53 status. Data represent the mean of at least three independent 
experiments ± SEM.
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Figure 8-2: Growth inhibition curves demonstrating the effect of rucaparib for a panel of 
ovarian cancer cell lines. Data represent the mean of at least three independent 
experiments. Wt, Wild-type; mut, Mutant. 
 
 
 
Figure 8-3: The sensitivity to rucaparib in a panel of wild-type and mutant TP53 ovarian 
cancer cell lines. The TP53 status has no effect on the sensitivity of cell lines in response 
to rucaparib (Mann-Whitney, p>0.05). Data shown are the average of at least three 
independent experiments and error bars represent SEM.
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 Rucaparib synergises with Nutlin-3/RG7388 and cisplatin for growth inhibition of 
wild-type TP53 ovarian cancer cell lines 
The effect of rucaparib in combination with Nutlin-3/RG7388 or cisplatin was investigated for 
three wild-type TP53 ovarian cancer cell lines using median-effect analysis. The sensitivity of 
the wild-type TP53 cell lines to growth inhibition during 72 hours exposure to rucaparib, 
Nutlin-3/RG7388 and cisplatin was determined as single agents, and in combination at 5 
equipotent concentrations between 0.25× and 4× their respective GI50 concentrations for the 
A2780 cell line. Owing to the high GI50 for IGROV-1 and OAW42 in response to rucaparib, 3 
equipotent concentrations between 0.25× and 1x their respective GI50 concentrations were used 
to evaluate the combination effect of rucaparib with cisplatin or Nutlin-3/RG7388. The effect 
of combined treatment was cell type and compound dependent. Overall, greater synergy was 
observed with the combination of rucaparib and Nutlin-3/RG7388 compared to the 
combination of rucaparib with cisplatin. The combination of rucaparib with Nutlin-3/RG7388 
or cisplatin at all concentrations led to greater growth inhibition compared to either agent alone 
for the A2780 and IGROV-1 cell lines (Figure 8-4 & Figure 8-5). As shown in Figure 8-4, 
combination treatment of rucaparib with cisplatin or with Nutlin-3/RG7388 at concentrations 
equal and lower than the individual 1x GI50 dose resulted in more growth arrest compared to 
doses higher than 1x GI50 for the A2780 cell line. For the OAW42 cell line, there was little 
change in the growth inhibitory effect of rucaparib combination with cisplatin compared to 
either agent alone while the combination of rucaparib with RG7388/Nutlin-3 resulted in more 
growth inhibition compared to either agent alone (Figure 8-6).  
To determine whether the observed differences in growth inhibition were additive, synergistic 
or antagonistic, the data were analysed using median-effect analysis and CI values calculated. 
CI values for each constant ratio combination and at effect levels of ED50, ED75 and ED90 were 
computed and the average of CI values at ED50, ED75 and ED90 was also determined (Figure 8-7 
& Table 8-2). Combined treatment of rucaparib with Nutlin-3/RG7388 ranged from additive 
to strong synergism based on the CI at ED50 and overall CI for A2780 and IGROV-1 cell lines, 
whereas only slight synergism to antagonism was observed for the OAW42 cell line (Figure 8-7 
& Table 8-2). Although the effect of combination treatment of rucaparib with cisplatin based 
on the CI at ED50 was antagonist, additive and synergistic for OAW42, IGROV-1 and A2780 
respectively, it was antagonistic based on overall CI across all three cell lines. Interestingly, 
rucaparib, Nutlin-3, RG7388 and cisplatin had favourable DRI values for combined treatment 
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with all experimental values, aside from two cases, ranging from 1.2-fold to 7.8-fold dose 
reduction (Table 8-3).  
 
Figure 8-4: Growth inhibition curves for the A2780 cell line exposed to rucaparib, Nutlin-
3/RG7388 or cisplatin alone, and in combination at constant 1:1 ratios of 0.25x, 0.5x, 1x, 
2x and 4x their respective GI50 concentrations for 72 hours. Data are shown as the average 
of at least three independent experiments and error bars represent SEM.  
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Figure 8-5: Growth inhibition curves for the IGROV-1 cell line exposed to rucaparib, 
Nutlin-3/RG7388 or cisplatin alone, and in combination at constant 1:1 ratios of 0.25x, 
0.5x and 1x their respective GI50 concentrations for 72 hours. Data are shown as the 
average of at least three independent experiments and error bars represent SEM.  
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Figure 8-6: Growth inhibition curves for the OAW42 cell line exposed to rucaparib, 
Nutlin-3/RG7388 or cisplatin alone, and in combination at constant 1:1 ratios of 0.25x, 
0.5x and 1x their respective GI50 concentrations for 72 hours. Data are shown as the 
average of at least three independent experiments and error bars represent SEM. 
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Figure 8-7: The growth inhibition combination index (CI) values for rucaparib in combination with cisplatin or Nutlin-3/RG7388 at the 
ED50 and the average of CI values at effect levels ED50, ED75 and ED90 for three wild-type TP53 ovarian cancer cell lines. (A) A2780, (B) 
IGROV-1 and (C) OAW42. Data are shown as the average of at least three independent experiments and error bars represent SEM. CI, 
Combination index; Ruc, Rucaparib; Nut-3, Nutlin-3; RG, RG7388; CDDP, Cisplatin; ED, Effective dose.
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Table 8-2: Growth inhibition CI values for rucaparib in combination with cisplatin or Nutlin-3/RG7388 for the wild-type TP53 ovarian 
cancer cell lines. The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. 
CI values were calculated for each constant ratio combination and at effect levels ED50, ED75 and ED90 from the average of at least three 
independent experiments. CI Average ED50-90 represents the average of CI values at effect levels of ED50, ED75 and ED90. CI range: < 0.1 
very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 0.85-0.9 slight synergism; 0.9-1.1 nearly 
additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 antagonism; 3.3-10 strong antagonism; > 10 very strong 
antagonism. Synergistic combinations are highlighted in bold font. CI, Combination index; ED, Effective dose.
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Table 8-3: DRI values for growth inhibition by rucaparib in combination with cisplatin or RG7388/Nutlin-3 for the wild-type TP53 ovarian 
cancer cell lines. The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. 
DRI values were calculated for each constant ratio combination from the average of at least three independent experiments. Favourable 
DRI values are highlighted in bold font. DRI, Dose reduction index. 
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 The effect of combination treatment with rucaparib and Nutlin-3/RG7388 or 
cisplatin on activation of the p53 pathway 
Western blotting was used to investigate the effect of combination treatment on the p53 
molecular pathway. Wild-type TP53 cell lines were treated with rucaparib, Nutlin-3/RG7388 
or cisplatin alone, and in combination at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations for 4 hours. Western blot analysis showed that rucaparib treatment as a single 
agent had no effect on p53 stabilisation, upregulation of p21WAF1or MDM2 compared to DMSO 
control (Figure 8-8 & Figure 8-9). Combination treatment of rucaparib with Nutlin-3/RG7388 
in all cases led to greater levels of p53 stabilization, together with p21WAF1 and MDM2 
upregulation only compared to rucaparib on its own. However, rucaparib caused no increase in 
the effect of MDM2 inhibitors on the p53 pathway. Rucaparib in combination with Nutlin-
3/RG7388 seems to increase stabilisation of p53 and its downstream transcriptional targets in 
some cases in IGROV-1, but otherwise there are no convincing differences. No evidence of 
synergy was observed at the molecular level to indicate that the mechanism of synergy involved 
enhancement of the p53 pathway activation by MDM2 inhibitors (Figure 8-8).  
In contrast, combination of rucaparib with cisplatin had no effect on p53 stabilisation and 
upregulation of p21WAF1 and MDM2 compared to either agent alone with the exception of 
A2780 and IGROV-1 cells treated with combination of rucaparib and cisplatin at constant 1:1 
ratio of their respective GI50 concentrations. Under these conditions there was a slight increase 
and decrease in upregulation of p21WAF1 compared to either agent alone respectively 
(Figure 8-9).   
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Figure 8-8: Combination of rucaparib with Nutlin-3/RG7388 increased stabilization of 
p53 and upregulation of its downstream targets, MDM2 and p21WAF1 compared to 
rucaparib on its own but not compared to Nutlin-3/RG7388. Total levels of p53, p21WAF1, 
MDM2 4 hours after the commencement of treatment with rucaparib alone and in 
combination with Nutlin-3/RG7388 at constant 1:1 ratios of 1/2x and 1x their respective 
GI50 concentrations analysed by western blot in three wild-type TP53 ovarian cancer cell 
lines.
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Figure 8-9: Combination of rucaparib with cisplatin had little or no effect on the stabilization of p53 and upregulation of its downstream 
targets, MDM2 and p21WAF1 compared to either agent alone. Total levels of p53, p21WAF1,and MDM2 4 hours after the commencement of 
treatment with rucaparib alone and in combination with cisplatin at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations 
analysed by western blot in three wild-type TP53 ovarian cancer cell lines.
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 Rucaparib in combination with Nutlin-3/RG7388 or cisplatin induces cell cycle 
distribution changes and/or apoptosis in wild-type TP53 ovarian cancer cell lines 
Wild-type TP53 cell lines were treated with rucaparib and Nutlin-3/RG7388 or cisplatin, alone 
and in simultaneous combination at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations for 24, 48 and 72 hours. Then, they were analysed by flow cytometry for cell 
cycle phase distribution changes and evidence of apoptosis in response to treatment. 
8.4.4.1 The effect of rucaparib in combination with Nutlin-3 on cell cycle distribution and 
SubG1 events in wild-type TP53 ovarian cancer cell lines 
Rucaparib slightly increased the proportion of cells in G2/M phase and the number of SubG1 
events in a dose and time-dependent manner. Combination treatment of rucaparib with Nutlin-
3 resulted in an increased percentage of cells in the G2/M cell cycle phase compared to either 
agent alone, in a treatment time and dose-dependent manner for A2780 and IGROV-1 cell lines 
(Figure 8-10 & Figure 8-11). For the OAW42 cell line after 24 hours, it led to an increased 
proportion of the cell population in the G2/M phase of the cell cycle compared to Nutlin-3 as 
a single agent. After 48 and 72 hours, there was little change in the cell cycle distribution 
following combination of rucaparib with Nutlin-3 compared to either agent alone (Figure 8-12). 
Across all 3 cell lines, in most cases combination treatments also induced SubG1 events in a 
concentration and time-dependent manner (Figure 8-10, Figure 8-11 & Figure 8-12).  
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Figure 8-10: Combination of rucaparib with Nutlin-3 affects the cell cycle distribution and apoptotic endpoints. A2780 cells were treated 
for 24, 48 and 72 hours with rucaparib or Nutlin-3 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of rucaparib with Nutlin-3 led to an increased proportion of cells in G2/M phase (A) and an increased % of SubG1 signals 
(B) compared to Nutlin-3 and/or rucaparib alone in a time and dose-dependent manner. Nut-3, Nutlin-3; Ruc, Rucaparib; *, p˂0.05. Data 
are shown as the average of at least three independent experiments and error bars represent SEM.
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Figure 8-11: Combination of rucaparib with Nutlin-3 affects the cell cycle distribution and apoptotic endpoints. IGROV-1 cells were 
treated for 24, 48 and 72 hours with rucaparib or Nutlin-3 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations. Combination of rucaparib with Nutlin-3 led to an increased proportion of cells in G2/M phase (A) and % of SubG1 signals 
(B) compared to rucaparib and/or Nutlin-3 alone in a time and dose-dependent manner. Nut-3, Nutlin-3; Ruc, Rucaparib; *, p˂0.05; **, 
p˂0.01. Data are shown as the average of at least three independent experiments and error bars represent SEM.
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Figure 8-12: Combination of rucaparib with Nutlin-3 affects the cell cycle distribution and apoptotic endpoints. OAW42 cells were treated 
for 24, 48 and 72 hours with rucaparib or Nutlin-3 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of rucaparib with Nutlin-3 led to an increased proportion of cells in G2/M phase after 24 hours (A) and % SubG1 signals in 
most cases (B) compared to rucaparib and/or Nutlin-3 alone in a time and dose-dependent manner. Nut-3, Nutlin-3; Ruc, Rucaparib; *, 
p˂0.05; **, p˂0.01. Data are shown as the average of at least three independent experiments and error bars represent SEM.
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8.4.4.2 The effect of Rucaparib in combination with RG7388 on cell cycle distribution and 
SubG1 events in wild-type TP53 ovarian cancer cell lines 
For A2780 cells, the combination of rucaparib with RG7388 increased the proportion of cells 
in G2/M phase and SubG1 signals compared to either agent alone, in a treatment time and dose-
dependent manner, with the exception of SubG1 events after 24 hours. It also decreased the 
proportion of cells in S-phase compared to either agent alone (Figure 8-13). In terms of the 
proportional distribution of IGROV-1 cells in G0/G1 or G2/M, the effect of rucaparib 
combination with RG7388 was time dependent. Combined treatment for 24 and 48 hours led 
to proportionally more cells in G0/G1 compared to the effect of rucaparib on its own and a 
higher proportion of cells in G2/M compared to the effect of RG7388 alone. After 72 hours 
treatment, the combination of rucaparib with RG7388 resulted in increased G2/M cell cycle 
arrest compared to RG7388 on its own, with little change in the percentage of cells in G0/G1 
cell cycle compared to rucaparib alone. Combined treatments also increased the percentage of 
SubG1 signals compared to either agent alone, in a time and dose-dependent manner 
(Figure 8-14). The effect of rucaparib combination with RG7388 for OAW42 cells is shown in 
Figure 8-15. Combination of rucaparib with RG7388 led to proportionally more G2/M cells 
and SubG1 signals compared to either agent alone. It also decreased the percentage of cells in 
S-phase compared to either agent alone after 24 and 48 hours.   
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Figure 8-13: Combination of rucaparib with RG7388 affects the cell cycle distribution and apoptotic endpoints. A2780 cells were treated 
for 24, 48 and 72 hours with rucaparib or RG7388 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of rucaparib with RG7388 led to an increased proportion of cells in G2/M phase (A) and SubG1 signals (B) compared to 
either agent alone in most cases. RG, RG7388; Ruc, Rucaparib; *, p˂0.05; **, p˂0.01. Data are shown as the average of at least three 
independent experiments and error bars represent SEM.
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Figure 8-14: Combination of rucaparib with RG7388 affects the cell cycle distribution and apoptotic endpoints. IGROV-1 cells were 
treated for 24, 48 and 72 hours with rucaparib or RG7388 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations. Combination of rucaparib with RG7388 led to an increased proportion of cells in G2/M phase compared to RG7388 on 
its own (A) and SubG1 signals compared to either agent alone (B). RG, RG7388; Ruc, Rucaparib; *, p˂0.05. Data are shown as the average 
of at least three independent experiments and error bars represent SEM.
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Figure 8-15: Combination of rucaparib with RG7388 affects the cell cycle distribution and apoptotic endpoints. OAW42 cells were treated 
for 24, 48 and 72 hours with rucaparib or RG7388 alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of rucaparib with RG7388 led to an increased proportion of cells in G2/M phase (A) and SubG1 signals (B) compared to 
rucaparib and RG7388 as single agents in most cases. RG, RG7388; Ruc, Rucaparib; *, p˂0.05; **, p˂0.01. Data are shown as the average 
of at least three independent experiments and error bars represent SEM. 
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8.4.4.3 The effect of rucaparib in combination with cisplatin on cell cycle distribution 
andSubG1 events in wild-type TP53 ovarian cancer cell lines 
Combination treatment of rucaparib with cisplatin for A2780 cells led to an increase in the 
proportion of cells in G2/M phase compared to either agent alone after 24 hours, whereas it 
had little effect on the cell cycle distribution after 48 and 72 hours post-treatment 
(Figure 8-16A). In most cases, it also resulted in a higher increase in the proportion of SubG1 
signals compared to either agent alone (Figure 8-16B). For IGROV-1 cells, there was little 
change in the proportion of cells in G2/M phase following combination treatment of rucaparib 
with cisplatin compared to either agent alone. The effect of combined treatments on SubG1 
signals was time and dose-dependent manner although the differences were not statistically 
significant (Figure 8-17). For OAW42 cells, combination of rucaparib with cisplatin 
significantly decreased the proportion of cells in G2/M compared to cisplatin alone after 48 
and 72 hours post-treatment at 1x GI50 dose. Furthermore, the combined treatments led to a 
decrease in SubG1 signals after 48 and 72 hours post-treatment compared to cisplatin on its 
own indicating a protective effect of rucaparib against cisplatin in this cell line (Figure 8-18).  
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Figure 8-16: Combination of rucaparib with cisplatin affects the cell cycle distribution and apoptotic endpoints. A2780 cells were treated 
for 24, 48 and 72 hours with rucaparib or cisplatin alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 concentrations. 
Combination of rucaparib with cisplatin led to an increased proportion of cells in G2/M phase (A) and SubG1 signals (B) compared to 
either agent alone in most cases. CDDP, cisplatin; Ruc, Rucaparib; *, p˂0.05; **, p˂0.01. Data are shown as the average of at least three 
independent experiments and error bars represent SEM.
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Figure 8-17: Combination of rucaparib with cisplatin affects the cell cycle distribution and apoptotic endpoints. IGROV-1 cells were 
treated for 24, 48 and 72 hours with rucaparib or cisplatin alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations. Combination of rucaparib with cisplatin led to little change in G2/M phase (A) and increased SubG1 signals with the 
exception of 72 hours’ time point at GI50 value (B) compared to either agent alone. CDDP, cisplatin; Ruc, Rucaparib. Data are shown as 
the average of at least three independent experiments and error bars represent SEM.
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Figure 8-18: Combination of rucaparib with cisplatin affects the cell cycle distribution and apoptotic endpoints. OAW42 cells were 
treated for 24, 48 and 72 hours with rucaparib or cisplatin alone and at constant 1:1 ratios of 1/2x and 1x their respective GI50 
concentrations. Combination of rucaparib with cisplatin led to a decreased proportion of cells in G2/M phase (A) and decreased 
SubG1 signals (B) after 48 and 72 hours compared to cisplatin on its own. CDDP, cisplatin; Ruc, Rucaparib; *, p˂0.05. Data are 
shown as the average of at least three independent experiments and error bars represent SEM.
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 Rucaparib results in clonogenic cell death of ovarian cancer cells in a p53-
independent manner 
To perform clonogenic survival assays for the panel of six ovarian cancer cell lines, 
logarithmically growing cells were counted and seeded at appropriate densities for colony 
formation and treated with different concentrations of rucaparib (0-16 µM) for 48 hours. Then, 
the media including drug were replaced with drug-free media and cells were allowed to form 
colonies. Overall, all cell lines were more sensitive to clonogenic cell killing by rucaparib than 
its effect on cell growth arrest. The results demonstrated a variety of responses for different 
cell lines, ranging from A2780 as the most sensitive cell line (LC50=1.1±0.2 µM) and OAW42 
as the most resistant cell line (LC50=12.1±2.3 µM). Rucaparib significantly decreased the 
clonogenic survival of A2780 cells and moderately reduced the colony formation of MDAH-
2774; however, other cell lines were resistant to the effect of rucaparib (Table 8-4 & 
Figure 8-19).  
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Table 8-4: LC50 concentrations for rucaparib for the panel of ovarian cancer cell lines of 
varying TP53 status. Data represent the mean of at least three independent experiments 
± SEM. 
 
 
 
Figure 8-19: Clonogenic survival curves for the panel of ovarian cancer cell lines treated 
with rucaparib. Data are shown as the average of at least three independent experiments 
and error bars represent SEM. Wt, Wild-type; mut, Mutant.
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8.5 Discussion 
PARP inhibitors, have been developed over a number of decades to potentiate DNA damage 
and in more recent years have been shown to have efficacy as single agents against tumour 
cells with intrinsic deficiencies in DNA repair. They currently have been undergoing clinical 
trials in different types of cancers including ovarian cancer (Anwar et al., 2015; Benafif and 
Hall, 2015; Frey and Pothuri, 2015). As mentioned in the Introduction (1.9.3), the efficacy of 
these drugs depends on defects in HRR (Rigakos and Razis, 2012; Ihnen et al., 2013; Anwar 
et al., 2015; Bowtell et al., 2015). They have also been shown to potentiate the effect of 
cytotoxic radiotherapy and chemotherapy agents (Weil and Chen, 2011; Ihnen et al., 2013; 
O'Sullivan et al., 2014). Encouraging clinical trial results for the use of PARP inhibitors have 
been reported for ovarian cancer (Brown et al., 2016; Drew et al., 2016). The promising results 
showing activity of MDM2-p53 antagonists against wild-type TP53 ovarian cancer cell lines 
(described in chapter 6) have prompted an investigation of combination treatment with 
rucaparib and Nutlin-3/RG7388 in a panel of wild-type TP53 ovarian cancer cell lines. 
Mechanistically it was of interest to investigate the combined effect of PARP inhibition and 
MDM2-p53 binding antagonists on the p53 pathway activation. 
 The growth inhibitory effect of rucaparib on ovarian cancer cell lines 
Growth inhibition assays were carried out to evaluate the effect of rucaparib in a panel of 7 
established ovarian cancer cell lines. Among the individual cell lines, A2780 and MDAH-2774 
were sensitive (GI50 < 10 µM) and other cell lines (IGROV-1, OAW42, CP70, MLH1-corrected 
CP70+ and SKOV-3) were resistant (GI50 > 10 µM). No relationship was found between the 
TP53 status of cells and response to rucaparib, which is consistent with other research (Daemen 
et al., 2012). Following the scheme suggested by Mukhopadhyay, the 10 µM cut-off value was 
used to categorise cell lines into sensitive and resistant to PARP inhibitor (Mukhopadhyay et 
al., 2012). These results are in line with those of previous studies demonstrating sensitivity of 
A2780 and resistance of OAW42, IGROV-1, CP70 and SKOV-3 in response to rucaparib 
(Ihnen et al., 2013; McCormick et al., 2013).  
Overall, the GI50 values for rucaparib across all cell lines were much higher than the concentration 
needed to reduce the enzymatic activity by half, Ki=1.4 nM (Thomas et al., 2007). However, 
they were in the range of rucaparib concentrations achievable in vivo and used in clinical trials 
(Javle and Curtin, 2011; Weil and Chen, 2011; Brown et al., 2016; Drew et al., 2016).  
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To explore the potential mechanism involved in the sensitivity of A2780 and MDAH-2774 and 
resistance of other cell lines to rucaparib, the status of genes implicated as biomarkers in 
response to PARP inhibitors were studied (Table 8-5). The most interesting finding is that 
A2780 cell line was the most sensitive cell line even though among the relevant genes 
previously implicated in the sensitivity to rucaparib (see Introduction, section 1.9.3) it has only 
a heterozygous mutation in PTEN (Deletion-In frame, heterozygous, 
(c.380_388delGAAAGGGAC) (89682879_89682887delAGGGACGAA) (Ihnen et al., 2013) 
(Table 8-5). MDAH-2774 is an ovarian endometrioid tumour with mutant TP53 and KRAS 
(Gilloteaux et al., 2015). 
The IGROV-1 cell line has a number of heterozygous mutations in BRCA1 (a.2080delA, 
Deletion-Frameshift and c.1961delA, Deletion-Frameshift), ATM (c.743G>A, Substitution-
Missense) and PTEN (c.950-953delTACT, Deletion-Frameshift and c.464A>G, Substitution-
Missense) genes . There are controversial results about the BRCA2 gene status of the IGROV-
1 cells. Sanger Institute reported a mutation in BRCA2 (c.9448C>A, Substitution-Missense) 
while Stordal et al. (2013) reported no mutation in BRCA2 gene in IGROV-1 cell line. 
Furthermore, there is a heterozygous mutation in RAD51C gene nonetheless it is silent mutation 
(c.765G>A, Substitution-Coding silent) (Table 8-5).  
The OAW42 cells were resistant to rucaparib, despite amplification of the AURKA gene, (Ihnen 
et al., 2013) and methylation of the FANCF gene (Taniguchi et al., 2003) , both of which have 
been suggested to be associated with sensitivity to rucaparib. A possible explanation for this is 
that the amplification level of the AURKA gene. Amplification is not over-expression but it 
might cause it. The mutation in the ATR gene in OAW42 is a silent mutation with no effect on 
the ATR function (c.4323A>G, Substitution, Coding-silent) (Table 8-5).  
The growth inhibitory effect of rucaparib on the SKOV-3 cell line is in agreement with Ihnen 
et al. (2013who reported the SKOV-3 cell line to be resistant to rucaparib. This result is 
consistent with the lack of mutations in the genes involved in the HRR pathway, aside from an 
unknown heterozygous mutation in the ATM gene ( c.4237-2A>G, Unknown) . Another study 
also found a significant association between deficiency in CDK12 and olaparib sensitivity in 
HGSC cell lines such as SKOV-3 cells, indicating resistance to PARP inhibitor for SKOV-3 
cells which is consistent with the result of this study (Bajrami et al., 2014).   
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For CP70 and MLH1-corrected CP70+ cell lines which are resistant to rucaparib more research 
is needed to check the status of genes implicated in response to PARP inhibitors (Table 8-5). 
No mutation in MRE11, XRCC3 and AURKA genes are reported across all cell lines .  
Overall, the reasons for the greater sensitivity of A2780 and MDAH-2774 to rucaparib are not 
clear. These differences may be explained by the potential involvement of off-target affinities 
for proteins other than PARPs including PIM1 and other kinases (Antolín and Mestres, 2014). 
However, further research is needed to identify reliable biomarkers to stratify patients who will 
benefit from treatment with PARP inhibitors. 
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Table 8-5: BRCA1/2 gene status and BRCAness in a panel of ovarian cancer cell lines used in this study. (1) ,(cancer.sanger.ac.uk); (2), 
(Stordal et al., 2013); (3), (Ihnen et al., 2013); (4), (Lim et al., 2008); (5), (Taniguchi et al., 2003); (6), (Olopade and Wei, 2003); ND, Not 
determined. 
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 Nutlin-3/RG7388 or cisplatin synergise with rucaparib for growth inhibition of 
wild-type TP53 ovarian cancer cell lines in a compound and cell type-dependent 
manner 
Combination treatment with drugs which have different mechanisms of action minimizes 
resistance to treatment (Kummar et al., 2010; Al-Lazikani et al., 2012; Yardley, 2013), a major 
obstacle for cancer therapy. Both MDM2-p53 antagonists and PARP inhibitors have been 
undergoing clinical trial as novel targeted therapeutics as single agents and/or in combination 
with conventional chemotherapy agents (Weil and Chen, 2011; Ding et al., 2013; Anwar et al., 
2015; Lakoma et al., 2015). This study set out to investigate the combined treatment effect of 
Nutlin-3/RG7388 or cisplatin with rucaparib as combined targeted therapeutics or combination 
of targeted therapy with conventional chemotherapy agent respectively. 
Overall, the effect of combined treatment was cell type and compound dependent, with a higher 
synergistic effect for the combination of Nutlin-3/RG7388 with rucaparib for A2780 and 
IGROV-1 cell lines. Interestingly, although both IGROV-1 and OAW42 were resistant to 
rucaparib, there was nevertheless a synergistic effect for the combination of Nutlin-3/RG7388 
with rucaparib. A possible explanation for this is that the defects conferring sensitivity to PARP 
inhibitors as single agents may be different from those which play an important role in the 
response to the combination treatment. For example, serious deficiencies in HRR may affect 
the sensitivity to PARP inhibitors as single agents, while mild defects in HRR may have no 
effect on response to PARP inhibitors alone but may nevertheless influence the effect of 
combination treatments (Turner and Ashworth, 2011; Ihnen et al., 2013). Another possibility 
is that off-target effects of rucaparib with respect to PARP1 and PARP2 may influence the 
growth inhibitory effect of rucaparib as a single agent compared to combined treatment (Murai 
et al., 2014).  
The effect of combination treatment of rucaparib with cisplatin, based on the CI at ED50, was 
synergism, additivity and antagonism for A2780, IGROV-1 and OAW42 respectively, and was 
antagonism based on the overall CI across three cell lines. A number of studies have 
investigated combination treatment of PARP inhibitors with cytotoxic therapeutic agents 
including cisplatin, carboplatin and oxaliplatin, showing a range of additive to synergistic 
effects of combination therapy (Ihnen et al., 2013; O'Sullivan et al., 2014; Benafif and Hall, 
2015; Livraghi and Garber, 2015). Ihnen et al. (2013) reported additive and synergistic 
interactions for the combination treatment of rucaparib with carboplatin in a panel of ovarian   
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cancer cell lines with differing sensitivity in response to rucaparib on its own. They observed 
a higher synergistic effect with A2780, the most sensitive cell line to rucaparib, which is in line 
with data obtained in this study. Michels et al. (2014) reported an additive effect of combination 
treatment between PARP inhibitors and cisplatin on cervical cancer and testicular germ cell 
tumour cell lines.  
The most important clinically relevant finding from the data is the favourable DRI values in 
both combination treatment of Nutlin-3/RG7388 or cisplatin with rucaparib. As mentioned in 
the literature review and chapter 7.4.1, additive and even mildly antagonistic results of 
combined treatment can nevertheless be of potential clinical use due to favourable DRI values 
(Ohnstad et al., 2011; Meng et al., 2015). These favourable DRI values demonstrate that 
combination of Nutlin-3/RG7388 or cisplatin with rucaparib has the potential to reduce the 
dose of drugs in most cases, indicating a potential clinical benefit of combining these 
therapeutic agents.  
 The effect of combination of Nutlin-3/RG7388 or cisplatin with rucaparib on 
functional activation of the p53 pathway in TP53 wild-type ovarian cancer cell 
lines 
Rucaparib on its own had no effect on p53 stabilisation and upregulation of its downstream 
targets p21WAF1 and MDM2 across all three cell lines. Combination treatment of Nutlin-
3/RG7388 with rucaparib induced stabilisation of p53 and upregulation of p21WAF1 and MDM2 
compared to rucaparib on its own, whereas rucaparib caused no enhancement of the p53 
activation by MDM2 inhibitors alone. These results demonstrate that the synergistic effect 
observed in the combination between rucaparib and Nutlin-3/RG7388 is not related to the p53 
molecular pathway. Combination of cisplatin with rucaparib caused little change on the 
functional activation of the p53 pathway with the exception of a little change in the expression 
of p21WAF1 at constant 1:1 ratios of GI50 values for A2780 and IGROV-1 cell lines.   
The interplay between PARP and p53 is controversial. Bai et al. (2015) showed that PARP 
inhibition by the small molecule PJ-34 caused an increased p53 stabilisation for MT2, MT4, 
C91PL T-cell leukemia cells, and induced p53 phosphorylation and p21WAF1 upregulation in 
MT4 cells. Another study performed by Valenzuela et al. (2002) used parental PARP-1 +/+ 
and deficient PARP-1 -/- primary mouse embryonic fibroblasts and determined the nuclear 
accumulation of p53 protein following ionising radiation (IR), ultraviolet light (UV) and alkylating 
agent N-methyl-N-nitrosourea (MNU) treatment. There was a very rapid accumulation of p53 for 
 311 
 
 
PARP-1 parental cells after IR treatment which remained at high levels for 24 hours while 
PARP-1 deficient cells showed little change. In contrast, p53 accumulation happened earlier 
and at higher levels in PARP-1 deficient cells following MNU treatment compared to parental 
cells. In terms of UV treatment, the p53 accumulation levels were similar for both parental and 
PARP-1 deficient cell lines. The authors suggested that the interplay between PARP-1 and p53 
depends on the type of DNA damage. A further study investigated the effect of olaparib and 
veliparib on cell cycle arrest and the p53 pathway for a panel of cancer cell lines (Jelinic and 
Levine, 2014). These results indicated a robust increase in p53 stabilisation, p21WAF1 
upregulation and CHK1 phosphorylation in U2OSDR-GFP and HCT116 cells treated with 
olaparib but the effect on p53 accumulation and p21WAF1 upregulation in veliparib-treatment 
cells was weak with no CHK1 activation. Jelinic et al. (2014) proposed that olaparib treatment 
led to strong replicative stress compared to veliparib, and its effect on cell cycle arrest and 
growth inhibition is p53-dependent. However, the effect of veliparib on growth inhibition and 
cell cycle arrest is p53-independent.  
 Combination of rucaparib with Nutlin-3/RG7388 or cisplatin affects cell cycle arrest 
and/or apoptosis in wild-type TP53 ovarian cancer cell lines 
Rucaparib had little effect on the cell cycle distribution of IGROV-1 and OAW42 cell lines, 
which is in agreement with the results obtained by Porcelli et al. (2013) that indicated no effect 
of rucaparib on the cell cycle progression of pancreatic cancer cells. However, in the current 
study rucaparib significantly decreased the proportion of cells in S-phase in A2780 cells, 
consistent with a recent study indicating a robust decrease in the percentage of cells in S-phase 
following treatment of U2OSDR-GFP cells with olaparib (Jelinic and Levine, 2014). Furthermore, 
there was only a slight increase in the SubG1 cell subpopulation across all cell lines treated 
with rucaparib compared to DMSO control, suggesting that cells are not undergoing apoptosis. 
These results are in line with those of Jelinic and Levine (2014) who observed low SubG1 
events in the cancer cells treated with olaparib or veliparib.  
Across all three cell lines, combined treatment of Nutlin-3/RG7388 with rucaparib increased 
the proportion of cells in the G2/M phase of the cell cycle, which was marked for A2780 and 
IGROV-1. Combination of rucaparib with cisplatin increased the proportion of cells in G2/M 
for A2780 cells, whereas there was little change in the percentage of cells in G2/M phase and 
a decrease in the proportion of SubG1 events for the OAW42 cell line.   
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The increased proportion of cells in G2/M phase following PARP inhibitor treatments may 
reflect their potency to trap PARP-1 and -2 to DNA and induce replicative stress response 
(Jelinic and Levine, 2014). Reported off-target effects of rucaparib include inhibition of nine 
different kinases (Antolín and Mestres, 2014); and this may contribute to the effect of rucaparib 
on cell cycle progression (Jelinic and Levine, 2014). For example, rucaparib presents 
micromolar IC50 values for PIM1 (1.2 µM), CDK1 (1.4 µM), and CDK9 (2.7 µM) proteins, 
which are known as cell cycle regulators (Antolín and Mestres, 2014).  
 Rucaparib results in clonogenic cell death in ovarian cancer cell lines 
Overall, the results of clonogenic survival assays were similar to the growth inhibition assays 
with A2780 as the most sensitive, and OAW42 as the most resistant cell lines. As explained in 
chapter 8.5.1, the reason for this difference between various cell lines in regard to response to 
rucaparib is not clear and it is difficult to explain this result. Drew et al. (2011) studied the 
effect of rucaparib on the clonogenic cell survival for a panel of cancer cell lines with different 
BRCA1/2 status. They used a 10 µM rucaparib as the cut-off value to categorise cell lines into 
sensitive and resistant based on the correlation of cytotoxicity with the HRR status determined 
by RAD51 foci in primary cultures. The results demonstrated a marked difference in the LC50 
data in relation to HRR functionality, with less toxicity to cell lines with functional HRR 
(LC50=20.2-50.7 µM) than those with mutant BRCA1/2 or XRCC3 (LC50=1.3-5.5 µM). The 
LC50 for our sensitive cell lines (LC50=1.1-4.4 µM) was in the same range defined by Drew et 
al (2011); however, we found no evidence of HRR deficiency in these cell lines. Therefore 
more research is clearly needed to identify reliable biomarkers for identifying patients likely to 
respond to PARP inhibitors. 
 Conclusion and further work 
Monitoring cell cycle markers and PARP expression and PARP activity in addition to HRR 
status is likely to be additional useful information to assess the effectiveness of PARP 
inhibitors. This information may be helpful to better clarify and stratify the patients who might 
benefit from PARP inhibitors. Using preclinical xenograft models is required to confirm 
evidence of synergy in vivo. 
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 Chapter 9: General Discussion 
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9       TP53 and ovarian cancer 
The studies and research presented in this thesis have focused on the genomic and functional 
status of TP53 as prognostic and predictive biomarkers in ovarian cancer patients, and targeting 
p53 by using a small molecule inhibitor of MDM2-p53 interaction for treatment of ovarian 
cancer. For the study of TP53 mutational status as prognostic and predictive biomarkers, a set 
of TMAs constructed from tumour samples collected from the ICON3 multicentre clinical trial 
was used. For the immunohistochemical prognostic biomarker studies, two sets of TMAs were 
used; the OVCA1-4 set representing a cohort of patients from which samples had been 
collected locally, and the same set of TMAs from the ICON3 clinical trial used for sequencing. 
For the preclinical evaluation of MDM2 inhibitors, a panel of 7 ovarian cancer cell lines with 
varying status of TP53 was studied to investigate their growth inhibitory and apoptotic response 
to three different MDM2-p53 binding antagonists, Nutlin-3, RG7112 and RG7388 as single 
agents. The growth inhibitory effect and induced apoptosis with a combination of Nutlin-3 or 
RG7388 with cisplatin or rucaparib were also investigated in the same panel of cell lines.   
9.1 Analysis of the prognostic and predictive value of mutational status of TP53 and TP53 
expression in ovarian cancer 
In spite of numerous studies which have investigated the role of genomic and/or functional 
status of TP53 as prognostic and predictive biomarkers in ovarian cancer, the results are 
inconsistent (Shahin et al., 2000; Fallows et al., 2001; Reles et al., 2001; Schuyer et al., 2001; 
Havrilesky et al., 2003; Nakayama et al., 2003; Canevari et al., 2006; Gadducci et al., 2006; 
Bartel et al., 2008; de Graeff et al., 2009; Ahmed et al., 2010; Bauerschlag et al., 2010; 
Nadkarni et al., 2013; Rechsteiner et al., 2013; Brachova et al., 2015; Seagle et al., 2015). 
Meta-analyses of p53 studies have been performed to increase power over individual studies, 
improve the estimates of the effect and resolve uncertainty amongst inconsistent results, but 
nevertheless methodological variability and publication bias are considerable problems (Crijns 
et al., 2003; de Graeff et al., 2009). Crijns et al. (2003) found fifty-three studies that 
investigated the prognostic impact of p53 status in ovarian cancer, among which thirty-two 
studies were appropriate for meta-analysis. The results confirmed that ovarian cancer patients 
harbouring tumour with overexpressed p53 had significantly worse probabilities of survival at 
five years (p=0.0006) and concluded that p53 targeted therapy may have therapeutic potential. 
De Graeff et al. (2009) included sixty-two studies in the meta-analysis and indicated that p53   
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protein expression had a modest effect on prognosis and overall survival despite the presence 
of heterogeneity between studies. They suggested that p53 immunostaining is unlikely to be 
useful as a predictive biomarker in clinical practice in a manner comparable to well-known 
clinicopathological predictive biomarkers such as tumour stage and residual disease. They also 
found the mutational status of TP53 had prognostic value in the meta-analysis even though it 
was of borderline significance. In addition to methodological variability and publication bias, 
the meta-regression analysis showed FIGO stage distribution has impact on the outcome of 
meta-analysis and p53 status was no longer of predictive value when the meta-analysis was 
restricted to studies reporting results for patients with stage III/IV tumours (de Graeff et al., 
2009;  Levidou., 2011). In contrast, when p53 meta-analysis was performed in the studies 
evaluating the predictive value of p53 in patients with serous tumours, p53 retained its 
significance as a predictor of survival ( Graeff et al., 2009). Overall, the results are highly 
influenced by a variety of methodological variables including fixation method of paraffin-
embedded tissues and storage time, type of primary antibody and IHC staining protocol, cut-
off values for protein expression, size of sample and diverse chemotherapy options (Levesque 
et al., 2000;  Crijns et al., 2003;  Graeff1, 2006; de Graeff et al., 2009; Rechsteiner et al., 2013) 
. In terms of mutational status of TP53, different techniques used for mutational analysis, the 
analysis of different exons and classification of mutations in addition to factors illustrated 
above effect the outcome of analysis (Shahin et al., 2000; Rose et al., 2003a; Canevari et al., 
2006; Liu et al., 2010; Nadkarni et al., 2013; Brachova et al., 2015; Seagle et al., 2015).  
In conclusion,  standard guidelines for use of FFPE tissue sections, standardised laboratory 
protocol and data collection (Graeff1, 2006), and analysis in homogeneous subgroups of 
patients such as those with a particular tumour type, stage or grade (de Graeff et al., 2009) can 
be helpful to achieve comparable results among studies related to prognostic and predictive 
value of p53 in ovarian cancer.  
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9.2 A comparison between two independent cohorts in relation to the TP53 expression 
and its correlation with overall survival 
In this study two independent cohorts were used to investigate the correlation between TP53 
expression and overall survival. One cohort named OVCA1-4 included 167 ovarian cancer 
samples from northern England and the other cohort consisted of 260 ovarian cancer samples 
from the ICON3 international multicentre trial. Based on the results of the OVCA1-4 cohort, 
TP53 expression levels was found to have prognostic significance for overall survival 
(p=0.003). However, the results of ICON3 clinical trial indicated that the observed difference 
in overall survival between patients in relation to TP53 expression levels was only marginally 
significant (p=0.06).  
Clinicopathological data from both cohorts had been recorded for histological subtype, stage, 
residual disease and grade (Table 9-1). In terms of histology, the proportion of HGSC in the 
ICON3 cohort is considerably higher than for OVCA1-4 and the reverse is true for 
endometrioid and mucinous histological subtypes. A higher proportion of patients in the 
ICON3 cohort was categorised in stages III/IV than for the OVCA1-4 cohort. There is also a 
greater percentage of patients with optimal or suboptimal cytoreductive surgery for patients 
from ICON3 compared to those from the OVCA1-4 cohort. Moreover, a lower frequency of 
well differentiated and a higher frequency of poorly differentiated tumours was observed for 
the ICON3 TMA sample set. Overall, a higher proportion of patients from the ICON3 cohort 
has aggressive ovarian cancer compared to those from OVCA1-4. The results suggest that stage 
of disease, grade of differentiation and histology may impact on the prognostic value of p53. 
Amongst the studies which have investigated the prognostic and predictive values of p53 in 
ovarian cancer, most of those with advanced stages and invasive ovarian cancer showed no or 
marginally significant association between TP53 expression levels and overall survival 
(Sagarra et al., 2002; Havrilesky et al., 2003; Gadducci et al., 2006; Green et al., 2006; Darcy 
et al., 2008; Rechsteiner et al., 2013).   
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Table 9-1: Clinicopathological data for 167 samples of the OVCA1-4 and 260 samples of 
the ICON3 cohorts.
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9.3 The effect of the genomic status of TP53 on survival following platinum-based 
chemotherapy in ovarian cancer 
Cells respond to platinum-based chemotherapy agents in both p53-dependent and p53-
independent manners, although which mechanism dominates is context dependent. Evidence 
suggests that wild-type TP53 tumours may be more sensitive to platinum-based chemotherapy 
than those with mutant TP53 and the tumours less aggressive, combining to result in longer 
patient survival. A number of studies have investigated the role of TP53 status in response to 
platinum-based chemotherapy, among which several indicated a significantly better overall 
survival for the patients with wild-type TP53 tumours compared to those with mutant TP53 
tumours (Kigawa et al., 2001; Reles et al., 2001; Canevari et al., 2006; Gadducci et al., 2009). 
In contrast, others found no statistically significant correlation between the genomic status of 
TP53 and overall survival in ovarian cancer patients (Fallows et al., 2001; Wang et al., 2004; 
Bauerschlag et al., 2010). 
Overall in this study, patients whose tumours have wild-type TP53 and who were treated with 
only single agent carboplatin had better overall survival than those with tumours harbouring 
mutant TP53, regardless of the sequencing method used. When the analysis is limited to 
patients treated with carboplatin alone and having serous histology tumours, TP53 status 
retained its predictive value based on the Sanger sequencing while it lost its significance based 
on the NGS. For patients treated with carboplatin or CAP, only analysis of data based on the 
Sanger sequencing or both sequencing methods showed significant predictive value of TP53 
status in response to single agent carboplatin or CAP. Adding paclitaxel to carboplatin led to 
loss of the significant effect of TP53 status on overall survival irrespective of sequencing 
methods used. However, a number of studies reported that patients with mutant TP53 tumours 
gain benefit from adding paclitaxel to platinum drugs (Lavarino et al., 2000; Ueno et al., 2006; 
Wong et al., 2013). The results from this study clearly show that sequencing methods and 
treatment types influence the prognostic value of TP53 for patients with ovarian cancer, and 
explain somewhat the observed discrepancies between various studies.     
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9.4 The limitation of the IHC approach as a biomarker assay 
Although IHC staining has wildly being used as a biomarker validation, it may present 
significant bias which is divided into reaction bias and interpretation bias. The former includes 
tissue handling, specimen fixation, tissue processing, antigen retrial and detection system, and 
the latter includes selection of antibody types, sensitivity of the chosen panel, results and 
literature interpretation. Therefore, the IHC results must be interpreted with caution (de Matos 
et al., 2010; O'Hurley et al., 2014). 
The antigenicity of an antigen may significantly be lost if fresh specimens are submitted to 
long periods of fixation. Formaldehyde fixation, the most used histological processing 
procedure, is a major cause of masking or damaging some antibody binding sites which results 
in a variably reversible loss of immunoreactivity (de Matos et al., 2010; O'Hurley et al., 2014). 
The thickness of slices has an impact on the IHC results. For example, slices less than 3 µm 
could result in less intensity and very weak immunostaining. Antigen retrieval and its different 
variables including heating, the type of solution and its pH and molarity are major variables 
that can affect IHC staining. Hence, using appropriate antigen retrieval which is dependent on 
both the target protein and chosen antibody is very important, and requires to be optimised for 
every antibody (O'Hurley et al., 2014). 
Appropriate choice of antibody and its validation is another major challenge in IHC staining 
which is a time consuming process. The portal Antibodypedia, (http://www.antibodypedia.com), 
is a suitable tool to search and find appropriate antibodies proper for IHC staining. However, 
antibody validation is a mandatory step before performing IHC staining because of not 
providing the sequence of the antigen which the antibody was raised against by many 
companies that produce the antibodies (de Matos et al., 2010). 
Interpretation and scoring of IHC data can be performed via manual and automated approaches. 
The manual scoring can be an inherently subjective and semi-quantitative process which is 
time intensive and laborious. To overcome these problems, use of image analysis systems has 
been proposed which decrease workload and outperform manual scoring by more 
reproducibility, accuracy and less subjectivity. In spite of having these advantages, automated 
image analysis is a semi-automated approach highly influenced by the quality of 
sections/TMAs due to inability of the system to identify the artefacts, edge effect staining and 
folding of tissue (de Matos et al., 2010).  
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A limitation of our study is how the used antibodies were validated for their specificity as 
described in section 3.3.2. In addition, the same antibodies were used for western blotting and 
confirmed antibody specificity by the presence of a single band corresponding to the predicted 
molecular weight of the target proteins including p53, p21 and MDM2. However, a band of the 
correct size is not complete evidence for targeting the expected protein due to some proteins 
with a similar molecular weight. Therefore, use of more appropriate positive and negative 
FFPE control cell lines known to express or not express the target protein will be needed to 
confirm the specificity of the antibodies used for MDM2 and WIP1 proteins in this study. 
Another limitation of this study is the modified H-score applied for immunoscoring, in which 
there was a possibility of obtaining scores more than 18. For example, the final score of a core 
is 20 if the intensity of 50% of the core is intermediate (4 * 2=8) and 50% of that is strong (4 
* 3=12). To overcome this possible challenge, all patient samples of OVCA1-4 were scored 
for p53 as follows: 0 = no staining, 1 = weak staining, 2 = intermediate, 3 = strong, and the 
percentage of each group was estimated (0-100%). H-score was calculated by multiplying the 
proportion of staining and intensity of staining ranged from 0 to 300. The results were 
compared to those of modified H-score, and the ROC curve analysis was used to examine the 
relationship between sensitivity and specificity for immunohistochemical staining scores and 
categorise the samples into low and high p53 expression (Appendix II). The Interclass 
Correlation Coefficient test was used to estimate the concordance in two different scoring 
systems, and the ICC value was 0.97 describing how strongly immunoscoring units in the same 
patient sample resemble each other (Appendix III). Also, the statistical significance of observed 
differences in patient survival was analysed (Appendix IV). As can be seen in Appendix II, III 
and IV, the results were very similar to those achieved by analysing the data based on the 
modified H-score. 
One more limitation is the single observer manual scoring was applied for immunoscoring of 
p53, p21 and MDM2 proteins (For WIP1 protein, the cores were scored by both the manual 
and the automated Aperio system, ICC=0.84) (Appendix V). This type of analysis has 
limitations because of being subjective and arbitrary. To avoid the bias, two independent 
observers must score each core, and reproducibility between the two scores should be measured 
using an appropriate statistical test.  
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9.5 The issues arisen from inclusion of different subtypes of ovarian cancer in a single 
cohort 
Ovarian cancer is a heterogeneous disease including different histological subtypes, which 
are considered as distinct diseases. There are dramatically different in frequency, response to 
current chemotherapy, genetic abnormalities and molecular events, and survival. Therefore, 
there is a possibility of misleading when association of biomarker expression with survival is 
analysed in whole cohort. There is a substantial difference in the correlation between 
biomarker expression and survival across different subtypes which is likely to be overlooked 
in the analyses of whole cohort (Köbel et al., 2008). 
 Most prognostic and predictive biomarker studies are not subtype specific for ovarian cancer 
patients. Kobel et al. (2008) investigated prognostic significance of twenty one candidate 
tissue-based biomarkers including p53 and p21 in a whole cohort of 500 ovarian carcinoma 
and within each specific subtype. Twenty of twenty one biomarkers had significantly different 
expression levels between different subtypes and only one biomarker showed a similar 
expression frequency across all subtypes which was EPCam. The survival analysis indicated 
nine of the twenty one biomarkers as prognostic biomarkers in the entire cohort while only 
three of the nine retained their prognostic significance in the HGSC subtype and one in the 
endometrioid subtype. Ki-67 was an unfavourable prognostic factor in the whole cohort; 
however, it did not remain its prognostic significance within any subtype. In some prognostic 
associations, there was an inverse correlation within entire cohort compared to a specific 
subtype. For example, WT1 was a favourable prognostic biomarker within the HGSC subtype 
while it was an unfavourable prognostic factor within the whole cohort. Furthermore, 
biomarker expression was studied within the entire cohort and compared to one specific 
subtype across FIGO stages. Ten of the twenty one biomarkers including p53 and p21 had 
significantly different expression levels, which suggest differences between early (I & II) and 
late (III & IV) stage disease. However, no biomarker retained its prognostic significance by 
stage when biomarker expression was compared within one specific subtype across FIGO 
stages. The results of biomarker expression levels in the entire cohort across subtypes 
generally showed smaller p-values than across stages, demonstrating a stronger relationship 
between survival and different subtypes than stages.  
Although a multivariate analysis was performed, a limitation of our study is that the biomarker 
studies was performed in the whole cohort. To avoid confounding the association between 
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biomarker expression and prognosis, different histological subtypes should be considered as 
distinct diseases in biomarker studies (Köbel et al., 2008). 
9.6 Targeting p53 using MDM2-p53 binding antagonists in ovarian cancer 
Use of MDM2-p53 inhibitors would be suitable for cancer types in which p53 mutations are 
rare or low including neuroblastoma (Chen et al., 2015), primary leukemia, sarcoma, testicular 
cancer, malignant melanoma and cervical cancer (Olivier et al., 2010). The rate of TP53 
mutations varies considerably in epithelial ovarian cancer according to histological subtype 
being less common in type I compared to type II (Koshiyama et al., 2014; Cobb et al., 2015; 
Skirnisdottir et al., 2015).  
The frequency of TP53 mutation reported in the literature is particularly high for HGSC 
ranging from 51% (Singer et al., 2005) to 97% (The Cancer Genome Atlas Research, 2011). 
In the current study 63% of patient samples were classified as HGSC, of which 62% were TP53 
mutant by Sanger sequencing and 71% by NGS (Table 9-2). As HGSC represents about 70% 
of all epithelial ovarian cancer (Kurman, 2013),  the other 30% of histological subtypes in 
which TP53 mutation is less frequent, and the small percentage of HGSC harbouring wild-type 
TP53 would gain benefit from MDM2-p53 inhibitors on their own or in combination with other 
therapeutic agents such as cisplatin or rucaparib. This may be particularly worth exploring with 
mucinous and clear cell histological subtypes which do not respond well to current 
chemotherapy strategies and are clinically challenging to treat.   
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Table 9-2: The frequency of TP53 mutation for different histological subtypes of epithelial ovarian cancer reported in different studies. 
WT, Wild type; Mut, Mutant; LGSC, Low-grade serous carcinoma; HGSC, High-grade serous carcinoma; NGS, Next generation 
sequencing.
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9.7 Nutlin-3 and RG7388 induce apoptosis in ovarian cancer 
A number of studies have reported that Nutlin-3 induces apoptosis in leukemia cells while only 
reversible cell cycle (quiescence) arrest in solid tumours (Huang et al., 2009; Demidenko et 
al., 2010; Hoe et al., 2014). Our study and two limited previous reports showed that wild-type 
TP53 ovarian cancer cells undergo both growth arrest and apoptosis following exposure to 
Nutlin-3 and some cell lines are more sensitive than others. The previous studies indicated that 
Nutlin-3a treatment induced both cell cycle arrest and apoptosis in sensitive cell lines (Crane 
et al., 2015) and potentiated apoptotic cell death in chemoresistant ovarian cancer cells to 
cisplatin (Mir et al., 2013). In our study, all wild-type TP53 cell lines were sensitive to Nutlin-
3 and the more potent clinical candidate RG7388. Both MDM2-p53 antagonists induced cell 
cycle arrest and apoptosis with RG7388 showing greater potency. In terms of apoptosis 
endpoints, treatment with both inhibitors resulted in increased SubG1 events in Flow cytometry 
and caspase3/7 activity, in a cell type, time and compound-dependent manner (Zanjirband et 
al., 2016).  
The mRNA levels of p53 transcriptional target genes implicated in apoptotic pathways 
increased in response to treatment with the MDM2 inhibitors, including AEN, PUMA, 
TNFRSF10B and TP53INP1.  The highest fold change was seen for PUMA in IGROV-1 cells. 
However, for the OAW42 cell line no significant changes were observed in SubG1 events and 
caspase3/7 activity, in spite of increased expression levels of genes involved in apoptosis, 
suggesting apoptotic pathway deficiencies in this cell line.  
A number of studies indicated that the cyclin-dependent kinase inhibitor p21WAF1 plays a dual 
role and may exert an anti-oncogenic or oncogenic role (Abbas and Dutta, 2009; Maria Teresa 
Piccolo1, 2012; Lu, 2016) which is dependent on the cancer type and drug treatment  (Maria 
Teresa Piccolo1, 2012). However, a recent study indicated that removal of p21WAF1 had no 
effect on Nutlin-3a induced apoptosis, and induction of p21WAF1 did not protect cancer cells 
against apoptosis induced by nongenotoxic p53 activation (Xia et al., 2011). In the current 
study, CDKN1A (p21WAF1) and a number of pro-apoptotic genes were induced upon treatment 
with both Nutlin-3 and RG7388 across all three wild-type TP53 cell lines, and two out of the 
three cell lines underwent apoptosis. The data extracted from this study suggest that Nutlin-3 
or RG7388-induced p21WAF1 levels do not prevent induction of apoptosis in ovarian cancer 
cells.  
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9.8 Mutant TP53 cells selected for resistance to treatment from parental wild-type TP53 
cell lines may retain their sensitivity to alternative therapies 
A major challenge in drug development and cancer therapy is acquired resistance of tumour 
cells to therapeutic agents. Due to the effect of MDM2-p53 antagonists only on the wild-type 
TP53 cells, they are likely to select the mutant TP53 cells that are present in the original 
populations at low frequencies, leading to resistance to other p53-dependent therapeutic agents 
(Aziz et al., 2011; Zhao et al., 2015; Burgess et al., 2016). In the current study, the mutant 
TP53 cell lines were sensitive to cisplatin in spite of being resistant to Nutlin-3 and RG7388. 
For example, there was a difference in the GI50 values in response to cisplatin between the 
MLH1-corrected CP70+ cell line with mutant TP53 and its parental cell line A2780. However, 
there is a very noticeable difference in GI50 values in response to Nutlin-3 and RG7388. The 
cell lines that were found to be resistant to cisplatin have a deletion in TP53, SKOV-3, or a 
mutation in MLH-1 in addition to TP53 mutation, CP70. A number of studies investigated the 
role of TP53 in response to cisplatin demonstrating increased sensitivity to cisplatin for head 
and neck squamous cell carcinoma lines with mutant TP53 (Bradford et al., 2003) or showing 
a marked response to cisplatin through both p53-dependent and p53-independent mechanisms 
for human ovarian xenografts (Clarke et al., 2004). Another study also indicated a relatively 
modest role of TP53-dependent apoptosis in response to ionising radiation (Gudkov and 
Komarova, 2003).  Furthermore, a recent study indicated that both NGP and SJSA-1 Nutlin-
3/MI63 resistant TP53 mutant cell lines have a response to ionising radiation which is similar 
to that of parental TP53 wild-type NGP and SJSA-1 cell lines (Drummond et al., 2016). The 
results from our study and those obtained by Drummond et al. are in accord with the data on 
the Sanger Genomics of Drug Sensitivity database, showing no marked difference in response 
to DNA damaging agents for the cell lines with wild-type TP53 compared to those with mutant 
TP53, in spite of indicating a very significant difference in sensitivity to Nutlin-3 
(http://www.cancerrxgene.org). Overall, these results demonstrate that selected mutant TP53 
cells following treatment with MDM2-p53 antagonists may retain their sensitivity to 
alternative therapies including platinum-based chemotherapy and ionising radiation. In 
addition, use of MDM2-p53 inhibitors in combination with chemotherapeutic agents or other 
targeted cancer treatments which act in a p53-independent manner may be a useful strategy.  
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9.9 MDM2-p53 antagonists in combination with other therapeutic agents in ovarian 
cancer 
Previous studies have indicated synergistic effects between chemotherapeutic drugs and 
MDM2-p53 inhibitors in different types of cancer, including two limited studies with ovarian 
cancer cell lines demonstrating that Nutlin-3a synergises with cisplatin (Mir et al., 2013) or 
resveratrol (Marimuthu et al., 2011). The results of the present study demonstrated a significant 
reduction of cell growth and induction of apoptosis when the cells were treated with a 
combination of Nutlin-3 or RG7388 with cisplatin or rucaparib, compared to the effects of 
cisplatin or rucaparib alone in a cell type, compound and time-dependent manner. The response 
to cisplatin or rucaparib was significantly enhanced upon disruption of the MDM2-p53 
interaction, with additive or synergistic effects and favourable DRI values in most cases. In 
terms of combined treatment between Nutlin-3 or RG7388 and cisplatin, the presence of wild-
type TP53 was the main predictive biomarker of response to MDM2-p53 antagonists. 
Nevertheless, an additional potential determinant of response in the current study involved the 
balance of expression between growth inhibitory/pro-survival and pro-apoptotic genes. Our 
results indicate that this dominates the small changes in the expression of DNA repair genes 
and provides a potential explanation for some differences in sensitivity between the TP53 wild-
type cell lines and for the synergy observed for treatment with cisplatin and MDM2-p53 
inhibitors. 
The use of much lower doses of genotoxic drugs may be possible by combining established 
chemotherapy agents with non-genotoxic MDM2-p53 inhibitors. Furthermore, combination of 
other targeted therapies such as RG7388 with rucaparib is a potential strategy to overcome 
intrinsic resistance and delay acquired resistance to either agent alone.  
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9.10 Conclusion remarks and future work 
This study set out to investigate the prognostic and predictive value of genomic and functional 
status of TP53 in ovarian cancer, and to investigate the effect of MDM2-p53 antagonists, 
Nutlin-3 and RG7388, as single agents or in combination with the chemotherapeutic agent 
cisplatin or another targeted therapy agent, rucaparib, in ovarian cancer. The present study 
indicates that TP53 genomic status can be considered to be a predictive biomarker of overall 
survival in response to single agent carboplatin for ovarian cancer patients. It also demonstrates 
that MDM2-p53 antagonists have activity as a single agent against wild-type TP53 ovarian 
cancer cells, leading to cell cycle arrest and/or apoptosis. In addition, combination treatment 
with MDM2 inhibitors and cisplatin has synergistic and/or dose reduction potential, dependent 
on cell genotype and compound, and merits further investigation. Our study clearly indicates 
that the presence of wild-type TP53 remains the main predictive biomarker of response to 
MDM2 inhibitors, and the balance of activity between growth inhibitory/pro-survival and pro-
apoptotic genes dominates the small changes in the expression of DNA repair genes as an 
explanation for the synergy observed for treatment with cisplatin and MDM2 inhibitors. 
Furthermore, combination treatment with MDM2 inhibitors and rucaparib has synergistic and 
dose reduction potential. However, more research is needed to clarify the interplay between 
p53 and PARP and confirmation of synergy with ex-vivo primary ovarian cancer cells and in 
vivo preclinical xenograft models. 
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Appendix I 
The average depth of sequencing for each exon. 
 
 
 
Appendix II 
The ROC curve in relation to p53 expression demonstrating the area under the curve 
(AUC=0.66, P=0.001), and the optimal categorisation cut-off point for patient samples based 
on the p53 expression (H-score: 0-300). 
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Appendix III 
The concordance in two different scoring methods (modified H-score and 0-300) used to score 
ovarian cancer samples for p53 expression, OVCA1-4 (ICC-0.97). 
 
Appendix IV 
The survival times in relation to low (H-Score≤123) and high (123<H-score≤300) expression 
of p53 (p<0.001). 
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Appendix V 
The concordance in two different scoring systems used to score ovarian cancer samples for 
WIP1 protein, OVCA3-4, (the manual and the automated Aperio system, ICC=0.84). 
 
 
 
 
 
 
 
 
 
 
 
 
